UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☑ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2016
OR
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number: 1-32258
Reynolds American Inc.
(Exact name of registrant as specified in its charter)
North Carolina |
|
20-0546644 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
401 North Main Street
Winston-Salem, NC 27101
(Address of principal executive offices) (Zip Code)
(336) 741-2000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Name of each exchange on which registered |
Common stock, par value $.0001 per share |
|
New York |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☑
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer |
☑ |
|
|
Accelerated filer |
☐ |
|
|
|
|
|
|
Non-accelerated filer |
☐ |
(Do not check if a smaller reporting company) |
|
Smaller reporting company |
☐ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The aggregate market value of common stock held by non-affiliates of Reynolds American Inc. on June 30, 2016, was approximately $44 billion, based on the closing price of $53.93. Directors, executive officers and a significant shareholder of Reynolds American Inc. are considered affiliates for purposes of this calculation, but should not necessarily be deemed affiliates for any other purpose.
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: January 23, 2017: 1,425,934,305 shares of common stock, par value $.0001 per share.
Documents Incorporated by Reference:
Portions of the Form 10-K/A of Reynolds American Inc. to be filed with the Securities and Exchange Commission on or before May 1, 2017, are incorporated by reference into Part III of this report.
|
|
|
|
|
|
|
|
Item 1. |
|
2 |
|
|
|
|
|
Item 1A. |
|
13 |
|
|
|
|
|
Item 1B. |
|
25 |
|
|
|
|
|
Item 2. |
|
25 |
|
|
|
|
|
Item 3. |
|
25 |
|
|
|
|
|
Item 4. |
|
25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 5. |
|
26 |
|
|
|
|
|
Item 6. |
|
28 |
|
|
|
|
|
Item 7. |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
30 |
|
|
|
|
Item 7A. |
|
62 |
|
|
|
|
|
Item 8. |
|
65 |
|
|
|
|
|
Item 9. |
|
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure |
177 |
|
|
|
|
Item 9A. |
|
177 |
|
|
|
|
|
Item 9B. |
|
177 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 10. |
|
178 |
|
|
|
|
|
Item 11. |
|
178 |
|
|
|
|
|
Item 12. |
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
178 |
|
|
|
|
Item 13. |
|
Certain Relationships and Related Transactions, and Director Independence |
178 |
|
|
|
|
Item 14. |
|
178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 15. |
|
179 |
|
|
|
||
186 |
1
On January 17, 2017, Reynolds American Inc., referred to as RAI, announced that it had entered into a Merger Agreement, as defined below, with British American Tobacco p.l.c., a public company incorporated under the laws of England and Wales, referred to as BAT, BATUS Holdings Inc., a Delaware corporation and a wholly owned subsidiary of BAT, and Flight Acquisition Corporation, a North Carolina corporation and a wholly owned subsidiary of BAT, referred to as Merger Sub. Unless stated otherwise, all forward-looking information contained in this report does not take into account or give any effect to the impact of the BAT Merger, as defined below. For additional details regarding the BAT Merger, see “Business” contained in Part I, Item 1, of this report, “Risk Factors” contained in Part I, Item 1A, of this report, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Part II, Item 7, of this report, and Note 22 to RAI’s consolidated financial statements, contained in Part II, Item 8, of this report.
RAI is a holding company whose wholly owned operating subsidiaries include the second largest tobacco company in the United States, R. J. Reynolds Tobacco Company; the manufacturer and marketer of the leading super-premium cigarette brand, Santa Fe Natural Tobacco Company, Inc., referred to as SFNTC; the second largest smokeless tobacco products manufacturer in the United States, American Snuff Company, LLC, referred to as American Snuff Co.; R. J. Reynolds Vapor Company, referred to as RJR Vapor, a marketer of digital vapor cigarettes in the United States, manufactured on its behalf by R. J. Reynolds Tobacco Company; Niconovum USA, Inc. and Niconovum AB, marketers of nicotine replacement therapy products in the United States and Sweden, respectively; and until their sale on January 13, 2016, as described below, SFR Tobacco International GmbH, referred to as SFRTI, and various foreign subsidiaries affiliated with SFRTI. RAI was incorporated in the State of North Carolina on January 2, 2004, and its common stock is listed on the New York Stock Exchange, referred to as NYSE, under the symbol “RAI.” RAI’s headquarters are located in Winston-Salem, North Carolina. On July 30, 2004, the U.S. assets, liabilities and operations of Brown & Williamson Tobacco Corporation, now known as Brown & Williamson Holdings, Inc., referred to as B&W, an indirect, wholly owned subsidiary of BAT were combined with R. J. Reynolds Tobacco Company, a wholly owned operating subsidiary of R.J. Reynolds Tobacco Holdings, Inc., a wholly owned subsidiary of RAI, referred to as RJR. These transactions on July 30, 2004, generally are referred to as the B&W business combination. As a result of the B&W business combination and BAT Share Purchase, as defined below, BAT, through wholly owned subsidiaries, beneficially owns approximately 42% of RAI’s outstanding common stock.
References to RJR Tobacco prior to July 30, 2004, relate to R. J. Reynolds Tobacco Company, a New Jersey corporation. References to RJR Tobacco on and subsequent to July 30, 2004 and until June 12, 2015, relate to the combined U.S. assets, liabilities and operations of B&W and R. J. Reynolds Tobacco Company. Concurrent with the completion of the B&W business combination, RJR Tobacco became a North Carolina corporation. References to RJR Tobacco on and subsequent to June 12, 2015, relate to R. J. Reynolds Tobacco Company, a North Carolina corporation, and reflect the effects of the Lorillard Merger and Divestiture, described below.
Proposed Merger with BAT
On January 16, 2017, RAI, BAT, a subsidiary of BAT, and Merger Sub entered into an Agreement and Plan of Merger, referred to as the Merger Agreement, pursuant to which, subject to the satisfaction or waiver of certain conditions, Merger Sub will merge with and into RAI, referred to as the BAT Merger, with RAI surviving as a wholly owned subsidiary of BAT.
The BAT Merger has been approved by the independent directors of RAI who formed a committee to negotiate with BAT, referred to as the Transaction Committee, given BAT’s existing ownership stake in RAI and representation on RAI’s Board, and by the Boards of Directors of both companies.
At the effective time of the BAT Merger, each share of RAI common stock (other than any shares of RAI common stock owned by BAT or any of its subsidiaries and by shareholders of RAI who have properly asserted and not lost or effectively withdrawn appraisal rights) will be converted into the right to receive 0.5260 of a BAT American Depositary Share, referred to as a BAT ADS, and $29.44 in cash, without interest, and subject to adjustment to prevent dilution.
The BAT Merger is subject to customary closing conditions, including RAI and BAT shareholder approvals, including the approval of the BAT Merger by a majority of the shares of RAI common stock not owned, directly or indirectly, by BAT or its subsidiaries or any of RAI’s subsidiaries, and regulatory approvals. The Merger Agreement contains certain other termination rights for each of RAI and BAT, including the right of each party to terminate the Merger Agreement if the BAT Merger has not been completed on or before December 31, 2017, subject to an extension of five business days if, on December 31, 2017, BAT has not
2
completed all or any portion of the financing it needs to fund the BAT Merger and the transactions contemplated by the Merger Agreement. Financing, however, is not a condition to the closing of the BAT Merger. Under certain circumstances, if the Merger Agreement is terminated, the terminating party must pay the non-terminating party a termination fee of $1 billion. In the event that the Merger Agreement is terminated due to an inability to obtain unconditional approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, referred to as the HSR Act, or any other antitrust laws, RAI will be entitled to receive a termination fee of $500 million from BAT. The BAT Merger is currently expected to close in the third quarter of 2017.
Each of RAI and BAT has made representations and warranties in the Merger Agreement. RAI and BAT each also have agreed to various covenants and agreements, including, among other things, to conduct their respective businesses in the ordinary course in all material respects during the period between the execution of the Merger Agreement and completion of the BAT Merger and not to engage in certain transactions during this period.
The foregoing description of the BAT Merger and the Merger Agreement is qualified in its entirety by reference to the Merger Agreement, a copy of which is attached as Exhibit 2.1 to RAI’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission, referred to as the SEC, on January 17, 2017, which is incorporated by reference herein.
There are a number of risks and uncertainties associated with the BAT Merger. For more information, see Item 1A. Risk Factors and “— Cautionary Information Regarding Forward-Looking Statements” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7. In connection with the BAT Merger, BAT will file with the SEC a registration statement on Form F-4 that will include the proxy statement of RAI that also constitutes a prospectus of BAT. Shareholders are urged to read the proxy statement/prospectus on Form F-4 once it becomes available because it will contain important information about the BAT Merger, including relevant risk factors.
Lorillard Transactions
On June 12, 2015, RAI acquired Lorillard, Inc., n/k/a Lorillard, LLC, referred to as Lorillard, in a cash and stock transaction, valued at $25.8 billion, referred to as the Lorillard Merger. Also on June 12, 2015, a wholly owned subsidiary, n/k/a ITG Brands, LLC, referred to as ITG, of Imperial Brands, PLC, f/k/a Imperial Tobacco Group, PLC, referred to as Imperial, acquired for approximately $7.1 billion, in a transaction referred to as the Divestiture, certain assets (1) owned by RAI subsidiaries or affiliates relating to the cigarette brands WINSTON, KOOL and SALEM, and (2) owned by Lorillard subsidiaries or affiliates related to the cigarette brand MAVERICK and the “e-vapor” brand blu (including SKYCIG), as well as Lorillard’s owned and leased real property, and certain transferred employees, together with associated liabilities. As a result of the Divestiture, RAI recognized a pre-tax gain of approximately $3.2 billion. Additionally, on June 12, 2015, shortly after the completion of the Lorillard Merger, Lorillard Tobacco Company, LLC, a wholly owned subsidiary of Lorillard, referred to as Lorillard Tobacco, merged with and into RJR Tobacco, with RJR Tobacco continuing as the surviving entity, referred to as the Lorillard Tobacco Merger.
On June 12, 2015, concurrently with the completion of the Lorillard Merger and Divestiture, BAT indirectly (through a wholly owned subsidiary) purchased 77,680,259 shares of RAI common stock, prior to giving effect to RAI’s 2015 two-for-one stock split, referred to as the BAT Share Purchase, for approximately $4.7 billion, which was sufficient for BAT and its subsidiaries collectively to maintain their approximately 42% beneficial ownership in RAI. For additional information on the Lorillard Merger and Divestiture, and related transactions, see Item 8, notes 2 and 13 to consolidated financial statements.
Sale of International Rights to the NATURAL AMERICAN SPIRIT Brand
On January 13, 2016, RAI, through various subsidiaries, referred to as the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with SFRTI and other international companies that distributed and marketed the brand outside the United States, to JT International Holding BV, referred to as JTI Holding, a subsidiary of Japan Tobacco Inc., referred to as JTI, in an all-cash transaction of approximately $5 billion, and recognized a pre-tax gain of approximately $4.9 billion. The transaction did not include the rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks in the U.S. market, U.S. duty-free locations, and U.S. territories or in U.S. military outlets, all of which have been retained by SFNTC. With this transaction completed, the international rights to nearly all of RAI’s operating companies’ cigarette trademarks are now owned by international tobacco companies. For additional information on the transaction, see Item 8, notes 3 and 13 to consolidated financial statements.
Operating Segments
RAI’s reportable operating segments are RJR Tobacco, Santa Fe and American Snuff. The RJR Tobacco segment consists of the primary operations of R. J. Reynolds Tobacco Company. The Santa Fe segment consists of the primary operations of SFNTC. The American Snuff segment consists of the primary operations of American Snuff Co. Included in All Other, among other RAI
3
subsidiaries, are RJR Vapor, Niconovum USA, Inc., Niconovum AB, and until their sale on January 13, 2016, as described above , SFRTI and various foreign subsidiaries affiliated with SFRTI. The segments were identified based on how RAI’s chief operating decision maker allocates resources and assesses performance. Certain of RAI’s operating subsidiaries have entered into intercompany agreements for products or services with other subsidiaries. As a result, certain activities of an operating subsidiary may be included in a different segment of RAI. For net sales and operating income attributable to each segment, see — “Overview and Business Initiatives” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and Item 8, note 1 7 to consolidated financial statements.
RAI’s website address is www.reynoldsamerican.com . RAI’s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, insider trading reports on Forms 3, 4 and 5 and all amendments to those reports are available through RAI’s website, as soon as reasonably practicable after such material is electronically filed with, or furnished to the SEC. RAI’s website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form 10-K. RAI’s website is the primary source of publicly disclosed news about RAI and its operating companies.
All dollar amounts, other than per share amounts, are presented in millions, except as otherwise noted.
RAI Strategy
RAI’s strategy continues to focus on transforming tobacco to deliver sustainable earnings growth, strong cash flow and enhanced long-term shareholder value. This transformation strategy includes growing the core cigarette and moist-snuff businesses, focusing on innovation and engaging with adult tobacco consumers, while maintaining efficient and effective operations.
To achieve its strategy, RAI encourages the migration of adult smokers to smoke-free tobacco products and other non-combustible nicotine-containing products, which it believes aligns consumer preferences for new alternatives to traditional tobacco products in view of societal pressure to reduce smoking. RAI’s operating companies facilitate this migration through innovation, including the development of digital vapor cigarettes, CAMEL Snus, heat-not-burn cigarettes, and nicotine replacement therapy technologies. RAI remains committed to maintaining high standards of corporate governance and business conduct in a high-performing culture.
RJR Tobacco
Overview
RAI’s largest reportable operating segment, RJR Tobacco, is the second largest tobacco company in the United States. RJR Tobacco’s brands include three of the top four best-selling cigarettes in the United States: NEWPORT, CAMEL and PALL MALL. These brands, and its other brands, including DORAL, MISTY and CAPRI, are manufactured in a variety of styles and marketed in the United States. As part of its total tobacco strategy, RJR Tobacco offers a smoke-free tobacco product, CAMEL Snus. RJR Tobacco manages contract manufacturing of cigarettes and tobacco products through arrangements with BAT affiliates, and manages the export of tobacco products to U.S. territories, U.S. duty-free shops and U.S. overseas military bases. RJR Tobacco also manages the super-premium cigarette brands, DUNHILL and STATE EXPRESS 555, which are licensed from BAT.
RJR Tobacco primarily conducts business in the highly competitive U.S. cigarette market. The international rights to substantially all of RJR Tobacco’s brands were sold in 1999 to JTI, and no international rights were acquired in connection with the B&W business combination in 2004 or the Lorillard Merger in 2015. The U.S. cigarette market, which has a few large manufacturers and many smaller participants, is a mature market in which overall adult consumer demand has declined since 1981, and is expected to continue to decline. Management Science Associates, Inc., referred to as MSAi, reported that U.S. cigarette shipments declined 2.4% in 2016, to 258.0 billion cigarettes, 0.1% in 2015 and 3.2% in 2014. From year to year, shipments are impacted by various factors including price increases, excise tax increases and wholesale inventory adjustments.
Profitability of the U.S. cigarette industry and RJR Tobacco continues to be adversely impacted by decreases in consumption, increases in state excise taxes and governmental regulations and restrictions, such as marketing limitations and product standards.
Competition
RJR Tobacco’s primary competitors are Philip Morris USA Inc. and ITG, as well as manufacturers of deep-discount brands. Deep-discount brands are brands manufactured by companies that are not original or subsequent participants in the Master Settlement Agreement, referred to as the MSA, and other state settlement agreements with the States of Mississippi, Florida, Texas and Minnesota, which together with the MSA are collectively referred to as the State Settlement Agreements. Accordingly, these manufacturers do not have cost structures burdened with payments related to State Settlement Agreements to the same extent as the
4
original or subsequent participating manufacturers. For further discussion of the State Settlement Agreements, see “— Litigation Affecting the Cigarette Industry — Health-Care Cost Recovery Cases — State Settlement Agreements” in Item 8, note 1 3 to consolidated financial statements.
Based on data collected by SymphonyIRI Group, Inc. and Capstone Research Inc., collectively referred to as IRI/Capstone, and processed and managed by MSAi, during each of 2016 and 2015, RJR Tobacco had an overall retail share of the U.S. cigarette market of 32.3%, reflecting the impact of the Lorillard Merger and Divestiture. During each of these same years, Philip Morris USA Inc. had an overall retail share of the U.S. cigarette market of 49.9%. RJR Tobacco believes that deep-discount brands made by small manufacturers had combined shipments of approximately 7% of total U.S. industry shipments during each of 2016 and 2015.
Domestic industry shipment volume and retail share of market data that appear in this document have been obtained from MSAi and IRI/Capstone, respectively. These organizations are the primary sources of volume and market share data relating to the tobacco industry. This information is included in this document because it is used primarily as an indicator of the relative performance of industry participants, brands and market trends. All share results that appear, except as noted otherwise, in this document are based on U.S. cigarette (or smokeless tobacco products, as applicable) shipments to retail outlets, referred to as STR data, based on information submitted by wholesale locations and processed and managed by MSAi. However, you should not rely on the STR data reported by MSAi as being a precise measurement of actual market share as the shipments to retail outlets do not reflect actual consumer sales and do not track all volume and trade channels. Accordingly, the STR data of the U.S. tobacco industry as reported by MSAi may overstate or understate actual market share. Moreover, you should be aware that in a product market experiencing overall declining consumption, a particular product can experience increasing market share relative to competing products, yet still be subject to declining consumption volumes.
Competition is based primarily on brand positioning, including price, product attributes and packaging, consumer loyalty, promotions, advertising and retail presence, as well as finding efficient and effective means of balancing market share and profit growth. Cigarette brands produced by the major manufacturers generally require competitive pricing, substantial marketing support, retail programs and other incentives to maintain or improve market position or to introduce a new brand or brand style. Competition among the major cigarette manufacturers continues to be highly competitive and includes product innovation and expansion into smoke-free tobacco categories.
Marketing
RJR Tobacco is committed to building and maintaining a portfolio of profitable brands. RJR Tobacco’s marketing programs are designed to strengthen brand image, build brand awareness and loyalty, and switch adult smokers of competing brands to RJR Tobacco brands. In addition to building strong brand equity, RJR Tobacco’s marketing approach utilizes a retail pricing strategy, including discounting at retail, to defend certain brands’ shares of market against competitive pricing pressure. RJR Tobacco’s competitive pricing methods may include list price changes, discounting programs, such as retail and wholesale buydowns, periodic price reductions, off-invoice price reductions, dollar-off promotions and consumer coupons. Retail buydowns refer to payments made to the retailer to reduce the price that consumers pay at retail. Consumer coupons are distributed by a variety of methods.
RJR Tobacco provides trade incentives through trade terms, wholesale partner programs and retail incentives. Trade discounts are provided to wholesalers based on compliance with certain terms. The wholesale partner programs provide incentives to RJR Tobacco’s direct buying customers based on performance levels. Retail incentives are paid to the retailer based on compliance with RJR Tobacco’s contract terms.
RJR Tobacco’s cigarette brand portfolio strategy is based upon two brand categories: drive and other. The drive brands consist of two premium brands, NEWPORT and CAMEL, and the largest traditional value brand, PALL MALL. These three drive brands are managed for long-term market share and profit growth, and receive the vast majority of RJR Tobacco’s equity support with an emphasis on the NEWPORT and CAMEL brands. The other brand category includes the premium brand, CAPRI, and the value brands, DORAL and MISTY, along with other smaller brands. All of the other brands receive limited marketing support and are managed to maximize profitability.
The key objectives of the portfolio strategy are designed to balance the long-term market share growth and profitability of the drive brands while managing the other brands for long-term sustainability and profitability. Consistent with that strategy, RJR Tobacco continues to evaluate some of its non-core cigarette styles for potential elimination.
RJR Tobacco’s portfolio also includes CAMEL Snus, a smoke-free, heat-treated tobacco product sold in individual pouches that provide convenient tobacco consumption.
5
Anti-tobacco groups continue to attempt to restrict cigarette sales, cigarette advertising, and the testing and introduction of new tobacco products as well as encourage smoking bans. The MSA and federal, state and local laws and regulations, including the Family Smoking Prevention and Tobacco Control Act, referred to as the FDA Tobacco Act, discussed below, and related regulations, restrict or prohibit utilization of television, radio or billboard advertising or certain other marketing and promotional tools for cigarettes and smoke-free tobacco products. RJR Tobacco continues to use direct mailings, websites and other means to market its brands and enhance their appeal among age-verified adults who use tobacco products. RJR Tobacco continues to advertise and promote at retail locations and in adult venues and also uses print advertising in newspapers and consumer magazines in the United States, where permitted.
Manufacturing and Distribution
RJR Tobacco owns its manufacturing facilities, located in the Winston-Salem, North Carolina area. RJR Tobacco has a total production capacity of approximately 115 billion cigarettes per year. RJR Tobacco distributes its cigarettes primarily through a combination of direct wholesale deliveries from two local distribution centers and public warehouses located throughout the United States.
RJR Tobacco has entered into various transactions with affiliates of BAT. RJR Tobacco sells contract-manufactured cigarettes, tobacco leaf and processed tobacco to BAT affiliates. In January 2016, RJR Tobacco received written notice from a BAT affiliate terminating the cigarette contract manufacturing agreement effective January 5, 2019. In July 2016, RJR Tobacco amended the contract manufacturing agreement with a BAT affiliate to permit an early transition of the cigarette production, covered by the agreement, to BAT facilities, which began in the fourth quarter of 2016. Net sales, primarily of cigarettes, to BAT affiliates represented approximately 2% of RAI’s total net sales in each of 2016 and 2015 and 4% in 2014. For additional information, see Item 8, notes 18 and 22 to consolidated financial statements.
Raw Materials
In its production of tobacco products, RJR Tobacco uses U.S. and foreign, grown primarily in Brazil, burley and flue-cured leaf tobaccos, as well as Oriental tobaccos grown primarily in Turkey, Macedonia and Bulgaria. RJR Tobacco believes there is a sufficient supply of leaf in the worldwide tobacco market to satisfy its current and anticipated production requirements.
RJR Tobacco purchases the majority of its U.S. flue-cured and burley leaf directly through contracts with tobacco growers. These short-term contracts are frequently renegotiated. RJR Tobacco believes the relationship with its leaf suppliers is good.
RJR Tobacco also uses other raw materials such as filter tow, filter rods and fire standards compliant paper, which are sourced from either one supplier or a few suppliers. RJR Tobacco believes it has reasonable measures in place designed to mitigate the risk posed by the limited number of suppliers of certain raw materials.
Santa Fe
Overview
RAI’s reportable operating segment, Santa Fe, manufactures and markets super-premium cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand in the U.S.
Competition
Santa Fe competes in the U.S. cigarette market with its Natural American Spirit brand, which is the fastest growing super-premium cigarette brand and is a top 10 best-selling cigarette brand. It is priced higher than most other competitive brands. Competition in the cigarette category is based primarily on brand positioning, including price, product attributes and packaging, consumer loyalty, promotions, advertising and retail presence. Based upon data collected by IRI/Capstone and processed and managed by MSAi, during 2016 and 2015, Santa Fe had an overall retail share of the U.S. cigarette market of 2.2% and 1.9%, respectively.
Marketing
Santa Fe has a commitment to its natural tobacco products, the environment and its consumers and uses its marketing programs to promote this commitment. SFNTC is a subsequent participating manufacturer in the MSA. The MSA and federal, state and local laws and regulations, including the FDA Tobacco Act and related regulations, restrict or prohibit utilization of television, radio or billboard advertising or certain other marketing and promotional tools for cigarettes and other tobacco products. Santa Fe continues to use direct mailings, websites and other means to market its brand and enhance its appeal among age-verified adults who use tobacco
6
products. Santa Fe continues to advertise and promote at retail locations and in adult venues, and uses print advertising in consumer magazines and other publications in the United States, where permitted.
Manufacturing and Distribution
SFNTC owns its manufacturing facility, which is located in Oxford, North Carolina. Santa Fe distributes its products primarily through a combination of direct wholesale deliveries from a distribution center in North Carolina and public warehouses located throughout the United States.
Raw Materials
Santa Fe’s support for sustainable agriculture and natural resources is part of its commitment to the environment. Santa Fe contracts directly with independent farmers and advocates earth-friendly practices through its two growing programs, Purity Residue Clean, which utilizes environmentally friendly cultivation practices, and Certified Organic, which follows the guidelines of the United States Department of Agriculture’s National Organic Program. In the production of its tobacco products, Santa Fe purchases electricity generated from renewable sources, including wind power, and operates a zero waste-to-landfill manufacturing facility.
American Snuff
Overview
RAI’s reportable operating segment, American Snuff, is the second largest smokeless tobacco products manufacturer in the United States, and offers adult tobacco consumers a range of differentiated smokeless tobacco products, primarily moist snuff. The moist snuff category is divided into premium, price-value and popular-price brands. American Snuff’s primary brands include its largest selling moist snuff brands, GRIZZLY, in the price-value category, and KODIAK, in the premium category.
In contrast to the declining U.S. cigarette market, U.S. moist snuff retail volumes grew approximately 3.6%, 2.0% and 2.3% in 2016, 2015 and 2014, respectively. Moist snuff’s growth is partially attributable to cigarette smokers switching from cigarettes to smokeless tobacco products or using both.
Moist snuff has been the key driver to American Snuff’s overall growth and profitability within the U.S. smokeless tobacco market and accounted for approximately 91%, 90% and 89% of its revenue in 2016, 2015 and 2014, respectively. Profit margins on moist snuff products are generally higher than on cigarette products.
Competition
American Snuff is dependent on the U.S. smokeless tobacco products market and competes in that market with other domestic and international companies. The highly competitive moist snuff category has developed many of the characteristics of the larger cigarette market, including multiple pricing tiers, focused marketing programs and significant product innovation. Similar to the cigarette market, competition is based primarily on brand positioning and price, as well as product attributes and packaging, consumer loyalty, promotions, advertising and retail presence.
American Snuff’s retail share of the U.S. moist snuff market, according to data collected by IRI/Capstone and processed and managed by MSAi, was 33.4% and 33.7% in 2016 and 2015, respectively. GRIZZLY moist snuff had a market share of 30.8% and 30.9% in 2016 and 2015, respectively. American Snuff’s largest competitor is U.S. Smokeless Tobacco Company LLC, referred to as USSTC, which had approximately 54.7% and 54.0% of the U.S. moist snuff market share in 2016 and 2015, respectively.
Marketing
American Snuff is committed to building and maintaining a portfolio of profitable brands. American Snuff’s marketing programs are designed to enhance brand image, build brand awareness and loyalty, and switch adult smokeless tobacco consumers of competing brands to American Snuff brands. Federal, state and local laws and regulations, including the FDA Tobacco Act and related regulations, restrict or prohibit utilization of television, radio or billboard advertising or certain other marketing and promotional tools for smoke-free tobacco products.
American Snuff’s brand portfolio strategy consists of the drive brand GRIZZLY, a leading moist snuff brand in the United States, and non-support brands that consist of all other brands. American Snuff is focusing on growing market share and profitability of its GRIZZLY branded products through equity-building initiatives and promotions. American Snuff also offers GRIZZLY pouches, which provide pre-measured portions that are more convenient than traditional, loose moist snuff. Pouches are the fastest growing
7
segment in the moist snuff category and represented approximately 20 % of the total U.S. moist snuff market as of December 31, 201 6 . During 201 6 , demand for pouches continued to grow at more than triple the overall category rate.
Manufacturing and Distribution
American Snuff Co. owns its manufacturing facilities located in Memphis, Tennessee; Clarksville, Tennessee; and Winston-Salem, North Carolina. American Snuff distributes its products primarily through a combination of direct wholesale deliveries from a distribution center in North Carolina and public warehouses located throughout the United States.
Raw Materials
In its production of moist snuff, American Snuff uses U.S. fire-cured and air-cured tobaccos as well as foreign, primarily Brazilian, burley and air-cured leaf tobaccos. American Snuff purchases the majority of its U.S. fire-cured and air-cured leaf directly through contracts with tobacco growers. These short-term contracts are frequently renegotiated. American Snuff believes the relationship with its leaf suppliers is good, and there is a sufficient supply of leaf in the worldwide tobacco market to satisfy its current and anticipated production requirements.
All Other
RJR Vapor is the marketer of VUSE Digital Vapor Cigarette products, which include VUSE Solo, VUSE Fob and VUSE Vibe. The national expansion of VUSE was completed in early 2015, and it is available in more than 110,000 retail outlets across the United States. VUSE is the top-selling vapor product in convenience/gas stores, and its innovative digital technology is designed to deliver a consistent flavor and vapor experience. In March 2016, RJR Vapor introduced its VUSE Fob power unit. This next-level VUSE Fob, which integrates Bluetooth® technology, offers an on-device display with information about battery and cartridge levels. When paired with the VUSE App, the device can be locked, preventing the use of the device by minors and others. VUSE Fob is available online to adult tobacco consumers. RJR Vapor began national distribution, in November 2016, of its VUSE Vibe high-volume cartridge and closed-tank system with a rechargeable battery. VUSE Vibe offers more liquid than previous VUSE products, as well as a stronger and longer-lasting battery.
Since the fourth quarter of 2015, all production of VUSE Solo cartridges is performed at RJR Tobacco’s manufacturing facility, pursuant to a services agreement between RJR Tobacco and RJR Vapor. For additional information, see Item 8, note 6 to consolidated financial statements.
Niconovum USA, Inc. is a marketer of a nicotine replacement therapy gum, ZONNIC, which is available in about 35,000 retail outlets across the United States. Niconovum AB is a marketer of nicotine replacement therapy products in Sweden under the ZONNIC brand name.
On January 13, 2016, RAI, through the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with SFRTI and other international companies that distributed and marketed the brand outside the United States, to JTI Holding. For additional information, see Item 8, note 3 to consolidated financial statements.
Consolidated RAI
Customers
The largest customer of RJR Tobacco, Santa Fe and American Snuff is McLane Company, Inc., referred to as McLane. Sales to McLane, a distributor, constituted approximately 28% of RAI’s consolidated revenue in each of 2016 and 2015 and 31% in 2014. RJR Tobacco, Santa Fe and American Snuff sales to Core-Mark International, Inc., referred to as Core-Mark, a distributor, represented approximately 14%, 10% and 11% of RAI’s consolidated revenue in 2016, 2015 and 2014, respectively. No other customer accounted for 10% or more of RAI’s consolidated revenue during those periods. Sales of RJR Tobacco, Santa Fe and American Snuff to McLane and Core-Mark are not governed by any written supply contract. RJR Tobacco, Santa Fe and American Snuff believe that their relationships with McLane and Core-Mark are good. No significant backlog of orders existed at RJR Tobacco, Santa Fe or American Snuff as of December 31, 2016 or 2015.
Sales to Foreign Countries
RAI’s operating subsidiaries’ sales to foreign countries, including sales to BAT affiliates, for the years ended December 31, 2016, 2015 and 2014 were $351 million, $482 million and $497 million, respectively.
8
In 2004, legislation was passed eliminating the U.S. government’s tobacco production controls and price support program. The buyout of tobacco quota holders provided for in the Fair and Equitable Tobacco Reform Act, referred to as FETRA, was funded by a direct quarterly assessment on every tobacco product manufacturer and importer, on a market-share basis measured on volume to which federal excise tax was applied. The aggregate cost of the buyout to the tobacco industry was approximately $9.9 billion, including approximately $9.6 billion payable to quota tobacco holders and growers through industry assessments over ten years, to 2014, and approximately $290 million for the liquidation of quota tobacco stock. The FETRA assessment expired in September 2014. RAI’s operating subsidiaries’ overall share of the buyout approximated $2.5 billion prior to the deduction of permitted offsets under the MSA. For additional information, see “— Tobacco Buyout Legislation” in Item 8, note 13 to consolidated financial statements.
Research and Development
The research and development activities of RAI’s operating subsidiaries are primarily conducted at RJR Tobacco’s facility in Winston-Salem, North Carolina through various intercompany service agreements. Scientists and engineers continue to explore the development of innovative products, packaging and processes, as well as harm reduction technologies, modified risk tobacco products and analytical methodologies. Another key activity for research and development is to assist RAI’s operating companies in complying with regulations of the U.S. Food and Drug Administration, referred to as the FDA, and to adhere to future FDA regulations and approval processes.
RAI’s operating subsidiaries’ research and development expense for the years ended December 31, 2016, 2015 and 2014, was $101 million, $107 million and $88 million, respectively.
Intellectual Property
RAI’s operating subsidiaries own or have the right to use numerous trademarks, including the brand names of their products and the distinctive elements of their packaging and displays, and numerous patents. RAI’s operating subsidiaries’ material patents and trademarks are registered with the U.S. Patent and Trademark Office, and certain corresponding patents and trademarks are registered in other countries throughout the world. Rights in the U.S. patents will expire in accordance with their individual statutory terms, and rights in the trademarks in the United States will last as long as RAI’s subsidiaries continue to use the trademarks. The operating subsidiaries consider the distinctive blends and recipes used to make each of their brands to be trade secrets. These trade secrets are not patented, but RAI’s operating subsidiaries take appropriate measures to protect the unauthorized disclosure of such information.
In 1999, RJR Tobacco sold most of its trademarks and patents outside the United States in connection with the sale of the international tobacco business to JTI. The sale agreement granted JTI the right to use certain of RJR Tobacco’s trade secrets outside the United States, but details of the ingredients or formulas for flavors and the blends of tobacco may not be provided to any sub-licensees or sub-contractors. The agreement also generally prohibits JTI and its licensees and sub-licensees from the sale or distribution of tobacco products of any description employing the purchased trademarks and other intellectual property rights in the United States. In 2005, the U.S. duty-free and U.S. overseas military businesses relating to certain brands were re-acquired from JTI.
In addition to intellectual property rights it directly owns, RJR Tobacco has certain rights with respect to BAT intellectual property that were available for use by B&W prior to the completion of the B&W business combination.
On June 12, 2015, pursuant to the Divestiture, ITG acquired certain assets (1) owned by RAI subsidiaries or affiliates relating to the cigarette brands WINSTON, KOOL and SALEM, and (2) owned by Lorillard subsidiaries or affiliates related to the cigarette brand MAVERICK and the “e-vapor” brand blu (including SKYCIG).
On January 13, 2016, RAI, through the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with SFRTI and other international companies that distributed and marketed the brand outside the United States to JTI Holding. Pursuant to that transaction, RAI has agreed not to, and agreed to cause its controlled affiliates not to, engage in the business of producing, selling, distributing and developing natural, organic and additive-free combustible tobacco cigarettes and roll-your-own or make-your-own tobacco products outside of the United States, and JTI has agreed not to, and agreed to cause its controlled affiliates not to, engage in the conduct of such business in the United States, in each case, for five years following the closing of the transaction.
For additional information, see Item 8, notes 2, 3 and 5 to consolidated financial statements.
9
Tobacco products are subject to a variety of federal, state and local laws and regulations. Since 1966, federal law has required a warning statement on cigarette packaging. In 2009, the FDA Tobacco Act was adopted, granting the FDA broad authority over the manufacture, sale, marketing and packaging of tobacco products. In 2016, the FDA issued a regulation deeming certain products, including e-cigarettes, to be subject to the FDA Tobacco Act. Many state, local and municipal governments and agencies have adopted laws or regulations prohibiting or restricting the public use of tobacco products. Cigarettes and other tobacco products also are subject to substantial taxation at both the federal and state levels. For more information regarding the nature of the regulation and taxation of tobacco products, see Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Governmental Activity.”
Litigation and Settlements
Litigation, claims and other legal proceedings relating to the use of, exposure to, or purchase of tobacco products are pending or may be instituted in the future against RJR Tobacco (including as successor by merger to Lorillard Tobacco), American Snuff Co., SFNTC, RJR Vapor, RAI, Lorillard, other RAI affiliates, and indemnitees, including but not limited to B&W, sometimes referred to collectively as Reynolds Defendants. Reynolds Defendants have been named in a number of tobacco-related legal actions, proceedings or claims seeking damages in amounts ranging into the hundreds of millions or even billions of dollars. As of December 31, 2016, RJR Tobacco had paid approximately $239 million since January 1, 2014, related to unfavorable smoking and health litigation judgments.
RAI’s management continues to conclude that the loss of any particular pending smoking and health tobacco-related litigation claims against Reynolds Defendants, or the loss of any particular case concerning the use of smokeless tobacco products against American Snuff Co., when viewed on an individual case-by-case basis, is not probable or estimable, except for certain Engle Progeny cases, as described in “— Litigation Affecting the Cigarette Industry — Overview” in Item 8, note 13 to consolidated financial statements. RAI and its subsidiaries believe that they have valid bases for appeal of adverse verdicts in their pending cases and valid defenses to all actions and intend to defend all actions vigorously. Nonetheless, the possibility of material losses related to tobacco-related litigation is more than remote. Litigation is subject to many uncertainties, and generally it is not possible to predict the outcome of the litigation pending against Reynolds Defendants, or to reasonably estimate the amount or range of any possible loss. Moreover, notwithstanding the quality of defenses available to it and its affiliates in tobacco-related litigation matters, it is possible that RAI’s consolidated results of operations, cash flows or financial position could be materially adversely affected by the ultimate outcome of certain pending or future litigation matters or difficulties in obtaining the bonds required to stay execution of judgments on appeal.
In 1998, RJR Tobacco, Lorillard Tobacco, B&W, SFNTC and the other major U.S. cigarette manufacturers entered into the MSA with attorneys general representing most U.S. states, territories and possessions. The State Settlement Agreements, of which the MSA is the most wide-reaching, impose a perpetual stream of future payment obligations on RJR Tobacco and the other major U.S. cigarette manufacturers and place significant restrictions on their ability to market and sell cigarettes in the future. The State Settlement Agreements have materially adversely affected RJR Tobacco’s shipment volumes. RAI believes that these settlement obligations may materially adversely affect the results of operations, cash flows or financial position of RAI and RJR Tobacco in future periods. The degree of the adverse impact will depend, among other things, on the rate of decline in U.S. cigarette sales in the premium and value categories, RJR Tobacco’s share of the domestic premium and value cigarette categories, and the effect of any resulting cost advantage of manufacturers not subject to the State Settlement Agreements.
For disclosure of legal proceedings involving RAI and its operating subsidiaries, see Item 8, note 13 to consolidated financial statements. For a description of RAI’s and its operating subsidiaries’ accounting treatment for tobacco-related litigation contingencies, see Item 8, note 13 “—Tobacco Litigation — General — Accounting for Tobacco-Related Litigation Contingencies.” For additional information related to State Settlement Agreements, see Item 8, note 1 “— Cost of Products Sold”, and note 13 “— Litigation Affecting the Cigarette Industry — State Settlement Agreements — Enforcement and Validity; Adjustments,” to consolidated financial statements.
Employees
At December 31, 2016, RAI and its subsidiaries had approximately 5,500 full-time employees and approximately 50 part-time employees. The 5,500 full-time employees include approximately 3,700 RJR Tobacco employees, 500 Santa Fe employees and 600 American Snuff employees. No employees of RAI or its subsidiaries are unionized.
10
Executive Officers and Certain Significant Employees of the Registrant
The executive officers of RAI are set forth below:
Debra A. Crew. Ms. Crew, 46, became President and Chief Executive Officer of RAI on January 1, 2017, after serving as President and Chief Executive Officer – Elect since October 2016. Ms. Crew also became President of RAI Services Company, a wholly owned subsidiary of RAI, and referred to as RAISC, on January 1, 2017. In addition, she joined the Board of RAI effective January 1, 2017. Ms. Crew served as President and Chief Operating Officer of RJR Tobacco from October 2015 to October 2016. She was previously the President and Chief Commercial Officer of RJR Tobacco from October 2014 to September 2015. Prior to joining RJR Tobacco, Ms. Crew was the President and General Manager of PepsiCo North America Nutrition from August 2014 to September 2014. She served as President of PepsiCo Americas Beverage from September 2012 until August 2014. Ms. Crew was also President of the Western Europe Region of PepsiCo Europe from April 2010 to August 2012. Prior to joining PepsiCo, Inc. in 2010, Ms. Crew held various positions with Mars, Incorporated, Nestle S.A. and Kraft Foods, Inc. Ms. Crew served in the U.S. Army from 1993 to 1997, rising to the rank of captain and military intelligence officer. She serves on the board of directors of Stanley Black & Decker, Inc.
Michael P. Auger. Mr. Auger, 49, became President of RAI Trade Marketing Services Company on November 14, 2016. He was Executive Vice President — Trade Marketing of RJR Tobacco from January 1, 2015 to December 31, 2016. Mr. Auger served as Vice President — Trade Marketing Development of RJR Tobacco from May 2011 to December 2014. Prior to 2011, Mr. Auger held numerous managerial positions with RJR Tobacco, including Area Vice President from May 2006 to April 2011. Prior to this, Mr. Auger held various additional positions with both RJR Tobacco and B&W. Mr. Auger currently serves on the Eckerd College Alumni Leadership Council and serves on the board of directors for Big Brothers Big Sisters Services, Inc. in Winston-Salem.
Lisa J. Caldwell. Ms. Caldwell, 56, has been Executive Vice President and Chief Human Resources Officer of RAI since May 2009, RAISC since January 2010 and RJR Tobacco since October 2014. Ms. Caldwell has served on the board of directors of RAISC since January 2010. She was previously Executive Vice President and Chief Human Resources Officer for RJR Tobacco from May 2009 to January 2010. Ms. Caldwell served as Executive Vice President — Human Resources of RAI and RJR Tobacco from June 2008 to May 2009. She served as Senior Vice President — Human Resources of RAI from November 2006 to June 2008, after having served as Vice President — Human Resources of RAI from September 2004 to November 2006. She also served as Senior Vice President — Human Resources of RJR Tobacco from July 2007 to June 2008, after having served as Vice President — Human Resources of RJR Tobacco from January 2002 to November 2006. Prior to 2002, Ms. Caldwell held numerous human resources positions with RJR Tobacco since joining RJR Tobacco in 1991. Ms. Caldwell serves on the Wake Forest University School of Business board of visitors and the board of directors for the Industries for the Blind Solutions (IFB Solutions).
Susan M. Cameron. Ms. Cameron, 58, resigned as the President and Chief Executive Officer of RAI on October 19, 2016, effective as of the close of business on December 31, 2016, and was elected by RAI’s Board of Directors to serve as Executive Chairman of the Board, effective January 1, 2017. Ms. Cameron had served as President and Chief Executive Officer of RAI since May 2014. Ms. Cameron also served as President of RAISC, from May 2014 to December 31, 2016, after previously serving as the President and Chief Executive Officer of RAI from 2004 through her retirement in February 2011. She also served as the Chairman of the Board of RAI from 2006 to October 2010. In addition, Ms. Cameron served as Chairman of the Board of RJR Tobacco from July 2004 to May 2008. From July 2004 to December 2006, she also served as Chief Executive Officer of RJR Tobacco. She served as President and Chief Executive Officer of B&W from 2001 to 2004, and also served as a director of B&W from 2000 to 2004, and Chairman of the Board from January 2003 to 2004. Prior to 2001, Ms. Cameron held various marketing positions with B&W and BAT after joining B&W in 1981. Ms. Cameron served on the Board of RAI from January 2004 through her retirement in February 2011 and then recommenced serving on the Board in December 2013. She also is a member of the boards of directors of R. R. Donnelley & Sons Company and Tupperware Brands Corporation. In addition, Ms. Cameron is a member of the board of visitors of the Wake Forest University School of Business.
Daniel A. Fawley. Mr. Fawley, 59, has served as Senior Vice President and Treasurer of RAI, RJR Tobacco and RJR since September 2004, and Senior Vice President and Treasurer of RAISC since January 2010. Since joining RJR in 1999, he was Vice President and Assistant Treasurer of RJR until August 2004. Mr. Fawley is a member of the boards of directors of the Reynolds American Foundation, Santa Fe Natural Tobacco Company Foundation, Novant Health Clemmons Medical Center Foundation, the Arts Council Endowment Fund, Inc. and the Finance Advisory Board for the Finance Academy. Mr. Fawley also serves on the Abbott Capital Private Equity Advisory Board.
McDara P. Folan, III. Mr. Folan, 58, has been Senior Vice President, Deputy General Counsel and Secretary of RAI since July 2004, and Senior Vice President, Deputy General Counsel and Secretary of RAISC since January 2010. He also serves as Assistant Secretary of RJR Tobacco. Prior to 2004, Mr. Folan served in various positions with RJR and RJR Tobacco since joining RJR in 1999.
11
Mr. Folan serves on the board of trustees for Salem College and Academy and the board s of directors of the Dow ntown Winston-Salem Foundation, the Arts Council Endowment Fund, Inc. and the UNC School of the Arts Foundation, Inc.
Joseph P. Fragnito. Mr. Fragnito, 44, became President and Chief Commercial Officer of RJR Tobacco on October 24, 2016. Mr. Fragnito served as the President of the U.S. Beverages and Snack Nuts business unit of The Kraft Heinz Company from June 2015 to August 2016. He was Vice President of Marketing for a number of key brands for Kraft Foods Group, Inc., referred to as Kraft Foods Group, from July 2013 to June 2015, at which time Kraft Foods Group merged with H.J. Heinz Company. Mr. Fragnito was Senior Director of Marketing for Kraft Foods Group from January 2011 to June 2013. Prior to 2011, he served in various other marketing and innovations roles with Kraft Foods Group after joining Kraft in 2000.
Andrew D. Gilchrist. Mr. Gilchrist, 44, has been Executive Vice President and Chief Financial Officer of RAI, and Executive Vice President, Chief Financial Officer and Chief Information Officer of RAISC since March 1, 2015. Mr. Gilchrist was the Executive Vice President of RAI from October 2014 to March 2015. He previously served as President and Chief Commercial Officer of RJR Tobacco from January 1, 2011 to September 30, 2014. He previously served as Executive Vice President and Chief Financial Officer of RJR Tobacco and Executive Vice President and Chief Information Officer of RAISC from January 2010 to December 2010. He previously served as Executive Vice President, Chief Financial Officer and Chief Information Officer of RJR Tobacco from July 2008 until January 2010. Mr. Gilchrist has served on the board of directors of RAISC since March 2015 and served on the board of directors of RJR Tobacco from May 2008 to March 2015. He also served as Senior Vice President and Chief Financial Officer of RJR Tobacco from November 2006 to July 2008, after having served as Vice President — Integrated Business Management of RJR Tobacco from January 2006 to November 2006. Prior to 2006, Mr. Gilchrist served as Senior Director — Business Development since joining RAI in 2004. Prior to July 2004, Mr. Gilchrist held various positions with B&W and its parent company, BAT. Mr. Gilchrist serves on the board of directors for the Winston-Salem Alliance.
Nancy H. Hawley. Ms. Hawley, 54, has been Executive Vice President of Operations at RJR Tobacco since October 2015. Ms. Hawley previously served as Senior Vice President of Operations for RJR Tobacco from July 2014 to October 2015. Prior to that, Ms. Hawley was Vice President of Manufacturing for RJR Tobacco from October 2008 through June 2014. Ms. Hawley joined RJR Tobacco in 1984 as a staff engineer and held a number of operations positions. Ms. Hawley currently serves on the boards of directors for the Foundation of Forsyth Technical College and the Reynolds American Foundation. In addition, Ms. Hawley currently serves as a member of the United Way Basic Needs Impact Committee and serves as a member of the Wake Forest School of Business Alumni Development Council.
Daniel J. Herko. Mr. Herko, 56, has been Executive Vice President – Scientific and Regulatory Affairs of RAISC since January 1, 2016, and Executive Vice President – Research and Development of RJR Tobacco since October 2015. Mr. Herko served as Executive Vice President of RAISC from October 2015 until December 2015. Mr. Herko previously served as Senior Vice President – Research and Development of RJR Tobacco from March 2008 to September 2015, after serving as Vice President – Product Development from November 2007 to March 2008. Mr. Herko joined RJR Tobacco in 1980 in the manufacturing division and held a variety of production positions in manufacturing before joining JTI, following the sale of the international tobacco business to JTI in 1999. In 2002, Mr. Herko returned to RJR Tobacco as Director of Product Development until becoming Senior Director of Product Development in 2005. He serves on the board of directors of the Riverwood Therapeutic Riding Center.
Martin L. Holton III. Mr. Holton, 59, has been Executive Vice President, General Counsel and Assistant Secretary of RAI and RAISC and Executive Vice President and General Counsel of RJR Tobacco since January 2011. Mr. Holton previously served as Senior Vice President and Deputy General Counsel of RAISC from January 2010 through December 2010 and Senior Vice President, General Counsel and Secretary of RJR Tobacco from November 2006 through December 2010. In addition, Mr. Holton has served on the board of directors of RAISC since January 2011. Previously, Mr. Holton served as Senior Vice President, Deputy General Counsel and Secretary of RJR Tobacco from February 2005 to November 2006 and Vice President and Assistant General Counsel — Litigation from July 2004 to February 2005. Mr. Holton serves on the board of managers for YMCA Camp Hanes and the boards of directors for the Winston-Salem Symphony and the United Way Forsyth County.
Cressida Lozano. Ms. Lozano, 43, has served as Executive Vice President — Consumer Marketing of RJR Tobacco since March 2016, after having served as Senior Vice President — Cigarettes of RJR Tobacco from March 2015 to March 2016. Ms. Lozano served as Vice President – Trade and Consumer Marketing of SFNTC from January 2012 to February 2015, and also was on the Board of SFNTC from December 2011 to February 2015. She also served as Vice President – Brand Stewardship for RJR Tobacco during January 2010, after previously serving as Vice President – Brand Stewardship for Reynolds Innovations Inc. from January 2009 to December 2009. Ms. Lozano was Vice President – Camel Business Unit of RJR Tobacco from January 2006 to January 2009, after serving as Vice President – Marketing for SFNTC from July 2003 to January 2006. Ms. Lozano is also the Chairman and President of the Santa Fe Natural Tobacco Company Foundation.
12
J. Brice O’Brien. Mr. O’Brien, 4 8 , has served as Executive Vice President — Public Affairs and Chief Communications Officer for RAI, RJR Tobacco, RAISC, RAI Innovations Inc. and RJR Vapor since March 2016. Previously, Mr. O’Brien served as Executive Vice President — Consumer Marketing of RJR Tobacco from January 2010 to February 2016, after having served as President of Reynolds Innovations Inc. since January 2009 to December 2009 . Mr. O’Brien served as Senior Vice President — Consumer Marketing of RJR Tobacco from January 2006 until January 2009, after serving as Vice President — Marketing from October 2004 through December 2005 . Prior to 2004, Mr. O’Brien held various positions with RJR Tobacco after joining RJR Tobacco in 1995.
Frederick W. Smothers. Mr. Smothers, 53, has served as Senior Vice President and Chief Accounting Officer of RAI since January 2008 and RAISC since January 2010. Mr. Smothers served as Vice President and Corporate Controller of RAI from October 2007 to December 2007. Prior to joining RAI, Mr. Smothers was an independent management consultant from 2002 until 2007, serving as Chief Executive Officer of ATRS Consulting from 2005 until October 2007, providing general management consulting to consumer products and manufacturing clients, including RAI. Prior to 2002, Mr. Smothers was employed by the accounting firm of Deloitte & Touche LLP, including four years as partner.
Other significant employees of the Registrant include the chief executive officers of SFNTC and American Snuff Co., as listed below:
Michael A. Little. Mr. Little, 57, has served as President of SFNTC since December 2011. Previously, he served as Senior Vice President — Manufacturing of SFNTC from January 2002 until November 2011. Prior to 2002, Mr. Little held various positions with SFNTC after joining SFNTC in 1995.
Randall M. (Mick) Spach. Mr. Spach, 58, has been President of American Snuff Co. since January 2011. Previously he served as Vice President — Operations of American Snuff Co. from February 2009 until December 2010. Mr. Spach served as Vice President — Manufacturing/R&D of American Snuff Co. from August 2007 to February 2009. He served as Assistant Vice President — Manufacturing at American Snuff Co. from 2001 to August 2007. Between 1977 and 2001, Mr. Spach held various positions with American Snuff Co.
RAI and its subsidiaries operate with certain known risks and uncertainties that could have a material adverse effect on their results of operations, cash flows and financial position. The risks below are not the only ones that could impact RAI and its subsidiaries. Additional risks not currently known or currently considered immaterial also could affect RAI’s business. You should carefully consider the following risk factors in connection with other information included in this Annual Report on Form 10-K and in other documents filed with the SEC.
Adverse litigation outcomes could have an adverse effect on the results of operations, cash flows and financial position of RAI. Additionally, RAI’s operating subsidiaries could be subject to substantial liabilities and bonding difficulties from litigation related to cigarette products or other products, which could also have an adverse effect on their results of operations, cash flows and financial position.
Reynolds Defendants have been named in a number of tobacco-related legal actions, proceedings or claims. The claimants seek recovery on a variety of legal theories, including negligence, strict liability in tort, design defect, failure to warn, fraud, misrepresentation, deceptive and unfair trade practices, conspiracy, medical monitoring, and violations of state and federal antitrust and racketeering laws. Various forms of relief are sought, including compensatory damages, attorneys’ fees, and, where available, punitive damages in amounts ranging in some cases into the hundreds of millions or even billions of dollars.
The tobacco-related legal actions range from individual lawsuits to class-actions and other aggregate claim lawsuits. In Engle v. R. J. Reynolds Tobacco Co ., the Florida Supreme Court issued a ruling that, while determining that the case could not proceed further as a class action, permitted members of the Engle class to file individual claims, including claims for punitive damages, through January 11, 2008. The decision preserved several of the Engle jury findings for use in adjudicating these subsequent individual actions, which are now known as Engle Progeny cases. As of December 31, 2016, RJR Tobacco had been served in 2,822 pending Engle Progeny cases filed on behalf of approximately 3,645 individual plaintiffs. Many of these cases are in active discovery or nearing trial. In all Engle Progeny cases tried to date, a central issue has been the proper use of the preserved Engle findings. RJR Tobacco has argued that use of the Engle findings to establish individual elements of claims (such as defect, negligence and concealment) is a violation of federal due process. In 2013, both the Florida Supreme Court and the U.S. Court of Appeals for the Eleventh Circuit rejected that argument.
13
The Engle Progeny cases have resulted in increased litigation and trial activity, including an increased number of adverse verdicts, and increased expenses. Through December 31, 2016, RJR Tobacco or Lorillard Tobacco cumulatively paid $297.9 million in compensatory and punitive damages and $107.7 million for attorneys’ and statutory interest, for a total of $405.6 million, in these cases. In addition, outstanding jury verdicts in favor of the Engle Progeny plaintiffs had been entered against RJR Tobacco or Lorillard Tobacco in the amount of $212.2 million in compensatory damages (as adjusted) and in the amount of $227.3 million in punitive damages, for a total of $439.5 million. All of these verdicts are in various stages in the appellate process and have been bonded as required by Florida law under the $200 million bond cap passed by the Florida legislature in 2009. Bills are pending in the Florida legislature that would repeal the existing $200 million bond cap. Such a repeal, depending upon the amount of any adverse judgment, could increase the amount RJR Tobacco would be required to bond. Although RJR Tobacco cannot currently predict when or how much it may be required to bond and pay, RJR Tobacco will likely be required to bond and pay additional judgments as the litigation proceeds. For a more complete description of this litigation, see “— Litigation Affecting the Cigarette Industry — Engle and Engle Progeny Cases” in Item 8, note 13 to consolidated financial statements.
Class-action suits have been filed in a number of states against individual cigarette manufacturers, including RJR Tobacco, and their parents, including RAI, alleging that the use of the terms “lights” and “ultra-lights” constitutes unfair and deceptive trade practices. In 2008, the U.S. Supreme Court ruled that neither the Federal Cigarette Labeling and Advertising Act nor the Federal Trade Commission’s regulation of “tar” and nicotine disclosures preempts (or bars) such claims. This ruling limits certain defenses available to RJR Tobacco and other cigarette manufacturers and has led to the filing of additional lawsuits. In addition, several class actions have been filed against SFNTC and RAI asserting that use of the terms “natural”, “additive-free” and “organic” in the product labeling and advertising for SFNTC’s NATURAL AMERICAN SPIRIT cigarette brand violates state disclosure, and deceptive and unfair trade practice, statutes. In addition, RJR Tobacco tendered to JTI the defense of the health-care cost reimbursement actions that Canadian provinces filed against RJR Tobacco and one of its affiliates, and RJR Tobacco also requested indemnification. JTI has accepted the defense of these cases, subject to full reservation of rights. In the event RJR Tobacco, SFNTC or their affiliates and indemnitees, or JTI lose one or more of the pending class-action or health-care reimbursement suits, RJR Tobacco, SFNTC or their affiliates and indemnitees could face, depending upon the amount of any damages ordered, difficulties in their ability to pay the judgment or obtain any bond required to stay execution of the judgment. For a more complete description of class-action litigation, see “— Class-Action Suits ” in Item 8, note 13 to consolidated financial statements.
In 1999, the U.S. Department of Justice bought an action against RJR Tobacco, Lorillard Tobacco, B&W, and other tobacco companies pursuant to the civil provisions of the federal Racketeer Influenced and Corrupt Organizations Act, referred to as RICO. The government sought, among other remedies, disgorgement of profits in an amount of approximately $280 billion allegedly earned as a consequence of a RICO racketeering “enterprise” and injunctive relief. In February 2005, an appellate court ruled that disgorgement was not an available remedy. In 2006, the trial court found certain defendants, including RJR Tobacco, liable for the RICO claims (but did not impose any direct financial penalties), enjoined the defendants from committing future racketeering acts, and ordered the defendants to issue “corrective communications” on five subjects, including smoking and health and addiction. The trial court’s “corrective-statements” remedy is subject to continuing proceedings to determine, among other things, whether the “corrective statements” will have to be displayed at retail points-of-sale. Implementation of the “corrective-statements” remedy could cause RJR Tobacco to incur significant compliance costs, have an adverse effect on the sales of RJR Tobacco’s products, and impact legal actions pending against Reynolds Defendants. For a more complete description of this litigation, see “— Health-Care Cost Recovery Cases — U.S. Department of Justice Case ” in Item 8, note 13 to consolidated financial statements.
It is likely that legal actions, proceedings and claims arising out of the sale, distribution, manufacture, development, advertising, marketing and claimed health effects of cigarettes and other tobacco products will continue to be filed against Reynolds Defendants and other tobacco companies for the foreseeable future. Actions by the FDA may further trigger such legal actions, proceedings and claims against RAI and its subsidiaries.
Victories by plaintiffs in highly publicized cases against RJR Tobacco and other tobacco companies regarding the health effects of smoking may stimulate further claims. A material increase in the number of pending claims could significantly increase defense costs. In addition, adverse outcomes in pending cases could have adverse effects on the ability of RJR Tobacco and its indemnitees, including B&W, to prevail in other smoking and health litigation.
Any or all of the events described above could impose substantial monetary obligations on RAI and its operating subsidiaries and could have an adverse effect on the results of operations, cash flows and financial position of these companies and RAI. For a more complete description of the above cases and other significant litigation involving RAI and its operating subsidiaries, including RJR Tobacco, Lorillard Tobacco and American Snuff Co., see “— Litigation Affecting the Cigarette Industry” and “— Smokeless Tobacco Litigation” in Item 8, note 13 to consolidated financial statements.
14
Any action by the FDA or any other governmental authority that could have the effect of banning or materially restricting the use of menthol in tobacco products could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
As a result of the Lorillard Merger, RAI, through its subsidiaries, acquired Lorillard’s NEWPORT brand, the leading U.S. menthol cigarette brand. NEWPORT menthol cigarette styles were added to the brand portfolio of RAI’s operating companies, a portfolio which includes other brands with menthol styles. RAI estimates that approximately 50% of its total net sales were attributable to menthol cigarettes for the year ended December 31, 2016. See Item 8, note 2 to consolidated financial statements.
In 2013, the FDA issued its preliminary scientific evaluation regarding menthol cigarettes, concluding that menthol cigarettes adversely affect initiation, addiction and cessation compared to non-menthol cigarettes. In 2013, the FDA also issued an Advance Notice of Proposed Rulemaking, seeking comments on various issues relating to the potential regulation of menthol cigarettes. Although it is not possible to predict whether or when the FDA will take actions, if the FDA or any other governmental authority were to adopt regulations banning or severely restricting the use of menthol in tobacco products or the sale of menthol cigarettes, those regulations could have a material adverse effect on sales of the NEWPORT brand, and the menthol styles of other brands in the portfolio of RAI’s operating companies. Such an effect on sales could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
In addition to regulatory action affecting the use of menthol in cigarettes, the FDA could regulate tobacco products, including electronic cigarettes, in other aspects that could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
The FDA Tobacco Act grants the FDA broad authority over the manufacture, sale, marketing and packaging of tobacco products. FDA actions taken pursuant to the FDA Tobacco Act could result in a decrease in cigarette and smokeless tobacco product sales in the United States, including sales of RJR Tobacco’s, American Snuff Co.’s and SFNTC’s brands, and has resulted in an increase in costs to RJR Tobacco, American Snuff Co. and SFNTC, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
The ability of RAI’s operating companies to introduce new tobacco products, a critical component of RAI’s strategy of focusing on innovation to transform the tobacco industry, could be adversely affected by FDA rules and regulations. Under the FDA Tobacco Act, for a manufacturer to launch a new tobacco product or modify an existing tobacco product after March 22, 2011, the manufacturer must obtain an order from the FDA’s “Center for Tobacco Products,” referred to as the CTP, allowing the new or modified product to be marketed. Similarly, a manufacturer that introduced a product between February 15, 2007, and March 22, 2011, was required to file a substantial equivalence report with the CTP demonstrating either (1) that the new or modified product had the same characteristics as a product commercially available as of February 15, 2007, referred to as a predicate product, or (2) if the new or modified product had different characteristics than the predicate product, that it did not raise different questions of public health. A product subject to such report is referred to as a provisional product. A manufacturer may continue to market a provisional product unless and until the CTP issues an order that the provisional product is not substantially equivalent, referred to as an NSE order, in which case the FDA could then require the manufacturer to remove the provisional product from the market. On September 15, 2015, the CTP issued four NSE orders to RJR Tobacco, determining that four cigarette styles were not substantially equivalent to their respective predicate products, and ordering that RJR Tobacco immediately stop all distribution, importation, sale, marketing and promotion of these provisional products. RJR Tobacco has complied with these NSE orders. Although the sales of the provisional products subject to the foregoing NSE orders are not material to RJR Tobacco, substantially all of RAI’s operating companies’ products currently on the market are provisional products. If the CTP were to issue NSE orders with respect to other provisional products of RAI’s operating companies, such orders, if not withdrawn or invalidated, would have an adverse impact on the sales of the products subject to the orders, and could have an adverse impact on the results of operations, cash flows and financial position of RAI and its subsidiaries.
On May 10, 2016, the FDA issued a final regulation deeming e-cigarettes and certain other tobacco products to be subject to the FDA’s regulatory authority under the FDA Tobacco Act. As a result, such newly “deemed” tobacco products will be subject to many of the same requirements of the FDA Tobacco Act that currently apply to cigarettes and smokeless tobacco products. Under the final regulation, any newly “deemed” tobacco products, including e-cigarettes, that were not on the market as of February 15, 2007, will be considered a new tobacco product subject to premarket review by the FDA. Neither RJR Vapor’s VUSE e-cigarette, nor virtually any other e-cigarette, was on the market as of such date. As a result, e-cigarette manufacturers, including RJR Vapor, will not be able to utilize the substantial equivalence pathway for clearing these products, but instead will have to file premarket tobacco product applications. These applications must be filed by August 8, 2018, for e-cigarette products in the market as of August 8, 2016. A manufacturer that files a premarket application for such a product may continue to market the product for a certain period of time pending the FDA’s review of the application. For products that were not in the market by August 8, 2016, manufacturers must file and await clearance of such premarket applications before placing such products into commerce.
15
For the FDA to clear a premarket tobacco product application covering an e-cigarette, the applicant must show that the marketing of the e-cigarette would be appropriate for the protection of the public health. At present, there is substantial uncertainty over how the FDA will interpret that standard when determining whether to clear an e-cigarette premarket tobacco application. If RJR Vapor is unable to obtain FDA clearance, or obtains FDA clearance on a delayed basis, of premarket applications for VUSE and other e-cigarette products, then there could be an adverse effect on RJR Vapor’s business which could have an adverse effect on the results of operations, cash flows, and financial position of RAI and its subsidiaries, including RJR Vapor.
On August 27, 2015, the FDA sent a warning letter to SFNTC claiming that SFNTC’s use of the terms “Natural” and “Additive Free” in the product labeling and advertising for Natural American Spirit cigarettes violates the Modified Risk Tobacco Products provision of the FDA Tobacco Act. Following discussions between the parties, on January 23, 2017, the FDA and SFNTC reached an agreement whereby, among other things, SFNTC committed to phasing out use of the terms “Natural” and “Additive Free” from product labeling and advertising for Natural American Spirit cigarettes on an established timeframe. The agreement also specifies that SFNTC may continue to use the term “Natural” in the Natural American Spirit brand name and trademarks. SFNTC’s scheduled deletion of the terms “Natural” and “Additive Free” from the labeling and advertising of its Natural American Spirit cigarettes could have an adverse effect on the sale of such cigarettes and, as a result, on the results of operations, cash flows and financial position of SFNTC and RAI .
Further, the FDA has the authority to require the reduction of nicotine levels under the FDA Tobacco Act and also may require reduction or elimination of other constituents. For instance, the FDA has proposed a rule that, if adopted, would require the reduction, over a three-year period, of the levels of N-nitrosonornicotine (NNN) contained in smokeless tobacco products. The adoption of this proposed rule is currently suspended by virtue of a federal regulatory freeze imposed by the U.S. President. It is not known whether or when this proposed rule will be adopted, and, if adopted, whether the final rule will be the same as or similar to the proposed rule. If the proposed rule is adopted, however, in its current form (or in a form substantially similar to its current form), management expects that compliance or the inability to comply could have a material adverse effect on the results of operations, cash flows and financial position of American Snuff and RAI.
For a detailed description of the FDA Tobacco Act, see “— Governmental Activity” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7.
Significant monetary obligations imposed under the State Settlement Agreements into perpetuity, may have an adverse effect on the results of operations, cash flows and financial position of RAI and RJR Tobacco. Certain amounts incurred pursuant to the MSA have been disputed by RJR Tobacco and are subject to future arbitration proceedings that may result in rulings that reduce or eliminate the recovery of disputed amounts by RJR Tobacco.
In 1998, RJR Tobacco, Lorillard Tobacco and the other major U.S. cigarette manufacturers entered into the MSA with attorneys general representing most U.S. states, territories and possessions. The State Settlement Agreements, of which the MSA is the most wide-reaching, impose a perpetual stream of future payment obligations on RJR Tobacco and the other major U.S. cigarette manufacturers, and place significant restrictions on their ability to market and sell tobacco products in the future. They have materially adversely affected RJR Tobacco’s shipment volumes, and they may have an adverse effect on the results of operations, cash flows and financial position of RAI and RJR Tobacco in future periods.
RJR Tobacco and Lorillard Tobacco disputed a total of $5.6 billion and $1.2 billion, respectively, in potential MSA non-participating manufacturer adjustment, referred to as the NPM Adjustment, claims for the years 2003 through 2014. A nationwide arbitration, referred to as the Arbitration Panel, was initiated with respect to the 2003 NPM Adjustment claim.
During the arbitration of the 2003 NPM Adjustment claim, RJR Tobacco, Lorillard Tobacco, SFNTC and certain other participating manufacturers, referred to as the PMs, and certain “signatory” states entered into a binding Term Sheet that set forth terms to resolve NPM Adjustment claims for 2003 through 2012. The Term Sheet also set forth a restructured NPM Adjustment process to be applied to future volume years, starting with the 2013 volume year. Under the settlement, RJR Tobacco is to receive more than $1.1 billion worth of credits, a portion of which has been applied to its MSA payments in 2014, 2015 and 2016, with the remainder to be applied against its 2017 and 2018 MSA payments. In addition, RJR Tobacco, SFNTC and certain other participating manufacturers entered into a settlement agreement with the state of New York that resolved NPM Adjustment claims for 2004 through 2014 and put in place a new method to determine future adjustment from 2015 forward as to New York.
In September 2013, the Arbitration Panel issued final awards on the 2003 NPM Adjustment claim. Unfavorable rulings against two states remain unresolved and are subject to lawsuits in those respective state courts. After the above NPM Adjustment settlements, $1.9 billion and $400 million of the 2004 through 2014 NPM Adjustment remain in dispute for RJR Tobacco and Lorillard Tobacco,
16
respectively. The arbitration proceeding of the 2004 NPM Adjustment claim is underway. RJR Tobacco’s and Lorillard Tobacco’s remaining claim with respect to 2004 is approximately $251 million.
Due to the uncertainty over the final resolutions of the NPM Adjustment asserted by RJR Tobacco and Lorillard Tobacco, no assurances can be made related to the amounts, if any, that will be realized or any amounts (including interest) that will be owed.
For a more complete description of the State Settlement Agreements and the Arbitration Panel’s awards, see “— Health-Care Cost Recovery Cases — State Settlement Agreements” and “— Health-Care Cost Recovery Cases — State Settlement Agreements — Enforcement and Validity; Adjustments” in Item 8, note 13 to consolidated financial statements.
RAI, through its subsidiaries, is dependent on the U.S. cigarette market, which is expected to continue to decline. In addition, RAI is dependent on premium and super-premium cigarette brands. The continued decline in U.S. cigarette consumption, or the transition of consumers away from premium cigarette brands, could have an adverse effect on the consolidated results of operations, cash flows and financial position of RAI.
RAI’s subsidiaries’ U.S. combustible cigarette brands include, among others, NEWPORT, CAMEL, PALL MALL and NATURAL AMERICAN SPIRIT. RAI’s sales in the United States attributable to combustible cigarettes represented approximately 89% of RAI’s 2016 net sales. U.S. cigarette consumption has declined since 1981 for a variety of reasons including, for example, price increases, restrictions on advertising and promotions, smoking prevention campaigns, increases in regulation and excise taxes, health concerns, a decline in the social acceptability of smoking, governmental and private restrictions on the locations where smoking is permitted, increased pressure from anti-tobacco groups, and migration to smoke-free products. U.S. consumption is expected to continue to decline. MSAi reported that, on a year-over-year basis, U.S. cigarette shipments declined 2.4% in 2016, 0.1% in 2015 and 3.2% in 2014.
The sale of the international rights to the NATURAL AMERICAN SPIRIT brand name to JTI Holding in early 2016 increased the reliance of RAI’s operating subsidiaries on the U.S. cigarette market. In addition, pursuant to that transaction, RAI has agreed not to, and agreed to cause its controlled affiliates not to, engage in the business of producing, selling, distributing and developing natural, organic and additive-free combustible tobacco cigarettes and roll-your-own or make-your-own tobacco products outside of the United States for a period of five years after the closing.
In addition, RAI’s subsidiaries’ brands are subject to consumer price sensitivities, with certain brands subject to greater price sensitivities than others or competitors’ brands. Some consumers may switch to a lower-priced brand than the brands offered by RAI’s subsidiaries. As a result of the acquisition of Lorillard’s subsidiaries’ brands, which principally consist of NEWPORT, RAI’s subsidiaries’ concentration of premium and super-premium brands increased significantly and in 2016, accounted for approximately 73% of RAI’s subsidiaries’ cigarette volume. As a result, RAI’s subsidiaries are more susceptible to consumer price sensitivities following the Lorillard Merger. A downturn in the economy or other adverse financial or economic conditions could increase the number of consumers switching to a lower-priced brand.
The continued decline in U.S. cigarette consumption, or the transition of consumers away from premium cigarette brands, could have an adverse effect on the consolidated results of operations, cash flows and financial position of RAI.
If RJR Tobacco and RAI’s other operating companies are not able to develop, produce or market new alternative products profitably, the results of operations, cash flows and financial position of RAI and its operating subsidiaries could be adversely affected.
Consumer health concerns, changes in adult tobacco consumer preferences and changes in regulations have prompted RJR Tobacco and other RAI operating companies to introduce new alternative products. Consumer acceptance of these new products, such as CAMEL Snus and e-cigarettes, may fall below expectations, in which event RAI’s operating subsidiaries may be unable to replace all or any significant portion of lost revenues resulting from the continuing decline in cigarette consumption generally.
Further, while VUSE, an RJR Vapor e-cigarette product, is currently the number one e-cigarette product sold in convenience/gas stores, sales of closed system products like VUSE continue to decline in comparison to the sale of tanks and liquid nicotine containers typically sold in vapor shops and on-line. The future success of VUSE and other RJR Vapor e-cigarette offerings, including VUSE Vibe, will depend on the ability to innovate in an evolving category of alternative tobacco products.
In addition, RAI’s operating companies may not be able to establish or maintain relationships, on favorable commercial terms, with vendors willing to produce alternative products, or components or raw materials used in such products, resulting in additional expenditures for RAI’s operating companies.
17
If RJR Tobacco and RAI’s other operating companies are not able to develop, produce or market new alternative products to replace declining cigarette sales, then there could be an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
Competitive actions and pricing pressures in the marketplace could have an adverse effect on the results of operations, cash flows and financial position of RJR Tobacco, Santa Fe and American Snuff.
The tobacco industry is highly competitive. Among the major manufacturers, brands primarily compete on product quality, price, brand recognition, brand imagery and packaging. Substantial marketing support, merchandising display, discounting, promotions and other financial incentives generally are required to maintain or improve a brand’s market position or introduce a new brand. Competitors may also have certain advantages, including stronger financial position and liquidity, enabling them to better withstand the effects of competition and declines in price.
In addition, substantial payment obligations under the State Settlement Agreements adversely affect RJR Tobacco’s ability to compete with manufacturers of deep-discount cigarettes that are not subject to such substantial obligations. For a more complete description of the State Settlement Agreements, see “— Health-Care Cost Recovery Cases — State Settlement Agreements” in Item 8, note 13 to consolidated financial statements.
Inability to compete effectively may result in loss of market share, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
In the United States, tobacco products are subject to substantial and increasing regulation and taxation, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
A wide variety of federal, state and local laws limit the advertising, sale and/or use of tobacco products. These laws have proliferated in recent years. For example, some local laws prohibit the sale of certain tobacco products. Another example is that some local laws prohibit certain types of marketing practices, such as consumer coupons. In addition, there are many local laws that prohibit the consumption of cigarettes and other tobacco products in restaurants and other public places. Private businesses also have adopted policies that prohibit or restrict, or are intended to discourage, smoking and tobacco use. These laws and regulations could result in a decline in the overall sales volume of tobacco products, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
Tobacco products are subject to substantial federal and state excise taxes in the United States. Certain city and county governments also impose substantial excise taxes on tobacco products sold. Over the last several years, these taxing authorities have significantly increased the magnitude of excise taxes on tobacco products. Increased excise taxes have resulted in declines in overall sales volume and shifts by consumers to less expensive brands, and additional increases could result in future sales declines. For additional information on the issues described above, see “— Governmental Activity” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7.
RAI’s largest operating subsidiaries are subject to significant limitations on advertising and marketing of tobacco products, which could harm the value of their existing brands and their ability to launch new brands, and could have an adverse effect on the results of operations, cash flows and financial position of these companies and RAI.
In the United States, television and radio advertisements of cigarettes have been prohibited since 1971, and television and radio advertisements of smokeless tobacco products have been prohibited since 1986. Under the MSA, RAI’s operating subsidiaries, RJR Tobacco and SFNTC, cannot use billboard advertising, cartoon characters, sponsorship of certain events, non-tobacco merchandise bearing their brand names and various other advertising and marketing techniques. The MSA also prohibits targeting of youth in advertising, promotion or marketing of tobacco products, including the smokeless tobacco products of RJR Tobacco. American Snuff Co. is not a participant in the MSA. Although these restrictions were intended to ensure that tobacco advertising was not aimed at young people, some of the restrictions also may limit the ability of RAI’s operating subsidiaries to communicate with adult tobacco consumers. In addition, pursuant to the FDA Tobacco Act, the FDA has reissued regulations addressing advertising and marketing restrictions that were originally promulgated in 1996. Additional restrictions under the FDA regulations, or otherwise, may be imposed or agreed to in the future. These limitations on the advertising and marketing of tobacco products inhibit RAI’s operating subsidiaries from promoting and maintaining the value of their existing brands and limit their ability to launch new brands, which could have an adverse effect on the results of operations, cash flows and financial position of these companies and RAI.
18
Fluctuations in the availability, quality and price of raw materials and commodities, including tobacco leaf, used in the products of RAI’s subsidiaries could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
Possible fluctuations in the availability, quality and price of raw materials and commodities, including tobacco leaf, used in RAI’s operating subsidiaries’ products could cause profits to decline which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
RAI’s operating subsidiaries rely on a limited number of suppliers for certain raw materials. An interruption in service from any of these suppliers could have an adverse effect on the results of operations, cash flows and financial position of RAI.
RAI’s operating subsidiaries rely on a limited number of suppliers for raw materials. If a supplier fails to meet any of RAI’s operating subsidiaries’ demands for raw materials, any such operating subsidiary may fail to operate effectively and may fail to meet shipment demand, which could have an adverse effect on the results of operations, cash flows and financial position of such subsidiary and RAI.
Fire, violent weather conditions and other disasters that affect manufacturing and other facilities of RAI’s operating subsidiaries, or of their suppliers and vendors, could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
A major fire, violent weather conditions or other disasters that affect manufacturing and other facilities of RAI’s operating subsidiaries, or of their suppliers and vendors, could have a material adverse effect on the operations of RAI’s operating subsidiaries. In particular, RJR Tobacco’s cigarette manufacturing is conducted primarily at a single facility. Additionally, SFNTC’s cigarette manufacturing is conducted at a single facility. Despite RAI’s insurance coverage for some of these events, a prolonged interruption in the manufacturing operations of RAI’s operating subsidiaries could have a material adverse effect on the ability of such subsidiaries to effectively operate their businesses, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries.
Certain of RAI’s operating subsidiaries may be required to write down intangible assets, including goodwill, due to impairment, thus reducing operating profit.
Intangible assets include goodwill, trademarks and other intangibles. The determination of fair value involves considerable estimates and judgment. For goodwill, the determination of fair value of a reporting unit involves, among other things, RAI’s market capitalization, and application of the income approach, which includes developing forecasts of future cash flows and determining an appropriate discount rate. If goodwill impairment is implied, the fair values of individual assets and liabilities, including unrecorded intangibles, must be determined. During the annual testing in the fourth quarter of 2016, the estimated fair value of each of RAI’s reporting units was substantially in excess of its respective carrying value.
Trademarks and other intangible assets with indefinite lives also are tested for impairment annually, in the fourth quarter. At December 31, 2016, the aggregate fair value of RAI’s operating units’ trademarks and other intangible assets was substantially in excess of their aggregate carrying value. However, at December 31, 2016, the individual fair values of five trademarks were less than 15% in excess of their respective carrying values. The aggregate carrying value of these five trademarks was $27.3 billion at December 31, 2016.
The methodology used to determine the fair value of trademarks includes assumptions with inherent uncertainty, including projected sales volumes and related projected revenues, long-term growth rates, royalty rates that a market participant might assume and judgments regarding the factors to develop an applied discount rate.
The carrying value of intangible assets is at risk of impairment if future projected revenues or long-term growth rates are lower than those currently projected, or if factors used in the development of a discount rate result in the application of a higher discount rate.
Goodwill, trademarks and other intangible assets are tested more frequently if events and circumstances indicate that the asset might be impaired. The carrying value of these intangible assets could be impaired if a significant adverse change in the use, life, or brand strategy of the asset is determined, or if a significant adverse change in the legal and regulatory environment, business or competitive climate occurs that would adversely impact the asset.
For additional information, see Item 8, note 5 to consolidated financial statements.
19
Increases in pension and postretirement expense that reduce profitability, or increases in pension and postretirement contributions that are required to be made, could have an adverse effect on the results of operations, cash flows and financial position of RAI.
RAI’s profitability is affected by the costs of pension and postretirement benefits available to employees, generally those hired prior to 2004. Adverse changes in investment returns earned on pension assets, discount rates and other assumptions used to calculate pension and postretirement obligations, which in most cases are beyond RAI’s control, may have an unfavorable impact on pension and postretirement expense. In addition, changes to pension legislation or changes in pension accounting may adversely affect pension and postretirement expense. As such, there can be no assurance that pension and postretirement expense will not increase in the future, and such increases may have an adverse effect on the results of operations and financial position of RAI.
In 2016, RAI contributed $335 million to its pension plans and $66 million to its postretirement plans. During 2017, RAI expects to contribute $111 million to its pension plans and $78 million to its postretirement plans. RAI may be required to make additional contributions beyond what is currently contemplated to fund its pension and postretirement benefit plans, and those contributions could have an adverse effect on the cash flows and financial position of RAI.
For additional information, see Item 8, note 16 to consolidated financial statements.
Certain of RAI’s operating subsidiaries face a customer concentration risk. The loss of such a customer would result in a decline in revenue and could have an adverse effect on the results of operations, cash flows and financial position of RAI.
Revenues from two distributors, McLane and Core-Mark, constituted approximately 28% and 14%, respectively, of RAI’s consolidated revenue in 2016. The loss of these customers, or a significant decline in their purchases, could have an adverse effect on the results of operations, cash flows and financial position of RAI.
Disruptions in information technology systems, including a security breach, or, more generally, the inability to effectively use digital technologies could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
RAI and its subsidiaries are dependent on information technology systems to operate and manage all aspects of their businesses, including, without limitation, to comply with regulatory, legal, financial reporting and tax requirements, and to collect and store confidential information. Such confidential information may include proprietary business information, and what is often referred to as “personally identifiable information,” or certain information about individuals (such as employees and, in the case of RAI’s subsidiaries, consumers). The use and handling of personally identifiable information is subject to developing regulations, which vary from jurisdiction to jurisdiction, and the cost of regulatory compliance may be significant.
RAI and its subsidiaries also rely on third party vendors to operate their information technology and to perform certain services for the companies. Certain of these vendors store, process or otherwise handle confidential information, including personally identifiable information. RAI’s and its subsidiaries’ information technology systems, and the systems of their vendors, may not function as intended, and may be vulnerable to damage, interruption, or shutdown from a variety of events, such as computer system and telecommunications failures, computer viruses, user errors and catastrophic events.
Cybersecurity threats, which are constantly evolving and becoming more prevalent, also pose a risk to the security and viability of RAI’s and its subsidiaries’ information technology systems, and the systems of their vendors. Security breaches could be committed by third parties intending to access, misappropriate or corrupt confidential information and personally identifiable information, or otherwise to disrupt the business of RAI and its subsidiaries. The techniques used in cybersecurity attacks change frequently, potentially delaying the detection of such an attack. Despite RAI’s investments to address cybersecurity threats, it may be difficult for RAI to anticipate and implement adequate preventative measures. Any interruptions, failures or breaches of RAI’s and its subsidiaries’ information technology systems, or the systems of their vendors, could result in: the loss of revenue and customers; transaction errors and processing inefficiencies; the loss or unauthorized disclosure of, or damage to, confidential and personally identifiable information and/or other assets; damage to the reputation of RAI and its subsidiaries and to the brands of those subsidiaries; litigation and regulatory enforcement actions; and increased costs. Any of these events could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
Competition in the tobacco industry is based, in part, on the effective use of digital technologies. In particular, the failure to (1) take advantage of opportunities, and respond to challenges, arising from the increasing digital influence on consumer purchasing decisions, (2) fully maximize evolving technology so as to (i) automate, or otherwise enhance the efficiencies of, business processes, (ii) support and accelerate product innovation and (iii) simplify regulatory compliance, and (3) adopt and implement effective e-
20
commerce strategies for the promotion of e-cigarettes and other vapor products, could lead to a competitive disadvantage, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
Difficulties attracting and retaining qualified employees, officers, and professionals due to the impact of health and social issues associated with the tobacco industry could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
Recruiting and retaining qualified employees, officers and professionals may be difficult given the health and social issues associated with the tobacco industry. If RAI and its subsidiaries are unable to recruit, retain and motivate key personnel to maintain the current businesses of these companies and support development of new products, it could have an adverse effect on the results of operations, cash flows and financial position of RAI and its subsidiaries.
RAI is obligated to indemnify ITG for specified matters and to retain certain liabilities related to the divested brands and other assets.
Under the asset purchase agreement related to the Divestiture, RAI will indemnify ITG against losses arising from, among other things, breaches of representations and warranties, breaches of covenants, assets excluded from the transaction, excluded liabilities, certain specific tobacco liabilities, certain assumed plaintiff fees, certain employment related obligations, and liabilities in connection with certain tobacco litigation, settlement and regulatory matters. The asset purchase agreement related to the Divestiture does not cap RAI’s indemnification obligations, except with respect to any indemnification arising from breaches of certain representations and warranties or pre-closing covenants. Accordingly, these indemnification obligations could be substantial and could have an adverse effect on RAI’s results of operations, cash flows and financial position.
SFNTC is obligated to indemnify JTI Holding for certain liabilities relating to specified pre-sale statements made by the disposed-of entities relating to NATURAL AMERICAN SPIRIT brand cigarettes consumed outside the United States.
Under the purchase agreement relating to the sale of the international rights to the NATURAL AMERICAN SPIRIT brand to JTI Holding, SFNTC and two other RAI subsidiaries will indemnify JTI Holding against liabilities resulting from breaches of representations, warranties, or covenants; certain pre-sale debts of the disposed-of entities; the operation of the NATURAL AMERICAN SPIRIT brand business in the United States; and liabilities arising from either personal injury actions commenced on or before January 13, 2019, or other actions commenced on or before January 13, 2021, where such actions are based on pre-sale statements by the disposed-of entities that NATURAL AMERICAN SPIRIT brand cigarettes intended to be consumed outside the United States were natural, organic, or additive free. Such purchase agreement does not cap these indemnification obligations, except with respect to breaches of representations or warranties. Accordingly, these indemnification obligations could be substantial and could have an adverse effect on RAI’s and SFNTC’s results of operations, cash flows and financial position.
The ability of RAI to access the debt capital markets could be impaired if the credit ratings of its debt securities fall. Borrowing costs under RAI’s revolving credit facility could increase as the credit ratings of RAI’s long-term debt falls.
RAI’s credit ratings impact the cost and availability of future borrowings and, accordingly, RAI’s cost of capital. As of December 31, 2016, the outstanding notes issued by RAI were rated investment grade. During 2016, Standard & Poor’s Ratings Services upgraded all of its BBB- ratings on RAI one notch, to BBB, Moody’s Investor Service reaffirmed RAI’s Baa3 senior unsecured debt rating and Fitch Ratings assigned a Long-Term Issuer Default Rating on RAI of BBB. If RAI’s credit ratings were to fall, RAI may not be able to sell additional debt securities or borrow money in such amounts, at the times, at the lower interest rates or upon the more favorable terms and conditions that might be available if its debt maintained its current or higher ratings. In addition, future debt security issuances or other borrowings may be subject to further negative terms, including provisions for collateral or limitations on indebtedness or more restrictive covenants, if RAI’s credit ratings decline.
RAI’s credit ratings are influenced by some important factors not entirely within the control of RAI or its affiliates, such as tobacco litigation, the regulatory environment and the performance of suppliers to RAI’s operating subsidiaries. Moreover, because the kinds of events and contingencies that may impair RAI’s credit ratings and the ability of RAI and its affiliates to access the debt capital markets are often the same kinds of events and contingencies that could cause RAI and its affiliates to seek to raise additional capital on an urgent basis, RAI and its affiliates may not be able to issue debt securities or borrow money with acceptable terms, or at all, at the times at which they may most need additional capital.
In addition, the interest rate RAI pays on borrowings under its revolving credit facility is equal to an underlying interest rate plus an applicable margin, which margin is based on the ratings of RAI’s senior, unsecured, long-term indebtedness. If these ratings decline, the applicable margin RAI is required to pay would increase. RAI pays a fee on commitments under its revolving credit facility based on the ratings of RAI’s senior, unsecured, long-term indebtedness. As a result, although the revolving credit facility
21
provides RAI with a source of liquidity, the cost of borrowing under, and of maintaining, that facility could be at a higher rate at a time when RAI most needs to utilize that facility.
For more complete information on RAI’s credit agreement and long-term debt, see Item 8, notes 11 and 12 to consolidated financial statements.
An adverse effect on the results of operations, cash flows and financial position of RAI or its operating subsidiaries could cause RAI’s Board to depart from or change its historical dividend policy.
RAI’s Board could, at its discretion, depart from or change its dividend policy at any time. RAI is not required to pay dividends and its shareholders do not have contractual or other legal rights to receive them. RAI’s ability to pay dividends is dependent on its earnings, capital requirements, financial condition, expected cash needs, debt covenant compliance and other factors considered relevant by RAI’s Board. To the extent that RAI or its operating subsidiaries experience an adverse effect on their results of operations, cash flows or financial position or such other relevant factors, as noted above, RAI’s Board may decide, at its discretion, to decrease the amount of dividends, change or revoke the dividend policy or discontinue paying dividends entirely. In addition, if RAI does not pay or reduces its historical dividend rate, the market price of its common stock could decline.
There are a variety of risks, contingencies and other uncertainties associated with the BAT Merger that could result in the failure of the BAT Merger to be completed or, if completed, to have an adverse effect on the results of operations, cash flows and financial position of RAI or the combined company, respectively, or on shareholders generally.
RAI’s ability to complete the BAT Merger is subject to risks and uncertainties, including, but not limited to, failure to satisfy required closing conditions to the BAT Merger, including the failure to obtain necessary shareholder, regulatory or other approvals, or complete the BAT Merger in a timely manner or at all; if necessary approvals are obtained, the possibility of being subjected to conditions that could reduce the expected synergies and other benefits of the BAT Merger, result in a material delay in, or the abandonment of, the BAT Merger or otherwise have an adverse effect on RAI or the combined company; and the occurrence of any event, change or other circumstances that could give rise to the right of a party to terminate the Merger Agreement, including such a circumstance where RAI would be required to pay BAT a termination fee of $1 billion. As a result, one or more conditions to closing of the BAT Merger may not be satisfied and the BAT Merger may not be completed. Any delay in completing the BAT Merger may adversely affect the synergies and other benefits that RAI and BAT expect to achieve assuming the BAT Merger and the integration of the companies’ respective businesses are completed within the expected timeframe.
During the pendency of the BAT Merger, RAI and its subsidiaries will be subject to business uncertainties, certain operating restrictions and merger-related costs. Further, the Merger Agreement contains restrictions on RAI’s ability to pursue other alternatives to the BAT Merger. The ability of RAI or its subsidiaries to retain customers, retain and hire key personnel and maintain relationships with suppliers may be subject to disruption due to uncertainty associated with the BAT Merger, which could have an adverse effect on the results of operations, cash flows and financial position of RAI and its operating subsidiaries. RAI’s management may be distracted from ongoing business operations due to the BAT Merger. Further, RAI’s directors and executive officers have interests in the BAT Merger that are different from, or in addition to, the interests of RAI shareholders generally. These interests may cause RAI’s directors and executive officers to view the BAT Merger differently and more favorably than RAI shareholders may view it.
Even if the BAT Merger is completed, there can be no assurance that the expected benefits of the merger will occur or be fully or timely realized. Further, there can be no assurance of the value of the merger consideration that RAI shareholders will receive; the BAT ADS exchange ratio for the non-cash portion of the merger consideration is fixed and will not be adjusted in the event of any change in either RAI’s or BAT’s stock price. Following the completion of the BAT Merger, RAI’s former shareholders will be subject to different rights as BAT shareholders. If the combined company is not able to successfully combine the businesses of RAI and BAT in an efficient and effective manner, the anticipated benefits and cost savings may not be realized fully, or at all, or may take longer to realize than expected, and the value of common stock of the combined company may be affected adversely. The value to former RAI shareholders of such common stock may be further adversely affected post-closing, as former RAI shareholders will be subject to exchange rate risk with respect to BAT ADSs, a risk not associated with RAI common stock prior to the BAT Merger. An inability to realize the full extent of the anticipated benefits of the BAT Merger, as well as any delays encountered in the integration process, could have an adverse effect upon the results of operations, cash flows and financial position of the combined company, which may adversely affect the value of its common stock following the BAT Merger. In addition, the actual integration may result in additional and unforeseen expenses, and the anticipated benefits of the integration plan may not be realized. Actual growth and cost savings, if achieved, may be lower than what the combined company expects and may take longer to achieve than anticipated. If the combined company is not able to adequately address integration challenges, the combined company may be unable to integrate successfully BAT’s and RAI’s operations or to realize the anticipated benefits of the integration of the two companies.
22
During the pendency of the BAT Merger, or in the event the BAT Merger is not completed, BAT’s significant beneficial equity interest in RAI could be determinative in matters submitted to a vote by RAI shareholders, resulting in RAI taking actions that RAI’s other shareholders do not support. BAT and B&W also have influence over RAI by virtue of the Governance Agreement, which requires B&W’s approval before RAI takes certain actions.
BAT, through its subsidiaries, beneficially owns approximately 42% of the outstanding shares of RAI common stock. No other shareholder owns more than 10% of the outstanding shares of RAI common stock. Unless substantially all of RAI’s public shareholders vote together on matters presented to RAI shareholders, BAT, through its subsidiaries, would have the power to determine the outcome of matters submitted to a shareholder vote, subject to the Governance Agreement described below.
Moreover, in connection with the B&W business combination, RAI, B&W and BAT entered into an agreement, referred to as the Governance Agreement, relating to various aspects of RAI’s corporate governance. RAI is currently subject to, and throughout the pendency of the BAT Merger will be subject to, the provisions of the Governance Agreement. Under the Governance Agreement, the approval of B&W, as a RAI shareholder, is required in connection with, among other things, the following matters:
|
• |
the sale or transfer of certain RAI intellectual property associated with B&W brands having an international presence, other than in connection with a sale of RAI; and |
|
• |
RAI’s adoption of any takeover defense measures that would apply to the acquisition of equity securities of RAI by BAT or its affiliates, other than a re-adoption of the RAI rights plan in the form permitted by the Governance Agreement. |
Such influence could result in RAI taking actions that RAI’s other shareholders do not support. The Governance Agreement and amendments thereto are filed as Exhibits 10.9 to 10.12 to this Annual Report on Form 10-K.
Under the Governance Agreement, B&W is entitled to nominate individuals to RAI’s Board, and the approvals of the majority of those individuals is required before certain actions may be taken, even though those individuals represent less than a majority of the entire Board.
Under the Governance Agreement, B&W, based upon the current beneficial ownership of BAT through its subsidiaries, is entitled to nominate five directors to RAI’s Board, at least three of whom are required to be independent directors and two of whom may be executive officers of BAT or any of its subsidiaries. RAI’s Board currently is composed of 14 persons, including five designees of B&W, the maximum number of designees that B&W is entitled to nominate under the Governance Agreement. Matters requiring the approval of RAI’s Board generally require the affirmative vote of a majority of the directors present at a meeting. Under the Governance Agreement, however, the approval of a majority of B&W’s designees on RAI’s Board is required in connection with the following matters:
|
• |
any issuance of RAI equity securities in excess of 5% of its outstanding voting stock, unless at such time BAT and its subsidiaries’ ownership interest in RAI is less than 32%; and |
|
• |
any repurchase of RAI common stock, subject to a number of exceptions, unless at such time BAT and its subsidiaries’ ownership interest in RAI is less than 25%. |
As a result, B&W’s designees on RAI’s Board may prevent the foregoing transactions from being effected, notwithstanding a majority of the entire Board may have voted to approve such transactions. Though such transactions are nonetheless restricted by the provisions of the Merger Agreement, should the BAT Merger not be completed, the Governance Agreement restrictions will remain in place.
Under the RAI articles of incorporation, neither BAT nor any director of RAI who is affiliated with, or employed by, BAT is required to present a business opportunity to RAI if the business opportunity does not primarily relate to the United States. The loss of favorable business opportunities could have an adverse effect on the results of operations, cash flows and financial position of RAI.
Unless otherwise agreed by the parties, under the RAI articles of incorporation, neither BAT or any of its subsidiaries or affiliates nor any director of RAI who is affiliated with, or employed by, BAT or its subsidiaries and affiliates, including any B&W designated director, is required to present a transaction, relationship, arrangement or other opportunity, all of which are collectively referred to as a business opportunity to RAI, RAI’s Board or any RAI officer or employee if the business opportunity does not relate primarily to the United States. RAI has renounced any expectancy or interest in, or in being offered an opportunity to participate in, any such business opportunity, and BAT and its subsidiaries and affiliates are entitled to act upon any such business opportunity and will not be liable to RAI or any RAI shareholders for taking any such action or not presenting such business opportunity to RAI. As a result, RAI may not be presented with certain favorable business opportunities that are known to BAT or a BAT affiliated director of
23
RAI, and BAT may take advantage and receive the benefits of those business opportunities. Because of this provision, if the BAT Merger is not completed, the loss of favorable business opportunities could have an adverse effect on the results of operations, cash flows and financial position of RAI.
Under the Merger Agreement, RAI is restricted from pursuing alternative takeover proposals. If the BAT Merger is not completed, BAT’s significant beneficial ownership interest in RAI could deter future acquisition proposals and make it difficult for a third party to acquire control of RAI without the cooperation of BAT. This could have a negative effect on the price of RAI common stock.
Pursuant to the terms of the Merger Agreement, RAI is restricted from pursuing alternative takeover proposals to the BAT Merger. Should RAI pursue an alternative takeover proposal instead of the BAT Merger, in certain instances, RAI would be required to pay a termination fee to BAT of $1 billion. Further, if the BAT Merger is not completed, BAT, through its subsidiaries, could vote its shares of RAI common stock against any future takeover proposal submitted for shareholder approval or refuse to accept any tender offer for shares of RAI common stock. As a result, it would make it very difficult for a third party to acquire RAI without BAT consent. BAT’s beneficial ownership interest in RAI and these defenses could discourage potential acquisition proposals and could delay or prevent a change in control of RAI. These deterrents could adversely affect the price of RAI common stock and make it very difficult to remove or replace members of the board of directors or management of RAI without cooperation of BAT.
In the event that the BAT Merger is not completed, RAI shareholders may be adversely affected if all or part of the Governance Agreement were to be terminated because in some circumstances the board composition and share transfer restrictions on BAT and its subsidiaries would no longer apply. These developments could enable BAT and its subsidiaries to, among other things, acquire some or all of the shares of RAI common stock not held by BAT and its subsidiaries, seek additional representation on RAI’s Board, replace existing RAI directors, solicit proxies, otherwise influence or gain control of RAI or transfer all or a significant percentage of their shares of RAI common stock to a third party.
The Governance Agreement provides that it will terminate automatically in its entirety if BAT and its subsidiaries own either 100% or less than 15% or if any third party or group controls more than 50% of the voting power of all RAI shares. In addition, BAT and B&W may terminate the Governance Agreement in its entirety if B&W nominees proposed in accordance with the Governance Agreement are not elected to serve on RAI’s Board or its committees or if RAI has deprived B&W nominees of such representation for “fiduciary” reasons or has willfully deprived B&W or its board nominees of any veto rights.
BAT and B&W also may terminate the obligation to vote their shares of RAI common stock for Board-proposed director nominees, the restriction on Board representation in excess of proportionate representation and the RAI share transfer restrictions of the Governance Agreement if RAI willfully and deliberately breaches the provisions regarding B&W’s Board and Board committee representation.
In the event that the BAT Merger is not completed and the share transfer restrictions in the Governance Agreement are terminated, there will be no contractual restrictions on the ability of BAT and its subsidiaries to sell or transfer their shares of RAI common stock on the open market, in privately negotiated transactions or otherwise. These sales or transfers could create a substantial decline in the price of shares of RAI common stock or, if these sales or transfers were made to a single buyer or group of buyers that own shares of RAI common stock, could result in a third party acquiring control of or influence over RAI.
The bylaws of RAI designate the state courts of North Carolina or the U.S. District Court for the Middle District of North Carolina as the sole and exclusive forum for certain legal actions, which could limit the ability of RAI shareholders to obtain a favorable judicial forum for disputes with RAI.
RAI’s bylaws provide that, unless RAI consents in writing to the selection of an alternative forum, the state courts of North Carolina or the U.S. District Court for the Middle District of North Carolina will be the sole and exclusive forum for:
|
• |
any derivative action or proceeding brought on behalf of RAI; |
|
• |
any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of RAI to RAI or its shareholders; |
|
• |
any action asserting a claim arising pursuant to any provision of the North Carolina Business Corporation Act, the bylaws or the articles of incorporation of RAI (as each may be amended from time to time); or |
|
• |
any action asserting a claim governed by the internal affairs doctrine. |
24
Any person or entity purchasing or otherwise acquiring any interest in shares of RAI’s capital stock may be deemed to have notice of and to have consented to the provisions described above. This forum selection provision may limit RAI shareholders’ ability to obtain a judicial forum that they find favorable for certain disputes with RAI or its directors, officers or other employees or shareholders.
Item 1B. Unresolved Staff Comments
None.
The executive offices of RAI and its material subsidiaries, other than SFNTC, are located in Winston-Salem, North Carolina. RJR Tobacco’s manufacturing facilities are located in the Winston-Salem, North Carolina area, and American Snuff Co.’s manufacturing facilities are located in Memphis, Tennessee; Clarksville, Tennessee; and Winston-Salem, North Carolina. SFNTC’s manufacturing facility is located in Oxford, North Carolina, and its executive offices are located in Santa Fe, New Mexico. All of RAI’s material operating subsidiaries’ executive offices and manufacturing facilities are owned.
See Item 8, note 13 to consolidated financial statements for disclosure of legal proceedings involving RAI and its operating subsidiaries.
Item 4. Mine Safety Disclosures
Not applicable.
25
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
RAI common stock, par value $.0001 per share, is listed on the NYSE under the trading symbol “RAI.” On January 23, 2017, there were approximately 11,830 holders of record of RAI common stock. Shareholders whose shares are held of record by a broker or clearing agency are not included in this amount; however, each of those brokers or clearing agencies is included as one holder of record. The closing price of RAI common stock on January 23, 2017, was $58.88 per share.
The cash dividends declared, and high and low sales prices per share for RAI common stock on the NYSE Composite Tape, as reported by the NYSE, were as follows:
|
|
Price Per Share |
|
|
Cash Dividends Declared Per |
|
||||||
|
|
High |
|
|
Low |
|
|
Share |
|
|||
2016: |
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
52.54 |
|
|
$ |
44.58 |
|
|
$ |
0.42 |
|
Second Quarter |
|
|
53.99 |
|
|
|
46.85 |
|
|
|
0.42 |
|
Third Quarter |
|
|
54.48 |
|
|
|
46.69 |
|
|
|
0.46 |
|
Fourth Quarter |
|
|
56.65 |
|
|
|
43.38 |
|
|
|
0.46 |
|
2015: |
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
38.12 |
|
|
$ |
31.35 |
|
|
$ |
0.335 |
|
Second Quarter |
|
|
38.98 |
|
|
|
34.33 |
|
|
|
0.335 |
|
Third Quarter |
|
|
44.44 |
|
|
|
35.70 |
|
|
|
0.360 |
|
Fourth Quarter |
|
|
49.56 |
|
|
|
43.02 |
|
|
|
0.360 |
|
On February 8, 2017, the board of directors of RAI declared a quarterly cash dividend of $0.51 per common share. The dividends will be paid on April 3, 2017, to shareholders of record as of March 10, 2017.
On July 25, 2016, the board of directors of RAI authorized the repurchase, from time to time, on or before December 31, 2018, of up to $2 billion of outstanding shares of RAI common stock in open-market or privately negotiated transactions, referred to as the Share Repurchase Program. The purchases are subject to prevailing market and business conditions, and the program may be terminated or suspended at any time. In connection with the Share Repurchase Program, B&W and Louisville Securities Limited, referred to as LSL, wholly owned subsidiaries of BAT, entered into an agreement, referred to as the Share Repurchase Agreement, with RAI, pursuant to which BAT and its subsidiaries will participate in the Share Repurchase Program on a basis approximately proportionate with BAT and its subsidiaries’ beneficial ownership of RAI’s common stock. During 2016, RAI repurchased 1,565,698 shares of RAI common stock for $75 million in accordance with the Share Repurchase Program. The Merger Agreement places restrictions on RAI’s ability to repurchase its common stock. As a result, RAI does not expect to make repurchases under the Share Repurchase Program while the Merger Agreement is in effect.
RAI, B&W and BAT entered into Amendment No. 3, dated November 11, 2011, to the Governance Agreement, pursuant to which RAI has agreed that, so long as the beneficial ownership interest of BAT and its subsidiaries in RAI has not dropped below 25%, if RAI issues shares of its common stock or any other RAI equity security to certain designated persons, including its directors, officers or employees, then RAI will repurchase a number of shares of outstanding RAI common stock so that the number of outstanding shares of RAI common stock are not increased, and the beneficial ownership interest of BAT and its subsidiaries in RAI is not decreased, by such issuance after taking into account such repurchase. During 2016, in accordance with the Governance Agreement, at a cost of $93 million, RAI repurchased 1,817,846 shares of RAI common stock in open-market transactions.
During 2016, RAI repurchased 1,146,978 shares of RAI common stock at a cost of $58 million that were forfeited and cancelled with respect to tax liabilities associated with vesting of restricted stock units granted under the Reynolds American Inc. 2009 Omnibus Incentive Compensation Plan, referred to as the Omnibus Plan. The Amended and Restated Omnibus Plan was approved by shareholders in 2014.
Due to RAI’s incorporation in North Carolina, which does not recognize treasury shares, the shares repurchased were cancelled at the time of repurchase.
26
The following table summarizes RAI’s purchases of its common stock during the fourth quarter of 2016:
|
|
Total Number of Shares Purchased (1) |
|
|
Average Price Paid per Share |
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2) |
|
|
Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (2) |
|
||||
October 1, 2016 to October 31, 2016 |
|
|
19,814 |
|
|
$ |
47.15 |
|
|
|
— |
|
|
$ |
1,925 |
|
November 1, 2016 to November 30, 2016 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,925 |
|
December 1, 2016 to December 31, 2016 |
|
|
8,655 |
|
|
|
55.65 |
|
|
|
— |
|
|
|
1,925 |
|
Total |
|
|
28,469 |
|
|
|
|
|
|
|
— |
|
|
|
|
|
(1) |
During the fourth quarter of 2016, RAI repurchased and cancelled the following shares of its common stock with respect to the tax liability associated with the vesting of restricted stock grants under the Omnibus Plan. For equity-based benefit plan information, see Item 8, note 15 to consolidated financial statements. |
( 2 ) |
During the fourth quarter of 2016, RAI did not repurchase any shares of its common stock under the Share Repurchase Program. For additional information, see Item 8, note 14 to consolidated financial statements. |
Performance Graph
Set forth below is a line graph comparing, for the period which commenced on December 31, 2011, and ended on December 31, 2016, the cumulative shareholder return of $100 invested in RAI common stock with the cumulative return of $100 invested in the Standard & Poor’s 500 Index and the Standard & Poor’s Tobacco Index.
|
|
12/31/11 |
|
|
12/31/12 |
|
|
12/31/13 |
|
|
12/31/14 |
|
|
12/31/15 |
|
|
12/31/16 |
|
||||||
Reynolds American Inc .(1) |
|
$ |
100.00 |
|
|
$ |
105.59 |
|
|
$ |
134.29 |
|
|
$ |
180.68 |
|
|
$ |
268.79 |
|
|
$ |
337.67 |
|
S&P 500 |
|
|
100.00 |
|
|
|
116.00 |
|
|
|
153.58 |
|
|
|
174.60 |
|
|
|
177.01 |
|
|
|
198.18 |
|
S&P Tobacco (2) |
|
|
100.00 |
|
|
|
110.42 |
|
|
|
129.15 |
|
|
|
146.98 |
|
|
|
179.12 |
|
|
|
206.98 |
|
(1) |
Assumes that $100 was invested in RAI common stock and indexes on December 31, 2011, and that in each case all dividends were reinvested. |
(2) |
The S&P Tobacco Index includes as of December 31, 2016, the following companies: Altria Group, Inc., Philip Morris International Inc. and Reynolds American Inc. |
27
Item 6. Selected Financial Data
The selected historical consolidated financial data as of December 31, 2016 and 2015, and for each of the years in the three-year period ended December 31, 2016, are derived from the consolidated financial statements and accompanying notes, which have been audited by RAI’s independent registered public accounting firm. The selected historical consolidated financial data as of December 31, 2014, 2013 and 2012, and for the years ended December 31, 2013 and 2012, are derived from audited consolidated financial statements not presented or incorporated by reference. For further information, you should read this table in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and the consolidated financial statements in Item 8.
|
|
For the Years Ended December 31, |
|
|||||||||||||||||
|
|
2016 (7) |
|
|
2015 (8) |
|
|
2014 |
|
|
2013 |
|
|
2012 |
|
|||||
|
|
(Dollars in Millions, Except Per Share Amounts) |
|
|||||||||||||||||
Results of Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales (1) |
|
$ |
12,503 |
|
|
$ |
10,675 |
|
|
$ |
8,471 |
|
|
$ |
8,236 |
|
|
$ |
8,304 |
|
Income from continuing operations (1)(2)(3)(4)(5)(6) |
|
|
6,073 |
|
|
|
3,253 |
|
|
|
1,445 |
|
|
|
1,718 |
|
|
|
1,272 |
|
Income from discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
25 |
|
|
|
— |
|
|
|
— |
|
Net income |
|
|
6,073 |
|
|
|
3,253 |
|
|
|
1,470 |
|
|
|
1,718 |
|
|
|
1,272 |
|
Per Share Data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income from continuing operations |
|
|
4.26 |
|
|
|
2.57 |
|
|
|
1.36 |
|
|
|
1.58 |
|
|
|
1.12 |
|
Diluted income from continuing operations |
|
|
4.25 |
|
|
|
2.57 |
|
|
|
1.35 |
|
|
|
1.57 |
|
|
|
1.12 |
|
Basic income from discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
0.02 |
|
|
|
— |
|
|
|
— |
|
Diluted income from discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
0.02 |
|
|
|
— |
|
|
|
— |
|
Basic net income |
|
|
4.26 |
|
|
|
2.57 |
|
|
|
1.38 |
|
|
|
1.58 |
|
|
|
1.12 |
|
Diluted net income |
|
|
4.25 |
|
|
|
2.57 |
|
|
|
1.37 |
|
|
|
1.57 |
|
|
|
1.12 |
|
Basic weighted average shares, in thousands |
|
|
1,426,987 |
|
|
|
1,264,182 |
|
|
|
1,066,320 |
|
|
|
1,089,849 |
|
|
|
1,131,139 |
|
Diluted weighted average shares, in thousands |
|
|
1,429,933 |
|
|
|
1,267,715 |
|
|
|
1,069,940 |
|
|
|
1,093,899 |
|
|
|
1,135,746 |
|
Cash dividends declared per share of common stock |
|
$ |
1.760 |
|
|
$ |
1.390 |
|
|
$ |
1.340 |
|
|
$ |
1.240 |
|
|
$ |
1.165 |
|
Balance Sheet Data (at end of periods): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets (9) |
|
|
51,095 |
|
|
|
52,100 |
|
|
|
14,781 |
|
|
|
14,790 |
|
|
|
16,063 |
|
Long-term debt (less current maturities) (10) |
|
|
12,664 |
|
|
|
16,849 |
|
|
|
4,602 |
|
|
|
5,065 |
|
|
|
5,003 |
|
Shareholders’ equity |
|
|
21,711 |
|
|
|
18,252 |
|
|
|
4,522 |
|
|
|
5,167 |
|
|
|
5,257 |
|
Cash Flow Data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash from operating activities |
|
|
1,280 |
|
|
|
196 |
|
|
|
1,623 |
|
|
|
1,308 |
|
|
|
1,568 |
|
Net cash from (used in) investing activities |
|
|
5,078 |
|
|
|
(10,005 |
) |
|
|
(205 |
) |
|
|
(113 |
) |
|
|
(54 |
) |
Net cash from (used in) financing activities |
|
|
(6,866 |
) |
|
|
11,438 |
|
|
|
(1,918 |
) |
|
|
(2,207 |
) |
|
|
(971 |
) |
Net cash related to discontinued operations, net of tax benefit |
|
|
— |
|
|
|
— |
|
|
|
25 |
|
|
|
— |
|
|
|
— |
|
Other Data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio of earnings to fixed charges (11) |
|
|
16.3 |
|
|
|
12.0 |
|
|
|
8.7 |
|
|
|
11.3 |
|
|
|
9.1 |
|
(1) |
Net sales and cost of products sold exclude excise taxes of $4,343 million, $4,209 million, $3,625 million, $3,730 million and $3,923 million for the years ended December 31, 2016, 2015, 2014, 2013 and 2012, respectively. |
(2) |
Includes restructuring and/or asset impairment charges of $99 million and $149 million for the years ended December 31, 2015 and 2012, respectively. |
(3) |
Includes trademark, goodwill and/or other intangible asset impairment charges of $32 million and $129 million for the years ended December 31, 2013 and 2012, respectively. |
(4) |
Includes NPM Adjustment credits of $390 million, $297 million, $345 million and $483 million for the years ended December 31, 2016, 2015, 2014 and 2013, respectively. |
(5) |
Includes a mark-to-market adjustment of $45 million, $246 million, $452 million and $329 million for the years ended December 31, 2016, 2015, 2014 and 2012, respectively. |
(6) |
Includes gain on divestitures of $4,861 million and $3,181 million for the years ended December 31, 2016 and 2015, respectively. |
(7) |
Reflects impact of the sale of the international rights to the NATURAL AMERICAN SPIRIT brand. See Item 8, note 3 to consolidated financial statements. |
(8) |
Reflects impact of the Lorillard Merger and Divestiture. See Item 8, note 2 to consolidated financial statements. |
(9) |
Includes a reclassification due to the adoption of Accounting Standards Updates 2015-17 and 2015-03 and was reduced by $968 million, $1.1 billion, $415 million, $612 million and $494 million for the years ended December 31, 2016, 2015, 2014, 2013 and 2012, respectively. See Item 8, note 1 to consolidated financial statements. |
28
(11) |
Earnings consist of income from continuing operations before equity earnings, income taxes and fixed charges. Fixed charges consist of interest on indebtedness, amortization of debt issuance costs and the interest portion of rental expense. |
29
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following is a discussion and analysis of RAI’s business initiatives, critical accounting estimates and its consolidated results of operations and financial position. Following the overview and discussion of business initiatives, the critical accounting estimates disclose certain accounting estimates that are material to RAI’s results of operations and financial position for the periods presented in this report. The discussion and analysis of RAI’s results of operations is presented in two comparative sections, 2016 compared with 2015, and 2015 compared with 2014. The statements of financial position and results of operations contained in the consolidated financial statements reflect the results of the Lorillard Merger, Divestiture and related transactions. Disclosures related to liquidity and financial position as well as governmental activity complete management’s discussion and analysis. You should read this discussion and analysis of RAI’s consolidated financial position and results of operations in conjunction with the consolidated financial statements and the related notes in Item 8, as of December 31, 2016 and 2015, and for each of the years in the three-year period ended December 31, 2016.
Proposed Merger with BAT
On January 16, 2017, RAI, BAT, a subsidiary of BAT, and Merger Sub entered into the Merger Agreement, pursuant to which, subject to the satisfaction or waiver of certain conditions, Merger Sub will merge with and into RAI, with RAI surviving as a wholly owned subsidiary of BAT.
The BAT Merger has been approved by the independent directors of RAI who formed the Transaction Committee to negotiate with BAT, given BAT’s existing ownership stake in RAI and representation on RAI’s Board, and by the Boards of Directors of both companies.
At the effective time of the BAT Merger, each share of RAI common stock (other than any shares of RAI common stock owned by BAT or any of its subsidiaries and by shareholders of RAI who have properly asserted and not lost or effectively withdrawn appraisal rights) will be converted into the right to receive 0.5260 of a BAT ADS and $29.44 in cash, without interest, and subject to adjustment to prevent dilution.
The BAT Merger is subject to customary closing conditions, including RAI and BAT shareholder approvals, including the approval of the BAT Merger by a majority of the shares of RAI common stock not owned, directly or indirectly, by BAT or its subsidiaries or any of RAI’s subsidiaries, and regulatory approvals. The Merger Agreement contains certain other termination rights for each of RAI and BAT, including the right of each party to terminate the Merger Agreement if the BAT Merger has not been completed on or before December 31, 2017, subject to an extension of five business days if, on December 31, 2017, BAT has not completed all or any portion of the financing it needs to fund the BAT Merger and the transactions contemplated by the Merger Agreement. Financing, however, is not a condition to the closing of the BAT Merger. Under certain circumstances, if the Merger Agreement is terminated, the terminating party must pay the non-terminating party a termination fee of $1 billion. In the event that the Merger Agreement is terminated due to an inability to obtain unconditional approval under the HSR Act or any other antitrust laws, RAI will be entitled to receive a termination fee of $500 million from BAT. The BAT Merger is currently expected to close in the third quarter of 2017.
Each of RAI and BAT has made representations and warranties in the Merger Agreement. RAI and BAT each also have agreed to various covenants and agreements, including, among other things, to conduct their respective businesses in the ordinary course in all material respects during the period between the execution of the Merger Agreement and completion of the BAT Merger and not to engage in certain transactions during this period.
The foregoing description of the BAT Merger and the Merger Agreement is qualified in its entirety by reference to the Merger Agreement, a copy of which is attached as Exhibit 2.1 to RAI’s Current Report on Form 8-K filed with the SEC on January 17, 2017, which is incorporated by reference herein.
There are a number of risks and uncertainties associated with the BAT Merger. For more information, see Item 1A. Risk Factors and “— Cautionary Information Regarding Forward-Looking Statements” in this Item 7. In connection with the BAT Merger, BAT will file with the SEC a registration statement on Form F-4 that will include the proxy statement of RAI that also constitutes a prospectus of BAT. Shareholders are urged to read the proxy statement/prospectus on Form F-4 once it becomes available because it will contain important information about the BAT Merger, including relevant risk factors.
Overview and Business Initiatives
RAI’s reportable operating segments are RJR Tobacco, Santa Fe and American Snuff. The RJR Tobacco segment consists of the primary operations of R. J. Reynolds Tobacco Company. The Santa Fe segment consists of the primary operations of SFNTC. The
30
American Snuff segment consists of the primary operations of American Snuff Co. Included in All Other, among other RAI subsidiaries, are RJR Vapor, Niconovum USA, Inc., Niconovum AB, and until th eir sale on January 13, 2016, SFRTI and various foreign subsidiaries affiliated with SFRTI. The segments were identified based on how RAI’s chief operating decision maker allocates resources and assesses performance. Certain of RAI’s operating subsidiaries have entered into intercompany agreements for products or services with other subsidiaries. As a result, certain activities of an operating subsidiary may be included in a different segment of RAI.
On January 13, 2016, RAI, through the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with SFRTI and other international companies that distributed and marketed the brand outside the United States, to JTI Holding, in an all-cash transaction of approximately $5 billion and recognized a pre-tax gain of approximately $4.9 billion. For additional information on the transaction, see Item 8, notes 3 and 13 to consolidated financial statements.
In June 2015, RAI completed the Lorillard Merger and Divestiture, which resulted in the acquisition of the premium cigarette brand, NEWPORT, which is the top selling menthol and second largest selling cigarette brand in the United States, and the divestiture of the WINSTON, KOOL and SALEM cigarette brands. The brands acquired and divested are included in the RJR Tobacco segment. For additional information on these transactions, see Item 8, notes 2 and 13 to consolidated financial statements.
RAI’s strategy continues to focus on transforming tobacco to deliver sustainable earnings growth, strong cash flow and enhanced long-term shareholder value. This transformation strategy includes growing the core cigarette and moist-snuff businesses, focusing on innovation and engaging with adult tobacco consumers, while maintaining efficient and effective operations.
To achieve its strategy, RAI encourages the migration of adult smokers to smoke-free tobacco products and other non-combustible nicotine-containing products, which it believes aligns consumer preferences for new alternatives to traditional tobacco products in view of societal pressure to reduce smoking. RAI’s operating companies facilitate this migration through innovation, including the development of digital vapor cigarettes, CAMEL Snus, heat-not-burn cigarettes and nicotine replacement therapy technologies. RAI remains committed to maintaining high standards of corporate governance and business conduct in a high-performing culture.
RAI’s largest reportable operating segment, RJR Tobacco, is the second largest tobacco company in the United States. RJR Tobacco’s brands include three of the top four best-selling cigarettes in the United States: NEWPORT, CAMEL and PALL MALL. These brands, and its other brands, including DORAL, MISTY and CAPRI, are manufactured in a variety of styles and marketed in the United States. As part of its total tobacco strategy, RJR Tobacco offers a smoke-free tobacco product, CAMEL Snus. RJR Tobacco manages contract manufacturing of cigarette and tobacco products through arrangements with BAT affiliates, and manages the export of tobacco products to U.S. territories, U.S. duty-free shops and U.S. overseas military bases. RJR Tobacco also manages the super-premium cigarette brands, DUNHILL and STATE EXPRESS 555, which are licensed from BAT.
Santa Fe manufactures and markets super-premium cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand in the United States.
American Snuff is the second largest smokeless tobacco products manufacturer in the United States. American Snuff’s primary brands include its largest selling moist snuff brands, GRIZZLY and KODIAK.
RJR Tobacco
RJR Tobacco primarily conducts business in the highly competitive U.S. cigarette market, which has a few large manufacturers and many smaller participants. The international rights to substantially all of RJR Tobacco’s brands were sold in 1999 to JTI, and no international rights were acquired in connection with the B&W business combination in 2004 or the Lorillard Merger in 2015. The U.S. cigarette market is a mature market in which overall adult consumer demand has declined since 1981, and is expected to continue to decline. Profitability of the U.S. cigarette industry and RJR Tobacco continues to be adversely impacted by decreases in consumption, increases in state excise taxes and governmental regulations and restrictions, such as marketing limitations, product standards and ingredients legislation.
RJR Tobacco’s cigarette brand portfolio strategy is based upon two brand categories: drive and other. The drive brands consist of two premium brands, NEWPORT and CAMEL, and the largest traditional value brand, PALL MALL. These three brands are managed for long-term market share and profit growth, and receive the vast majority of RJR Tobacco’s equity support with an emphasis on the NEWPORT and CAMEL brands. The other brand category includes the premium brand, CAPRI, and the value brands, DORAL and MISTY, along with other smaller brands. All of the other brands receive limited marketing support and are managed to maximize profitability.
31
The key objectives of the portfolio strategy are designed to balance the long-term market share growth and profitability of the drive brands while managing the other brands for long-term sustainability and profitability. Consistent with that strategy, RJR Tobacco continues to evaluate some of its non-core cigarette styles for potential elimination.
RJR Tobacco’s portfolio also includes CAMEL Snus, a smoke-free, heat-treated tobacco product sold in individual pouches that provide convenient tobacco consumption.
Competition is based primarily on brand positioning, including price, product attributes and packaging, consumer loyalty, promotions, advertising and retail presence as well as finding efficient and effective means of balancing market share and profit growth. Cigarette brands produced by the major manufacturers generally require competitive pricing, substantial marketing support, retail programs and other incentives to maintain or improve market position or to introduce a new brand or brand style. Competition among the major cigarette manufacturers continues to be highly competitive and includes product innovation and expansion into smoke-free tobacco categories.
RJR Tobacco is committed to building and maintaining a portfolio of profitable brands. RJR Tobacco’s marketing programs are designed to strengthen brand image, build brand awareness and loyalty, and switch adult smokers of competing brands to RJR Tobacco brands. In addition to building strong brand equity, RJR Tobacco’s marketing approach utilizes a retail pricing strategy, including discounting at retail, to defend certain brands’ shares of market against competitive pricing pressure. RJR Tobacco’s competitive pricing methods may include list price changes, discounting programs, such as retail and wholesale buydowns, periodic price reductions, off-invoice price reductions, dollar-off promotions and consumer coupons. Retail buydowns refer to payments made to the retailer to reduce the price that consumers pay at retail. Consumer coupons are distributed by a variety of methods.
Santa Fe
Santa Fe competes in the U.S. cigarette market with its Natural American Spirit brand, which is the fastest growing super-premium cigarette brand and is a top 10 best-selling cigarette brand. It is priced higher than most other competitive brands. Competition in the cigarette category is based primarily on brand positioning, including price, product attributes and packaging, consumer loyalty, promotions, advertising and retail presence.
American Snuff
American Snuff offers adult tobacco consumers a range of differentiated smokeless tobacco products, primarily moist snuff, with its GRIZZLY and KODIAK brands. The moist snuff category is divided into premium, price-value and popular-price brands. The highly competitive moist snuff category has developed many of the characteristics of the larger, cigarette market, including multiple pricing tiers, focused marketing programs and significant product innovation.
In contrast to the declining U.S. cigarette market, U.S. moist snuff retail volumes grew approximately 3.6% in 2016. Profit margins on moist snuff products are generally higher than on cigarette products. Moist snuff’s growth is partially attributable to cigarette smokers switching from cigarettes to smokeless tobacco products or using both.
American Snuff faces significant competition in the smokeless tobacco category. Similar to the cigarette market, competition is based primarily on brand positioning and price, as well as product attributes and packaging, consumer loyalty, promotions, advertising and retail presence.
All Other
RJR Vapor is a marketer of VUSE Digital Vapor Cigarette products, which include VUSE Solo, VUSE Fob and VUSE Vibe. The national expansion of VUSE was completed in early 2015, and it is available in more than 110,000 retail outlets across the United States. VUSE is the top-selling vapor product in convenience/gas stores, and its innovative digital technology is designed to deliver a consistent flavor and vapor experience. In March 2016, RJR Vapor introduced its VUSE Fob power unit. This next-level VUSE Fob, which integrates Bluetooth® technology, offers an on-device display with information about battery and cartridge levels. When paired with the VUSE App, the device can be locked, preventing use by minors and others. VUSE Fob is available online to adult tobacco consumers. RJR Vapor began national distribution, in November 2016, of its VUSE Vibe high-volume cartridge and closed-tank system with a rechargeable battery. VUSE Vibe offers more liquid than previous VUSE products, as well as a stronger and longer-lasting battery.
Since the fourth quarter of 2015, all production of VUSE Solo cartridges is performed at RJR Tobacco’s manufacturing facility, pursuant to a services agreement between RJR Tobacco and RJR Vapor. For additional information, see Item 8, note 6 to consolidated financial statements.
32
Niconovum USA, Inc. is a marketer of a nicotine replacement therapy gum, Z ONNIC , which is available in about 35,000 retail outlets across the United States. Niconovum AB is a marketer of nicotine replacement therapy products in Sweden under the ZONNIC brand name.
Accounting principles generally accepted in the United States of America, referred to as GAAP, require estimates and assumptions to be made that affect the reported amounts in RAI’s consolidated financial statements and accompanying notes. Some of these estimates require difficult, subjective and/or complex judgments about matters that are inherently uncertain, and as a result, actual results could differ from those estimates. Due to the estimation processes involved, the following summarized accounting policies and their application are considered to be critical to understanding the business operations, financial position and results of operations of RAI and its subsidiaries. For information related to these and other significant accounting policies, see Item 8, note 1 to consolidated financial statements.
Litigation
RAI discloses information concerning litigation for which an unfavorable outcome is more than remote. RAI and its subsidiaries record their legal expenses and other litigation costs and related administrative costs as selling, general and administrative expenses as those costs are incurred. RAI and its subsidiaries will record any loss related to litigation at such time as an unfavorable outcome becomes probable and the amount can be reasonably estimated on an individual case-by-case basis. When the reasonable estimate is a range, the recorded loss will be the best estimate within the range. If no amount in the range is a better estimate than any other amount, the minimum amount of the range will be recorded.
Reynolds Defendants have been named in a number of tobacco-related legal actions, proceedings or claims seeking damages in amounts ranging into the hundreds of millions or even billions of dollars. Unfavorable judgments have been returned in a number of tobacco-related cases and state enforcement actions. For further discussion of the litigation and legal proceedings pending against RAI or its affiliates or indemnitees, see Item 8, note 13 to consolidated financial statements.
State Settlement Agreements
RJR Tobacco (itself, and as successor by merger to Lorillard Tobacco) and SFNTC are participants in the MSA, and RJR Tobacco (itself, and as successor by merger to Lorillard Tobacco) is a participant in the other state settlement agreements. Their obligations and the related expense charges under these agreements are subject to adjustments based upon, among other things, the volume of cigarettes sold by the operating subsidiaries, their relative market share, their operating profits and inflation. Since relative market share is based on cigarette shipments, the best estimate of the allocation of charges to RJR Tobacco and SFNTC under these agreements is recorded in cost of products sold as the products are shipped. Adjustments to these estimates are recorded in the period that the change becomes probable and the amount can be reasonably estimated. American Snuff Co. is not a participant in the State Settlement Agreements. For additional information related to the State Settlement Agreements, see “— Litigation Affecting the Cigarette Industry — Health-Care Cost Recovery Cases — State Settlement Agreements” and “— State Settlement Agreements — Enforcement and Validity; Adjustments” in Item 8, note 13 to consolidated financial statements.
Pension and Postretirement Benefits
RAI sponsors a number of non-contributory defined benefit pension plans covering certain employees of RAI and its subsidiaries. RAI and a subsidiary provide health and life insurance benefits for certain retired employees, of RAI and its subsidiaries, and their dependents. These benefits are generally no longer provided to employees hired on or after January 1, 2004.
Because pension and postretirement obligations ultimately will be settled in future periods, the determination of annual benefit cost (income) and liabilities is subject to estimates and assumptions. RAI reviews these assumptions annually or coincidental with a major event based on historical experience and expected future trends and modifies them as needed. Demographic assumptions such as termination of employment, mortality and retirement date are reviewed periodically as expectations change.
Actuarial (gains) losses are changes in the amount of either the benefit obligation or the fair value of plan assets resulting from experience different from that assumed or from changes in assumptions. Actuarial (gains) losses are immediately recognized in the operating results in the year in which they occur, to the extent the net (gains) losses are in excess of 10% of the greater of the fair value of plan assets or benefit obligations, referred to as the corridor. Net (gains) losses outside the corridor are recognized annually as of December 31, or when a plan is remeasured during an interim period, and are recorded as a mark-to-market adjustment, referred to as an MTM adjustment. Additionally, for the purpose of calculating the expected return on plan assets, RAI uses the actual fair value of plan assets.
33
Prior service costs (credits) of pension benefits, which are changes in benefit obligations due to plan amendments, are amortized on a straight-line basis over the average remaining service period for active employees, or average remaining life expectancies for inactive employees if most of the plan obligations are due to inactive employees. Prior service costs (credits) of postretirement benefits, which are changes in benefit obligations due to plan amendments, are amortized on a straight-line basis over the expected service period to full eligibility age for active employees, or average remaining life expectancies for inactive employees if most of the plan obligations are due to inactive employees.
Assumed discount rate and asset return are the most critical assumptions, and their respective sensitivity to change can have a significant effect on the amounts reported for the benefit plans. A one-percentage point change in the assumed discount rate for the pension plans and postretirement plans would have had the following effects, excluding any potential MTM adjustments:
|
|
1-Percentage Point Increase |
|
|
1-Percentage Point Decrease |
|
||||||||||
|
|
Pension Plans |
|
|
Postretirement Plans |
|
|
Pension Plans |
|
|
Postretirement Plans |
|
||||
Effect on 2016 net periodic benefit cost |
|
$ |
23 |
|
|
$ |
5 |
|
|
$ |
(34 |
) |
|
$ |
(7 |
) |
Effect on December 31, 2016, projected benefit obligation and accumulated postretirement benefit obligation |
|
|
(665 |
) |
|
|
(103 |
) |
|
|
812 |
|
|
|
123 |
|
A one-percentage point change in assumed asset return would have had the following effects:
|
|
1-Percentage Point Increase |
|
|
1-Percentage Point Decrease |
|
||||||||||
|
|
Pension Plans |
|
|
Postretirement Plans |
|
|
Pension Plans |
|
|
Postretirement Plans |
|
||||
Effect on 2016 net periodic benefit cost |
|
$ |
(55 |
) |
|
$ |
(2 |
) |
|
$ |
55 |
|
|
$ |
2 |
|
For additional information relating to pension and postretirement benefits, see Item 8, note 16 to consolidated financial statements.
Intangible Assets
Intangible assets include goodwill, trademarks and other intangible assets. The determination of fair value involves considerable estimates and judgment. Intangible assets with indefinite lives are tested annually for impairment in the fourth quarter or more frequently if events and circumstances indicate that an impairment may have occurred.
For goodwill, the determination of fair value of a reporting unit involves, among other things, RAI’s market capitalization, and application of the income approach, which includes developing forecasts of future cash flows and determining an appropriate discount rate. If goodwill impairment is implied, the fair values of individual assets and liabilities, including unrecorded intangibles, must be determined. RAI believes it has based its goodwill impairment testing on reasonable estimates and assumptions, and during the annual testing, the estimated fair value of each of RAI’s reporting units was substantially in excess of its respective carrying value.
The methodology used to determine the fair value of trademarks includes assumptions with inherent uncertainty, including projected sales volumes and related projected revenues, long-term growth rates, royalty rates that a market participant might assume and judgments regarding the factors to develop an applied discount rate. The carrying value of intangible assets is at risk of impairment if future projected revenues or long-term growth rates are lower than those currently projected, or if factors used in the development of a discount rate result in the application of a higher discount rate. The aggregate fair value of RAI’s operating units’ trademarks and other intangible assets at December 31, 2016, was substantially in excess of their aggregate carrying value. However, at December 31, 2016, the individual fair values of five trademarks were less than 15% in excess of their respective carrying values. The aggregate carrying value of these five trademarks was $27.3 billion at December 31, 2016.
Goodwill, trademarks and other intangible assets are tested more frequently if events and circumstances indicate that the asset might be impaired. The carrying value of these intangible assets could be impaired if a significant adverse change in the use, life, or brand strategy of the asset is determined, or if a significant adverse change in the legal and regulatory environment, business or competitive climate occurs that would adversely impact the asset. For information related to intangible assets, see Item 8, note 5 to consolidated financial statements.
34
RAI determines fair value of assets and liabilities using a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity, and the reporting entity’s own assumptions about market participant assumptions based on the best information available in the circumstances.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.
For information on assets and liabilities recorded at fair value, see Item 8, notes 4, 12 and 16 to consolidated financial statements.
Income Taxes
Tax law requires certain items to be excluded or included in taxable income at different times than is required for book reporting purposes. These differences may be permanent or temporary in nature.
RAI determines its annual effective income tax rate based on forecasted pre-tax book income and forecasted permanent book and tax differences. The rate is established at the beginning of the year and is evaluated on a quarterly basis. Any changes to the forecasted information may cause the effective rate to be adjusted. Additional tax, interest and penalties associated with uncertain tax positions are recognized in tax expense on a quarterly basis.
To the extent that any book and tax differences are temporary in nature, that is, the recognition and measurement of assets and liabilities under the tax law may differ from recognition and measurement under GAAP, a deferred tax asset or liability is recorded. To the extent that a deferred tax asset is recorded, management evaluates RAI’s ability to realize this asset. A valuation allowance is required for deferred tax assets if, based on available evidence, it is more likely than not that all or some portion of the assets will not be realized.
The financial statements reflect management’s best estimate of RAI’s current and deferred tax liabilities and assets. Future events, including, but not limited to, additional resolutions with taxing authorities, could have an impact on RAI’s current estimate of tax liabilities, realization of tax assets and effective income tax rate. For additional information on income taxes, see Item 8, note 10 to consolidated financial statements.
Business Combination
RAI accounts for business combination transactions in accordance with the Financial Accounting Standards Board, referred to as FASB, Accounting Standards Codification 805, Business Combinations , referred to as ASC 805. RAI allocates the cost of an acquisition to the assets acquired and liabilities assumed based on their fair values as of the acquisition date. Any excess of the purchase price over the estimated fair value of net assets acquired is recorded as goodwill. Determining the fair value of these items requires management’s judgment and may require utilization of independent valuation experts to assist such valuations. These valuations involve the use of significant estimates and assumptions with respect to the timing and amounts of future cash flows, discount rates, market prices and asset lives, among other items. The judgments made in the determination of the estimated fair value of the assets acquired and the liabilities assumed as well as the estimated useful life of each asset and the duration of each liability can materially impact the financial statements in periods after the acquisition, such as depreciation, amortization, or in certain situations, impairment charges. For further information related to accounting for the Lorillard Merger and Divestiture, see Item 8, notes 1 and 2 to consolidated financial statements.
Recently Adopted and Issued Accounting Pronouncements
For information relating to recently adopted and issued accounting guidance, see Item 8, note 1 to consolidated financial statements.
35
RJR Tobacco’s net sales and operating income include the WINSTON, KOOL and SALEM brands until the date of their sale on June 12, 2015, and the NEWPORT, KENT, OLD GOLD and TRUE brands after June 12, 2015. All Other net sales and operating income include SFRTI and the various foreign subsidiaries affiliated with SFRTI, until the date of their sale on January 13, 2016.
|
|
For the Twelve Months Ended December 31, |
|
|||||||||||||||||
|
|
2016 |
|
|
2015 |
|
|
% Change |
|
|
2014 |
|
|
% Change |
|
|||||
Net sales: (1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco |
|
$ |
10,314 |
|
|
$ |
8,634 |
|
|
|
19.5 |
% |
|
$ |
6,767 |
|
|
|
27.6 |
% |
Santa Fe |
|
|
973 |
|
|
|
818 |
|
|
|
18.9 |
% |
|
|
658 |
|
|
|
24.3 |
% |
American Snuff |
|
|
914 |
|
|
|
855 |
|
|
|
6.9 |
% |
|
|
783 |
|
|
|
9.2 |
% |
All Other |
|
|
302 |
|
|
|
368 |
|
|
|
(17.9 |
)% |
|
|
263 |
|
|
|
39.9 |
% |
Net sales |
|
|
12,503 |
|
|
|
10,675 |
|
|
|
17.1 |
% |
|
|
8,471 |
|
|
|
26.0 |
% |
Cost of products sold (1)(2) |
|
|
4,841 |
|
|
|
4,688 |
|
|
|
3.3 |
% |
|
|
4,058 |
|
|
|
15.5 |
% |
Selling, general and administrative expenses |
|
|
1,931 |
|
|
|
2,098 |
|
|
|
(8.0 |
)% |
|
|
1,871 |
|
|
|
12.1 |
% |
Gain on divestitures |
|
|
(4,861 |
) |
|
|
(3,181 |
) |
|
|
52.8 |
% |
|
|
— |
|
|
NM (3) |
|
|
Amortization expense |
|
|
23 |
|
|
|
18 |
|
|
|
27.8 |
% |
|
|
11 |
|
|
|
63.6 |
% |
Asset impairment and exit charges |
|
|
— |
|
|
|
99 |
|
|
NM (3) |
|
|
|
— |
|
|
NM (3) |
|
||
Operating income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco |
|
|
4,922 |
|
|
|
3,359 |
|
|
|
46.5 |
% |
|
|
2,173 |
|
|
|
54.6 |
% |
Santa Fe |
|
|
546 |
|
|
|
449 |
|
|
|
21.6 |
% |
|
|
337 |
|
|
|
33.2 |
% |
American Snuff |
|
|
541 |
|
|
|
502 |
|
|
|
7.8 |
% |
|
|
438 |
|
|
|
14.6 |
% |
All Other |
|
|
(145 |
) |
|
|
(265 |
) |
|
|
(45.3 |
)% |
|
|
(234 |
) |
|
|
13.2 |
% |
Gain on divestitures |
|
|
4,861 |
|
|
|
3,181 |
|
|
|
52.8 |
% |
|
|
— |
|
|
NM (3) |
|
|
Corporate expense |
|
|
(156 |
) |
|
|
(273 |
) |
|
|
(42.9 |
)% |
|
|
(183 |
) |
|
|
49.2 |
% |
Operating income |
|
$ |
10,569 |
|
|
$ |
6,953 |
|
|
|
52.0 |
% |
|
$ |
2,531 |
|
|
NM (3) |
|
(1) |
Excludes excise taxes of: |
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
RJR Tobacco |
|
$ |
3,997 |
|
|
$ |
3,590 |
|
|
$ |
3,068 |
|
Santa Fe |
|
|
287 |
|
|
|
254 |
|
|
|
211 |
|
American Snuff |
|
|
54 |
|
|
|
54 |
|
|
|
53 |
|
All Other |
|
|
5 |
|
|
|
311 |
|
|
|
293 |
|
|
|
$ |
4,343 |
|
|
$ |
4,209 |
|
|
$ |
3,625 |
|
(2) |
See below for further information related to State Settlement Agreements, FDA user fees and federal tobacco buyout included in cost of products sold. |
(3) |
Percentage change not meaningful. |
In the following discussion, the amounts presented in the operating companies’ shipment volume and share tables are rounded on an individual basis and, accordingly, may not sum in the aggregate. Percentages are calculated on unrounded numbers.
36
RJR Tobacco
Net Sales
Domestic cigarette shipment volume, in billions of units, for RJR Tobacco and the industry, was as follows:
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
% Change |
|
|||
RJR Tobacco: |
|
|
|
|
|
|
|
|
|
|
|
|
Drive brands: |
|
|
|
|
|
|
|
|
|
|
|
|
NEWPORT |
|
|
34.4 |
|
|
|
18.9 |
|
|
NM (2) |
|
|
CAMEL |
|
|
20.3 |
|
|
|
20.8 |
|
|
|
(2.2 |
)% |
PALL MALL |
|
|
18.9 |
|
|
|
19.9 |
|
|
|
(5.2 |
)% |
Total RJR Tobacco drive brands |
|
|
73.5 |
|
|
|
59.5 |
|
|
|
23.5 |
% |
Other brands |
|
|
5.9 |
|
|
|
11.8 |
|
|
|
(50.0 |
)% |
Total RJR Tobacco domestic cigarette shipment volume |
|
|
79.4 |
|
|
|
71.3 |
|
|
|
11.3 |
% |
Total premium |
|
|
56.5 |
|
|
|
47.0 |
|
|
|
20.1 |
% |
Total value |
|
|
23.0 |
|
|
|
24.3 |
|
|
|
(5.6 |
)% |
Premium/total mix |
|
|
71.1 |
% |
|
|
65.9 |
% |
|
|
|
|
Industry (1) : |
|
|
|
|
|
|
|
|
|
|
|
|
Premium |
|
|
187.4 |
|
|
|
190.3 |
|
|
|
(1.5 |
)% |
Value |
|
|
70.6 |
|
|
|
74.0 |
|
|
|
(4.6 |
)% |
Total industry domestic cigarette shipment volume |
|
|
258.0 |
|
|
|
264.3 |
|
|
|
(2.4 |
)% |
Premium/total mix |
|
|
72.6 |
% |
|
|
72.0 |
% |
|
|
|
|
(1) |
Based on information from MSAi. |
(2) |
Percentage of change not meaningful. |
RJR Tobacco’s net sales are dependent upon its cigarette shipment volume in a declining market, premium versus value-brand mix and list pricing, offset by promotional spending, trade incentives and federal and state excise taxes.
RJR Tobacco’s net sales for the year ended December 31, 2016, increased from the year ended December 31, 2015, primarily due to higher volume and favorable product mix of $1.3 billion and higher net pricing of $490 million .
Market Share
Market share information is included for RJR Tobacco to provide enhanced analysis of its brand performance. For brands that were acquired in the Lorillard Merger, share information is displayed as if the brands were part of the portfolio for all time periods shown. Brands that were part of the Divestiture have been removed for all presented time periods. Accordingly, this pro forma market share data is presented for informational purposes only and is not necessarily indicative of what the market share of the acquired brands would have been if the Lorillard Merger and Divestiture had occurred at the beginning of the periods presented, nor is it necessarily indicative of future market share.
37
The shares of RJR Tobacco’s cigarette brands as a percentage of total share of U.S. cigarette STR data were as follows (1) :
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
Share Point Change |
|
|||
Drive brands: |
|
|
|
|
|
|
|
|
|
|
|
|
NEWPORT |
|
|
13.9 |
% |
|
|
13.5 |
% |
|
|
0.4 |
|
CAMEL |
|
|
8.2 |
% |
|
|
8.3 |
% |
|
|
(0.1 |
) |
PALL MALL |
|
|
7.7 |
% |
|
|
7.9 |
% |
|
|
(0.3 |
) |
Total drive brands |
|
|
29.9 |
% |
|
|
29.7 |
% |
|
|
0.1 |
|
Other brands |
|
|
2.4 |
% |
|
|
2.6 |
% |
|
|
(0.2 |
) |
Total RJR Tobacco domestic cigarette retail share of market |
|
|
32.3 |
% |
|
|
32.3 |
% |
|
|
(0.1 |
) |
(1) |
In 2016, the universe of industry participants that MSAi uses to estimate RJR Tobacco’s cigarette shipments to retail market share has been revised to reflect the new universe of direct customers as a result of the Lorillard Merger. The revision results in higher absolute share levels in 2015 on some of RJR Tobacco’s brands, but does not affect overall share trends. Prior-year market share data, herein, has been restated on this basis for comparison purposes. |
The retail share of market of NEWPORT, at 13.9 share points, was up 0.4 share points compared with the prior-year period in the highly competitive U.S. cigarette category. NEWPORT’s cigarette market share continued to be favorably impacted by its strength in the menthol category, as well as its continued momentum in the non-menthol category.
The retail share of market of CAMEL, at 8.2 share points, was down 0.1 share points compared with the prior-year period in the highly competitive U.S. cigarette category. CAMEL’s cigarette market share demonstrated relatively stable performance in its menthol styles that offer its innovative capsule technology offered in CAMEL Crush. CAMEL Crush styles provide adult smokers the choice of switching from non-menthol to menthol. CAMEL Crush menthol styles allow adult smokers to choose the level of menthol flavor on demand. CAMEL SNUS, a smoke-free tobacco product, continues to lead the U.S. snus category with a market share of approximately 75%.
PALL MALL, a product that offers a high quality, longer-lasting cigarette at a value price, continues to attract interest from adult tobacco consumers. PALL MALL’s 2016 market share of 7.7% was down 0.3 share points compared with the prior-year period due to continued competitive pressure.
The combined share of market of RJR Tobacco’s drive brands during 2016 was up slightly compared with 2015. RJR Tobacco’s total cigarette market share was down slightly from the prior year due to increases in the company’s drive brands, offset by decreases in the company’s other brands, consistent with its strategy of focusing on drive brands.
Operating Income
RJR Tobacco’s operating income for the year ended December 31, 2016, increased from the year ended December 31, 2015, primarily due to higher volume, higher cigarette pricing and favorable product mix. The results for the year ended December 31, 2016, include a full year net benefit from the Lorillard Merger and Divestiture compared with approximately six months in 2015. In addition, the MTM adjustment expense in 2016 was $42 million compared with an MTM adjustment expense of $229 million in 2015. The 2016 MTM adjustment was driven primarily by a decrease in the discount rate partially offset by the impact of assumption changes and better than expected asset returns. The 2015 MTM adjustment was primarily a result of lower than expected asset returns partially offset by an increase in the discount rate.
RJR Tobacco’s expense under the State Settlement Agreements and its FDA user fees included in cost of products sold were:
|
|
For the Twelve Months Ended December 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
State Settlement Agreements |
|
$ |
2,563 |
|
|
$ |
2,254 |
|
FDA user fees |
|
|
179 |
|
|
|
162 |
|
Expenses under the State Settlement Agreements are expected to be approximately $2.8 billion in 2017, subject to adjustment based upon, among other things, the volume of cigarettes sold by RJR Tobacco, its relative market share, its operating profits and
38
inflation. Pursuant to the Term Sheet, RJR Tobacco will receive credits with respect to its NPM Adjustment claims to be applied against annual payments under the MSA through 2018.
As a result of meeting the performance requirements associated with the Term Sheet, RJR Tobacco recognized credits of $295 million and $279 million for the years ended December 31, 2016 and 2015, respectively. RJR Tobacco expects to recognize additional credits through 2017.
In September 2013, the Arbitration Panel ruled six states had not diligently enforced their qualifying statutes in 2003 related to the NPM Adjustment. Two of the six states subsequently joined the Term Sheet in 2014. In 2015, three of the states dropped their challenge of the finding of non-diligence and in 2016, the remaining state dropped its challenge. As such, a portion of the potential recovery from those states was certain and estimable, and RJR Tobacco recognized $6 million and $93 million as a reduction of cost of products sold for the years ended December 31, 2016 and 2015, respectively. A final issue regarding the judgment reduction method adopted by the Arbitration Panel was being contested in these four states. In 2016, the U.S. Supreme Court denied RJR Tobacco’s petition for writ of certiorari against two states, thus eliminating RJR Tobacco’s remaining recovery from these states. The final outcome in the remaining two states is uncertain.
In October 2015, RJR Tobacco and certain other PMs entered into a settlement agreement, referred to as the NY Settlement Agreement, with the State of New York to settle certain claims related to the NPM Adjustment. The NY Settlement Agreement resolved NPM Adjustment claims related to payment years from 2004 through 2014, providing RJR Tobacco with credits of approximately $285 million, plus interest, subject to meeting various performance obligations. These credits will be applied against annual payments under the MSA over a four-year period, which commenced with the April 2016 MSA payment. Accordingly, RJR Tobacco recognized credits of $93 million and $14 million as a reduction to cost of products sold for the years ended December 31, 2016 and 2015, respectively. In addition, the NY Settlement Agreement put in place a new method to determine future adjustments from 2015 forward as to New York.
For additional information, see “— Cost of Products Sold” in Item 8, note 1 and “— Litigation Affecting the Cigarette Industry — Health-Care Cost Recovery Cases — State Settlement Agreements” and “— State Settlement Agreements — Enforcement and Validity; Adjustments” in Item 8, note 13 to consolidated financial statements.
Expenses for FDA user fees are expected to be approximately $160 million to $190 million in 2017. For additional information, see “— Governmental Activity” below.
Selling, general and administrative expenses include the costs of litigating and administering product liability claims, as well as other legal expenses. For the years ended December 31, 2016 and 2015, RJR Tobacco’s product liability defense costs were $208 million and $198 million, respectively.
“Product liability” cases generally include the following types of smoking and health related cases:
|
• |
Individual Smoking and Health; |
|
• |
West Virginia IPIC ; |
|
• |
Engle Progeny; |
|
• |
Broin II ; |
|
• |
Class Actions; |
|
• |
Filter Cases; and |
|
• |
Health-Care Cost Recovery Claims. |
“Product liability defense costs” include the following items:
|
• |
direct and indirect compensation, fees and related costs and expenses for internal legal and related administrative staff administering the defense of product liability claims; |
|
• |
fees and cost reimbursements paid to outside attorneys; |
|
• |
direct and indirect payments to third party vendors for litigation support activities; and |
|
• |
expert witness costs and fees. |
39
Numerous factors affect product liability defense costs. The most important factors are the number of cases pending and the number of cases in trial or in preparation for trial, that is, with active discovery and motions practice. See “— Litigation Affecting the Cigarette Industry — Overview — Introduction” in Item 8, note 13 to consolidated financial statements for detailed information regarding the number and type of cases pending, and “— Litigation Affecting the Cigarette Industry — Overview — Scheduled Trials” in Item 8, note 13 to consolidated financial statements for detailed information regarding the number and nature of cases in trial and scheduled for trial through December 31, 2017.
RJR Tobacco expects that the items described above will continue to comprise its product liability defense costs in the future. Given the level of activity in RJR Tobacco’s pending cases, including the number of cases in trial and scheduled for trial, particularly with respect to the Engle Progeny cases, RJR Tobacco’s product liability defense costs are expected to remain at a high level. See “— Litigation Affecting the Cigarette Industry — Engle and Engle Progeny Cases” in Item 8, note 13 to consolidated financial statements for additional information.
In addition, it is possible that other adverse developments in the items discussed above, as well as other circumstances beyond the control of RJR Tobacco, could have a material adverse effect on the consolidated results of operations, cash flows or financial position of RAI or its subsidiaries. Those other circumstances beyond the control of RJR Tobacco include the results of present and future trials and appeals, and the development of possible new theories of liability by plaintiffs and their counsel.
Santa Fe
Net Sales
Domestic cigarette shipment volume, in billions of units, for Santa Fe was as follows:
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
% Change |
|
|||
NATURAL AMERICAN SPIRIT |
|
|
5.4 |
|
|
|
4.8 |
|
|
|
13.6 |
% |
Santa Fe’s net sales for the year ended December 31, 2016, increased over 2015 primarily due to higher volume and higher net pricing.
Market Share
The shares of Santa Fe’s NATURAL AMERICAN SPIRIT cigarette brand as a percentage of total share of U.S. cigarette STR data were as follows (1) :
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
Share Point Change |
|
|||
NATURAL AMERICAN SPIRIT |
|
|
2.2 |
% |
|
|
1.9 |
% |
|
|
0.3 |
|
(1) |
In 2016, the universe of industry participants that MSAi uses to estimate Santa Fe’s cigarette shipments to retail market share has been revised to reflect the new universe of direct customers as a result of the Lorillard Merger. The revision results in higher absolute share levels in 2015 on some of Santa Fe’s brand styles, but does not affect overall share trends. Prior-year market share data, herein, has been restated on this basis for comparison purposes. |
Natural American Spirit continues to be the fastest growing super-premium cigarette brand in the industry as the product resonates with adult tobacco consumers looking for an authentic brand founded on principles of quality.
Operating Income
Santa Fe’s operating income for the year ended December 31, 2016, increased as compared with the prior-year period primarily due to higher volume and higher net pricing.
40
Santa Fe’s expense under the MSA and its FDA user fees, included in cost of products sold were:
|
|
For the Twelve Months Ended December 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
MSA |
|
$ |
164 |
|
|
$ |
140 |
|
FDA user fees |
|
|
13 |
|
|
|
10 |
|
Expenses under the MSA are expected to be approximately $175 million to $205 million in 2017, subject to adjustment for changes in volume and other factors.
In October 2015, SFNTC and certain other PMs entered into the NY Settlement Agreement to settle certain claims related to the NPM Adjustment. The NY Settlement Agreement resolved NPM Adjustment claims related to payment years from 2004 through 2014, providing SFNTC with credits of approximately $5 million, plus interest, subject to meeting various performance obligations. These credits will be applied against annual payments under the MSA over a four-year period, which commenced with the April 2016 MSA payment. In addition, the NY Settlement Agreement put in place a new method to determine future adjustments from 2015 forward as to New York.
For additional information, see “— Cost of Products Sold” in Item 8, note 1 and “— Litigation Affecting the Cigarette Industry — Health-Care Cost Recovery Cases — State Settlement Agreements” and “— State Settlement Agreements — Enforcement and Validity; Adjustments” in Item 8, note 13 to consolidated financial statements.
American Snuff
Net Sales
The moist snuff shipment volume, in millions of cans, for American Snuff was as follows:
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
% Change |
|
|||
GRIZZLY |
|
|
460.6 |
|
|
|
454.4 |
|
|
|
1.4 |
% |
Other |
|
|
42.4 |
|
|
|
44.7 |
|
|
|
(5.2 |
)% |
Total American Snuff moist snuff shipment volume |
|
|
502.9 |
|
|
|
499.1 |
|
|
|
0.8 |
% |
American Snuff’s net sales for the year ended December 31, 2016, increased compared with the prior-year period primarily due to higher net pricing and higher moist snuff volume.
Moist snuff has been the key driver to American Snuff’s overall growth and profitability within the U.S. smokeless tobacco market. Moist snuff accounted for approximately 91% of American Snuff’s revenue in 2016 and approximately 90% in 2015.
Market Share
The shares of American Snuff’s moist snuff brands as a percentage of total share of U.S. moist snuff STR data were as follows (1) :
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
Share Point Change |
|
|||
GRIZZLY |
|
|
30.8 |
% |
|
|
30.9 |
% |
|
|
(0.1 |
) |
Other |
|
|
2.6 |
% |
|
|
2.8 |
% |
|
|
(0.2 |
) |
Total American Snuff moist snuff retail share of market |
|
|
33.4 |
% |
|
|
33.7 |
% |
|
|
(0.3 |
) |
(1) |
In 2016, the universe of industry participants that MSAi uses to estimate American Snuff’s moist snuff shipments to retail market share has been revised to reflect the new universe of direct customers as a result of the Lorillard Merger. The revision results in higher absolute share levels in 2015 on some of American Snuff’s brands, but does not affect overall share trends. Prior-year market share data, herein, has been restated on this basis for comparison purposes. |
41
GRIZZLY, a leading U.S. moist snuff brand, declined 0.1 share points in 2016 in a significantly competitive marketplace. GRIZZLY’s increase in full-year shipment volume was driven by growth in the wintergreen styles and pouch offerings. GRIZZLY continues its market-leading position in wintergreen, with long cut and pouch styles remaining strong and the GRIZZLY Dark Wintergreen style enhancing the GRIZZLY wintergreen offerings. GRIZZLY Dark Wintergreen offers a differentiated and bolder wintergreen flavor, and is made from 100% U.S. tobacco grown in Kentucky and Tennessee.
GRIZZLY continues to show strength with its soft pouch design, which offers smokeless tobacco consumers a flavorful, moist experience that is easy to use, positioning it to be the fastest growing leading pouch brand. The pouch category represents approximately 20% of the moist snuff industry.
In September 2016, GRIZZLY expanded its product offerings with the national launch of Premium Dark Mint. This style offers 100% dark-fired U.S. tobacco with mint flavor.
Operating Income
American Snuff’s operating income for the year ended December 31, 2016, increased compared with the prior-year period primarily due to higher net pricing and higher moist snuff volume.
All Other
RJR Vapor is the marketer of VUSE Digital Vapor Cigarette products. Since the fourth quarter of 2015, all production of VUSE Solo cartridges is performed at RJR Tobacco’s manufacturing facility, pursuant to a services agreement between RJR Tobacco and RJR Vapor. As a result of this consolidation, pre-tax asset impairment and exit charges of $99 million were recorded in All Other in the third quarter of 2015. For additional information, see Item 8, note 6 to consolidated financial statements.
Gain on divestitures
The results of operations of SFRTI were reported in All Other until their sale on January 13, 2016. SFRTI and various foreign subsidiaries affiliated with SFRTI distributed the NATURAL AMERICAN SPIRIT brand outside the United States. RAI, through the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with the international companies that distributed and marketed the brand outside the United States, to JTI Holding in an all-cash transaction for approximately $5 billion and recognized a pre-tax gain of approximately $4.9 billion in the first quarter of 2016. See Item 8, note 3 to consolidated financial statements for additional information.
For the year ended December 31, 2015, the $3.2 billion pre-tax gain is a result of the divestiture of the WINSTON, KOOL and SALEM cigarette brands, previously owned by RAI subsidiaries, as well as the cigarette brand MAVERICK and the “e-vapor” brand blu (including SKYCIG), previously owned by Lorillard subsidiaries, and other assets and certain liabilities. For additional information, see Item 8, note 2 to consolidated financial statements.
Corporate Expense
Corporate operating costs and expenses decreased for the year ended December 31, 2016, compared with 2015, primarily due to a lower MTM adjustment expense in 2016, and costs associated with the Lorillard Merger and Divestiture in 2015.
RAI Consolidated
Interest and debt expense for the year ended December 31, 2016, increased $56 million compared with the prior period. The change is primarily due to costs associated with the notes issued to fund part of the merger consideration in the Lorillard Merger and the notes assumed from Lorillard Tobacco in connection with the Lorillard Merger, offset by decreases in interest and debt expenses related to the repurchase and redemption during the first six months of 2016 of approximately $3.7 billion of outstanding notes, and the repayment at maturity in August 2016 of approximately $500 million of outstanding notes. RAI expects that interest expense will be lower in future periods, compared with prior periods due to the retirement of debt that occurred in 2016.
Provision for income taxes reflected an effective rate of 37.3%, for the year ended December 31, 2016, compared with an effective rate of 49.0%, for the year ended December 31, 2015. The effective tax rate for 2016 was impacted by the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with the international companies that distributed and marketed the brand outside the United States. The effective tax rate for 2015 was unfavorably impacted by an increase in tax attributable to nondeductible acquisition costs, nondeductible goodwill in the amount of $1,849 million
42
associated with the Lorillard Merger and Divestiture and an increase in uncertain tax positions, offset by a decrease in tax attributable to the release of valuation allowance and a reduction in state income taxes.
The effective tax rate for each period differed from the federal statutory rate of 35% due to the domestic manufacturing deduction of the American Jobs Creation Act of 2004, state income taxes and certain nondeductible items.
RAI expects its effective tax rate to be between 36.5% and 37.5% in 2017.
2015 Compared with 2014
RJR Tobacco
Net Sales
Domestic cigarette shipment volume, in billions of units, for RJR Tobacco and the industry, was as follows:
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2015 |
|
|
2014 |
|
|
% Change |
|
|||
RJR Tobacco: |
|
|
|
|
|
|
|
|
|
|
|
|
Drive brands: |
|
|
|
|
|
|
|
|
|
|
|
|
NEWPORT |
|
|
18.9 |
|
|
|
— |
|
|
NM (2) |
|
|
CAMEL |
|
|
20.8 |
|
|
|
20.9 |
|
|
|
(0.5 |
)% |
PALL MALL |
|
|
19.9 |
|
|
|
20.6 |
|
|
|
(3.4 |
)% |
Total RJR Tobacco drive brands |
|
|
59.5 |
|
|
|
41.5 |
|
|
|
43.5 |
% |
Other brands |
|
|
11.8 |
|
|
|
19.5 |
|
|
|
(39.4 |
)% |
Total RJR Tobacco domestic cigarette shipment volume |
|
|
71.3 |
|
|
|
61.0 |
|
|
|
17.0 |
% |
Total premium |
|
|
47.0 |
|
|
|
35.6 |
|
|
|
32.1 |
% |
Total value |
|
|
24.3 |
|
|
|
25.4 |
|
|
|
(4.1 |
)% |
Premium/total mix |
|
|
65.9 |
% |
|
|
58.4 |
% |
|
|
|
|
Industry (1) : |
|
|
|
|
|
|
|
|
|
|
|
|
Premium |
|
|
190.3 |
|
|
|
189.1 |
|
|
|
0.7 |
% |
Value |
|
|
74.0 |
|
|
|
75.5 |
|
|
|
(2.1 |
)% |
Total industry domestic cigarette shipment volume |
|
|
264.3 |
|
|
|
264.6 |
|
|
|
(0.1 |
)% |
Premium/total mix |
|
|
72.0 |
% |
|
|
71.5 |
% |
|
|
|
|
(1) |
Based on information from MSAi. |
(2 ) |
Percentage of change not meaningful. |
RJR Tobacco’s net sales for the year ended December 31, 2015, increased from the year ended December 31, 2014, primarily due to higher volume and favorable product mix of $1,614 million and higher net pricing of $238 million.
Market Share
Market share information is included for RJR Tobacco to provide enhanced analysis of its brand performance. For brands that were acquired in the Lorillard Merger, share information is displayed as if the brands were part of the portfolio for all time periods shown. Brands that were part of the Divestiture have been removed for all presented time periods. Accordingly, this pro forma market share data is presented for informational purposes only and is not necessarily indicative of what the market share of the acquired brands would have been if the Lorillard Merger and Divestiture had occurred at the beginning of the periods presented, nor is it necessarily indicative of future market share .
43
The shares of RJR Tobacco’s cigarette brands as a percentage of total share of U.S. cigarette STR data were as follows (1) :
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2015 |
|
|
2014 |
|
|
Share Point Change |
|
|||
Drive brands: |
|
|
|
|
|
|
|
|
|
|
|
|
NEWPORT |
|
|
13.4 |
% |
|
|
12.9 |
% |
|
|
0.4 |
|
CAMEL |
|
|
8.2 |
% |
|
|
8.2 |
% |
|
|
— |
|
PALL MALL |
|
|
7.8 |
% |
|
|
8.1 |
% |
|
|
(0.3 |
) |
Total drive brands |
|
|
29.4 |
% |
|
|
29.2 |
% |
|
|
0.2 |
|
Other brands |
|
|
2.6 |
% |
|
|
2.9 |
% |
|
|
(0.3 |
) |
Total RJR Tobacco domestic cigarette retail share of market |
|
|
32.0 |
% |
|
|
32.1 |
% |
|
|
(0.1 |
) |
(1) |
In 2016, the universe of industry participants that MSAi uses to estimate RJR Tobacco’s cigarette shipments to retail market share was revised to reflect the new universe of direct customers as a result of the Lorillard Merger. Data provided herein reflects previously published data using MSAi’s historical universe of industry participants prior to the Lorillard Merger. |
The retail share of market of NEWPORT, at 13.4 share points, was up 0.4 share points compared with prior-year period in the highly competitive U.S. cigarette industry. NEWPORT’s cigarette market share continued to be favorably impacted by its strength in the menthol category, as well as its continued momentum in the non-menthol category.
The retail share of market of CAMEL, at 8.2 share points, was flat compared with the prior-year period in the highly competitive U.S. cigarette category. CAMEL’s cigarette market share continued to be favorably impacted by its innovative capsule technology offered in CAMEL Crush and CAMEL Crush menthol styles.
PALL MALL’s 2015 market share of 7.8% was down 0.3 share points compared with prior year period due to continued competitive pressure.
The combined share of market of RJR Tobacco’s drive brands during 2015 was up slightly compared with 2014 and the 2015 market share of other brands was down slightly compared with 2014, consistent with its strategy of focusing on drive brands. RJR Tobacco’s total cigarette market share was down slightly from the prior year.
Operating Income
RJR Tobacco’s operating income for the year ended December 31, 2015, increased from the year ended December 31, 2014, primarily due to higher cigarette pricing, favorable product mix, the expiration of the federal tobacco quota buyout and the lower impact of the MTM adjustment, partially offset by expense associated with the Engle Progeny litigation, and inventory valuation and other costs associated with the Lorillard Merger. The MTM adjustment expense in 2015 was $229 million, primarily as a result of pension asset returns that were less than expected returns and was partially offset by an increase in the discount rate. The MTM adjustment expense in 2014 was $422 million, which primarily resulted from the adoption of new mortality assumptions.
RJR Tobacco’s expense under the State Settlement Agreements, FDA user fees and federal tobacco quota buyout, which expired in September 2014, included in cost of products sold, were:
|
|
For the Twelve Months Ended December 31, |
|
|||||
|
|
2015 |
|
|
2014 |
|
||
State Settlement Agreements |
|
$ |
2,254 |
|
|
$ |
1,808 |
|
FDA user fees |
|
|
162 |
|
|
|
125 |
|
Federal tobacco quota buyout |
|
|
— |
|
|
|
151 |
|
For the years ended December 31, 2015 and 2014, RJR Tobacco recognized credits of $293 million and $341 million, respectively, related to the Term Sheet.
Selling, general and administrative expenses include the costs of litigating and administering product liability claims, as well as other legal expenses. For the years ended December 31, 2015 and 2014, RJR Tobacco’s product liability defense costs were $198 million and $180 million, respectively.
44
Net Sales
Domestic cigarette shipment volume, in billions of units for Santa Fe, was as follows:
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2015 |
|
|
2014 |
|
|
% Change |
|
|||
NATURAL AMERICAN SPIRIT |
|
|
4.8 |
|
|
|
3.9 |
|
|
|
21.4 |
% |
Santa Fe’s net sales for the year ended December 31, 2015, increased over 2014 primarily due to higher volume and higher net pricing. Expansion of the distribution network and sales force contributed to greater awareness of the NATURAL AMERICAN SPIRIT brand and increased interest of adult tobacco consumers.
Market Share
The shares of Santa Fe’s NATURAL AMERICAN SPIRIT cigarette brand as a percentage of total share of U.S. cigarette STR data were as follows (1) :
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2015 |
|
|
2014 |
|
|
Share Point Change |
|
|||
NATURAL AMERICAN SPIRIT |
|
|
1.9 |
% |
|
|
1.5 |
% |
|
|
0.3 |
|
(1) |
In 2016, the universe of industry participants that MSAi uses to estimate Santa Fe’s cigarette shipments to retail market share was revised to reflect the new universe of direct customers as a result of the Lorillard Merger. Data provided herein reflects previously published data using MSAi’s historical universe of industry participants prior to the Lorillard Merger. |
Operating Income
Santa Fe’s operating income for the year ended December 31, 2015, increased as compared with the prior-year period primarily due to higher volume and higher net pricing.
Santa Fe’s expense under the MSA, FDA user fees and federal tobacco quota buyout, which expired in September 2014, included in cost of products sold, were:
|
|
For the Twelve Months Ended December 31, |
|
|||||
|
|
2015 |
|
|
2014 |
|
||
MSA |
|
$ |
140 |
|
|
$ |
108 |
|
FDA user fees |
|
|
10 |
|
|
|
8 |
|
Federal tobacco quota buyout |
|
|
— |
|
|
|
10 |
|
As a result of meeting the performance requirements associated with the Term Sheet, Santa Fe recognized credits.
American Snuff
Net Sales
The moist snuff shipment volume, in millions of cans, for American Snuff was as follows:
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2015 |
|
|
2014 |
|
|
% Change |
|
|||
GRIZZLY |
|
|
454.4 |
|
|
|
433.8 |
|
|
|
4.7 |
% |
Other |
|
|
44.7 |
|
|
|
44.9 |
|
|
|
(0.4 |
)% |
Total American Snuff moist snuff shipment volume |
|
|
499.1 |
|
|
|
478.6 |
|
|
|
4.3 |
% |
45
American Snuff’s net sales for the year ended December 31, 2015, increased compared with the prior-year period primarily due to higher net pricing and higher moist snuff volume.
Moist snuff accounted for approximately 90% of American Snuff’s revenue in 2015 and approximately 89% in 2014.
Market Share
The shares of American Snuff’s moist snuff brands as a percentage of total share of U.S. moist snuff STR data were as follows (1) :
|
|
For the Twelve Months Ended December 31, |
|
|||||||||
|
|
2015 |
|
|
2014 |
|
|
Share Point Change |
|
|||
GRIZZLY |
|
|
30.7 |
% |
|
|
30.0 |
% |
|
|
0.8 |
|
Other |
|
|
2.8 |
% |
|
|
2.9 |
% |
|
|
(0.1 |
) |
Total American Snuff moist snuff retail share of market |
|
|
33.5 |
% |
|
|
32.9 |
% |
|
|
0.6 |
|
(1) |
In 2016, the universe of industry participants that MSAi uses to estimate American Snuff’s moist snuff shipments to retail market share was revised to reflect the new universe of direct customers as a result of the Lorillard Merger. Data provided herein reflects previously published data using MSAi’s historical universe of industry participants prior to the Lorillard Merger. |
GRIZZLY, a leading U.S. moist snuff brand, grew 0.8 share points in 2015 despite significant competitive activity. GRIZZLY’s increase in full-year shipment volume was driven by growth in the wintergreen styles and pouch offerings. The brand expanded distribution of GRIZZLY Dark Wintergreen in early 2015.
Operating Income
American Snuff’s operating income for the year ended December 31, 2015, increased compared with the prior-year period primarily due to higher net pricing and higher moist snuff volume.
All Other
During 2015, RJR Vapor announced that all production of VUSE Solo cartridges will be performed at RJR Tobacco’s manufacturing facility, pursuant to a services agreement between RJR Tobacco and RJR Vapor. As a result of this consolidation, pre-tax asset impairment and exit charges of $99 million were recorded in All Other in the third quarter of 2015.
Gain on divestitures
The $3.2 billion pre-tax gain in 2015 is a result of the divestiture of the WINSTON, KOOL and SALEM cigarette brands, previously owned by RAI subsidiaries, as well as the cigarette brand MAVERICK and the “e-vapor” brand blu (including SKYCIG), previously owned by Lorillard subsidiaries, and other assets and certain liabilities. For additional information, see Item 8, note 2 to consolidated financial statements.
Corporate Expense
Corporate operating costs and expenses increased for the year ended December 31, 2015, compared with 2014, primarily due to costs associated with the Lorillard Merger and Divestiture.
RAI Consolidated
Interest and debt expense for the year ended December 31, 2015, increased $284 million compared with the prior-year period. The change is primarily due to costs associated with the Lorillard Merger.
Provision for income taxes reflected an effective rate of 49.0%, for the year ended December 31, 2015, compared with an effective rate of 36.1%, for the year ended December 31, 2014. The effective tax rate for 2015 was unfavorably impacted by an increase in tax attributable to nondeductible acquisition costs, nondeductible goodwill in the amount of $1,849 million associated with the Divestiture and an increase in uncertain tax positions, offset by a decrease in tax attributable to the release of valuation allowance in the amount of $37 million and a reduction in state income tax rates. The effective rate for 2014 was favorably impacted by a
46
decrease in uncertain tax positions related to a federal audit settlement and an increase in the domestic manufacturing deduction, partially offset by an increase in tax attributable to nondeductible acquisition costs.
Income from discontinued operations, net of tax was $25 million for the year ended December 31, 2014. The audit of the 2010 and 2011 tax years by the Internal Revenue Service was closed on February 27, 2014. A tax benefit of $25 million attributable to a decrease in uncertain tax positions was recorded in discontinued operations.
Liquidity and Financial Condition
Liquidity
The principal sources of liquidity for RAI’s operating subsidiaries’ businesses and operating needs are internally generated funds from their operations and intercompany loans and advances. The principal sources of liquidity for RAI, in turn, are proceeds from intercompany dividends and distributions, as well as issuances of debt securities and the Credit Agreement described below under “— Long-Term Debt and Credit Agreement.” Cash flows from operating activities are believed to be sufficient for the foreseeable future to enable the operating subsidiaries to meet their obligations under the State Settlement Agreements, to make required debt-service payments, to fund their capital expenditures and to make payments to RAI that, when combined with RAI’s cash balances, proceeds from any financings and loans under the Credit Agreement, will enable RAI to make its required debt-service payments, make any share repurchases pursuant to the Governance Agreement and to pay dividends to its shareholders.
The negative impact, if any, on the sources of liquidity that could result from a decrease in demand for products due to short-term inventory adjustments by wholesale and retail distributors, changes in competitive pricing, adverse regulatory actions, increases in excise taxes, or adverse impacts from financial markets, cannot be predicted. RAI cannot predict its cash requirements or those of its subsidiaries related to any future settlements or judgments, including cash required to be held in escrow or to bond any appeals, if necessary, and RAI makes no assurance that it or its subsidiaries will be able to meet all of those requirements.
RAI’s operating companies monitor the liquidity of key suppliers and customers, and where liquidity concerns are identified, appropriate contingency or response plans are developed. During 2016, no business interruptions occurred due to key supplier liquidity, and no liquidity issues were identified involving significant suppliers or customers.
RAI’s excess cash may be invested in money market funds, commercial paper, corporate debt securities, U.S. treasury securities, U.S. and international government agency obligations and time deposits in major institutions to minimize risk. At present, RAI primarily invests cash in U.S. treasuries and U.S. government agencies.
Contractual obligations of RAI and its subsidiaries as of December 31, 2016, were as follows:
|
|
Payments Due by Period |
|
|||||||||||||||||
|
|
Total |
|
|
Less than 1 Year-2017 |
|
|
1-3 Years 2018-2019 |
|
|
4-5 Years 2020-2021 |
|
|
Thereafter |
|
|||||
Long-term debt, exclusive of interest (1) |
|
$ |
12,950 |
|
|
$ |
500 |
|
|
$ |
2,000 |
|
|
$ |
1,521 |
|
|
$ |
8,929 |
|
Interest payments related to long-term debt (1) |
|
|
9,208 |
|
|
|
649 |
|
|
|
1,202 |
|
|
|
982 |
|
|
|
6,375 |
|
Operating leases (2) |
|
|
27 |
|
|
|
20 |
|
|
|
5 |
|
|
|
2 |
|
|
|
— |
|
Non-qualified pension obligations (3) |
|
|
119 |
|
|
|
11 |
|
|
|
22 |
|
|
|
24 |
|
|
|
62 |
|
Postretirement benefit obligations (3) |
|
|
533 |
|
|
|
78 |
|
|
|
115 |
|
|
|
106 |
|
|
|
234 |
|
Qualified pension funding (3) |
|
|
100 |
|
|
|
100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase obligations (4) |
|
|
81 |
|
|
|
81 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other noncurrent liabilities (5) |
|
|
31 |
|
|
N/A |
|
|
|
11 |
|
|
|
2 |
|
|
|
18 |
|
|
State Settlement Agreements’ obligations (6) |
|
|
14,800 |
|
|
|
2,800 |
|
|
|
6,000 |
|
|
|
6,000 |
|
|
|
|
|
Gross unrecognized income tax benefit (7) |
|
|
118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FDA user fee (8) |
|
|
995 |
|
|
|
195 |
|
|
|
400 |
|
|
|
400 |
|
|
|
|
|
Total cash obligations |
|
$ |
38,962 |
|
|
$ |
4,434 |
|
|
$ |
9,755 |
|
|
$ |
9,037 |
|
|
$ |
15,618 |
|
(1) |
For more information about RAI’s and RJR Tobacco’s long-term debt, see Item 8, note 12 to consolidated financial statements. |
(2) |
Operating lease obligations represent estimated lease payments primarily related to vehicles, office space, warehouse space and equipment. See Item 8, note 13 to consolidated financial statements for additional information. |
(3) |
For more information about RAI’s pension plans and postretirement benefits, see Item 8, note 16 to consolidated financial statements. Non-qualified pension and postretirement benefit obligations captioned under “Thereafter” include obligations for a five-year period. These obligations are not reasonably estimable beyond a ten-year period. Qualified pension plan funding is based on the Pension Protection Act of 2006 and tax deductibility and is not reasonably estimable beyond one year. |
47
(5) |
Other noncurrent liabilities primarily include long-term disability insurance and bonus compensation. Certain other noncurrent liabilities are excluded from the table above, for which timing of payments are not estimable. |
(6) |
State Settlement Agreements’ obligation amounts in the aggregate beyond five years are not presented as these are obligations into perpetuity. For more information about the State Settlement Agreements, see Item 8, note 13 to consolidated financial statements. |
(7) |
For more information on gross unrecognized income tax benefits, see Item 8, note 10 to consolidated financial statements. Due to inherent uncertainties regarding the timing of payment of these amounts, RAI cannot reasonably estimate the payment period. |
(8) |
FDA user fee obligation amounts in the aggregate beyond five years are not presented as these obligations are assumed to extend into perpetuity. For more information about FDA user fees, see “— Governmental Activity” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. |
Long-Term Debt and Credit Agreement
RAI Notes
As of December 31, 2016, the principal amount of RAI’s outstanding notes was $12.7 billion, with maturity dates ranging from 2017 to 2045. RAI, at its option, may redeem any or all of its outstanding notes, in whole or in part at any time, subject to the payment of a make-whole premium. Interest on the notes is payable semi-annually. At December 31, 2016, RAI had aggregate principal amount of $447 million of current maturities of long-term debt. In August 2016, RAI repaid at maturity, with available cash, $415 million in principal amount of notes.
RJR Tobacco Notes
As of December 31, 2016, the principal amount of RJR Tobacco’s outstanding notes was $284 million, with maturity dates ranging from 2017 to 2041. Interest on the notes is payable semi-annually. At December 31, 2016, RJR Tobacco had aggregate principal amount of $53 million of current maturities of long-term debt. In August 2016, RJR Tobacco repaid at maturity, with available cash, $85 million in principal amount of notes. In June 2016, RJR Tobacco repurchased, prior to maturity, from available cash, $8 million of its outstanding notes.
Tender Offer and Redemption
In February 2016, pursuant to its previously announced cash tender offer, RAI purchased $2.69 billion in aggregate principal amount of certain of its outstanding senior notes. RAI paid, with cash on hand, aggregate consideration of $2.81 billion, which included a premium of approximately $118 million, but excluded accrued and unpaid interest, for such notes accepted for purchase.
In March 2016, pursuant to its previously announced redemption call, RAI redeemed all $700 million outstanding aggregate principal amount of its 6.750% Senior Notes due 2017 and all $250 million outstanding aggregate principal amount of its 7.750% Senior Notes due 2018. RAI paid, with cash on hand, aggregate consideration of $1.0 billion for the redemption, which included $88 million of early redemption premiums, but excluded accrued and unpaid interest, on such notes. See Item 8, note 12 to consolidated financial statements for additional information on the tender offer and redemption.
Credit Agreement
In December 2014, RAI entered into a credit agreement, referred to as the Credit Agreement, with a syndicate of lenders, providing for a five-year, $2 billion senior unsecured revolving credit facility, which may be increased to $2.35 billion at the discretion of the lenders upon the request of RAI. The Credit Agreement replaced RAI’s four-year, $1.35 billion senior unsecured revolving credit facility dated October 8, 2013. The original maturity date of the Credit Agreement was December 18, 2019. Pursuant
48
to the maturity date extension provision of the Credit Agreement, the requisite lenders have agreed on two separate occasions, upon RAI’s request, to extend the maturity date of the Credit Agreement by 12 months. As a result, the maturity date of the Credit Agreement is December 18, 2021.
Certain of RAI’s subsidiaries, including its Material Subsidiaries, as such term is defined in the Credit Agreement, have guaranteed, on an unsecured basis, RAI’s obligations under the Credit Agreement.
As of December 31, 2016, there were no outstanding borrowings and $6 million of letters of credit outstanding under the Credit Agreement.
See Item 8, notes 11 and 12 to consolidated financial statements for additional information on the Credit Agreement and Long-Term Debt.
Other
The lowering of RAI’s credit ratings, or concerns over such a lowering, could have an adverse impact on RAI’s ability to access the debt markets and could increase borrowing costs.
RAI, RJR Tobacco and their affiliates were in compliance with all covenants and restrictions imposed by RAI’s indebtedness and RJR Tobacco’s indebtedness, as the case may be, at December 31, 2016.
Dividends
RAI’s board of directors declared a quarterly cash dividend of $0.51 per common share, on February 8, 2017. The dividend will be paid on April 3, 2017, to shareholders of record as of March 10, 2017.
Share Repurchases
On July 25, 2016, the board of directors of RAI approved the Share Repurchase Program, which authorized the repurchase, from time to time, on or before December 31, 2018, of up to $2 billion of outstanding shares of RAI common stock in open-market or privately negotiated transactions. During 2016, in accordance with the Share Repurchase Program, RAI repurchased 1,565,698 shares of RAI common stock for $75 million. The Merger Agreement places restrictions on RAI’s ability to repurchase its common stock. As a result, RAI does not expect to make repurchases under the Share Repurchase Program while the Merger Agreement is in effect.
During 2016, in accordance with the Governance Agreement, at a cost of $93 million, RAI repurchased 1,817,846 shares of RAI common stock in open-market transactions.
Additionally, during 2016, at a cost of $58 million, RAI purchased 1,146,978 shares of RAI common stock that were forfeited and cancelled with respect to tax liabilities associated with restricted stock units vesting under the Omnibus Plan.
Due to RAI’s incorporation in North Carolina, which does not recognize treasury shares, the shares repurchased were cancelled at the time of purchase.
For additional information, see Item 8, note 14 to consolidated financial statements.
Capital Expenditures
RAI’s operating subsidiaries recorded cash capital expenditures of $206 million, $174 million and $204 million in 2016, 2015 and 2014, respectively. Of the 2016 amount, $130 million related to RJR Tobacco, $12 million related to Santa Fe and $22 million related to American Snuff. During 2017, capital expenditures, primarily on non-discretionary business requirements, are planned to be $140 million to $160 million for RJR Tobacco, $5 million to $15 million for Santa Fe and $15 million to $25 million for American Snuff. Other capital investments include upgrading corporate and manufacturing facilities and information management infrastructure. Capital expenditures are funded primarily by cash flows from operations. RAI’s operating subsidiaries’ capital expenditure programs are expected to continue at a level sufficient to support their strategic and operating needs. There were no material long-term commitments for capital expenditures as of December 31, 2016.
49
RAI assesses the asset allocation and investment strategy of its pension plans and phases in appropriate changes to balance funded status, interest rate risk and asset returns. These changes will reduce the pension fund’s exposure to equities and increase exposure to fixed income. As a result of changes to the asset allocation and investment strategy, RAI’s expected long-term return on pension assets, referred to as the ELTRA, was 6.82% in 2016, 6.83% in 2015, and 7.13% in 2014 and will be 7.07% in 2017. Asset performance, changes in assumptions and the discount rate may impact the funded status of RAI’s pension plans.
RAI contributed $335 million to its pension plans and $66 million to its postretirement plans in 2016. During 2017, RAI expects to contribute $111 million to its pension plans and $78 million to its postretirement plans.
Income Taxes
At December 31, 2016, RAI had a net long-term deferred tax liability of $9.6 billion.
As of December 31, 2016, no valuation allowance was established on deferred tax assets as RAI believes it is more likely than not that the deferred tax assets will be realized through the generation of future taxable income. At December 31, 2015, RAI had recorded a valuation allowance of $8 million to fully offset the deferred tax assets attributable to its Puerto Rico subsidiaries. In 2016, reorganization of the Puerto Rico business in connection with the Lorillard Merger and Divestiture resulted in the $8 million valuation allowance being reversed.
On December 18, 2015, the Protecting Americans from Tax Hikes (PATH) Act, was signed into law. The PATH Act extends the research credit permanently, retroactive to January 1, 2015. The PATH Act did not significantly impact RAI’s annual effective income tax rate in 2015.
On December 19, 2014, the Tax Increase Prevention Act of 2014, referred to as the TIPA, was signed into law. The TIPA retroactively reinstated and extended the Federal Research and Development Tax Credit from January 1, 2014 to December 31, 2014. The impact of the TIPA did not significantly impact RAI’s annual effective income tax rate in 2014.
Litigation and Settlements
As discussed in Item 8, note 13 to consolidated financial statements, various legal proceedings or claims, including litigation claiming cancer and other diseases, as well as addiction, have resulted from the use of, or exposure to, RAI’s operating subsidiaries’ products, and seeking damages in amounts ranging into the hundreds of millions or even billions of dollars, are pending or may be instituted against Reynolds Defendants. Unfavorable judgments have been returned in a number of tobacco-related cases and state enforcement actions. As of December 31, 2016, RJR Tobacco had paid approximately $239 million since January 1, 2014, related to unfavorable smoking and health litigation judgments.
RAI’s consolidated balance sheet as of December 31, 2016 contains accruals for certain individual Engle Progeny cases. Other accruals include an amount for the estimated costs of the corrective communications in the U.S. Department of Justice case. For a more complete description of the Engle Progeny cases and U.S. Department of Justice case, see “— Litigation Affecting the Cigarette Industry — Overview”, “— Engle and Engle Progeny Cases” and “— Health-Care Cost Recovery Cases — U.S. Department of Justice Case ” in Item 8, note 13 to consolidated financial statements.
RAI’s management continues to conclude that the loss of any particular tobacco-related litigation claim against Reynolds Defendants, or the loss of any particular claim concerning the use of smokeless tobacco products against American Snuff Co., when viewed on an individual case-by-case basis, is not probable or estimable except for certain Engle Progeny cases, as described in “— Litigation Affecting the Cigarette Industry — Overview” in Item 8, note 13 to consolidated financial statements. Reynolds Defendants believe that they have valid bases for appeal of adverse verdicts in their pending cases and valid defenses to all actions, and intend to defend all actions vigorously. Nonetheless, the possibility of material losses related to tobacco-related litigation is more than remote. Litigation is subject to many uncertainties, and generally it is not possible to predict the outcome of the litigation pending against Reynolds Defendants, or to reasonably estimate the amount or range of any possible loss. Moreover, notwithstanding the quality of defenses available to it and its affiliates in tobacco-related litigation matters, it is possible that RAI’s consolidated results of operations, cash flows or financial position could be materially adversely affected by the ultimate outcome of certain pending or future litigation matters or difficulties in obtaining the bonds required to stay execution of judgments on appeal.
In 1998, RJR Tobacco, Lorillard Tobacco, B&W, SFNTC and the other major U.S. cigarette manufacturers entered into the MSA with attorneys general representing most U.S. states, territories and possessions. The State Settlement Agreements, of which the MSA is the most wide-reaching, impose a perpetual stream of future payment obligations on RJR Tobacco and the other major
50
U.S. cigarette manufacturers and place significant restrictions on their ability to market and sell cigarettes in the future. The State Settlement Agreements have materially adversely affected RJR Tobacco’s shipment volumes. RAI believes that these settlement obligations may materially adversely affect the results of operations, cash flows or financial position of RAI and RJR Tobacco in future periods. The degree of the adverse impact will depend, among other things, on the rate of decline in U.S. cigarette sales in the premium and value categories, RJR Tobacco’s share of the domestic premium and value cigarette categories, and the effect of any resulting cost advantage of manufacturers not subject to the State Settlement Agreements.
RJR Tobacco and Lorillard Tobacco disputed a total of $5.6 billion and $1.2 billion, respectively, with respect to the NPM Adjustment, for the years 2003 through 2014.
In 2012, RJR Tobacco, Lorillard Tobacco, certain other PMs, including SFNTC, and certain settling states entered into a Term Sheet that sets forth terms for resolving accrued and potential NPM Adjustment claims for 2003 through 2012. The Term Sheet also set forth a restructured NPM Adjustment process to be applied to future volume years, starting with the 2013 volume year. Under the Term Sheet settlement, RJR Tobacco and SFNTC are to collectively receive more than $1.1 billion in credits, a majority of which have been applied to their MSA payments in 2014 through 2016, with the remainder to be applied against its 2017 and 2018 MSA payments. Credits are recognized when RJR Tobacco and Santa Fe meet the performance requirements associated with the Term Sheet. Credits recognized in a given year are available to offset the payments made in April of the following year.
In September 2013, the Arbitration Panel ruled six states had not diligently enforced their qualifying statutes in 2003 related to the NPM Adjustment. Two of the six states subsequently joined the Term Sheet in 2014. In 2015, three of the states dropped their challenge of the finding of non-diligence and in 2016, the remaining state dropped its challenge. As such, a portion of the potential recovery from those states was certain and estimable and RJR Tobacco recognized the appropriate credits in those years. A final issue regarding the judgment reduction method adopted by the Arbitration Panel was being contested in these four states. In 2016, the U.S. Supreme Court denied RJR Tobacco’s petition for writ of certiorari against two states, thus eliminating RJR Tobacco’s remaining recovery from these states. The final outcome in the remaining two states is uncertain.
In October 2015, RJR Tobacco, SFNTC and certain other PMs entered into the NY Settlement Agreement to settle certain claims related to the NPM Adjustment. The NY Settlement Agreement resolved NPM Adjustment claims related to payment years from 2004 through 2014, providing RJR Tobacco and SFNTC, collectively, with credits of approximately $290 million, plus interest, subject to meeting various performance obligations. These credits will be applied against annual payments under the MSA over a four-year period, which commenced with the April 2016 MSA payment. In addition, the NY Settlement Agreement put in place a new method to determine future adjustments from 2015 forward as to New York.
For additional information related to the State Settlement Agreements, see “— Cost of Products Sold” in Item 8, note 1 and “— Litigation Affecting the Cigarette Industry — State Settlement Agreements —Enforcement and Validity; Adjustments”, in Item 8, note 13 to consolidated financial statements.
Governmental Activity
The marketing, sale, taxation and use of tobacco products have been subject to substantial regulation by government and health officials for many years. Various state governments have adopted or are considering, among other things, legislation and regulations that would:
|
• |
significantly increase their taxes on tobacco products; |
|
• |
restrict displays, advertising and sampling of tobacco products; |
|
• |
raise the minimum age to possess or purchase tobacco products; |
|
• |
restrict or ban the use of menthol in cigarettes or prohibit mint or wintergreen as a flavor in smokeless tobacco products and vapor products; |
|
• |
require the disclosure of ingredients used in the manufacture of tobacco products; |
|
• |
require the disclosure of nicotine yield information for cigarettes; |
|
• |
impose restrictions on smoking and vaping in public and private areas; and |
|
• |
restrict the sale of tobacco products directly to consumers or other unlicensed recipients, including by mail or over the Internet. |
51
Together with substantial increases in state and federal taxes on tobacco products, and the granting to the FDA of broad authority over the manufacture, sale, marketing and packaging of tobacco products, these developments have had and will likely continue to have an adverse effect on the sale of tobacco products. Products that are alternatives to traditional tobacco products also have become subject to increasing regulation. For example, in addition to the regulation by the FDA of e-cigarettes, as described below, various states have adopted, or are considering adoption of taxes on e-cigarettes, restrictions on the promotion and distribution of e-cigarettes, and tamper resistant and child resistant packaging requirements for e-cigarettes.
Taxation
General
Cigarettes and other tobacco products are subject to substantial taxes in the United States. As a result of a 2009 federal law which increased taxes on cigarettes and other tobacco products:
|
• |
the federal excise tax per pack of 20 cigarettes is $1.01; and |
|
• |
the federal excise tax rate for chewing tobacco is $0.5033 per pound, and for snuff is $1.51 per pound. |
Currently, there is no federal tax on vapor products, such as e-cigarettes.
On February 9, 2016, President Obama released a budget in which he proposed increasing the federal excise tax: on a pack of cigarettes from $1.01 to $1.95; for snuff from $1.51 per pound to $2.93 per pound; and for chewing tobacco from $0.5033 per pound to $0.98 per pound. These proposed tax increases would fund a new initiative for pre-kindergarten education for lower-income children. RAI’s management believes that such tax increases would have an adverse impact on the sale of tobacco products by RAI’s operating companies and could have a material adverse effect on the results of operations, cash flows or financial position of RAI, including impairment of the value of its operating subsidiaries’ trademarks.
Cigarettes
The 2009 federal excise tax increase on tobacco products increased taxes on ready-made cigarettes, such as those made by RJR Tobacco and SFNTC, at a much higher rate than taxes on loose tobacco. As a result of that tax disparity, the number of retailers selling loose tobacco and operating roll-your-own machines, allowing consumers to convert the loose tobacco into finished cigarettes, greatly increased following the 2009 federal tax hike on tobacco products. On July 6, 2012, President Obama signed into law a provision classifying retailers which operate roll-your-own machines as cigarette manufacturers, and thus requiring those retailers to pay the same tax rate as other cigarette manufacturers. As of December 31, 2016, 26 states also had passed legislation classifying retailers operating roll-your-own machines as cigarette manufacturers.
All states and the District of Columbia currently impose cigarette excise taxes at levels ranging from $0.17 per pack in Missouri to $4.35 per pack in New York. As of December 31, 2016, the weighted average state cigarette excise tax per pack, calculated on a 12-month rolling average basis, was approximately $1.39, compared with the 12-month rolling average of $1.34 as of December 31, 2015. Certain city and county governments, such as New York, Philadelphia and Chicago, also impose substantial excise taxes on cigarettes sold in those jurisdictions. During 2016, 23 states proposed increases in their respective cigarette excise taxes, with increases being adopted in four states (Louisiana, Pennsylvania, West Virginia and California) and failing in 19 states. In connection with the November 2016 general election, California approved a ballot proposal increasing, effective April 1, 2017, that state’s cigarette excise tax per pack from $0.87 to $2.87. Ballot proposals in Colorado, Missouri and North Dakota to increase those states’ respective cigarette excise taxes failed in the November 2016 general election. If the foregoing California cigarette excise tax increase had been in effect as of December 31, 2016, the weighted average state cigarette excise tax per pack, calculated on a 12-month rolling average basis, would have been $1.526, instead of $1.39.
Six states now require NPMs to pay a fee on each pack of cigarettes sold in their respective states, ranging from $0.25 per pack in Alaska to $0.55 per pack in Texas.
The Texas equity fee has been challenged by a coalition of small tobacco manufacturers. This group asserts that the Texas fee violates the Texas Constitution’s “Equal and Uniform” Clause, as well as the Equal Protection and Due Process Clauses of the U.S. Constitution. On November 15, 2013, a state trial court in Texas declared the equity fee unconstitutional and enjoined the state from “assessing, collecting, and enforcing” the fee. The State of Texas appealed the court’s order. In doing so, enforcement of the trial court’s order, including the injunction, is suspended. On August 15, 2014, the three-judge panel unanimously affirmed the ruling, and on October 29, 2014, the State of Texas filed its petition for review with the Texas Supreme Court. On April 1, 2016, the Texas Supreme Court reversed the Texas Court of Appeals, and ruled that the Texas equity fee legislation does not violate the Equal and Uniform Clause of the Texas constitution. The Texas Supreme Court remanded the case back to the Texas Court of Appeals for that
52
court to consider the non-settling manufacturers’ remaining challenges to the equity fee. On June 20, 2016, plaintiffs filed a motion for rehearing with the Texas Supreme Court. That motion was denied. After the case was remanded back to the Texas Court of Appeals, both the plaintiffs and the State of Texas filed supplemental briefs with the court. Further proceedings before the Texas Court of Appeals are anticipated .
Smokeless
As of December 31, 2016, all states and the District of Columbia subject smokeless tobacco products to excise taxes, as summarized below:
|
• |
26 states taxed moist snuff on an ad valorem basis, at rates ranging from 5% in South Carolina to 210% in Massachusetts; |
|
• |
21 states and the District of Columbia had weight-based taxes on moist snuff, ranging from $0.02 for cans weighing between 5 / 8 of an ounce and 1 5 / 8 ounces in Alabama to $2.02 per ounce in Maine; and |
|
• |
two states imposed a unit tax on moist snuff: Kentucky with a tax of $0.19 per unit, and Washington, with a tax of $2.526 per unit for units weighing 1.2 ounces or less and a proportionate amount above that weight. In addition, Minnesota imposed a tax on moist snuff at a rate equal to the greater of (1) 95% of the wholesale price and (2) generally, the tax equal to the rate imposed on a pack of 20 cigarettes. |
During 2016, 16 states proposed increases in, or in the case of Pennsylvania, proposed to adopt for the first time, excise taxes on smokeless tobacco products, with such increases being adopted in three states (Pennsylvania, West Virginia and, effective as of April 1, 2017, California), failing in 11 states and remaining pending, as of December 31, 2016, in two states.
Vapor Products
As of December 31, 2016, five states and the District of Columbia imposed a tax on vapor products, such as e-cigarettes, as follows: Minnesota, which taxes vapor products at the same rate as it taxes smokeless tobacco products; Louisiana, North Carolina, Kansas and West Virginia, which tax vapor products at a per fluid milliliter rate of $0.05, $0.05, $0.20 and $0.075, respectively; and the District of Columbia, which taxes vapor products on an ad valorem basis at a 70% rate. Further, during 2016, 20 states proposed taxes on vapor products, including, in some cases, implementing a tax on a per fluid milliliter basis, taxing vapor products on the same basis as “other tobacco products” and, in other cases, taxing vapor products at a rate equivalent to cigarette excise taxes. Such legislation was adopted in three states (Pennsylvania, West Virginia and, effective April 1, 2017, California), and failed in 17 states.
Federal Regulation - General
In 1964, the Report of the Advisory Committee to the Surgeon General of the U.S. Public Health Service concluded that cigarette smoking was a health hazard of sufficient importance to warrant appropriate remedial action. Since 1966, federal law has required a warning statement on cigarette packaging, and cigarette advertising in other media also is required to contain a warning statement. Since 1971, television and radio advertising of cigarettes has been prohibited in the United States.
The warnings currently required on cigarette packages and advertisements are:
|
• |
“SURGEON GENERAL’S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, And May Complicate Pregnancy;” |
|
• |
“SURGEON GENERAL’S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health;” |
|
• |
“SURGEON GENERAL’S WARNING: Smoking By Pregnant Women May Result in Fetal Injury, Premature Birth, And Low Birth Weight;” and |
|
• |
“SURGEON GENERAL’S WARNING: Cigarette Smoke Contains Carbon Monoxide.” |
As noted below, the FDA has proposed regulations that would revise the foregoing warnings.
Since the initial report in 1964, the Secretary of Health, Education and Welfare, now the Secretary of Health and Human Services, and the U.S. Surgeon General have issued a number of other reports which purport to find the nicotine in cigarettes addictive and to link cigarette smoking and exposure to cigarette smoke with certain health hazards, including various types of cancer, coronary heart disease and chronic obstructive lung disease. These reports have recommended various governmental measures to reduce the incidence of smoking. In 1992, the federal Alcohol, Drug Abuse and Mental Health Act was signed into law. This act required states to adopt a minimum age of 18 for purchase of tobacco products and to establish a system to monitor, report and reduce the illegal sale of tobacco products to minors in order to continue receiving federal funding for mental health and drug abuse programs. In 1996, the
53
U.S. Department of Health and Human Services announced regulations implementing this legislation. And in 2006, the U.S. Surgeon General released a report entitled “The Health Consequences of Involuntary Exposure to Tobacco Smoke.” Among its conclusions, the report found the following: exposure of adults to secondhand smoke causes coronary heart disease and lung cancer, exposure of children to secondhand smoke results in an increased risk of sudden infant death syndrome, acute respiratory infections, ear problems and more severe asthma; and that there is no risk-free level of exposure to secondhand smoke. A follow-up report issued by the U.S. Surgeon General in 2010, “How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease,” determined that tobacco smoke causes immediate cellular damage and tissue inflammation and that repeated exposure impedes the healing of such damage and inflammation. On January 17, 2014, the U.S. Surgeon General issued an additional report that contends that smoking is linked to a higher number of deaths to Americans than previous estimates, and that cigarettes are a causal factor in ten conditions and diseases that had not previously been directly linked to cigarette smoking.
In December 2016, the U. S. Surgeon General issued a report on e-cigarettes, raising public health concerns regarding the use of e-cigarettes by U.S. youth and young adults. The report recommended that state, local, tribal, and territorial governments implement additional laws and regulations to address e-cigarette use among youth and young adults, including:
|
• |
incorporating e-cigarettes into existing smoke-free policies; |
|
• |
preventing youth access to e-cigarettes through various restrictions on sales of e-cigarettes to minors (including age verification requirements, prohibitions against self-service displays, and active enforcement of existing laws); |
|
• |
implementing taxation and other price policies for e-cigarettes; |
|
• |
increasing regulation of e-cigarette marketing by expanding evidence and facilitating the development of constitutionally feasible restrictions on such marketing; and |
|
• |
targeting youth and young adults with educational initiatives on e-cigarettes and their potential for nicotine addiction and adverse health consequences. |
The report also calls for expanded federal funding of e-cigarette research efforts, including research on health risks and the impact of governmental policies on initiation and use patterns for e-cigarettes and other tobacco products. Finally, the report recommends continued surveillance of e-cigarette marketing to assess the link between exposure to e-cigarette marketing and use of these products.
In 1986, Congress enacted the Comprehensive Smokeless Tobacco Health Education Act of 1986, which, among other things, required health warning notices on smokeless tobacco packages and advertising and prohibited the advertising of smokeless tobacco products on any medium of electronic communications subject to the jurisdiction of the Federal Communications Commission. In 2009, the FDA Tobacco Act (discussed below) amended the Comprehensive Smokeless Tobacco Health Education Act of 1986 to require the following warnings on smokeless tobacco packaging and advertising, displayed randomly and as equally as possible in each 12-month period:
|
• |
“WARNING: THIS PRODUCT CAN CAUSE MOUTH CANCER;” |
|
• |
“WARNING: THIS PRODUCT CAN CAUSE GUM DISEASE AND TOOTH LOSS;” |
|
• |
“WARNING: THIS PRODUCT IS NOT A SAFE ALTERNATIVE TO CIGARETTES;” and |
|
• |
“WARNING: SMOKELESS TOBACCO IS ADDICTIVE.” |
FDA Tobacco Act
General
In 2009, President Obama signed into law the FDA Tobacco Act, which grants the FDA broad authority over the manufacture, sale, marketing and packaging of tobacco products. Pursuant to the FDA Tobacco Act:
|
• |
charitable distributions of tobacco products are prohibited; |
|
• |
statements that would lead consumers to believe that a tobacco product is approved, endorsed, or deemed safe by the FDA are prohibited; |
|
• |
pre-market approval by the FDA is required for claims made with respect to reduced risk or reduced exposure products; |
|
• |
the marketing of tobacco products in conjunction with any other class of product regulated by the FDA is prohibited; |
54
|
• |
all manufacturers are required to register with the FDA their domestic manufacturing facilities as well as all cigarette and smokeless tobacco products sold in the United States; |
|
• |
the FDA reissued regulations addressing advertising and marketing restrictions that were originally promulgated in 1996 (including, among other restrictions, prohibitions on: the sale of cigarettes and smokeless tobacco products to persons under the age of 18; the sale of packages of cigarettes with less than 20 cigarettes; the distribution of free samples of cigarettes; and brand name sponsorship of any athletic, musical or other social/cultural events); |
|
• |
manufacturers were required to produce health-related documents generated from and after June 22, 2009 through December 31, 2009 (the FDA has interpreted the FDA Tobacco Act as establishing an ongoing requirement to submit health-related documents; however, the FDA has not yet established a timetable for further production); |
|
• |
manufacturers are required to make by-brand ingredient submissions, place different and larger warnings on packaging and advertising for smokeless tobacco products and eliminate the use of descriptors on tobacco products, such as “low-tar” and “lights”; |
|
• |
the FDA issued a final regulation for the imposition of larger, graphic health warnings on cigarette packaging and advertising, which was scheduled to take effect September 22, 2012, but the FDA is currently enjoined from enforcing such regulation; |
|
• |
as described in greater detail below, new or modified products introduced in the market after February 15, 2007, are subject to certain FDA clearance requirements; |
|
• |
the FDA announced that it would inspect every domestic establishment that manufactured cigarettes, cigarette tobacco, roll-your-own tobacco or smokeless tobacco products once in a two-year cycle beginning October 1, 2011; |
|
• |
in April 2012, the FDA issued draft guidance on: (1) the reporting of harmful and potentially harmful constituents in tobacco products and tobacco smoke pursuant to Section 904(a)(3) of the FDA Tobacco Act, and (2) preparing and submitting applications for modified risk tobacco products pursuant to Section 911 of the FDA Tobacco Act; and |
|
• |
in December 2016, the FDA issued a revised final guidance document entitled, “Demonstrating the Substantial Equivalence of a New Tobacco Product: Response to Frequently Asked Questions (Edition 3).” The revised guidance was the result of a decision by the United States District Court for the District of Columbia finding that the FDA’s prior guidance that labeling changes trigger the requirement for premarket review contradicts the language of the FDA Tobacco Act and exceeds the agency’s authority. However, the court ruled that the FDA could require a premarket review submission for a product quantity change, as such a change would constitute a “new” tobacco product. |
The FDA Tobacco Act grants the FDA the authority to impose broad additional restrictions. On a going forward basis, the FDA:
|
• |
will require manufacturers to test ingredients and constituents identified by the FDA and disclose this information to the public; |
|
• |
will prohibit use of tobacco containing a pesticide chemical residue at a level greater than allowed under Federal law; |
|
• |
will establish “good manufacturing practices” to be followed at tobacco manufacturing facilities; |
|
• |
may place more severe restrictions on the advertising, marketing and sale of tobacco products; and |
|
• |
may require the reduction of nicotine and the reduction or elimination of other constituents. |
55
Pursuant to the foregoing authority, the FDA has proposed a rule that, if adopted, would require the reduction, over a three-year period, of the levels of N-nitrosonornicotine (NNN) contained in smokeless tobacco products. The adoption of this proposed rule is currently suspended by virtue of a federal regulatory freeze imposed by the U.S. President. It is not known whether or when this proposed rule will be adopted, and, if adopted, whether the final rule will be the same as or similar to the proposed rule. If the proposed rule is adopted, however, in its current form (or in a form substantially similar to its current form), management expects that compliance or the inability to comply could have a material adverse effect on the results of operations, cash flows and financial position of American Snuff and RAI.
The U.S. Congress did limit the FDA’s authority in two areas, prohibiting it from:
|
• |
banning all tobacco products; and |
|
• |
requiring the reduction of nicotine yields of a tobacco product to zero. |
In 2009, a “Center for Tobacco Products”, referred to as the CTP, was established within the FDA, funded through quarterly user fees that are assessed against tobacco product manufacturers and importers based on market share. The total amount of user fees to be collected over the first ten years is expected to be approximately $5.4 billion.
Within the CTP, a Tobacco Products Scientific Advisory Committee, referred to as the TPSAC, was established on March 22, 2010, to provide advice, information and recommendations with respect to the safety, dependence or health issues related to tobacco products. The TPSAC is scheduled to meet periodically to address matters brought to it by the Center as well as those required of it by the FDA Tobacco Act, including:
|
• |
a recommendation on modified risk applications; |
|
• |
a recommendation as to whether there is a threshold level below which nicotine yields do not produce dependence; |
|
• |
a report on the impact of the use of menthol in cigarettes on the public health; and |
|
• |
a report on the impact of dissolvable tobacco products on the public health. |
Potential Regulation of Menthol
At a meeting held on March 18, 2011, the TPSAC presented its final report on the use of menthol, which concluded that removal of menthol cigarettes from the marketplace would benefit public health in the United States. On July 24, 2013, the FDA issued a report detailing its own preliminary scientific evaluation of public health issues related to the use of menthol in cigarettes, including a determination that there is likely a public health impact of menthol in cigarettes. The FDA’s report found that the weight of the evidence supports the conclusion that menthol in cigarettes is associated with:
|
• |
increased initiation among youth and young adults; |
|
• |
reduced success in smoking cessation; and |
|
• |
increased dependence. |
The report found that menthol in cigarettes is not associated with:
|
• |
increased smoke toxicity; |
|
• |
increased levels of biomarkers of exposure; or |
|
• |
increased disease risk. |
The FDA concurrently published in the Federal Register an Advance Notice of Proposed Rulemaking, referred to as the ANPRM, to obtain information related to the potential regulation of menthol in cigarettes. The ANPRM sought comments from interested stakeholders on the FDA’s preliminary evaluation, as well as any data, research, or other information on various topics, including, but not limited to:
|
• |
potential product standards for menthol and the potential period for compliance with such standards; |
|
• |
potential restrictions on the sale and/or distribution of menthol products; and |
|
• |
evidence regarding illicit trade in menthol cigarettes (including the public health impact thereof) should the use of menthol in cigarettes be restricted or banned. |
56
In November 2013, RAI’s operating companies submitted comments on the ANPRM. The FDA will evaluate all comments it has received from interested stakeholders in response to the ANPRM, as the agency considers whether to require additional standards or restrictions with respect to menthol cigarettes. The FDA Tobacco Act does not require the FDA to adopt any such standards or restrictions. Any rule that the FDA may propose will be subject to a 60-day comment period, and may only become effective at least one year after the rule’s adoption. If the FDA were to adopt a rule banning or severely restricting the use of menthol in cigarettes, such rule could have an adverse effect on the sale of RAI’s subsidiaries’ products containing menthol and, as a result, on the results of operations, cash flows and financial position of RAI.
On February 25, 2011, RJR Tobacco, Lorillard, Inc. and Lorillard Tobacco Company jointly filed in the U.S. District Court for the District of Columbia a lawsuit, Lorillard, Inc. v. U.S. Food and Drug Administration , challenging the composition of the TPSAC. For additional information concerning this case, see “— Litigation Affecting the Cigarette Industry — Other Litigation and Developments — FDA Litigation” in Item 8, note 13 to consolidated financial statements.
At a meeting on March 1, 2012, the TPSAC presented to the FDA its final report and recommendations with respect to dissolvable tobacco products. The FDA will consider the report and recommendations and determine what future action, if any, is warranted with respect to dissolvable tobacco products. There is no timeline or statutory requirement for the FDA to act on the TPSAC’s recommendations.
Final Deeming Regulation
On May 10, 2016, the FDA issued a final regulation, referred to as the Final Rule, deeming all products that meet the FDA Tobacco Act’s definition of “tobacco product” to be subject to the FDA’s regulatory authority under the FDA Tobacco Act. The Final Rule became effective as of August 8, 2016, though each requirement of the Final Rule has its own compliance date. Such newly “deemed” tobacco products subject to the FDA Tobacco Act include, among others, electronic nicotine delivery systems (including e-cigarettes, e-hookah, e-cigars, vape pens, advanced refillable personal vaporizers, electronic pipes and e-liquids mixed in vape shops), certain dissolvable tobacco products, cigars, and pipe tobacco. In addition, “components” and “parts” (e.g., batteries), but not “accessories” (e.g., lighters, pipe pouches), of newly deemed products are themselves subject to the FDA Tobacco Act by virtue of the Final Rule.
Deemed products are subject to the provisions of the FDA Tobacco Act to which currently regulated tobacco products have been subject since the FDA Tobacco Act’s adoption in 2009, including: adulteration and misbranding provisions; requirements relating to ingredient listing and reporting of harmful and potentially harmful constituents; registration of tobacco product manufacturing establishments and product listing; restrictions against the sale and distribution of products with modified risk descriptions (such as use of “light,” “low,” and “mild”); prohibition on the distribution of free samples; a required health warning; and, as described in more detail below, premarket review requirements.
The “grandfather” date under the Final Rule for newly deemed products remains the same as the “grandfather” date for those tobacco products already subject to the FDA Tobacco Act – February 15, 2007. Any tobacco product that was not legally marketed as of February 15, 2007, will be considered a new tobacco product subject to premarket review by the FDA.
The FDA has recognized that few, if any, e-cigarettes were on the market as of February 15, 2007, but thousands of such products (including RJR Vapor’s VUSE Digital Vapor Cigarette) subsequently have entered into commerce. To address this issue, the FDA has established a compliance policy regarding its premarket review requirements for all newly deemed tobacco products that are not grandfathered products, but that were on the market as of August 8, 2016. For these products, the FDA will allow such products to remain on the market so long as the manufacturer has filed the appropriate premarket review application by the applicable deadline: Substantial Equivalence Exemption Report – August 8, 2017; Substantial Equivalence Report – February 8, 2018; and Premarket Tobacco Product Application, referred to as a PMTA, – August 8, 2018. During the third quarter, and prior to August 8, 2016, RJR Vapor introduced into the market additional newly deemed tobacco products.
RJR Vapor intends to file a PMTA with respect to VUSE and certain other of its e-cigarette products. Further, RJR Vapor believes that substantially all other e-cigarette manufacturers likewise will be unable to use the substantial equivalence pathway to obtain FDA clearance of their respective e-cigarettes, but instead, will be required to file PMTAs to obtain FDA clearance of such products. Based on the FDA’s draft guidance setting forth the type of evidence that must be included within a premarket review application, RJR Vapor expects the costs of preparing a PMTA to be significant, and a cost more easily borne by larger manufacturers.
In order for the FDA to clear a PMTA covering an e-cigarette, the applicant must show that the marketing of such e-cigarette would be appropriate for the protection of the public health. Under the FDA Tobacco Act, whether a tobacco product is appropriate for the protection of the public health is to be determined “…with respect to the risks and benefits to the population as a whole, including users and nonusers of the tobacco product, and taking into account – (A) the increased or decreased likelihood that existing
57
users of tobacco products will stop using such products; and (B) the increased or decreased likelihood that those who do not use tobacco products will start using such products.” In draft guidance issued by the FDA, the agency has stated that to completely assess whether a PMTA shows that a product is appropriate for the protection of the public health, the “FDA will look at the product in the context of the current tobacco product market. FDA can do this by understanding the spectrum of risk of currently available tobacco products and assessing the new product within that spectrum.” At present, there is substantial uncertainty over how the FDA will apply the foregoing principles in practice when determining whether to clear an e-cigarette PMTA. To date, few PMTAs have been filed, and the only PMTAs that the FDA has cleared relate to snus products of other manufacturers.
As part of its compliance policy, the FDA has stated that for any product for which the appropriate premarket review application has been timely filed, the manufacturer may continue to market the product for an additional year from the deadline for filing the appropriate application (i.e., August 8, 2019 for PMTAs) while the FDA reviews the application. If the FDA rejects the premarket review application (even if the rejection occurs prior to the end of the one-year period), then the manufacturer must immediately remove that product from commerce. At the end of the one-year compliance period, if the product has not yet been given market authorization, the Final Rule authorizes the FDA to take enforcement action. However, if review of a pending premarket review application is substantially complete and the manufacturer has provided all required information, then the FDA may defer enforcement for a reasonable time period on a case-by-case basis. For deemed products that were not on the market as of August 8, 2016, the above compliance policy does not apply and, instead, manufacturers must file the appropriate premarket review application and obtain FDA clearance before marketing such product.
FDA Warning Letter to SFNTC
On August 27, 2015, the FDA sent a warning letter to SFNTC claiming that SFNTC’s use of the terms “Natural” and “Additive Free” in the product labeling and advertising for Natural American Spirit cigarettes violates the Modified Risk Tobacco Products provision of the FDA Tobacco Act. Following discussions between the parties, on January 23, 2017 the FDA and SFNTC reached an agreement whereby, among other things, SFNTC committed to phasing out use of the terms “Natural” and “Additive Free” from product labeling and advertising for Natural American Spirit cigarettes on an established timeframe. The agreement also specifies that SFNTC may continue to use the term “Natural” in the Natural American Spirit brand name and trademarks. SFNTC’s scheduled deletion of the terms “Natural” and “Additive Free” from the labeling and advertising of its Natural American Spirit cigarettes could have an adverse effect on the sale of such cigarettes and, as a result, on the results of operations, cash flows and financial position of SFNTC and RAI .
Premarket Review
RAI’s strategy of focusing on innovation to help transform the tobacco industry is dependent on its operating companies’ ability to introduce new products into the market. For a manufacturer to launch a new product or modify an existing one after March 22, 2011, the FDA Tobacco Act requires a manufacturer to file one of three types of product applications (a new product application, a substantial equivalence application or a substantial equivalence exemption application) with the CTP, depending on the type and level of change being sought. In all cases, however, the manufacturer may not market the new or modified product in the United States until the CTP issues a marketing order, allowing the product to be marketed. Although the FDA Tobacco Act has now been in effect for more than six years, uncertainty remains as to the timing of the review and the requirements for clearance of new or modified tobacco products introduced in the market after March 22, 2011. These uncertainties, in conjunction with the clearance requirement itself, could have an adverse impact on the ability of RAI’s operating companies to innovate in the future.
Similarly, a manufacturer that introduced a new tobacco product or modified a tobacco product between February 15, 2007 and March 22, 2011, was required to file a substantial equivalence report with the CTP, demonstrating either (1) that the new or modified product had the same characteristics as a product commercially available as of February 15, 2007, referred to as a predicate product, or (2) if the new or modified product had different characteristics than the predicate product, that it did not raise different questions of public health. A product subject to such report is referred to as a provisional product. A manufacturer may continue to market a provisional product unless and until the CTP issues an order that the provisional product is not substantially equivalent, in which case the FDA could then require the manufacturer to remove the provisional product from the market. On September 15, 2015, the CTP issued four Not Substantially Equivalent orders, referred to as NSE orders, to RJR Tobacco, determining that four cigarette styles are not substantially equivalent to their respective predicate products, and ordering that RJR Tobacco immediately stop all distribution, importation, sale, marketing and promotion of these provisional products. On September 29, 2015, RJR Tobacco provided the FDA with a compliance plan with respect to these NSE orders. On January 20, 2016, RJR Tobacco received notification from the CTP’s office of Compliance and Enforcement that no further action was necessary on the compliance plan.
As with new or modified tobacco products introduced after March 22, 2011, uncertainty remains over the timing of review of substantial equivalence reports for provisional products. Moreover, although the sales of the provisional products subject to the NSE orders described in the preceding paragraph are not material to RJR Tobacco, substantially all of RAI’s operating companies’ products
58
currently on the market are provisional products. If the CTP were to issue NSE orders with respect to other provisional products of RAI’s operating companies, such orders, if not withdrawn or invalidated, would have a material adverse impact on the sales of the products subject to the orders, and could have an adverse impact on the results of operations, cash flows and financial position of RAI.
Other Matters
All 50 states and a large number of local jurisdictions have introduced or enacted legislation imposing various restrictions on public smoking. Additionally, many employers have initiated programs restricting or eliminating smoking in the workplace. A number of states have enacted legislation designating a portion of increased cigarette excise taxes to fund anti-smoking programs, health-care programs or cancer research. In addition, educational and research programs addressing health-care issues related to smoking are being funded from industry payments made or to be made under settlements with state attorneys general. Federal law prohibits smoking in scheduled passenger aircraft, and the U.S. Interstate Commerce Commission has banned smoking on interstate passenger buses. Certain common carriers have imposed additional restrictions on passenger smoking.
In July 2007, the State of Maine became the first state to enact a statute that prohibits the sale of cigarettes and cigars that have a characterizing flavor. The legislation defines characterizing flavor as “a distinguishable taste or aroma that is imparted to tobacco or tobacco smoke either prior to or during consumption, other than a taste or aroma from tobacco, menthol, clove, coffee, nuts or peppers.” As of December 31, 2016, New Jersey was the only other state that had adopted a statute banning the sale of cigarettes containing certain characterizing flavors; the New Jersey statute exempts menthol from the prohibition. Since Maine’s adoption of such legislation, numerous counties and municipalities have adopted laws prohibiting or restricting the sale of certain tobacco products containing “characterizing flavors.” The scope of these laws varies from jurisdiction to jurisdiction; for example, some, but not all, of these laws exempt menthol from the definition of a “characterizing flavor,” and certain laws apply to tobacco products other than cigarettes. The “characterizing flavor” ordinances in New York City, and Providence, Rhode Island were each challenged on the grounds, among others, that the FDA Tobacco Act preempts such local laws. The U.S. Courts of Appeals for the Second Circuit and First Circuit have held that the FDA Tobacco Act does not preempt the New York City and Providence, Rhode Island ordinances, respectively.
A price differential (principally resulting from different tax rates) exists between tobacco products manufactured for sale abroad and tobacco products manufactured for sale in the United States. Consequently, a market has developed for tobacco products manufactured for sale abroad, but instead diverted for sale in the United States at prices substantially lower than tobacco products produced for sale in the United States. Furthermore, within the United States, tobacco products are often purchased in states having low excise taxes and then resold illegally in states having higher excise taxes. These smuggling activities are often conducted by criminal organizations on a large scale. The sale of diverted or smuggled tobacco products is unlawful, and facilitates the sale of tobacco products to underage persons — undermining a key objective of RAI and its operating companies to prevent youth access to tobacco products. In addition, smuggling activities adversely impact the sale of tobacco products by RAI’s operating companies by: disrupting the contractual relationships between RAI’s operating companies and their wholesalers and retailers; damaging the equity of the brands sold by RAI’s operating companies in terms of the pricing and positioning of those brands; injuring the reputation of RAI’s operating companies by wrongly associating their brands with illegal smuggling activity; and making it difficult for retailers located in high tax jurisdictions to sell the products of RAI’s operating companies, given the competitive price advantage that smuggled products have in such jurisdictions. RAI undertakes a variety of actions to help combat illicit trade in tobacco products, including (1) promoting greater awareness among government officials, law enforcement and the public of the problem, (2) supporting law enforcement investigations of illicit trade in tobacco products, and (3) supporting legislative efforts to increase both the enforcement of anti-illicit trade laws and the penalties for the violations of such laws.
RJR Tobacco expects to benefit from certain state legislative activity aimed at leveling the playing field between PMs under the MSA and “nonparticipating manufacturers” under the MSA, referred to as NPMs. Forty-six states have passed legislation to ensure NPMs are making required escrow payments. Under this legislation, a state would only permit distribution of brands by manufacturers who are deemed by the states to be MSA-compliant or that are making required escrow payments. Failure to make escrow payments could result in the loss of an NPM’s ability to sell tobacco products in a respective state.
Additionally, 45 states have enacted legislation that closes a loophole in the MSA. The loophole allows NPMs that concentrate their sales in a single state, or a limited number of states, to recover most of the funds from their escrow accounts. To obtain the refunds, the manufacturers must establish that their escrow deposit was greater than the amount the state would have received had the manufacturer been a “subsequent participating manufacturer” under the MSA, that is, the state’s “allocable share.” The National Association of Attorneys General, referred to as NAAG, has endorsed adoption of the allocable share legislation needed to eliminate this loophole.
Forty-two states by statute or court rule have limited, in at least some circumstances, the amount of the bond required to stay execution of an adverse judgment pending an appeal in state court. The limitation on the amount of such bonds ranges generally from $1 million to $150 million. In five states and Puerto Rico, the filing of a notice of appeal automatically stays the judgment of the trial
59
court. For information regarding the bonding requirements applicable to Engle Progeny cases, see “— Litigation Affecting the Cigarette Industry — Engle and Engle Progeny Cases” in Item 8, note 13 to consolidated financial statements.
In 2003, the World Health Organization adopted a broad tobacco-control treaty, the Framework Convention on Tobacco Control, which entered into force in February 2005. The treaty recommends and requires enactment of legislation establishing specific actions to prevent youth smoking, restrict and gradually eliminate tobacco products marketing, provide greater regulation and disclosure of ingredients, increase the size and scope of package warning labels to cover at least 30% of each package and include graphic pictures on packages. The United States was an original signatory to the treaty. The treaty, however, has not been referred to, or ratified by, the U.S. Senate and, as a result, the United States is not a party to the treaty. Ratification of the treaty by the United States could lead to broader regulation of the industry.
The FDA Tobacco Act could result in a decrease in cigarette, smokeless tobacco product and e-cigarette sales in the United States, including sales of RJR Tobacco’s, American Snuff Co.’s, SFNTC’s and RJR Vapor’s brands, that, together with increased costs incurred by RAI’s operating companies arising from the FDA Tobacco Act, could have a material adverse effect on RAI’s financial condition, results of operations and cash flows. It is not possible to determine what additional federal, state or local legislation or regulations relating to smoking or cigarettes will be enacted or to predict the effect of new legislation or regulations on RJR Tobacco, SFNTC or the cigarette industry in general, but any new legislation or regulations could have an adverse effect on RJR Tobacco, SFNTC or the cigarette industry in general. Similarly, it is not possible to determine what additional federal, state or local legislation or regulations relating to smokeless tobacco products or e-cigarettes will be enacted or to predict the effect of new regulations on American Snuff Co. or smokeless tobacco products in general, or on RJR Vapor or e-cigarettes in general, as the case may be, but any new legislation or regulations could have an adverse effect on American Snuff Co. or smokeless tobacco products in general, or on RJR Vapor or e-cigarettes in general, as the case may be.
Other Contingencies
For information relating to other contingencies of RAI, RJR, RJR Tobacco, Lorillard Tobacco, American Snuff Co., SFNTC and RJR Vapor, see “— Other Contingencies” in Item 8, note 13 to consolidated financial statements.
Off-Balance Sheet Arrangements
RAI has no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on its financial position, results of operations, liquidity, capital expenditures or capital resources.
Cautionary Information Regarding Forward-Looking Statements
Statements included in this report that are not historical in nature are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. When used in this document and in documents incorporated by reference, forward-looking statements include, without limitation, statements regarding financial forecasts or projections, and RAI’s and its subsidiaries’ expectations, beliefs, intentions or future strategies that are signified by the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “should” and similar expressions. These statements regarding future events or the future performance or results of RAI and its subsidiaries inherently are subject to a variety of risks, contingencies and other uncertainties that could cause actual results, performance or achievements to differ materially from those described in or implied by the forward-looking statements. These risks, contingencies and other uncertainties include:
|
• |
the effect of (1) possible unfavorable outcomes in litigation based on allegations relating to the sale, distribution, manufacture, development, advertising, marketing and health effects of tobacco products (including smokeless tobacco products and electronic cigarettes) that is pending or may be instituted against RAI or its subsidiaries, including the Engle Progeny cases, and (2) potential bonding difficulties related to adverse judgments resulting from such litigation, including Engle Progeny cases; |
|
• |
the possibility that the FDA will issue regulations prohibiting or restricting the use of menthol in cigarettes, which could adversely affect the sales of, among other products, RJR Tobacco’s NEWPORT cigarettes; |
|
• |
the possibility that the CTP fails to grant a marketing order allowing an RAI subsidiary to launch a new tobacco product or modify an existing product; |
|
• |
the adverse effects (including damage to RAI’s reputation, recall costs and decreased sales) arising from potential CTP orders (1) finding that provisional products sold by RAI subsidiaries are not substantially equivalent to predicate products and (2) as a result, requiring that the provisional products be removed from the market; |
60
|
• |
the adverse effects arising out of FDA actions (or agreements between the FDA and RAI or its subsidiaries) related to product labeling and advertising, potentially resulting in decreased sales; |
|
• |
the adverse effects arising from the FDA’s May 2016 regulation extending the agency’s control and authority over tobacco products to e-cigarettes, which regulation (1) subjects e-cigarettes to restrictions on, among other things, the manufacturing, marketing and sale of such products, and (2) requires FDA clearance of e-cigarettes introduced to the market after February 15, 2007; |
|
• |
the possibility that the FDA will issue regulations further controlling constituents in cigarettes, including requiring the reduction of nicotine levels or the reduction or elimination of other constituents; |
|
• |
possible additional effects on the sales of RAI’s subsidiaries’ products of the substantial, sales-based payment obligations under the State Settlement Agreements, coupled with continuing effects of the State Settlement Agreements’ substantial limitations on the sale, advertising and marketing of cigarettes (and of RJR Tobacco’s smoke-free tobacco products); |
|
• |
the possibility that NPM Adjustment awards could be vacated or otherwise modified; |
|
• |
considering RAI’s subsidiaries’ dependence on the U.S. cigarette market, the continued decline in U.S. cigarette consumption; |
|
• |
the possible transition of consumers away from premium brands to lower-cost brands considering RAI’s subsidiaries’ dependence on premium and super-premium cigarette brands; |
|
• |
the success or failure of new products (including vapor category product offerings and other non-traditional tobacco products), marketing strategies and promotional programs; |
|
• |
competitive actions and pricing pressures from other manufacturers, including manufacturers of deep-discount cigarette brands; |
|
• |
significant current and anticipated federal, state and local governmental regulation of tobacco products, including limitations on advertising, marketing, sale and use of tobacco products; |
|
• |
substantial and increasing taxation of tobacco products; |
|
• |
fluctuations in the availability, quality and price of raw materials and commodities, including tobacco leaf, used in the products of RAI’s subsidiaries; |
|
• |
the reliance on a few significant manufacturing facilities and single source suppliers for certain key raw materials; |
|
• |
the possible impairment of goodwill and other intangible assets, including trademarks; |
|
• |
the effect of market conditions on the investment returns earned on pension assets or any adverse effects of any new legislation or regulations changing pension and postretirement benefits accounting or required pension funding levels; |
|
• |
the concentration of a material amount of sales with a limited number of customers and potential loss of these customers; |
|
• |
possible security breaches or disruptions in critical information technology systems, many of which are managed by third party service providers; |
|
• |
the possible inability to use digital technologies effectively, including any failure to use such technologies to engage with customers and consumers, automate business processes and support product innovation; |
|
• |
the impact of the health and social issues associated with the tobacco industry on RAI’s and its subsidiaries’ ability to attract and retain qualified employees, officers, and professionals; |
|
• |
indemnification obligations for specified matters, and retention of certain liabilities related to assets transferred in transactions with ITG and JTI Holding; |
|
• |
the impact of a potential decrease in RAI’s credit ratings on RAI’s ability to access the debt capital markets and on RAI’s borrowing costs; |
|
• |
the possibility of changes in RAI’s dividend policy; |
|
• |
the significant collective ownership interest in RAI of BAT and its subsidiaries, and their associated rights under the Governance Agreement, which should the BAT Merger not be completed and the Governance Agreement be terminated, in whole or in part, in accordance with its terms, could eliminate the board composition and share transfer restrictions placed on BAT and its subsidiaries; |
61
|
• |
the absence of significant anti-takeover measures, together with the effects of the declassification of the board of directors, in the event that the BAT Merger is not completed; and |
|
• |
additional risks, contingencies and uncertainties associated with the BAT Merger that could result in the failure of the BAT Merger to be completed or, if completed, to have an adverse effect on the results of operations, cash flows and financial position of RAI or the combined company, respectively, including: |
|
o |
the failure to obtain necessary shareholder approvals for the BAT Merger; |
|
o |
the failure to obtain necessary regulatory or other approvals for the BAT Merger, or if obtained, the possibility of being subjected to conditions that could reduce the expected synergies and other benefits of the BAT Merger, result in a material delay in, or the abandonment of, the BAT Merger or otherwise have an adverse effect on RAI or the combined company; |
|
o |
the failure to satisfy required closing conditions or complete the BAT Merger in a timely manner or at all; |
|
o |
the effect of restrictions placed on RAI’s and its subsidiaries’ business activities and the limitations put on RAI’s ability to pursue alternatives to the BAT Merger pursuant to the Merger Agreement; |
|
o |
risks related to disruption of management time from ongoing business operations due to the BAT Merger; |
|
o |
the failure to realize projected synergies and other benefits from the BAT Merger; |
|
o |
failure to promptly and effectively integrate RAI into BAT; |
|
o |
the uncertainty of the value of the merger consideration that RAI shareholders will receive in the BAT Merger due to a fixed exchange ratio and a potential fluctuation in the market price of BAT common stock; |
|
o |
the difference in rights provided to RAI shareholders under North Carolina law, the RAI articles of incorporation and the RAI bylaws, as compared to the rights RAI shareholders will obtain as BAT shareholders under the laws of England and Wales and BAT’s governing documents; |
|
o |
the possibility of RAI’s and BAT’s directors and officers having interests in the BAT Merger that are different from, or in addition to, the interests of RAI shareholders generally; |
|
o |
the effect of the announcement of the BAT Merger on the ability to retain and hire key personnel, maintain business relationships, and on operating results and businesses generally; |
|
o |
the incurrence of significant pre- and post-transaction related costs in connection with the BAT Merger; |
|
o |
evolving legal, regulatory and tax regimes; and |
|
o |
the occurrence of any event giving rise to the right of a party to terminate the Merger Agreement. |
Due to these risks, contingencies and other uncertainties, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as provided by federal securities laws, RAI is not required to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
Market risk represents the risk of loss that may impact the consolidated results of operations, cash flows and financial position due to adverse changes in financial market prices and rates. RAI and its subsidiaries are exposed to interest rate risk directly related to their normal investing and funding activities. In addition, RAI and its subsidiaries have immaterial exposure to foreign currency exchange rate risk related primarily to purchases and foreign operations denominated in euros, British pounds, Swiss francs, Swedish krona, Chinese renminbi, Japanese yen and Canadian dollars. RAI and its subsidiaries have established policies and procedures to manage their exposure to market risks.
62
The table below provides information, as of December 31, 2016, about RAI’s financial instruments that are sensitive to changes in interest rates. The table presents principal amounts and weighted average interest rates by contractual maturity dates for the years ending December 31 (1) :
|
|
|
2017 |
|
|
2018 |
|
|
2019 |
|
|
2020 |
|
|
2021 |
|
|
Thereafter |
|
|
Total |
|
|
Fair Value (1) |
|
||||||||
Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Variable Rate |
|
|
$ |
2,006 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2,006 |
|
|
$ |
2,006 |
|
Average Interest Rate |
|
|
|
0.2 |
% |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.2 |
% |
|
|
— |
|
Debt: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed-Rate |
|
|
$ |
500 |
|
|
$ |
1,250 |
|
|
$ |
750 |
|
|
$ |
1,521 |
|
|
$ |
— |
|
|
$ |
8,929 |
|
|
$ |
12,950 |
|
|
$ |
14,283 |
|
Average Interest Rate (2) |
|
|
|
2.3 |
% |
|
|
2.3 |
% |
|
|
8.1 |
% |
|
|
5.0 |
% |
|
|
— |
|
|
|
5.3 |
% |
|
|
5.0 |
% |
|
|
— |
|
(1) |
Fair values are based on current market rates available or on rates available for instruments with similar terms and maturities and quoted fair values. |
(2) |
Based upon coupon interest rates for fixed-rate instruments. |
RAI’s exposure to foreign currency transactions was not material to results of operations for the year ended December 31, 2016. RAI currently has no hedges for its exposure to foreign currency.
63
Index to Consolidated Financial Statements
|
65 |
||
Management’s Report on Internal Control over Financial Reporting |
|
66 |
|
|
67 |
||
|
68 |
||
|
69 |
||
|
70 |
||
|
71 |
||
|
72 |
||
|
73 |
||
|
|
73 |
|
|
|
81 |
|
|
3 Sale of International Rights to the NATURAL AMERICAN SPIRIT Brand |
|
83 |
|
|
84 |
|
|
|
85 |
|
|
|
87 |
|
|
|
87 |
|
|
|
87 |
|
|
|
88 |
|
|
|
88 |
|
|
|
90 |
|
|
|
92 |
|
|
|
96 |
|
|
|
139 |
|
|
|
142 |
|
|
|
145 |
|
|
|
152 |
|
|
|
154 |
|
|
19 RAI Guaranteed, Unsecured Notes — Condensed Consolidating Financial Statements |
|
155 |
|
20 RJR Tobacco Guaranteed, Unsecured Notes — Condensed Consolidating Financial Statements |
|
165 |
|
|
175 |
|
|
|
175 |
64
Item 8. Financial Stateme nts and Supplementary Data
Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Reynolds American Inc.:
We have audited the accompanying consolidated balance sheets of Reynolds American Inc. and subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three‑year period ended December 31, 2016. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Reynolds American Inc. and subsidiaries as of December 31, 2016 and 2015, and the results of their operations and their cash flows for each of the years in the three‑year period ended December 31, 2016, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Reynolds American Inc.’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 9, 2017 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
/s/ KPMG LLP
Greensboro, North Carolina
February 9, 2017
65
Management’s Report on Internal C ontrol over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Securities Exchange Act of 1934. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles and includes those policies and procedures that:
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of RAI,
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of RAI are being made only in accordance with authorizations of management and directors of RAI, and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of RAI’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements and even when determined to be effective, can only provide reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.
Management conducted an evaluation of the effectiveness of RAI’s internal control over financial reporting based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that RAI’s system of internal control over financial reporting was effective as of December 31, 2016.
KPMG LLP, independent registered public accounting firm, has audited RAI’s consolidated financial statements and issued an attestation report on RAI’s internal control over financial reporting as of December 31, 2016.
Dated: February 9, 2017
66
Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Reynolds American Inc.:
We have audited Reynolds American Inc.’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Reynolds American Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, Reynolds American Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Reynolds American Inc. and subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and our report dated February 9, 2017 expressed an unqualified opinion on those consolidated financial statements.
/s/ KPMG LLP
Greensboro, North Carolina
February 9, 2017
67
CONSOLIDATED STATEMENTS OF INCOME
(Dollars in Millions, Except Per Share Amounts)
|
|
For the Years Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Net sales (1) |
|
$ |
12,277 |
|
|
$ |
10,416 |
|
|
$ |
8,160 |
|
Net sales, related party |
|
|
226 |
|
|
|
259 |
|
|
|
311 |
|
Net sales |
|
|
12,503 |
|
|
|
10,675 |
|
|
|
8,471 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold (1) |
|
|
4,841 |
|
|
|
4,688 |
|
|
|
4,058 |
|
Selling, general and administrative expenses |
|
|
1,931 |
|
|
|
2,098 |
|
|
|
1,871 |
|
Gain on divestitures |
|
|
(4,861 |
) |
|
|
(3,181 |
) |
|
|
— |
|
Amortization expense |
|
|
23 |
|
|
|
18 |
|
|
|
11 |
|
Asset impairment and exit charges |
|
|
— |
|
|
|
99 |
|
|
|
— |
|
Operating income |
|
|
10,569 |
|
|
|
6,953 |
|
|
|
2,531 |
|
Interest and debt expense |
|
|
626 |
|
|
|
570 |
|
|
|
286 |
|
Interest income |
|
|
(8 |
) |
|
|
(6 |
) |
|
|
(3 |
) |
Other (income) expense, net |
|
|
260 |
|
|
|
5 |
|
|
|
(14 |
) |
Income from continuing operations before income taxes |
|
|
9,691 |
|
|
|
6,384 |
|
|
|
2,262 |
|
Provision for income taxes |
|
|
3,618 |
|
|
|
3,131 |
|
|
|
817 |
|
Income from continuing operations |
|
|
6,073 |
|
|
|
3,253 |
|
|
|
1,445 |
|
Income from discontinued operations, net of tax |
|
|
— |
|
|
|
— |
|
|
|
25 |
|
Net income |
|
$ |
6,073 |
|
|
$ |
3,253 |
|
|
$ |
1,470 |
|
Basic income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
4.26 |
|
|
$ |
2.57 |
|
|
$ |
1.36 |
|
Income from discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
0.02 |
|
Net income |
|
$ |
4.26 |
|
|
$ |
2.57 |
|
|
$ |
1.38 |
|
Diluted income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
4.25 |
|
|
$ |
2.57 |
|
|
$ |
1.35 |
|
Income from discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
0.02 |
|
Net income |
|
$ |
4.25 |
|
|
$ |
2.57 |
|
|
$ |
1.37 |
|
Dividends declared per share |
|
$ |
1.76 |
|
|
$ |
1.39 |
|
|
$ |
1.34 |
|
(1) |
Excludes excise taxes of $4,343 million, $4,209 million and $3,625 million for the years ended December 31, 2016, 2015 and 2014, respectively. |
See Notes to Consolidated Financial Statements
68
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Dollars in Millions)
|
|
For the Years Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Net income |
|
$ |
6,073 |
|
|
$ |
3,253 |
|
|
$ |
1,470 |
|
Other comprehensive income (loss), net of tax (benefit) expense: |
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits, net of tax (2016 — $(6); 2015 — $32; 2014 — $(178)) |
|
|
(11 |
) |
|
|
50 |
|
|
|
(277 |
) |
Long-term investments, net of tax (2016 — $10; 2014 — $1) |
|
|
14 |
|
|
|
— |
|
|
|
2 |
|
Hedging instruments, net of tax (2016 — $6; 2015 — $1; 2014 — $1 ) |
|
|
11 |
|
|
|
1 |
|
|
|
1 |
|
Cumulative translation adjustment and other, net of tax (2016 — $6; 2015 — $(12); 2014 — $(15)) |
|
|
10 |
|
|
|
(25 |
) |
|
|
(34 |
) |
Comprehensive income |
|
$ |
6,097 |
|
|
$ |
3,279 |
|
|
$ |
1,162 |
|
See Notes to Consolidated Financial Statements
69
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in Millions)
|
|
For the Years Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Cash flows from (used in) operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
6,073 |
|
|
$ |
3,253 |
|
|
$ |
1,470 |
|
Income from discontinued operations, net of tax |
|
|
— |
|
|
|
— |
|
|
|
(25 |
) |
Adjustments to reconcile to net cash flows from (used in) operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Gain on divestitures |
|
|
(4,861 |
) |
|
|
(3,181 |
) |
|
|
— |
|
Loss on early extinguishment of debt and related expenses |
|
|
239 |
|
|
|
— |
|
|
|
— |
|
Asset impairment and exit charges, net of cash payments |
|
|
— |
|
|
|
94 |
|
|
|
|
|
Depreciation and amortization expense |
|
|
123 |
|
|
|
122 |
|
|
|
106 |
|
Deferred income tax expense (benefit) |
|
|
387 |
|
|
|
(659 |
) |
|
|
(180 |
) |
Other changes that provided (used) cash: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts and other receivables |
|
|
24 |
|
|
|
86 |
|
|
|
(3 |
) |
Inventories |
|
|
89 |
|
|
|
31 |
|
|
|
(154 |
) |
Related party, net |
|
|
(5 |
) |
|
|
14 |
|
|
|
— |
|
Accounts payable |
|
|
42 |
|
|
|
32 |
|
|
|
(43 |
) |
Accrued liabilities, including other working capital |
|
|
(160 |
) |
|
|
(242 |
) |
|
|
30 |
|
Tobacco settlement accruals |
|
|
(314 |
) |
|
|
239 |
|
|
|
92 |
|
Pension and postretirement |
|
|
(415 |
) |
|
|
91 |
|
|
|
317 |
|
Other, net |
|
|
58 |
|
|
|
316 |
|
|
|
13 |
|
Net cash flows from operating activities |
|
|
1,280 |
|
|
|
196 |
|
|
|
1,623 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(206 |
) |
|
|
(174 |
) |
|
|
(204 |
) |
Proceeds from settlement of investments |
|
|
266 |
|
|
|
332 |
|
|
|
4 |
|
Acquisition, net of cash acquired |
|
|
— |
|
|
|
(17,220 |
) |
|
|
— |
|
Proceeds from divestitures |
|
|
5,015 |
|
|
|
7,056 |
|
|
|
— |
|
Proceeds from termination of joint venture |
|
|
— |
|
|
|
— |
|
|
|
35 |
|
Other, net |
|
|
3 |
|
|
|
1 |
|
|
|
(40 |
) |
Net cash flows from (used in) investing activities |
|
|
5,078 |
|
|
|
(10,005 |
) |
|
|
(205 |
) |
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(2,369 |
) |
|
|
(1,583 |
) |
|
|
(1,411 |
) |
Repurchase of common stock |
|
|
(226 |
) |
|
|
(124 |
) |
|
|
(440 |
) |
Repayments of long-term debt |
|
|
(500 |
) |
|
|
(450 |
) |
|
|
— |
|
Early extinguishment of debt |
|
|
(3,650 |
) |
|
|
— |
|
|
|
— |
|
Premiums paid for early extinguishment of debt |
|
|
(207 |
) |
|
|
— |
|
|
|
— |
|
Proceeds from termination of interest rate swaps |
|
|
66 |
|
|
|
— |
|
|
|
— |
|
Proceeds from BAT Share Purchase |
|
|
— |
|
|
|
4,673 |
|
|
|
— |
|
Issuance of long-term debt |
|
|
— |
|
|
|
8,975 |
|
|
|
— |
|
Debt issuance costs and financing fees |
|
|
(8 |
) |
|
|
(70 |
) |
|
|
(79 |
) |
Borrowings under revolving credit facility |
|
|
— |
|
|
|
1,400 |
|
|
|
1,000 |
|
Repayments of borrowings under revolving credit facility |
|
|
— |
|
|
|
(1,400 |
) |
|
|
(1,000 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
28 |
|
|
|
17 |
|
|
|
12 |
|
Net cash flows from (used in) financing activities |
|
|
(6,866 |
) |
|
|
11,438 |
|
|
|
(1,918 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
(8 |
) |
|
|
(28 |
) |
|
|
(34 |
) |
Net change in cash and cash equivalents |
|
|
(516 |
) |
|
|
1,601 |
|
|
|
(534 |
) |
Cash and cash equivalents at beginning of year |
|
|
2,567 |
|
|
|
966 |
|
|
|
1,500 |
|
Cash and cash equivalents at end of year |
|
$ |
2,051 |
|
|
$ |
2,567 |
|
|
$ |
966 |
|
Income taxes paid, net of refunds |
|
$ |
3,179 |
|
|
$ |
3,744 |
|
|
$ |
974 |
|
Interest paid |
|
$ |
712 |
|
|
$ |
510 |
|
|
$ |
252 |
|
Fair value of equity consideration issued in the Lorillard Merger |
|
$ |
— |
|
|
$ |
7,555 |
|
|
$ |
— |
|
See Notes to Consolidated Financial Statements
70
(Dollars in Millions)
|
|
December 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
2,051 |
|
|
$ |
2,567 |
|
Short-term investments |
|
|
— |
|
|
|
149 |
|
Accounts receivable |
|
|
66 |
|
|
|
68 |
|
Accounts receivable, related party |
|
|
113 |
|
|
|
38 |
|
Other receivables |
|
|
10 |
|
|
|
35 |
|
Inventories |
|
|
1,645 |
|
|
|
1,734 |
|
Other current assets |
|
|
353 |
|
|
|
564 |
|
Total current assets |
|
|
4,238 |
|
|
|
5,155 |
|
Property, plant and equipment, at cost: |
|
|
|
|
|
|
|
|
Land and land improvements |
|
|
95 |
|
|
|
94 |
|
Buildings and leasehold improvements |
|
|
757 |
|
|
|
727 |
|
Machinery and equipment |
|
|
2,064 |
|
|
|
1,967 |
|
Construction-in-process |
|
|
94 |
|
|
|
110 |
|
Total property, plant and equipment |
|
|
3,010 |
|
|
|
2,898 |
|
Accumulated depreciation |
|
|
(1,662 |
) |
|
|
(1,643 |
) |
Property, plant and equipment, net |
|
|
1,348 |
|
|
|
1,255 |
|
Trademarks and other intangible assets, net of accumulated amortization |
|
|
29,444 |
|
|
|
29,467 |
|
Goodwill |
|
|
15,992 |
|
|
|
15,993 |
|
Other assets and deferred charges |
|
|
73 |
|
|
|
230 |
|
|
|
$ |
51,095 |
|
|
$ |
52,100 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
221 |
|
|
$ |
179 |
|
Tobacco settlement accruals |
|
|
2,498 |
|
|
|
2,816 |
|
Due to related party |
|
|
7 |
|
|
|
9 |
|
Deferred revenue, related party |
|
|
66 |
|
|
|
33 |
|
Current maturities of long-term debt |
|
|
501 |
|
|
|
506 |
|
Dividends payable on common stock |
|
|
656 |
|
|
|
514 |
|
Other current liabilities |
|
|
1,036 |
|
|
|
1,234 |
|
Total current liabilities |
|
|
4,985 |
|
|
|
5,291 |
|
Long-term debt (less current maturities) |
|
|
12,664 |
|
|
|
16,849 |
|
Long-term deferred income taxes, net |
|
|
9,607 |
|
|
|
9,204 |
|
Long-term retirement benefits (less current portion) |
|
|
1,869 |
|
|
|
2,265 |
|
Long-term deferred revenue, related party |
|
|
39 |
|
|
|
— |
|
Other noncurrent liabilities |
|
|
220 |
|
|
|
239 |
|
Commitments and contingencies: |
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock (shares issued: 2016 — 1,425,824,955; 2015 — 1,427,341,341) |
|
|
— |
|
|
|
— |
|
Paid-in capital |
|
|
18,285 |
|
|
|
18,402 |
|
Retained earnings |
|
|
3,740 |
|
|
|
188 |
|
Accumulated other comprehensive loss |
|
|
(314 |
) |
|
|
(338 |
) |
Total shareholders’ equity |
|
|
21,711 |
|
|
|
18,252 |
|
|
|
$ |
51,095 |
|
|
$ |
52,100 |
|
See Notes to Consolidated Financial Statements
71
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(Dollars in Millions, Except Per Share Amounts)
|
|
Common Stock |
|
|
Paid-In Capital |
|
|
Retained Earnings (Accumulated Deficit) |
|
|
Accumulated Other Comprehensive Loss |
|
|
Total Shareholders’ Equity |
|
|||||
Balance at December 31, 2013 |
|
$ |
— |
|
|
$ |
6,571 |
|
|
$ |
(1,348 |
) |
|
$ |
(56 |
) |
|
$ |
5,167 |
|
Net income |
|
|
— |
|
|
|
— |
|
|
|
1,470 |
|
|
|
— |
|
|
|
1,470 |
|
Retirement benefits, net of $178 tax benefit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(277 |
) |
|
|
(277 |
) |
Long-term investments, net of $1 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
|
2 |
|
Hedging instruments, net of $1 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
1 |
|
Cumulative translation adjustment and other, net of $15 tax benefit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(34 |
) |
|
|
(34 |
) |
Dividends — $1.34 per share |
|
|
— |
|
|
|
— |
|
|
|
(1,436 |
) |
|
|
— |
|
|
|
(1,436 |
) |
Common stock repurchased |
|
|
— |
|
|
|
(440 |
) |
|
|
— |
|
|
|
— |
|
|
|
(440 |
) |
Equity incentive award plan and stock-based compensation |
|
|
— |
|
|
|
57 |
|
|
|
— |
|
|
|
— |
|
|
|
57 |
|
Excess tax benefit on stock-based compensation plans |
|
|
— |
|
|
|
12 |
|
|
|
— |
|
|
|
— |
|
|
|
12 |
|
Balance at December 31, 2014 |
|
|
— |
|
|
|
6,200 |
|
|
|
(1,314 |
) |
|
|
(364 |
) |
|
|
4,522 |
|
Net income |
|
|
— |
|
|
|
— |
|
|
|
3,253 |
|
|
|
— |
|
|
|
3,253 |
|
Retirement benefits, net of $32 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
50 |
|
|
|
50 |
|
Hedging instruments, net of $1 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
1 |
|
Cumulative translation adjustment and other, net of $12 tax benefit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(25 |
) |
|
|
(25 |
) |
Dividends — $1.39 per share |
|
|
— |
|
|
|
— |
|
|
|
(1,751 |
) |
|
|
— |
|
|
|
(1,751 |
) |
Issuance of additional shares as Lorillard Merger Consideration |
|
|
— |
|
|
|
7,555 |
|
|
|
— |
|
|
|
— |
|
|
|
7,555 |
|
Issuance of additional shares for BAT Share Purchase |
|
|
— |
|
|
|
4,673 |
|
|
|
— |
|
|
|
— |
|
|
|
4,673 |
|
Common stock repurchased |
|
|
— |
|
|
|
(124 |
) |
|
|
— |
|
|
|
— |
|
|
|
(124 |
) |
Equity incentive award plan and stock-based compensation |
|
|
— |
|
|
|
81 |
|
|
|
— |
|
|
|
— |
|
|
|
81 |
|
Excess tax benefit on stock-based compensation plans |
|
|
— |
|
|
|
17 |
|
|
|
— |
|
|
|
— |
|
|
|
17 |
|
Balance at December 31, 2015 |
|
|
— |
|
|
|
18,402 |
|
|
|
188 |
|
|
|
(338 |
) |
|
|
18,252 |
|
Net income |
|
|
— |
|
|
|
— |
|
|
|
6,073 |
|
|
|
— |
|
|
|
6,073 |
|
Retirement benefits, net of $6 tax benefit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(11 |
) |
|
|
(11 |
) |
Long-term investments, net of $10 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14 |
|
|
|
14 |
|
Hedging instruments, net of $6 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11 |
|
|
|
11 |
|
Cumulative translation adjustment and other, net of $6 tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
|
|
10 |
|
Dividends — $1.76 per share |
|
|
— |
|
|
|
— |
|
|
|
(2,521 |
) |
|
|
— |
|
|
|
(2,521 |
) |
Common stock repurchased |
|
|
— |
|
|
|
(226 |
) |
|
|
— |
|
|
|
— |
|
|
|
(226 |
) |
Equity incentive award plan and stock-based compensation |
|
|
— |
|
|
|
81 |
|
|
|
— |
|
|
|
— |
|
|
|
81 |
|
Excess tax benefit on stock-based compensation plans |
|
|
— |
|
|
|
28 |
|
|
|
— |
|
|
|
— |
|
|
|
28 |
|
Balance at December 31, 2016 |
|
$ |
— |
|
|
$ |
18,285 |
|
|
$ |
3,740 |
|
|
$ |
(314 |
) |
|
$ |
21,711 |
|
See Notes to Consolidated Financial Statements
72
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1 — Business and Summary of Significant Accounting Policies
Overview
The consolidated financial statements include the accounts of Reynolds American Inc., referred to as RAI, and its wholly owned subsidiaries. RAI’s wholly owned operating subsidiaries include R. J. Reynolds Tobacco Company; Santa Fe Natural Tobacco Company, Inc., referred to as SFNTC; American Snuff Company, LLC, referred to as American Snuff Co.; R. J. Reynolds Vapor Company, referred to as RJR Vapor; Niconovum USA, Inc.; Niconovum AB; and until their sale on January 13, 2016, as described below, SFR Tobacco International GmbH, referred to as SFRTI, and various foreign subsidiaries affiliated with SFRTI.
RAI was incorporated as a holding company in the State of North Carolina on January 2, 2004, and its common stock is listed on the New York Stock Exchange, referred to as the NYSE, under the symbol “RAI.” On July 30, 2004, the U.S. assets, liabilities and operations of Brown & Williamson Tobacco Corporation, now known as Brown & Williamson Holdings, Inc., referred to as B&W, an indirect, wholly owned subsidiary of British American Tobacco p.l.c., referred to as BAT, were combined with R. J. Reynolds Tobacco Company, a wholly owned operating subsidiary of R.J. Reynolds Tobacco Holdings, Inc., referred to as RJR. These July 30, 2004, transactions generally are referred to as the B&W business combination.
References to RJR Tobacco prior to July 30, 2004, relate to R. J. Reynolds Tobacco Company, a New Jersey corporation. References to RJR Tobacco on and subsequent to July 30, 2004 and until June 12, 2015, relate to the combined U.S. assets, liabilities and operations of B&W and R. J. Reynolds Tobacco Company. Concurrent with the completion of the B&W business combination, RJR Tobacco became a North Carolina corporation. References to RJR Tobacco on and subsequent to June 12, 2015, relate to R. J. Reynolds Tobacco Company, a North Carolina corporation, and reflect the effects of the Lorillard Merger and Divestiture, described below.
Proposed Merger with BAT
On January 17, 2017, RAI announced that it had entered into an Agreement and Plan of Merger, referred to as the Merger Agreement, with BAT, BATUS Holdings Inc., a Delaware corporation and a wholly owned subsidiary of BAT, and Flight Acquisition Corporation, a North Carolina corporation and a wholly owned subsidiary of BAT, referred to as Merger Sub. For additional information, see note 22 to consolidated financial statements.
Recent Transactions
On June 12, 2015, RAI acquired Lorillard, Inc., n/k/a Lorillard, LLC, referred to as Lorillard, in a cash and stock transaction, valued at $25.8 billion, referred to as the Lorillard Merger. Also on June 12, 2015, a wholly owned subsidiary, n/k/a ITG Brands, LLC, referred to as ITG, of Imperial Brands, PLC, f/k/a Imperial Tobacco Group, PLC, referred to as Imperial, acquired for approximately $7.1 billion, in a transaction referred to as the Divestiture, certain assets (1) owned by RAI subsidiaries or affiliates relating to the cigarette brands WINSTON, KOOL and SALEM, and (2) owned by Lorillard subsidiaries or affiliates related to the cigarette brand MAVERICK and the “e-vapor” brand blu (including SKYCIG), as well as Lorillard’s owned and leased real property, and certain transferred employees, together with associated liabilities. As a result of the Divestiture, RAI recognized a pre-tax gain of approximately $3.2 billion. Additionally on June 12, 2015, shortly after the completion of the Lorillard Merger, Lorillard Tobacco Company, LLC, a wholly owned subsidiary of Lorillard, referred to as Lorillard Tobacco, merged with and into RJR Tobacco, with RJR Tobacco continuing as the surviving entity, referred to as the Lorillard Tobacco Merger. The statements of financial position and results of operations contained in the consolidated financial statements reflect the results of the Lorillard Merger and Divestiture and related transactions. For additional information on the Lorillard Merger and Divestiture, and related transactions, see note 2 to consolidated financial statements.
On June 12, 2015, concurrently with the completion of the Lorillard Merger and Divestiture, BAT indirectly (through a wholly-owned subsidiary) purchased 77,680,259 shares of RAI common stock, prior to giving effect to RAI’s 2015 two-for-one stock split, referred to as the BAT Share Purchase, for approximately $4.7 billion, which was sufficient for BAT and its subsidiaries collectively to maintain their approximately 42% beneficial ownership of RAI.
On January 13, 2016, RAI, through various subsidiaries, referred to as the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with SFRTI and other international companies that distributed and marketed the brand outside the United States, to JT International Holding BV, referred to as JTI Holding, a subsidiary of Japan Tobacco Inc., referred to as JTI, in an all-cash transaction of approximately $5 billion and recognized a pre-tax
73
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
gain of approximately $4.9 billion. The transaction did not include the rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks in the U.S. market, U.S. duty-free locations and U.S. territories or in U.S. military outlets, all of which were retained by SFNTC. With this transaction completed, the international rights to nearly all of RAI’s operating companies’ cigarette trademarks are now owned by international tobacco companies. For additional information on the transaction, see note 3.
Operating segments
RAI’s reportable operating segments are RJR Tobacco, Santa Fe and American Snuff. The RJR Tobacco segment consists of the primary operations of R. J. Reynolds Tobacco Company. The Santa Fe segment consists of the primary operations of SFNTC. The American Snuff segment consists of the primary operations of American Snuff Co. Included in All Other, among other RAI subsidiaries, are RJR Vapor, Niconovum USA, Inc., Niconovum AB, and until their sale on January 13, 2016, as described above, SFRTI, and various foreign subsidiaries affiliated with SFRTI. The segments were identified based on how RAI’s chief operating decision maker allocates resources and assesses performance. Certain of RAI’s operating subsidiaries have entered into intercompany agreements for products or services with other subsidiaries. As a result, certain activities of an operating subsidiary may be included in a different segment of RAI.
RAI’s operating subsidiaries primarily conduct their business in the United States.
Basis of Presentation
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, referred to as GAAP, requires estimates and assumptions to be made that affect the reported amounts in the consolidated financial statements and accompanying notes. Volatile credit and equity markets, changes to regulatory and legal environments, and consumer spending may affect the uncertainty inherent in such estimates and assumptions. Actual results could materially differ from those estimates. All material intercompany balances have been eliminated.
Certain reclassifications were made to conform prior years’ financial statements to the current presentation. Certain amounts presented in note 13 are rounded in the aggregate and may not sum from the individually presented components. All dollar amounts, other than per share amounts, are presented in millions, except for amounts set forth in note 13 and as otherwise noted.
Business Combination
RAI accounts for business combination transactions in accordance with the Financial Accounting Standards Board, referred to as the FASB, Accounting Standards Codification 805, Business Combinations , referred to as ASC 805. RAI allocates the cost of an acquisition to the assets acquired and liabilities assumed based on their fair values as of the acquisition date. Any excess of the purchase price over the estimated fair value of net assets acquired is recorded as goodwill. Determining the fair value of these items requires management’s judgment and may require utilization of independent valuation experts to assist with such valuations. These valuations involve the use of significant estimates and assumptions with respect to the timing and amounts of future cash flows, discount rates, market prices, and asset lives, among other items. The judgments made in the determination of the estimated fair value of the assets acquired and the liabilities assumed as well as the estimated useful life of each asset and the duration of each liability can materially impact the financial statements in periods after the acquisition, such as depreciation, amortization, or in certain situations, impairment charges.
The fair value of acquired intangible assets measured on a nonrecurring basis, was determined based on inputs that are unobservable and significant to the overall fair value measurement. As such, acquired intangible assets are classified as Level 3. RAI engaged the services of a third party valuation expert to assist in determining the fair value of acquired trademarks and customer lists. The acquired trademarks and customer lists were valued utilizing the income approach and were based on a discounted cash flow valuation model. This approach utilized unobservable factors, such as royalty rate, projected revenues and a discount rate, applied to the estimated cash flows. The determination of the discount rate was based on a cost of equity model, using a risk-free rate, adjusted by a stock beta-adjusted risk premium and size premium.
The fair value of acquired long-term debt was determined based on significant inputs that are observable either directly or indirectly, and are quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. As such, acquired long-term debt is classified as Level 2. RAI engaged the services of a financial institution in determining the fair value of acquired long-term debt. The acquired long-term debt was valued utilizing market quotes, credit spreads and discounted cash flows, as appropriate. RAI performed its own independent valuation to assess the reasonableness of that calculated by the financial institution.
74
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
As a market participant, RAI determined the fair value of inventories and property, plant and equipment utilizing internal resources and external experts. The fair value of finished goods inventories was determined using selling price less estimated costs to dispose. The fair value of other inventories, primarily leaf tobacco acquired, was based on recent costs for similar inventory purchased by RAI and its subsidiaries or historical cost as appropriate. To fair value property, plant and equipment, which consisted primarily of machinery used in the manufacture of cigarettes, RAI utilized internal engineering resources and external vendor experts familiar with pricing for similar machinery on the secondary market. The fair value of long-term retirement benefits represents the funded status of the employee benefit plans assumed by RAI in the Lorillard Merger . RAI engaged its actuaries to determine the fair value of the projected benefit obligations at the date of the Lorillard Merger utilizing management’s assumptions and estimates relative to the benefit plans acquired. For the fair value of benefit plan assets, an independent valuation expert was engaged, in addition to internal treasury resources, to project the fair value of the benefit plan assets at the Lorillard Merger date.
For further information related to accounting for the Lorillard Merger and Divestiture, see note 2.
Cash and Cash Equivalents
Cash balances are recorded net of book overdrafts when a bank right-of-offset exists. All other book overdrafts are recorded in accounts payable. Cash equivalents may include money market funds, commercial paper and time deposits in major institutions to minimize investment risk. As short-term, highly liquid investments readily convertible to known amounts of cash, with remaining maturities of three months or less at the time of purchase, cash equivalents have carrying values that approximate fair values.
Fair Value Measurement
RAI determines the fair value of assets and liabilities using a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity, and the reporting entity’s own assumptions about market participant assumptions based on the best information available in the circumstances.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.
The levels of the fair value hierarchy are:
Level 1: inputs are quoted prices, unadjusted, in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2: inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. A Level 2 input must be observable for substantially the full term of the asset or liability.
Level 3: inputs are unobservable and reflect the reporting entity’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.
RAI sponsors a number of non-contributory defined benefit pension plans covering certain employees of RAI and its subsidiaries, and holds investments in plan assets to support these obligations. For additional information regarding the fair value of these plan assets, see note 16.
Inventories
Inventories are stated at the lower of cost or market. The cost of RJR Tobacco’s leaf tobacco inventories is determined principally under the last-in, first-out, or LIFO, method and is calculated at the end of each year. The cost of work in process and finished goods includes materials, direct labor, variable costs and overhead and full absorption of fixed manufacturing overhead. Stocks of tobacco, which have an operating cycle that exceeds 12 months due to aging requirements, are classified as current assets, consistent with recognized industry practice. The remaining inventories not valued under LIFO are valued under the first-in, first-out method.
Long-lived Assets
Long-lived assets, such as property, plant and equipment, trademarks and other intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable.
75
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Impairment of the carrying value of long-lived assets would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Useful lives range from 20 to 50 years for buildings and improvements, and from 3 to 30 years for machinery and equipment. The cost and related accumulated depreciation of assets sold or retired are removed from the accounts and the gain or loss on disposition is recognized in operating income. Depreciation expense was $100 million, $104 million and $95 million for the years ended December 31, 2016, 2015 and 2014, respectively.
Software Costs
Computer software and software development costs incurred in connection with developing or obtaining computer software for internal use that has an extended useful life are capitalized. These costs are amortized over their estimated useful life, which is typically five years or less. The following is a summary of balances and expenses for software costs as of and for the years ended December 31:
Balances:
|
|
2016 |
|
|
2015 |
|
||
Unamortized software costs balance |
|
$ |
49 |
|
|
$ |
37 |
|
Software costs — capitalized or included in construction-in-process |
|
|
27 |
|
|
|
13 |
|
Expenses:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Software amortization expense |
|
$ |
14 |
|
|
$ |
17 |
|
|
$ |
15 |
|
Intangible Assets
Intangible assets include goodwill, trademarks and other intangible assets and are capitalized when acquired. The determination of fair value involves considerable estimates and judgment. In particular, the fair value of a reporting unit involves, among other things, developing forecasts of future cash flows, determining an appropriate discount rate, and when goodwill impairment is implied, determining the fair value of individual assets and liabilities, including unrecorded intangibles. Although RAI believes it has based its impairment testing of its intangible assets on reasonable estimates and assumptions, the use of different estimates and assumptions could result in materially different results. If the current legal and regulatory environment, business or competitive climate worsens, or RAI’s operating companies’ strategic initiatives adversely affect their financial performance, the fair value of goodwill, trademarks and other intangible assets could be impaired in future periods. Goodwill, trademarks and other intangible assets with indefinite lives are not amortized, but are tested for impairment annually, in the fourth quarter, and more frequently if events and circumstances indicate that the asset might be impaired.
Finite lived trademarks and acquired customer lists are amortized using the straight-line method over their remaining useful lives, of 2 to 19 years, consistent with the pattern of economic benefits estimated to be received.
Revenue Recognition
Revenue from product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. These criteria are generally met when title and risk of loss pass to the customer. Payments received in advance of shipments are deferred and recorded in other accrued liabilities until shipment occurs. Certain sales of leaf to a related party, considered as bill-and-hold for accounting purposes, are recorded as deferred revenue when all of the above revenue recognition criteria are met except delivery, postponed at the customer’s request. Revenue is subsequently recognized upon delivery. The revenues recorded are presented net of excise tax collected on behalf of government authorities.
76
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Shipping and handling costs are classified as cost of products sold. Net sales include certain sales incentives, including retail discounting, promotional allowances and coupons.
Cost of Products Sold
RJR Tobacco (itself, and as successor by merger to Lorillard Tobacco) and SFNTC are participants in the Master Settlement Agreement, referred to as the MSA, and RJR Tobacco (itself, and as successor by merger to Lorillard Tobacco) is a participant in the other state settlement agreements with the States of Mississippi, Florida, Texas and Minnesota, which together with the MSA are collectively referred to as the State Settlement Agreements. RJR Tobacco’s and SFNTC’s obligations and the related expense charges under these agreements are subject to adjustments based upon, among other things, the volume of cigarettes sold by the operating subsidiaries, their relative market share, and their operating profit and inflation. Since relative market share is based on cigarette shipments, the best estimate of the allocation of charges to RJR Tobacco and SFNTC under these agreements is recorded in cost of products sold as the products are shipped. Included in these adjustments is the MSA non-participating manufacturer adjustment, referred to as the NPM Adjustment, that potentially reduces the annual payment obligation of RJR Tobacco, SFNTC and other participating manufacturers, referred to as the PMs. Adjustments to these estimates are recorded in the period that the change becomes probable and the amount can be reasonably estimated. American Snuff Co. is not a participant in the State Settlement Agreements.
Cost of products sold includes, among other expenses, the expenses for the State Settlement Agreements; the user fees charged by the U.S. Food and Drug Administration, referred to as the FDA; and the federal tobacco quota buyout that expired in 2014. These expenses were as follows for the years ended December 31:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
State Settlement Agreements |
|
$ |
2,727 |
|
|
$ |
2,403 |
|
|
$ |
1,917 |
|
FDA user fees |
|
|
194 |
|
|
|
174 |
|
|
|
135 |
|
Federal tobacco quota buyout |
|
|
— |
|
|
|
— |
|
|
|
163 |
|
In 2012, RJR Tobacco, Lorillard Tobacco, SFNTC and certain other participating manufacturers, referred to as the PMs, entered into a term sheet, referred to as the Term Sheet, with 17 states, the District of Columbia and Puerto Rico to settle certain claims related to the NPM Adjustment. The Term Sheet resolved claims related to volume years from 2003 through 2012 and puts in place a revised method to determine future adjustments from 2013 forward. Subsequently, five additional states joined the Term Sheet, including two states that were found to not have diligently enforced their qualifying statutes in 2003. The parties to the Term Sheet represent an allocable share of 49.87%.
In June 2014, two additional states agreed to settle the NPM Adjustment disputes on similar terms as set forth in the Term Sheet, except for certain provisions related to the determination of credits to be received by the PMs. RJR Tobacco and SFNTC, collectively, will receive credits, currently estimated to total approximately $170 million, with respect to their NPM Adjustment claims from 2003 through 2012. The credits related to these two states will be applied against annual payments under the MSA over a five-year period effectively beginning with the April 2014 MSA payment. As a result, expenses for the MSA were reduced by $34 million for the year ended December 31, 2014. As a result of the Lorillard Tobacco Merger, RJR Tobacco will receive approximately $5 million of additional credits, attributable to Lorillard Tobacco, which will be applied against annual MSA payments through 2018.
As a result of meeting the performance requirements associated with the Term Sheet, RJR Tobacco and Santa Fe, collectively, recognized additional credits of $295 million, $282 million and $311 million for the years ended December 31, 2016, 2015 and 2014, respectively. Credits recognized in the years ended December 31, 2016 and 2015, include the benefit of the additional credits received as a result of the Lorillard Tobacco Merger. RJR Tobacco expects to recognize additional credits through 2017.
In September 2013, the Arbitration Panel ruled six states had not diligently enforced their qualifying statutes in 2003 related to the NPM Adjustment. Two of the six states subsequently joined the Term Sheet in 2014. In 2015, three of the states dropped their challenge of the finding of non-diligence and in 2016, the remaining state dropped its challenge. As such, a portion of the potential recovery from those states was certain and estimable, and RJR Tobacco recognized $6 million and $93 million as a reduction of cost of products sold for the years ended December 31, 2016 and 2015, respectively. A final issue regarding the judgment reduction method adopted by the Arbitration Panel was being contested in these four states. In 2016, the U.S. Supreme Court denied RJR Tobacco’s petition for writ of certiorari against two states, thus eliminating RJR Tobacco’s remaining recovery from these states. The final outcome in the remaining two states is uncertain.
In October 2015, RJR Tobacco, SFNTC and certain other PMs entered into a settlement agreement, referred to as the NY Settlement Agreement, with the State of New York to settle certain claims related to the NPM Adjustment. The NY Settlement Agreement resolves NPM Adjustment claims related to payment years from 2004 through 2014, providing RJR Tobacco and SFNTC,
77
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
collectively, with credits, of approximately $290 million, plus interest, subject to meeting various performance obligations. These credits will be applied against annual payments under the MSA over a four-year period, which commenced with the April 2016 MSA payment. RJR Tobacco and Santa Fe, collectively, recognized credits of $95 million and $15 million as a reduction to costs of products sold for the years ended December 31, 2016 and 2015, respectively. In addition, the NY Settlement Agreement put in place a new method to determine future adjustments from 2015 forward as to New York.
For additional information related to the NPM Adjustment settlement, see “— Litigation Affecting the Cigarette Industry — State Settlement Agreements — Enforcement and Validity; Adjustments” in note 13.
Advertising
Advertising costs, which are expensed as incurred, were $80 million, $140 million and $140 million for the years ended December 31, 2016, 2015 and 2014, respectively.
Research and Development
Research and development costs, which are expensed as incurred, were $101 million, $107 million and $88 million for the years ended December 31, 2016, 2015 and 2014, respectively.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Interest and penalties related to uncertain tax positions are accounted for as tax expense. Federal income taxes for RAI and its subsidiaries are calculated on a consolidated basis. State income taxes for RAI and its subsidiaries are primarily calculated on a separate return basis.
RAI accounts for uncertain tax positions which require that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not (a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.
Stock-Based Compensation
Stock-based compensation expense is recognized for all forms of share-based payment awards, including shares issued to employees under restricted stock units.
Litigation
RAI discloses information concerning litigation for which an unfavorable outcome is more than remote. RAI and its subsidiaries record their legal expenses and other litigation costs and related administrative costs as selling, general and administrative expenses as these costs are incurred. RAI and its subsidiaries will record any loss related to litigation at such time as an unfavorable outcome becomes probable and the amount can be reasonably estimated on an individual case-by-case basis. When the reasonable estimate is a range, the recorded loss will be the best estimate within the range. If no amount in the range is a better estimate than any other amount, the minimum amount of the range will be recorded. For additional information related to litigation, see note 13.
Pension and Postretirement
Pension and postretirement benefits require balance sheet recognition of the net asset or liability for the overfunded or underfunded status of defined benefit pension and postretirement benefit plans, on a plan-by-plan basis, and recognition of changes in the funded status in the year in which the changes occur.
Actuarial (gains) losses are changes in the amount of either the benefit obligation or the fair value of plan assets resulting from experience different from that assumed or from changes in assumptions. Differences between actual results and actuarial assumptions
78
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
are accumulated and recognized as a mark-to-market adjustment, referred to as an MTM adjustment, to the extent such accumulated net (gains) losses exceed 10% of the greater of the fair value of plan assets or benefit obligations, referred to as the corridor. Net (gains) losses outside the corridor are generally recognized annually as of December 31, or when a plan is remeasured during an interim period.
Prior service costs (credits) of pension benefits, which are changes in benefit obligations due to plan amendments, are amortized on a straight-line basis over the average remaining service period for active employees, or average remaining life expectancies for inactive employees if most of the plan obligations are due to inactive employees. Prior service costs (credits) of postretirement benefits, which are changes in benefit obligations due to plan amendments, are amortized on a straight-line basis over the expected service period to full eligibility age for active employees, or average remaining life expectancies for inactive employees if most of the plan obligations are due to inactive employees.
Recently Adopted Accounting Pronouncements
In April 2015, the FASB issued an Accounting Standards Update, referred to as ASU, 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amended guidance requires debt issuance costs to be presented as a direct reduction of the debt liability with which it is associated similar to the way debt discounts are presented. The amended guidance did not change the requirement to amortize the costs as interest expense over the life of the associated debt. At RAI’s election, and as permitted in ASU 2015-15, Interest—Imputation of Interest (Subtopic 835-30), the unamortized debt issuance costs associated with its credit facility are included in other assets and deferred charges in the balance sheets. The guidance, which required retrospective application, was effective for RAI for interim and annual reporting periods, beginning January 1, 2016, and resulted in a $68 million and $92 million reclassification of debt issuance costs for the years ended December 31, 2016 and 2015, respectively. The adoption of the amended guidance did not have an impact on RAI’s results of operations or cash flows.
In April 2015, the FASB issued ASU 2015-05, Internal Use Software, for determining if an arrangement for cloud services includes a license of software. This new guidance does not change the accounting standard for cloud service providers, but does base the criteria for determining if a license of software is part of the arrangement based on the existing guidance. If a license of software is present in the arrangement, the fee associated with the license portion will be capitalized when the criteria for capitalization of internal-use software are met. This guidance was effective for interim and annual periods beginning January 1, 2016. As permitted, RAI adopted the guidance on a prospective basis and, accordingly, its adoption did not have a material impact on RAI’s results of operations, cash flows or financial position.
In May 2015, the FASB issued ASU 2015-07, Fair Value Measurement – Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent), eliminating the requirement to categorize investments in the fair value hierarchy if their fair value is measured at net asset value per share (or its equivalent) using the practical expedient in the FASB’s fair value measurement guidance. The amended guidance, which requires retrospective application, is effective for financial statements issued for the fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted, RAI adopted this amended guidance as of January 1, 2016, with retrospective application to the fair value hierarchy as of December 31, 2015. As of December 31, 2016, the reduction of Level 2 and Level 3 investments was $785 and $670 million, respectively. The retrospective application resulted in the removal of certain investments classified as Level 2 and Level 3 from the fair value hierarchy, resulting in a reduction of Level 2 and Level 3 investments of $819 million and $679 million, respectively, as of December 31, 2015. The adoption of the amended guidance did not have an impact on RAI’s results of operations, cash flows or financial position. For additional information, see note 16.
In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, requiring that all deferred income tax balances in the consolidated balance sheets be classified as non-current. The amended guidance is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. As permitted, RAI adopted the amended guidance as of December 31, 2016, with retrospective application to the consolidated balance sheet as of December 31, 2015. The retrospective application resulted in a reclassification of deferred income taxes, net in current assets to deferred income taxes, net in long-term liabilities of approximately $900 million and $1 billion for the years ended December 31, 2016 and 2015, respectively. The adoption of the amended guidance did not have an impact on RAI’s results of operations or cash flows.
79
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Recently Issued Accounting Pronouncements
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which replaces most existing GAAP revenue recognition guidance. The effective date for adoption of this guidance was subsequently deferred to interim and annual reporting periods beginning after December 15, 2017. In 2016, the FASB issued supplemental implementation guidance related to ASU 2014-09, including:
|
• |
ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which is intended to provide further clarification on the application of the principal versus agent implementation; |
|
• |
ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which is intended to clarify the guidance for identifying promised goods or services in a contract with a customer; |
|
• |
ASU 2016-11, Revenue Recognition (Topic 605) and Derivative and Hedging (Topic 815) – Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting; |
|
• |
ASU 2016-12, Revenue Recognition from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends certain aspects of ASU 2014-09 to address certain implementation issues; and |
|
• |
ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers , which includes thirteen technical corrections and improvements affecting narrow aspects of the guidance issued in ASU 2014-09. |
During 2016, RAI substantially completed its assessment of ASU 2014-09 to identify any potential changes in the amount and timing of revenue recognition for its current contracts and the expected impact on its business processes, systems and controls. Based on this assessment, RAI does not expect the adoption of ASU 2014-09 to have a material impact on RAI’s results of operations, cash flows and financial position. The new guidance may be applied retrospectively to each prior period presented (full retrospective method) or retrospectively with the cumulative effect recognized as of the date of initial application (modified retrospective method). RAI is continuing to evaluate the impact of ASU 2014-09 primarily to determine the transition method to utilize at adoption and the additional disclosures required. The new guidance will be adopted effective January 1, 2018.
In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities, which supersedes existing guidance to classify equity securities with readily determinable fair values into different categories and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. An entity’s equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of this amended guidance. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of impairment. The amended guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. As permitted, RAI adopted the amended guidance as of January 1, 2017, and it is not expected to have a material impact on RAI’s results of operations, cash flows and financial position.
In February 2016, the FASB issued ASU 2016-02, Leases, requiring lessees to recognize lease assets and lease liabilities in the balance sheet and disclose key information about leasing arrangements, such as information about variable lease payments and options to renew and terminate leases. The amended guidance will require both operating and finance leases to be recognized in the balance sheet. Additionally, the amended guidance aligns lessor accounting to comparable guidance in Accounting Standard Codification Topic 606, Revenue from Contracts with Customers. The amended guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. RAI expects to adopt the amended guidance in ASU 2016-02 effective January 1, 2019, and is currently early in its assessment of the impact of this new standard. However, if at adoption RAI has similar obligations for leases as it had at December 31, 2016, RAI believes this guidance will not have a material impact on its results of operations, cash flows and financial position. RAI expects to substantially complete its assessment of the new standard during 2017.
In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee share-based payment transactions, including accounting for income tax, forfeitures, statutory tax withholding requirements, classifications of awards as either equity or liabilities, and classification of taxes in the statement of cash flows. The amended guidance also requires an entity to record excess tax benefits and deficiencies in the income statement rather than as a change to paid-in capital. The amended guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. RAI adopted this amended guidance effective January 1, 2017, and determined that it will not have a material impact to RAI’s results of operations, cash flows and financial position. If adoption of this amended guidance occurred in 2016, the primary impact to RAI’s results of operations would have been a reduction in the provision
80
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
for income taxes of $28 million, $17 million and $12 million, for the years ended December 31, 2016, 2015 and 2014, respectively. Early adoption would have also resulted in a reclassification of cash from financing activities to cash from operations on the statement of cash flows for the same amounts. The impact of the new guidance will be applied prospectively.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, which replaces the current incurred loss impairment methodology for recognizing credit losses for financial instruments with a methodology that reflects expected credit losses and requires consideration for a broader range of reasonable and supportable information for estimating credit losses. The amended guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018. RAI has not yet determined if it will adopt this amended guidance earlier than the effective date and has not initiated its assessment of the impact that this guidance will have on its results of operations, cash flows and financial position.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, addressing eight specific cash flow issues in an effort to reduce diversity in practice. The amended guidance is effective for fiscal years beginning after December 31, 2017, and for interim periods within those years. RAI will adopt this amended guidance effective January 1, 2018. The amended guidance will not have a material impact on RAI’s statements of cash flows.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows – Restricted Cash, addressing the diversity in practice that exists regarding the classification and the presentation of changes in restricted cash on the statement of cash flows. The amended guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, restricted cash and restricted cash equivalents. The amended guidance does not provide a definition of restricted cash or restricted cash equivalents. The amended guidance is effective for fiscal years beginning after December 15, 2017, and for interim periods within those years. RAI will adopt this amended guidance effective January 1, 2018. The amended guidance will not have a material impact on RAI’s statements of cash flows.
Note 2 — Lorillard Merger, Divestiture and BAT Share Purchase
Lorillard Merger
On June 12, 2015, the Lorillard Merger was completed, with Lorillard surviving as a wholly owned subsidiary of RAI. Each outstanding share of Lorillard common stock was converted into the right to receive (1) 0.2909 of a share of RAI common stock, prior to giving effect to RAI’s 2015 two-for-one stock split, referred to as the stock split, plus (2) $50.50 in cash (the foregoing collectively referred to as the Lorillard Merger Consideration). RAI issued 104,706,847 shares of RAI common stock at a price of $72.15 per share, prior to giving effect to the stock split, to Lorillard shareholders in the Lorillard Merger. After giving effect to the stock split, RAI issued 209,413,694 shares of RAI common stock to Lorillard shareholders in the Lorillard Merger.
As a part of the Lorillard Merger, RAI acquired the premium cigarette brand, NEWPORT, which is the top-selling menthol and second largest selling cigarette brand overall in the United States. In addition to NEWPORT, RAI acquired three additional brand families marketed under the KENT, TRUE and OLD GOLD brand names.
In accordance with ASC 805, the Lorillard Merger was accounted for using the acquisition method of accounting with RAI considered the acquirer of Lorillard. RAI recorded assets acquired, including identifiable intangible assets, and liabilities assumed, from Lorillard at their respective fair values at the date of completion of the Lorillard Merger. The excess of the purchase price over the net fair value of such assets and liabilities was recorded as goodwill.
Purchase Price
The purchase price of $25.8 billion consisted of the Lorillard Merger Consideration together with the payment of certain Lorillard equity awards and certain change of control payments as follows:
Fair value of RAI common stock issued |
|
$ |
7,555 |
|
Cash paid to Lorillard shareholders at $50.50 per share |
|
|
18,205 |
|
Cash paid for Lorillard stock options and stock appreciation rights |
|
|
73 |
|
Purchase price |
|
$ |
25,833 |
|
81
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The purchase price as allocated to the assets acquired and liabilities assumed in the Lorillard Merger is set forth below:
|
|
Final Allocation |
|
|
Assets |
|
|
|
|
Cash and cash equivalents |
|
$ |
1,058 |
|
Short-term investments |
|
|
347 |
|
Accounts and other receivables |
|
|
47 |
|
Inventories |
|
|
576 |
|
Income taxes receivable |
|
|
135 |
|
Other current assets |
|
|
1,673 |
|
Property, plant and equipment |
|
|
82 |
|
Trademarks and other intangible assets |
|
|
27,443 |
|
Goodwill |
|
|
9,853 |
|
Other assets and deferred charges |
|
|
207 |
|
|
|
|
|
|
Liabilities |
|
|
|
|
Tobacco settlement accruals |
|
|
755 |
|
Other current liabilities |
|
|
602 |
|
Long-term debt (less current maturities) |
|
|
3,895 |
|
Deferred income taxes, net |
|
|
9,998 |
|
Long-term retirement benefits (less current portion) |
|
|
274 |
|
Other noncurrent liabilities |
|
|
64 |
|
Allocation of purchase price |
|
$ |
25,833 |
|
The allocation of the purchase price reflected in the accompanying financial statements was based upon estimates and assumptions. The $9,853 million allocated to goodwill, which was primarily attributable to the establishment of deferred tax liabilities associated with the trademarks acquired and the expected synergies from future growth, was allocated to the RJR Tobacco segment, and is non-deductible for tax purposes.
The results of operations of the acquired Lorillard brands are included in RAI’s consolidated statements of income from the date of acquisition and include $2.7 billion of total net sales for the year ended December 31, 2015, and are included in the RJR Tobacco segment’s financial results. RAI does not maintain discrete financial information on a brand basis in order to determine the impact to net income for the periods presented. In addition, as a result of the acquisition, $9 billion of debt was issued and approximately $3.9 billion of Lorillard Tobacco debt, at fair value, was assumed. The interest expense related to the acquisition was approximately $282 million for the year ended December 31, 2015.
Divestiture
On June 12, 2015, the Divestiture was completed, and ITG acquired the cigarette brands WINSTON, KOOL and SALEM, previously owned by RAI subsidiaries and included in the RJR Tobacco segment, as well as the cigarette brand MAVERICK and the “e-vapor” brand blu (including SKYCIG), previously owned by Lorillard subsidiaries, and other assets and certain liabilities, including inventory, fixed assets and employee benefit plans, for an aggregate purchase price of approximately $7.1 billion. A summary of the pre-tax gain is as follows:
Purchase price |
|
$ |
7,056 |
|
Net assets and liabilities divested |
|
|
(2,026 |
) |
Goodwill associated with divested RJR Tobacco brands |
|
|
(1,849 |
) |
Gain on divestiture |
|
$ |
3,181 |
|
BAT Share Purchase and Other
In connection with the Lorillard Merger and Divestiture, on July 15, 2014, RAI, BAT, and for limited purposes only, B&W, entered into a subscription and support agreement, referred to as the Subscription Agreement, pursuant to which BAT agreed to
82
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
subscribe for and purchase, directly or indirectly through one or more of its wholly owned subsidiaries, simultaneously with the completion of the Lorillard Merger and at a price of approximately $4.7 billion in the aggregate, shares of RAI common stock such that BAT, directly or indirectly through its affiliates, would maintain its approximately 42% beneficial ownership in RAI (the foregoing purchase is referred to as the BAT Share Purchase).
On June 12, 2015, concurrently with the completion of the Lorillard Merger and Divestiture and pursuant to the Subscription Agreement, BAT indirectly (through a wholly owned subsidiary) purchased 77,680,259 shares of RAI common stock, prior to giving effect to the stock split, for approximately $4.7 billion, which was sufficient for BAT and its subsidiaries collectively to maintain their approximately 42% beneficial ownership in RAI. Upon completion of the transactions on June 12, 2015, BAT and its subsidiaries collectively owned 301,014,278 shares, prior to giving effect to the stock split, or approximately 42%, of RAI’s outstanding common stock. After giving effect to the stock split, BAT indirectly purchased 155,360,518 shares of RAI common stock, and BAT and its subsidiaries collectively owned 602,028,556 shares of RAI common stock.
RAI financed the cash portion of the Lorillard Merger Consideration and related fees and expenses with (1) the net proceeds from a public offering of $9 billion aggregate principal amount of newly issued RAI senior notes, (2) the proceeds from the Divestiture, (3) the proceeds from the BAT Share Purchase and (4) available cash. Transaction related costs of $54 million and $38 million, for the years ended December 31, 2015 and 2014, respectively, were expensed as incurred and included in selling, general and administrative expenses in RAI’s consolidated statements of income.
Note 3 — Sale of International Rights to the NATURAL AMERICAN SPIRIT Brand
On January 13, 2016, RAI, through the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with the international companies that distributed and marketed the brand outside the United States, to JTI Holding in an all-cash transaction of approximately $5 billion and recognized a pre-tax gain of approximately $4.9 billion.
The purchase agreement, dated as of September 28, 2015, between the Sellers and JTI Holding, referred to as the 2015 Purchase Agreement, contains customary representations, warranties and covenants made by the Sellers and JTI Holding, and, for certain provisions, RAI and JTI, and contains indemnification provisions, subject to customary limitations, with respect to these and other matters, including potential litigation relating to specified claims. The 2015 Purchase Agreement also contains a guarantee of Sellers’ obligations by RAI, and a guarantee of JTI Holding’s obligations by JTI. Further, in the 2015 Purchase Agreement, RAI has agreed not to, and agreed to cause its controlled affiliates not to, engage in the business of producing, selling, distributing and developing natural, organic and additive-free combustible tobacco cigarettes and roll-your-own or make-your-own tobacco products outside of the United States, and JTI has agreed not to, and agreed to cause its controlled affiliates not to, engage in the conduct of such business in the United States, in each case, for five years following the closing of the transaction.
The transaction did not include the rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks in the U.S. market, U.S. duty-free locations, and U.S. territories or in U.S. military outlets, all of which have been retained by SFNTC. With this transaction completed, the international rights to nearly all of RAI’s operating companies’ cigarette trademarks are now owned by international tobacco companies.
The components of the pre-tax gain, which was recorded during the year ended December 31, 2016, were as follows:
Purchase price |
|
$ |
5,015 |
|
Net assets and liabilities divested |
|
|
(154 |
) |
Gain on divestiture |
|
$ |
4,861 |
|
83
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Note 4 — Fair Va lue Measurement
Fair Value of Financial Assets
Financial assets carried at fair value as of December 31, were as follows:
|
|
2016 |
|
|
2015 |
|
||||||||||||||||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||||||
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
2,006 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2,006 |
|
|
$ |
2,454 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2,454 |
|
Short-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate debt securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
96 |
|
|
|
— |
|
|
|
96 |
|
U.S. Government agency obligations |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
|
|
43 |
|
Commercial paper |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
|
|
— |
|
|
|
10 |
|
Other assets and deferred charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Auction rate securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
79 |
|
|
|
79 |
|
Mortgage-backed security |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
|
|
10 |
|
Marketable equity security |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Interest rate swaps |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
53 |
|
|
|
— |
|
|
|
53 |
|
There were no transfers between the levels during the years ended December 31, 2016 and 2015.
As of December 31, 2015, RAI’s short-term investments included corporate debt securities, U.S. Government agency obligations and commercial paper. The fair value of these investments, classified as Level 2, utilized quoted prices for identical assets in less active markets or quoted prices for similar assets in active markets. The fair value of the interest rate swaps, classified as Level 2, utilized a market approach model using the notional amount of the interest rate swaps and observable inputs of time to maturity and market interest rates. All investments classified as short-term investments as of December 31, 2015, were sold or matured and an immaterial loss was recorded during the year ended December 31, 2016.
As of December 31, 2015, RAI had investments in auction rate securities linked to corporate credit risk, in auction rate securities related to financial insurance companies, and in a mortgage-backed security. The fair value of these investments, each classified as Level 3, was determined with pricing models using inputs that were unobservable and assumptions made by RAI about the assumptions that market participants would use in pricing the assets. In addition, RAI had an investment in a marketable equity security classified as Level 1. During the year ended December 31, 2016, the auction rate securities related to financial insurance companies, the marketable equity security and mortgage-backed security were sold, and an immaterial loss was recognized. The auction rate securities linked to corporate credit risk were called by the issuers at their par value of $95 million. No other-than-temporary impairment losses were recognized for the years ended December 31, 2016 and 2015, respectively. Any unrealized gains and losses, net of tax, related to investments held at December 31, 2015, were included in accumulated other comprehensive loss in RAI’s consolidated balance sheet as of December 31, 2015.
Interest Rate Management
From time to time, RAI and RJR have used interest rate swaps to manage interest rate risk on a portion of their respective debt obligations.
As part of the Lorillard Tobacco Merger, RJR Tobacco assumed fixed to floating interest rate swap agreements that Lorillard Tobacco designated as fair value hedges of its 8.125% notes due in 2019. Under the swap agreements, RJR Tobacco received interest based on a fixed rate of 8.125% and paid interest based on a floating one-month LIBOR rate plus a spread of 4.625%. The net settlement reduced interest expense by approximately $3 million and $13 million for the years ended December 31, 2016 and 2015 respectively. During 2016, RJR Tobacco terminated these interest rate swap agreements and received $66 million in cash. The remaining fair value adjustment of $7 million for the notes designated as the hedging instrument is being amortized as a reduction of interest expense over the expected remaining life of the notes. As of December 31, 2016, RAI, RJR and RJR Tobacco had no outstanding interest rate swaps. See notes 2 and 12 for additional information related to interest rate swap agreements.
84
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The changes in the carrying amounts of goodwill by segment were as follows:
|
|
RJR Tobacco |
|
|
Santa Fe |
|
|
American Snuff |
|
|
All Other |
|
|
Consolidated |
|
|||||
Balance as of December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
$ |
9,065 |
|
|
$ |
197 |
|
|
$ |
2,501 |
|
|
$ |
44 |
|
|
$ |
11,807 |
|
Less: accumulated impairment charges |
|
|
(3,763 |
) |
|
|
— |
|
|
|
(28 |
) |
|
|
— |
|
|
|
(3,791 |
) |
Net goodwill balance as of December 31, 2014 |
|
|
5,302 |
|
|
|
197 |
|
|
|
2,473 |
|
|
|
44 |
|
|
|
8,016 |
|
2015 Activity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lorillard Merger goodwill |
|
|
9,853 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9,853 |
|
Divestiture goodwill |
|
|
(1,849 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,849 |
) |
Reclassified to assets held for sale (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(27 |
) |
|
|
(27 |
) |
Balance as of December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
17,069 |
|
|
|
197 |
|
|
|
2,501 |
|
|
|
17 |
|
|
|
19,784 |
|
Less: accumulated impairment charges |
|
|
(3,763 |
) |
|
|
— |
|
|
|
(28 |
) |
|
|
— |
|
|
|
(3,791 |
) |
Net goodwill balance as of December 31, 2015 |
|
|
13,306 |
|
|
|
197 |
|
|
|
2,473 |
|
|
|
17 |
|
|
|
15,993 |
|
2016 Activity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
(1 |
) |
Balance as of December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
17,069 |
|
|
|
197 |
|
|
|
2,501 |
|
|
|
16 |
|
|
|
19,783 |
|
Less: accumulated impairment charges |
|
|
(3,763 |
) |
|
|
— |
|
|
|
(28 |
) |
|
|
— |
|
|
|
(3,791 |
) |
Net goodwill balance as of December 31, 2016 |
|
$ |
13,306 |
|
|
$ |
197 |
|
|
$ |
2,473 |
|
|
$ |
16 |
|
|
$ |
15,992 |
|
(1) |
Related to the sale of international rights to the NATURAL AMERICAN SPIRIT brand. See note 3. |
The changes in the carrying amounts of indefinite-lived intangible assets by segment not subject to amortization were as follows:
|
|
RJR Tobacco |
|
|
Santa Fe |
|
|
American Snuff |
|
|
All Other |
|
|
Consolidated |
|
|||||||||||||
|
|
Trademarks |
|
|
Other |
|
|
Trademarks |
|
|
Trademarks |
|
|
Other |
|
|
Trademarks |
|
|
Other |
|
|||||||
Balance as of December 31, 2014 |
|
$ |
977 |
|
|
$ |
99 |
|
|
$ |
155 |
|
|
$ |
1,136 |
|
|
$ |
4 |
|
|
$ |
2,268 |
|
|
$ |
103 |
|
Trademarks acquired in Lorillard Merger |
|
|
27,193 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
27,193 |
|
|
|
— |
|
Trademarks divested |
|
|
(344 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(344 |
) |
|
|
— |
|
Other intangibles divested |
|
|
— |
|
|
|
(12 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(12 |
) |
Reclassified to assets held for sale (1) |
|
|
— |
|
|
|
— |
|
|
|
(19 |
) |
|
|
— |
|
|
|
(4 |
) |
|
|
(19 |
) |
|
|
(4 |
) |
Balance as of December 31, 2015 |
|
|
27,826 |
|
|
|
87 |
|
|
|
136 |
|
|
|
1,136 |
|
|
|
— |
|
|
|
29,098 |
|
|
|
87 |
|
Balance as of December 31, 2016 |
|
$ |
27,826 |
|
|
$ |
87 |
|
|
$ |
136 |
|
|
$ |
1,136 |
|
|
$ |
— |
|
|
$ |
29,098 |
|
|
$ |
87 |
|
(1) |
Related to the sale of international rights to the NATURAL AMERICAN SPIRIT brand. See note 3. |
85
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The changes in the carrying amounts of finite-lived intangible assets by segment subject to amortization were as follows:
|
|
RJR Tobacco |
|
|
American Snuff |
|
|
All Other |
|
|
Consolidated |
|
||||||||||||
|
|
Trademarks |
|
|
Other |
|
|
Trademarks |
|
|
Other |
|
|
Trademarks |
|
|
Other |
|
||||||
Balance as of December 31, 2013 |
|
$ |
18 |
|
|
$ |
20 |
|
|
$ |
8 |
|
|
$ |
— |
|
|
$ |
26 |
|
|
$ |
20 |
|
Amortization |
|
|
(6 |
) |
|
|
(4 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
(7 |
) |
|
|
(4 |
) |
Acquisition |
|
|
— |
|
|
|
15 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
15 |
|
Balance as of December 31, 2014 |
|
|
12 |
|
|
|
31 |
|
|
|
7 |
|
|
|
— |
|
|
|
19 |
|
|
|
31 |
|
Trademarks acquired in Lorillard Merger |
|
|
10 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
|
|
— |
|
Customer lists acquired in Lorillard Merger |
|
|
— |
|
|
|
240 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
240 |
|
Amortization |
|
|
(5 |
) |
|
|
(12 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
(6 |
) |
|
|
(12 |
) |
Balance as of December 31, 2015 |
|
|
17 |
|
|
|
259 |
|
|
|
6 |
|
|
|
— |
|
|
|
23 |
|
|
|
259 |
|
Intercompany transfer |
|
|
— |
|
|
|
(13 |
) |
|
|
— |
|
|
|
13 |
|
|
|
— |
|
|
|
— |
|
Amortization |
|
|
(5 |
) |
|
|
(17 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
(6 |
) |
|
|
(17 |
) |
Balance as of December 31, 2016 |
|
$ |
12 |
|
|
$ |
229 |
|
|
$ |
5 |
|
|
$ |
13 |
|
|
$ |
17 |
|
|
$ |
242 |
|
Details of finite-lived intangible assets were as follows:
|
|
December 31, 2016 |
|
|
December 31, 2015 |
|
||||||||||||||||||
|
|
Gross |
|
|
Accumulated Amortization |
|
|
Net |
|
|
Gross |
|
|
Accumulated Amortization |
|
|
Net |
|
||||||
Customer lists |
|
$ |
240 |
|
|
$ |
(19 |
) |
|
$ |
221 |
|
|
$ |
240 |
|
|
$ |
(7 |
) |
|
$ |
233 |
|
Contract manufacturing agreement |
|
|
151 |
|
|
|
(143 |
) |
|
|
8 |
|
|
|
151 |
|
|
|
(139 |
) |
|
|
12 |
|
Trademarks |
|
|
124 |
|
|
|
(107 |
) |
|
|
17 |
|
|
|
124 |
|
|
|
(101 |
) |
|
|
23 |
|
Other intangibles |
|
|
15 |
|
|
|
(2 |
) |
|
|
13 |
|
|
|
15 |
|
|
|
(1 |
) |
|
|
14 |
|
|
|
$ |
530 |
|
|
$ |
(271 |
) |
|
$ |
259 |
|
|
$ |
530 |
|
|
$ |
(248 |
) |
|
$ |
282 |
|
The remaining amortization expense associated with finite-lived intangible assets is expected to be as follows:
Year |
|
Amount |
|
|
2017 |
|
$ |
23 |
|
2018 |
|
|
22 |
|
2019 |
|
|
16 |
|
2020 |
|
|
15 |
|
2021 |
|
|
14 |
|
Thereafter |
|
|
169 |
|
|
|
$ |
259 |
|
The impairment testing of trademarks in the fourth quarters of 2016, 2015 and 2014 assumed a rate of decline in projected net sales of certain brands, comparable with that assumed in RAI’s strategic plan. The fair value of trademarks used in impairment testing was determined by an income approach using a discounted cash flow valuation model under a relief from royalty methodology. The relief-from-royalty model includes the estimates of the royalty rate that a market participant might assume, projected revenues and judgment regarding the discount rate applied to those estimated cash flows, with that discount rate being 10.0% during 2016, 2015 and 2014. The determination of the discount rate was based on a cost of equity model, using a risk-free rate, adjusted by a stock beta-adjusted risk premium and a size premium. As a result of these analyses, an impairment charge is recognized if the carrying value of a trademark exceeds its estimated fair value. No impairment charges were indicated for 2016, 2015 or 2014.
For the annual impairment testing of the goodwill of RAI’s reporting units, each reporting unit’s estimated fair value was compared with its carrying value. A reporting unit is an operating segment or one level below an operating segment. The determination of estimated fair value of each reporting unit was calculated primarily utilizing an income approach model, based on the present value of the estimated future cash flows of the reporting unit assuming a discount rate during each of 2016, 2015 and 2014 of 9.75% for each of RJR Tobacco and American Snuff and 10.25% for Santa Fe. The determination of the discount rate was based on a weighted average cost of capital. Additionally, the aggregate estimated fair value of the reporting units, determined with the use of the
86
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
income approach model, was compared with RAI’s market capitalization. The estimated fair value of each reporting unit was substantially greater than its respective carrying value.
Note 6 — Asset Impairment and Exit Charges
In 2015, RAI announced that certain of its operating companies consolidated manufacturing operations for the VUSE Digital Vapor Cigarette. In addition to in-house production at RJR Tobacco’s manufacturing facility, certain production of VUSE Solo cartridges was previously performed for RJR Vapor at a contractor’s facility in Kansas. Since the fourth quarter of 2015, all production of VUSE Solo cartridges is performed at RJR Tobacco’s facility, pursuant to a services agreement between RJR Tobacco and RJR Vapor. As a result of this consolidation, pre-tax asset impairment and exit charges of $99 million, consisting primarily of equipment, were recorded in the consolidated statements of income for the year ended December 31, 2015, and were allocated to All Other.
The components of the calculation of income per share were as follows:
|
|
For the Years Ended December 31, |
|
|||||||||
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Income from continuing operations |
|
$ |
6,073 |
|
|
$ |
3,253 |
|
|
$ |
1,445 |
|
Income from discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
25 |
|
Net income |
|
$ |
6,073 |
|
|
$ |
3,253 |
|
|
$ |
1,470 |
|
Basic weighted average shares, in thousands |
|
|
1,426,987 |
|
|
|
1,264,182 |
|
|
|
1,066,320 |
|
Effect of dilutive potential shares: |
|
|
|
|
|
|
|
|
|
|
|
|
Restricted stock units |
|
|
2,946 |
|
|
|
3,533 |
|
|
|
3,620 |
|
Diluted weighted average shares, in thousands |
|
|
1,429,933 |
|
|
|
1,267,715 |
|
|
|
1,069,940 |
|
The major components of inventories at December 31 were as follows:
|
|
2016 |
|
|
2015 |
|
||
Leaf tobacco |
|
$ |
1,436 |
|
|
$ |
1,495 |
|
Other raw materials |
|
|
77 |
|
|
|
110 |
|
Work in process |
|
|
81 |
|
|
|
88 |
|
Finished products |
|
|
165 |
|
|
|
173 |
|
Other |
|
|
25 |
|
|
|
22 |
|
Total |
|
|
1,784 |
|
|
|
1,888 |
|
LIFO allowance |
|
|
(139 |
) |
|
|
(154 |
) |
|
|
$ |
1,645 |
|
|
$ |
1,734 |
|
Inventories valued under the LIFO method were $791 million and $922 million at December 31, 2016 and 2015, respectively, net of the LIFO allowance. The LIFO allowance reflects the excess of the current cost of LIFO inventories at December 31, 2016 and 2015, over the amount at which these inventories were carried on the consolidated balance sheets. RAI recognized income of $15 million, $50 million and $2 million from LIFO inventory changes during 2016, 2015, and 2014, respectively.
87
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Note 9 — Other Cur rent Liabilities
Other current liabilities at December 31 included the following:
|
|
2016 |
|
|
2015 |
|
||
Payroll and employee benefits |
|
$ |
268 |
|
|
$ |
210 |
|
Pension and postretirement benefits |
|
|
89 |
|
|
|
91 |
|
Marketing and advertising |
|
|
155 |
|
|
|
213 |
|
Excise, franchise and property tax |
|
|
172 |
|
|
|
217 |
|
Other |
|
|
352 |
|
|
|
503 |
|
|
|
$ |
1,036 |
|
|
$ |
1,234 |
|
The components of the provision for income taxes from continuing operations for the years ended December 31 were as follows:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Current: |
|
|
|
|
|
|
|
|
|
|
|
|
Federal |
|
$ |
2,794 |
|
|
$ |
3,313 |
|
|
$ |
809 |
|
State and other |
|
|
437 |
|
|
|
477 |
|
|
|
188 |
|
|
|
|
3,231 |
|
|
|
3,790 |
|
|
|
997 |
|
Deferred: |
|
|
|
|
|
|
|
|
|
|
|
|
Federal |
|
|
350 |
|
|
|
(597 |
) |
|
|
(151 |
) |
State and other |
|
|
37 |
|
|
|
(62 |
) |
|
|
(29 |
) |
|
|
|
387 |
|
|
|
(659 |
) |
|
|
(180 |
) |
|
|
$ |
3,618 |
|
|
$ |
3,131 |
|
|
$ |
817 |
|
Significant components of deferred tax assets and liabilities for the years ended December 31 included the following:
|
|
2016 |
|
|
2015 |
|
||
Deferred tax assets: |
|
|
|
|
|
|
|
|
Pension and postretirement liabilities |
|
$ |
759 |
|
|
$ |
916 |
|
Tobacco settlement accruals |
|
|
955 |
|
|
|
1,088 |
|
Other accrued liabilities |
|
|
169 |
|
|
|
175 |
|
Other noncurrent liabilities |
|
|
210 |
|
|
|
283 |
|
Subtotal |
|
|
2,093 |
|
|
|
2,462 |
|
Less: valuation allowance |
|
|
— |
|
|
|
(8 |
) |
|
|
|
2,093 |
|
|
|
2,454 |
|
Deferred tax liabilities: |
|
|
|
|
|
|
|
|
LIFO inventories |
|
|
(257 |
) |
|
|
(266 |
) |
Property and equipment |
|
|
(290 |
) |
|
|
(259 |
) |
Trademarks and other intangibles |
|
|
(10,972 |
) |
|
|
(11,002 |
) |
Other |
|
|
(181 |
) |
|
|
(131 |
) |
|
|
|
(11,700 |
) |
|
|
(11,658 |
) |
Net deferred tax asset (liability) |
|
$ |
(9,607 |
) |
|
$ |
(9,204 |
) |
RAI had no federal capital loss carryforwards at December 31, 2016 and 2015, respectively.
As of December 31, 2016, no valuation allowance was established on deferred tax assets as RAI believes it is more likely than not that the deferred tax assets will be realized through the generation of future taxable income. At December 31, 2015, RAI had recorded a valuation allowance of $8 million to fully offset the deferred tax assets attributable to its Puerto Rico subsidiaries. In 2016, reorganization of the Puerto Rico business in connection with the Lorillard Merger and Divestiture resulted in the $8 million valuation allowance being reversed.
88
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Pre-tax income for domestic and foreign continuing operations for the years ended December 31 consisted of the following:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Domestic (includes U.S. exports) |
|
$ |
9,610 |
|
|
$ |
6,342 |
|
|
$ |
2,235 |
|
Foreign |
|
|
81 |
|
|
|
42 |
|
|
|
27 |
|
|
|
$ |
9,691 |
|
|
$ |
6,384 |
|
|
$ |
2,262 |
|
The differences between the provision for income taxes from continuing operations and income taxes computed at statutory U.S. federal income tax rates for the years ended December 31 were as follows:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Income taxes computed at the statutory U.S. federal income tax rate |
|
$ |
3,392 |
|
|
$ |
2,233 |
|
|
$ |
792 |
|
State and local income taxes, net of federal tax benefits |
|
|
306 |
|
|
|
235 |
|
|
|
107 |
|
Domestic manufacturing deduction |
|
|
(114 |
) |
|
|
(104 |
) |
|
|
(80 |
) |
Nondeductible goodwill |
|
|
9 |
|
|
|
761 |
|
|
|
— |
|
Other items, net |
|
|
25 |
|
|
|
6 |
|
|
|
(2 |
) |
Provision for income taxes from continuing operations |
|
$ |
3,618 |
|
|
$ |
3,131 |
|
|
$ |
817 |
|
Effective tax rate |
|
|
37.3 |
% |
|
|
49.0 |
% |
|
|
36.1 |
% |
The effective tax rate for 2016 was impacted by the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with the international companies that distributed and marketed the brand outside the United States. The effective tax rate for 2015 was unfavorably impacted by an increase in tax attributable to nondeductible acquisition costs, nondeductible goodwill in the amount of $1,849 million associated with the Divestiture and an increase in uncertain tax positions, offset by a decrease in tax attributable to the release of a valuation allowance in the amount of $37 million and a reduction in state income taxes. The effective tax rate for 2014 was favorably impacted by a decrease in uncertain tax positions related to a federal audit settlement and an increase in the domestic manufacturing deduction, partially offset by an increase in tax attributable to nondeductible acquisition costs. The effective tax rate for each period differed from the federal statutory rate of 35% due to the domestic manufacturing deduction, state income taxes and certain nondeductible items.
The audit of the 2010 and 2011 tax years by the Internal Revenue Service was closed in 2014. A tax benefit of $25 million attributable to a decrease in uncertain tax positions was recorded in discontinued operations.
On December 19, 2014, the Tax Increase Prevention Act of 2014, referred to as the TIPA, was signed into law. The TIPA retroactively reinstated and extended the Federal Research and Development Tax Credit from January 1, 2014 to December 31, 2014. The impact of the TIPA did not significantly impact RAI’s annual effective income tax rate in 2014.
On December 18, 2015, the Protecting Americans from Tax Hikes (PATH) Act, was signed into law. The PATH Act extends the research credit permanently, retroactive to January 1, 2015. The PATH Act did not significantly impact RAI’s annual effective income tax rate in 2015.
At December 31, 2016, there were $393 million of accumulated and undistributed foreign earnings. Of this amount, RAI has invested $15 million and has plans to invest an additional $52 million overseas. RAI has recorded either current or deferred income taxes related to the $326 million of accumulated foreign earnings in excess of its historical and planned overseas investments.
The components of deferred tax benefits included in accumulated other comprehensive loss for the years ended December 31 were as follows:
|
|
2016 |
|
|
2015 |
|
||
Retirement benefits |
|
$ |
215 |
|
|
$ |
209 |
|
Long-term investments |
|
|
— |
|
|
|
10 |
|
Hedging instruments |
|
|
— |
|
|
|
6 |
|
Cumulative translation adjustment and other |
|
|
25 |
|
|
|
31 |
|
|
|
$ |
240 |
|
|
$ |
256 |
|
89
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The accruals for gross unrecognized income tax benefits, including interest and penalties, reflected in other noncurrent liabilities for the years ended December 31 were as follows:
|
|
2016 |
|
|
2015 |
|
||
Unrecognized tax benefits |
|
$ |
118 |
|
|
$ |
97 |
|
Accrued interest |
|
|
13 |
|
|
|
17 |
|
Accrued penalties |
|
|
7 |
|
|
|
8 |
|
|
|
$ |
138 |
|
|
$ |
122 |
|
A reconciliation of the gross unrecognized income tax benefits is as follows:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Balance at beginning of year |
|
$ |
97 |
|
|
$ |
27 |
|
|
$ |
62 |
|
Gross increases related to current period tax positions |
|
|
30 |
|
|
|
28 |
|
|
|
5 |
|
Gross increases related to tax positions in prior periods |
|
|
3 |
|
|
|
46 |
|
|
|
— |
|
Gross decreases related to tax positions in prior periods |
|
|
(3 |
) |
|
|
(1 |
) |
|
|
(31 |
) |
Gross decreases related to audit settlements |
|
|
(2 |
) |
|
|
— |
|
|
|
(6 |
) |
Gross decreases related to lapse of applicable statute of limitations |
|
|
(7 |
) |
|
|
(3 |
) |
|
|
(3 |
) |
Balance at end of year |
|
$ |
118 |
|
|
$ |
97 |
|
|
$ |
27 |
|
At December 31, 2016, $92 million of unrecognized income tax benefits including interest and penalties, if recognized, would decrease RAI’s effective tax rate.
For the year ended December 31, 2016, the gross increases in unrecognized income tax benefits related to tax positions in the current period are primarily attributable to the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with the international companies that distributed and marketed the brand outside the United States.
RAI and its subsidiaries are subject to income taxes in the United States, certain foreign jurisdictions and multiple state jurisdictions. A number of years may elapse before a particular matter, for which RAI has established an accrual, is audited and finally resolved. The number of years with open tax audits varies depending on the tax jurisdiction.
RAI and its subsidiaries file income tax returns in the U.S. federal and various state and foreign jurisdictions. The U.S. federal statute of limitations remains open for the year 2013 and forward. State and foreign jurisdictions have statutes of limitations generally ranging from three to five years. Certain of RAI’s state tax returns are currently under examination by various states as part of routine audits conducted in the ordinary course of business.
Credit Agreement
In December 2014, RAI entered into a credit agreement, referred to as the Credit Agreement, with a syndicate of lenders, providing for a five-year, $2 billion senior unsecured revolving credit facility, which may be increased to $2.35 billion at the discretion of the lenders upon the request of RAI. The Credit Agreement replaced RAI’s four-year, $1.35 billion senior unsecured revolving credit facility dated October 8, 2013.
Subject to certain conditions, RAI is able to use the revolving credit facility under the Credit Agreement for borrowings and issuances of letters of credit at its option, subject to a $300 million sublimit on the aggregate amount of letters of credit. Issuances of letters of credit reduce availability under such revolving credit facility.
The original maturity date of the Credit Agreement was December 18, 2019. Pursuant to the maturity date extension provision of the Credit Agreement, the requisite lenders have agreed on two separate occasions upon RAI’s request, to extend the maturity date of the Credit Agreement by 12 months. Pursuant to the Credit Agreement’s second and sole remaining maturity date extension provision, the lenders agreed, in November 2016 and at RAI’s request, to extend the maturity date of the Credit Agreement by 12 months, to December 18, 2021. In connection with the maturity date extension, RAI and its guarantor subsidiaries entered into a second amendment to the Credit Agreement, dated November 4, 2016, with additional provisions added to address new European
90
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
economic area regulations that give European bank regulators powers to eliminate, convert to equity or other wise modify failing European financial institutions’ unsecured liabilities, including loan commitments.
The Credit Agreement contains certain customary restrictive covenants, and two financial covenants – a consolidated leverage ratio covenant and a consolidated interest coverage ratio covenant. The Credit Agreement contains customary events of default, including upon a change in control, as defined therein, which could result in the acceleration of all amounts and cancellation of all commitments outstanding under the Credit Agreement.
The lenders’ obligations under the Credit Agreement to fund borrowings are subject to the accuracy of RAI’s representations and warranties and the absence of any default, provided, however, that the accuracy of RAI’s representation as to the absence of any material adverse effect, as defined in the Credit Agreement, is not a condition to borrowing for the purpose of refinancing any maturing commercial paper.
Under the terms of the Credit Agreement, RAI is required to pay a facility fee per annum of between 0.100% and 0.275%, based generally on the ratings of RAI’s senior, unsecured, long-term indebtedness, on the lender commitments in respect of the revolving credit facility thereunder.
Borrowings under the Credit Agreement bear interest, at the option of RAI, at a rate equal to an applicable margin based generally on the ratings of RAI’s senior, unsecured, long-term indebtedness, plus:
|
• |
the alternate base rate, which is the higher of (1) the federal funds effective rate from time to time plus 0.5%, (2) the prime rate and (3) the reserve adjusted eurodollar rate for a one month interest period plus 1%; or |
|
• |
the eurodollar rate, which is the reserve adjusted rate at which eurodollar deposits for one, two, three or six months are offered in the interbank eurodollar market. |
Overdue principal outstanding under the revolving credit facility under the Credit Agreement bears interest at a rate equal to the rate then in effect with respect to such borrowings, plus 2.0% per annum. Any amount besides principal that becomes overdue bears interest at a rate equal to 2.0% per annum in excess of the rate of interest applicable to base rate loans.
Certain of RAI’s subsidiaries, including its Material Subsidiaries, as defined in the Credit Agreement, have guaranteed, on an unsecured basis, RAI’s obligations under the Credit Agreement. Under the Credit Agreement, any new Material Subsidiary of RAI must be added as a guarantor of the Credit Agreement.
As of December 31, 2016, there were no outstanding borrowings and $6 million of letters of credit outstanding under the Credit Agreement.
Bridge Facility
In September 2014, RAI entered into a bridge credit agreement, referred to as the Bridge Facility, with a syndicate of lenders, for the purpose of financing a portion of the Lorillard Merger Consideration. RAI issued notes, in lieu of borrowing any funds under the Bridge Facility, to finance part of the cash portion of the Lorillard Merger Consideration. By its terms, the Bridge Facility terminated on June 12, 2015. All associated fees were fully amortized by June 30, 2015. Amortization and fees related to the Bridge Facility were $48 million and $39 million for the years ended December 31, 2015 and 2014, respectively, and were included in interest and debt expense.
91
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Information, including a schedule of maturities, regarding RAI’s and RJR Tobacco’s long-term debt is provided below:
RAI and RJR Tobacco Long-Term Debt
|
|
For the years ended December 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
RAI |
|
|
|
|
|
|
|
|
3.500% notes due 08/04/2016 |
|
$ |
— |
|
|
$ |
415 |
|
6.750% notes due 06/15/2017 |
|
|
— |
|
|
|
700 |
|
2.300% notes due 08/21/2017 |
|
|
447 |
|
|
|
447 |
|
7.750% notes due 06/01/2018 |
|
|
— |
|
|
|
250 |
|
2.300% notes due 06/12/2018 |
|
|
1,250 |
|
|
|
1,250 |
|
8.125% notes due 06/23/2019* |
|
|
669 |
|
|
|
669 |
|
6.875% notes due 05/01/2020 |
|
|
641 |
|
|
|
641 |
|
3.250% notes due 06/12/2020 |
|
|
771 |
|
|
|
1,250 |
|
4.000% notes due 06/12/2022 |
|
|
1,000 |
|
|
|
1,000 |
|
3.250% notes due 11/01/2022 |
|
|
158 |
|
|
|
1,100 |
|
3.750% notes due 05/20/2023 |
|
|
30 |
|
|
|
474 |
|
4.850% notes due 09/15/2023 |
|
|
550 |
|
|
|
550 |
|
4.450% notes due 06/12/2025 |
|
|
2,500 |
|
|
|
2,500 |
|
5.700% notes due 08/15/2035 |
|
|
750 |
|
|
|
750 |
|
7.250% notes due 06/15/2037 |
|
|
450 |
|
|
|
450 |
|
8.125% notes due 05/01/2040 |
|
|
237 |
|
|
|
237 |
|
7.000% notes due 08/04/2041 |
|
|
240 |
|
|
|
240 |
|
4.750% notes due 11/01/2042 |
|
|
173 |
|
|
|
1,000 |
|
6.150% notes due 09/15/2043 |
|
|
550 |
|
|
|
550 |
|
5.850% notes due 08/15/2045 |
|
|
2,250 |
|
|
|
2,250 |
|
Total principal |
|
|
12,666 |
|
|
|
16,723 |
|
Fair value adjustments |
|
|
282 |
|
|
|
348 |
|
Unamortized discounts |
|
|
(28 |
) |
|
|
(37 |
) |
Unamortized debt issuance costs |
|
|
(68 |
) |
|
|
(92 |
) |
Total RAI long-term debt at carrying value |
|
$ |
12,852 |
|
|
$ |
16,942 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco |
|
|
|
|
|
|
|
|
3.500% notes due 08/04/2016 |
|
$ |
— |
|
|
$ |
85 |
|
2.300% notes due 08/21/2017 |
|
|
53 |
|
|
|
53 |
|
8.125% notes due 06/23/2019* |
|
|
81 |
|
|
|
81 |
|
6.875% notes due 05/01/2020 |
|
|
109 |
|
|
|
109 |
|
3.750% notes due 05/20/2023 |
|
|
19 |
|
|
|
26 |
|
8.125% notes due 05/01/2040 |
|
|
13 |
|
|
|
13 |
|
7.000% notes due 08/04/2041 |
|
|
9 |
|
|
|
10 |
|
Total principal |
|
|
284 |
|
|
|
377 |
|
Fair value adjustments |
|
|
29 |
|
|
|
36 |
|
Total RJR Tobacco long-term debt at carrying value |
|
$ |
313 |
|
|
$ |
413 |
|
Total long-term debt at carrying value |
|
$ |
13,165 |
|
|
$ |
17,355 |
|
Less current maturities of long-term debt at carrying value |
|
|
501 |
|
|
|
506 |
|
Total long-term debt (less current maturities) at carrying value |
|
$ |
12,664 |
|
|
$ |
16,849 |
|
* |
The interest rate payable on these notes generally is subject to adjustment from time to time (as detailed in the form of these notes) based upon the credit rating assigned to these notes, provided that in no event will (1) the interest rate for these notes be reduced below 8.125% or (2) the total increase in the interest rate on these notes exceed 2.0% above 8.125%. |
92
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
During the year ended December 31, 2016, RJR Tobacco repurchased $8 million of its outstanding notes. As of December 31, 2016, the maturities of RAI’s and RJR Tobacco’s notes, excluding fair value adjustments and unamortized discounts and debt issuance costs, were as follows:
Year |
|
RAI |
|
|
RJR Tobacco |
|
|
Total |
|
|||
2017 |
|
$ |
447 |
|
|
$ |
53 |
|
|
$ |
500 |
|
2018 |
|
|
1,250 |
|
|
|
— |
|
|
|
1,250 |
|
2019 |
|
|
669 |
|
|
|
81 |
|
|
|
750 |
|
2020 |
|
|
1,412 |
|
|
|
109 |
|
|
|
1,521 |
|
2022 and thereafter |
|
|
8,888 |
|
|
|
41 |
|
|
|
8,929 |
|
|
|
$ |
12,666 |
|
|
$ |
284 |
|
|
$ |
12,950 |
|
Fair Value of Debt
The estimated fair value of RAI’s outstanding consolidated debt, in the aggregate, was $14.3 billion and $18.2 billion as of December 31, 2016 and 2015, respectively, with an effective annual interest rate of approximately 5.0% and 4.6% for the years ended December 31, 2016 and 2015, respectively. The fair value is derived from a third party pricing source and is classified in Level 2 of the fair value hierarchy.
Termination of Interest Rate Swap Agreements
On June 12, 2015, RJR Tobacco assumed the interest rate swap agreements associated with the 8.125% Lorillard Tobacco Notes due June 23, 2019. The interest rate swap agreements qualified for hedge accounting and were designated as fair value hedges at the date of the Lorillard Merger. Under the swap agreements, RJR Tobacco received a fixed rate settlement and paid a variable rate settlement with the difference recorded in interest expense. During 2016, RJR Tobacco terminated these interest rate swap agreements. The remaining fair value adjustment of $7 million for the 8.125% notes due June 23, 2019, is being amortized as a reduction of interest expense over the expected remaining life of the notes.
See note 2 for additional information on the Lorillard Merger and note 4 for additional information on interest rate management.
Tender Offer and Redemption
RAI completed a cash tender offer for an aggregate purchase price of $2.81 billion (excluding accrued and unpaid interest to, but not including, the settlement date of February 22, 2016, and excluding related fees and expenses), referred to as the Tender Cap, for certain of its outstanding notes listed in the table below, collectively referred to as the Tender Notes.
RAI accepted for purchase $2.69 billion in aggregate principal amount of Tender Notes validly tendered and not validly withdrawn on or prior to 5 p.m., New York City time, on February 18, 2016, referred to as the Early Tender Date. On February 22, 2016, RAI paid, with cash on hand, aggregate consideration of $2.81 billion (including a premium of approximately $118 million, but excluding accrued and unpaid interest) for such Tender Notes accepted for purchase. In addition, RAI recognized $22 million of unamortized discount and unamortized debt issuance costs related to the Tender Notes as a loss on early extinguishment of debt.
93
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
RAI accepted for purchase 100% of the Tender Notes validly tendered and not validly withdrawn for the series listed in the table below in acceptance priority levels 1 through 3. Due to oversubscription, RAI accepted for purchase Tender Notes validly tendered and not validly withdrawn for the series listed in the table below in acceptance priority level 4 on a pro rata basis in accordance with the proration procedures described in the tender offer documents. RAI did not accept for purchase any of the Tender Notes for the series listed in the table below in acceptance priority levels 5 through 7.
Title of Security |
|
Acceptance Priority Level |
|
Principal Amount Tendered at Expiration |
|
|
Principal Amount of Tender Notes Accepted for Purchase |
|
|
Percentage of Outstanding Tender Notes Purchased |
|
|||
4.750% Senior Notes due 2042 |
|
1 |
|
$ |
827 |
|
|
$ |
827 |
|
|
|
82.71% |
|
3.250% Senior Notes due 2022 |
|
2 |
|
|
942 |
|
|
|
942 |
|
|
|
85.59% |
|
3.750% Senior Notes due 2023 |
|
3 |
|
|
444 |
|
|
|
444 |
|
|
|
93.76% |
|
3.250% Senior Notes due 2020 (1) |
|
4 |
|
|
1,039 |
|
|
|
479 |
|
|
|
38.34% |
|
4.000% Senior Notes due 2022 |
|
5 |
|
|
766 |
|
|
|
— |
|
|
|
0.00% |
|
4.450% Senior Notes due 2025 |
|
6 |
|
|
1,773 |
|
|
|
— |
|
|
|
0.00% |
|
4.850% Senior Notes due 2023 |
|
7 |
|
|
416 |
|
|
|
— |
|
|
|
0.00% |
|
(1) |
Series Prorated |
Since aggregate consideration payable to holders of Tender Notes validly tendered and not validly withdrawn exceeded the Tender Cap on or prior to the Early Tender Date, RAI did not accept for purchase any additional tenders of Tender Notes made after the Early Tender Date.
In May 2012, RAI entered into forward starting interest rate contracts with an aggregate notional amount of $1 billion. RAI designated those derivatives as cash flow hedges of a future debt issuance. In October 2012, RAI completed the sale of notes that had been forecasted, and the 3.250% Tender Notes due 2022 and the 4.750% Tender Notes due 2042 were designated as the hedged instruments under these derivative contracts. The forward starting interest rate contracts were immediately terminated, and the effective portion of the loss incurred was recorded in accumulated other comprehensive loss in the consolidated balance sheets and was amortized over the life of the related debt. The amount of 3.250% Tender Notes due 2022 and the 4.750% Tender Notes due 2042 repurchased in the tender offer exceeded the original notional amount of the forward starting interest rate contracts and, accordingly, the remaining unamortized loss related to the forward starting interest rate contracts of $16 million was recognized as expense upon completion of the tender offer.
The 3.750% Tender Notes due 2023 have a carrying value that exceeds face value as these notes, which were assumed in the Lorillard Tobacco Merger, were recorded at fair value in purchase accounting. Approximately 94% of this fair value adjustment, or $11 million, which represents the proportional amount of Tender Notes repurchased in this series, was recognized as part of the loss on early extinguishment of debt.
Pursuant to its previously announced redemption call, on March 5, 2016, RAI redeemed all $700 million outstanding aggregate principal amount of its 6.750% Senior Notes due 2017 and all $250 million outstanding aggregate principal amount of its 7.750% Senior Notes due 2018. In connection with the redemption, RAI recorded a loss on early extinguishment of debt of $90 million, which consisted of $88 million in make-whole premiums paid to noteholders as part of the redemption and $2 million for unamortized discount and unamortized debt issuance costs related to the redeemed notes.
In 2009, RAI and RJR entered into offsetting floating to fixed interest rate swap agreements with the same financial institution that held certain fixed to floating interest rate swaps for the same notional amount. The swaps were designated as fair value hedges. In September 2011, the original and offsetting interest rate swap agreements were terminated with the carrying value of the hedged debt reflecting a fair value adjustment treated as a premium, at the date of termination. At that point, RAI began amortizing the fair value adjustment. As of December 31, 2015, the $700 million of 6.750% notes due 2017 represented the remaining debt that had been hedged with these interest rate swap agreements. Upon the redemption of these notes, the remaining unamortized fair value adjustment for the terminated swaps of $25 million was recognized and, accordingly, reduced the loss on early extinguishment of debt.
In the aggregate, expenses related to the cash tender offer and redemption of approximately $239 million, which included legal and bank fees of approximately $7 million, were recognized in other (income) expense, net in the consolidated statements of income for the year ended December 31, 2016.
94
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
On June 12, 2015, RAI completed an underwritten public offering of $9.0 billion aggregate principal amount of its senior notes. The proceeds from this offering were used to fund part of the cash portion of the Lorillard Merger Consideration, the unpaid fees and expenses incurred in connection with the Lorillard Merger and related transactions, and the payment of certain Lorillard equity awards and certain change of control payments, also in connection with the Lorillard Merger.
The notes are unsecured, and are fully and unconditionally guaranteed on a senior unsecured basis by certain of RAI’s subsidiaries, including its material domestic subsidiaries, which are the same guarantors that guarantee its other outstanding senior notes and its Credit Agreement. RAI may redeem the notes in whole or in part at any time at the applicable redemption price. If RAI experiences specific kinds of changes of control, accompanied by a certain credit ratings downgrade of any series of the notes, RAI must offer to repurchase such series.
Lorillard Tobacco Notes; Exchange Offers and Consent Solicitations
Immediately prior to the Lorillard Merger, Lorillard Tobacco had outstanding an aggregate of $3.5 billion in principal amount of senior unsecured notes in seven series, referred to as the Lorillard Tobacco Notes, all of which were guaranteed by Lorillard. In connection with the Lorillard Tobacco Merger, RJR Tobacco assumed Lorillard Tobacco’s obligations under the Lorillard Tobacco Notes and the indenture governing the Lorillard Tobacco Notes, referred to as the Lorillard Tobacco Indenture, and RJR assumed Lorillard’s obligations as guarantor under the Lorillard Tobacco Notes and the Lorillard Tobacco Indenture.
On June 11, 2015, RAI commenced (1) private offers to exchange, referred to as the Exchange Offers, any and all (to the extent held by eligible holders) of the Lorillard Tobacco Notes for a series of new RAI senior notes, referred to as the Exchange Notes, having the same interest payment and maturity dates and interest rate provisions as the corresponding series of Lorillard Tobacco Notes, and (2) related consent solicitations, referred to as the Consent Solicitations, of the eligible holders of each series of Lorillard Tobacco Notes to amend the Lorillard Tobacco Indenture, with such amendments referred to as the Indenture Amendments. Eligible holders who validly tendered, and did not validly withdraw, their Lorillard Tobacco Notes in the Exchange Offers (and thereby gave, and did not validly revoke, their consents to the Indenture Amendments) received, upon settlement of the Exchange Offers and Consent Solicitations on July 15, 2015, Exchange Notes in the same principal amount as the Lorillard Tobacco Notes tendered therefor plus a consent payment of $2.50 per $1,000 principal amount of Lorillard Tobacco Notes tendered. Lorillard Tobacco Notes in the aggregate principal amount of $3.1 billion were tendered in the Exchange Offers.
RJR Tobacco is the principal obligor of the Lorillard Tobacco Notes that were not tendered in the Exchange Offers and that remain outstanding, and currently RAI and RJR are the guarantors of such notes. The Exchange Notes are the principal obligations of RAI and are guaranteed by the same guarantors as RAI’s other outstanding senior notes. Unlike RAI’s outstanding senior notes, the Lorillard Tobacco Notes (with a limited exception for the 3.75% Lorillard Tobacco Notes due 2023) are not redeemable at the option of the issuer prior to maturity.
The Exchange Notes were issued in a private offering exempt from, or not subject to, the registration requirements of the Securities Act of 1933, referred to as the 1933 Act. Pursuant to a registration rights agreement it had entered into, RAI subsequently conducted, in 2015, registered offers to exchange any and all (to the extent held by eligible holders) of the Exchange Notes for its newly issued notes registered under the 1933 Act, referred to as the Registered Notes. Of the total aggregate principal amount of Exchange Notes outstanding, 99.7% were exchanged for Registered Notes in the registered exchange offers. Each series of Registered Notes is substantially identical to the Exchange Notes of the corresponding series, except that, among other things, certain additional interest provisions pertaining to the Exchange Notes do not apply to the Registered Notes. The Registered Notes are unsecured, and are fully and unconditionally guaranteed on a senior unsecured basis by the same RAI subsidiaries that guarantee RAI’s other outstanding senior notes and its Credit Agreement. Any guarantor that is released from its guarantee under the Credit Agreement, or any replacement or refinancing thereof, also will be released automatically from its guarantee of the Registered Notes and RAI’s other outstanding notes. RAI may redeem the Registered Notes, in whole or in part, at any time at the applicable redemption price. If RAI experiences specific kinds of change of control, accompanied by a certain credit rating downgrade of any series of Registered Notes, RAI must offer to repurchase such series.
95
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
In addition, in connection with the Consent Solicitations, RAI received the requisite number of consents to adopt the Indenture Amendments, which became operative on the July 15, 2015, settlement date, with respect to each of the seven series of Lorillard Tobacco Notes. The Indenture Amendments:
|
• |
eliminated substantially all of the restrictive covenants and a bankruptcy event of default for the issuer and the guarantor of the Lorillard Tobacco Notes under the Lorillard Tobacco Indenture; |
|
• |
eliminated the requirement under the Lorillard Tobacco Indenture that the guarantor of the Lorillard Tobacco Notes continue to provide holders of the Lorillard Tobacco Notes with financial statements and other financial information similar to that provided in periodic reports under the Securities Exchange Act of 1934 when it is not subject to such reporting requirements; and |
|
• |
relieved the issuer of the Lorillard Tobacco Notes of the requirement (if any) under the Lorillard Tobacco Indenture that the issuer offer to repurchase the Lorillard Tobacco Notes upon certain change of control events combined with certain credit ratings events to the extent such change of control events relate to, arise out of or are undertaken in connection with the Lorillard Merger or the Lorillard Tobacco Merger. |
Note 13 — Commitmen ts and Contingencies
Tobacco Litigation — General
Introduction
Litigation, claims, and other legal proceedings relating to the use of, exposure to, or purchase of tobacco products are pending or may be instituted in the future against RJR Tobacco (including as successor by merger to Lorillard Tobacco), American Snuff Co., SFNTC, RJR Vapor, RAI, Lorillard, other RAI affiliates, and indemnitees (including but not limited to B&W), sometimes referred to collectively as Reynolds Defendants. These pending legal proceedings include claims relating to cigarette products manufactured by RJR Tobacco, Lorillard Tobacco, SFNTC or certain of their affiliates or indemnitees, smokeless tobacco products manufactured by American Snuff Co., and e-cigarette products manufactured on behalf of and marketed by RJR Vapor. A discussion of the legal proceedings relating to cigarette products (and e-cigarettes) is set forth below under the heading “— Litigation Affecting the Cigarette Industry.” All of the references under that heading to tobacco-related litigation, smoking and health litigation and other similar references are references to legal proceedings relating to cigarette products or e-cigarettes, as the case may be, and are not references to legal proceedings involving smokeless tobacco products, and case numbers under that heading include only cases involving cigarette products and e-cigarettes. The legal proceedings relating to the smokeless tobacco products manufactured by American Snuff Co. are discussed separately under the heading “— Smokeless Tobacco Litigation” below.
In connection with the B&W business combination, RJR Tobacco undertook certain indemnification obligations with respect to B&W and its affiliates, including its indirect parent, BAT. See “— Litigation Affecting the Cigarette Industry – Overview – Introduction” below. In connection with the Lorillard Merger and Divestiture, as applicable, RAI and RJR Tobacco undertook certain indemnification obligations. See “— Litigation Affecting the Cigarette Industry – Overview – Introduction,” “— Other Contingencies – ITG Indemnity,” and “— Other Contingencies – Loews Indemnity” below. In addition, in connection with the sale of the non-U.S. operations and business of the NATURAL AMERICAN SPIRIT brand, the Sellers have agreed to indemnify the buyer for certain claims. See “— Other Contingencies – JTI Indemnities” below.
Certain Terms and Phrases
Certain terms and phrases used in this footnote may require some explanation. The term “judgment” or “final judgment” refers to the final decision of the court resolving the dispute and determining the rights and obligations of the parties. At the trial court level, for example, a final judgment generally is entered by the court after a jury verdict and after post-verdict motions have been decided. In most cases, the losing party can appeal a verdict only after a final judgment has been entered by the trial court.
The term “damages” refers to the amount of money sought by a plaintiff in a complaint, or awarded to a party by a jury or, in some cases, by a judge. “Compensatory damages” are awarded to compensate the prevailing party for actual losses suffered, if liability is proved. In cases in which there is a finding that a defendant has acted willfully, maliciously or fraudulently, generally based on a higher burden of proof than is required for a finding of liability for compensatory damages, a plaintiff also may be awarded “punitive damages.” Although damages may be awarded at the trial court stage, a losing party generally may be protected from paying any damages until all appellate avenues have been exhausted by posting a supersedeas bond. The amount of such a bond is governed by the law of the relevant jurisdiction and generally is set at the amount of damages plus some measure of statutory interest, modified at the discretion of the appropriate court or subject to limits set by a court or statute.
96
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The term “ per curiam ” refers to a decision entered by an appellate court that is not signed by an individual judge. In most cases, it is used to indicate that the opinion entered is a brief announcement of the court’s decision and is not accompanied by an opinion explaining the court’s reasoning.
The term “settlement” refers to certain types of cases in which cigarette manufacturers, including RJR Tobacco, B&W and Lorillard Tobacco, have agreed to resolve disputes with certain plaintiffs without resolving the cases through trial. The principal terms of certain settlements entered into by RJR Tobacco, B&W and Lorillard Tobacco are explained below under “— Accounting for Tobacco-Related Litigation Contingencies.”
Theories of Recovery
The plaintiffs seek recovery on a variety of legal theories, including negligence, strict liability in tort, design defect, failure to warn, fraud, misrepresentation, violations of unfair and deceptive trade practices statutes, conspiracy, medical monitoring and violations of state and federal antitrust laws. In certain of these cases, the plaintiffs claim that cigarette smoking exacerbated injuries caused by exposure to asbestos or, in the case of certain claims asserted against Lorillard Tobacco, that they were injured by exposure to filters containing asbestos used in one cigarette brand for roughly four years before 1957, the latter cases referred to as Filter Cases.
The plaintiffs seek various forms of relief, including compensatory and, where available, punitive damages, treble or multiple damages and statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and other equitable relief. Although alleged damages often are not determinable from a complaint, and the law governing the pleading and calculation of damages varies from jurisdiction to jurisdiction, compensatory and punitive damages have been specifically pleaded in a number of cases, sometimes in amounts ranging into the hundreds of millions and even billions of dollars.
Defenses
The defenses raised by Reynolds Defendants include, where applicable and otherwise appropriate, preemption by the Federal Cigarette Labeling and Advertising Act of some or all claims arising after 1969, or by the Comprehensive Smokeless Tobacco Health Education Act for claims arising after 1986, the lack of any defect in the product, assumption of the risk, contributory or comparative fault, lack of proximate cause, remoteness, lack of standing, statutes of limitations or repose and others. RAI, RJR and Lorillard have asserted additional defenses, including jurisdictional defenses, in many of the cases in which they are named.
Accounting for Tobacco-Related Litigation Contingencies
In accordance with GAAP, RAI and its subsidiaries record any loss concerning litigation at such time as an unfavorable outcome becomes probable and the amount can be reasonably estimated on an individual case-by-case basis. For the reasons set forth below, RAI’s management continues to conclude that the loss of any particular pending tobacco-related litigation claim against the Reynolds Defendants, when viewed on an individual basis, is not probable, except for certain Engle Progeny cases noted below.
Reynolds Defendants believe that they have valid defenses to the tobacco-related litigation claims against them, as well as valid bases for appeal of adverse verdicts against them. Reynolds Defendants have, through their counsel, filed pleadings and memoranda in pending tobacco-related litigation that set forth and discuss a number of grounds and defenses that they and their counsel believe have a valid basis in law and fact. With the exception of the Engle Progeny cases described below, Reynolds Defendants continue to win the majority of tobacco-related litigation claims that reach trial, and a very high percentage of the tobacco-related litigation claims brought against them, including Engle Progeny cases, continue to be dismissed at or before trial. Based on their experience in tobacco-related litigation and the strength of the defenses available to them in such litigation, Reynolds Defendants believe that their successful defense of tobacco-related litigation in the past will continue in the future.
RAI’s consolidated balance sheet as of December 31, 2016, contains accruals for the following Engle Progeny cases: Starr-Blundell , Buonomo, and Ward (for attorneys’ fees and interest only) . In the fourth quarter of 2016, RJR Tobacco paid approximately $17 million in satisfaction of the judgment, including attorneys’ fees and interest, in Wilcox . Other accruals include an amount for the estimated costs of the corrective communications in the U.S. Department of Justice case. As other cases proceed through the appellate process, RAI will evaluate the need for further accruals on an individual case-by-case basis if an unfavorable outcome becomes probable and the amount can be reasonably estimated.
It is the policy of Reynolds Defendants to defend tobacco-related litigation claims vigorously; generally, Reynolds Defendants and indemnitees do not settle such claims. However, Reynolds Defendants may enter into settlement discussions in some cases, if they believe it is in their best interests to do so. Exceptions to this general approach include, but are not limited to, actions taken pursuant to
97
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
“offer of judgment” statutes, as described below in “ — Litigation Affecting the Cigarette Industry – Overview,” and Filter Cases, as described below in “— Litigation Affecting the Cigarette Industry – Filter Cases ,” as well as other historical examples discussed below.
With respect to smoking and health tobacco litigation claims, the only significant settlements reached by RJR Tobacco, Lorillard Tobacco and B&W involved:
|
• |
the State Settlement Agreements and the funding by various tobacco companies of a $5.2 billion trust fund contemplated by the MSA to benefit tobacco growers; |
|
• |
the original Broin flight attendant case discussed below under “— Litigation Affecting the Cigarette Industry – Broin II Cases,” and |
|
• |
most of the Engle Progeny cases pending in federal court, after the initial docket of over 4,000 such cases was reduced to approximately 400 cases. |
The circumstances surrounding the State Settlement Agreements and the funding of a trust fund to benefit the tobacco growers are readily distinguishable from the current categories of tobacco-related litigation claims involving Reynolds Defendants. In the claims underlying the State Settlement Agreements, the states sought to recover funds paid for health care and medical and other assistance to state citizens suffering from diseases and conditions allegedly related to tobacco use. The State Settlement Agreements settled all the health-care cost recovery actions brought by, or on behalf of, the settling jurisdictions and contain releases of various additional present and future claims. In accordance with the MSA, various tobacco companies agreed to fund a $5.2 billion trust fund to be used to address the possible adverse economic impact of the MSA on tobacco growers. A discussion of the State Settlement Agreements, and a table depicting the related payment schedule, is set forth below under “— Litigation Affecting the Cigarette Industry – Health-Care Cost Recovery Cases.”
As with claims that were resolved by the State Settlement Agreements, the other cases settled by RJR Tobacco can be distinguished from existing cases pending against the Reynolds Defendants. The original Broin case, discussed below under “— Litigation Affecting the Cigarette Industry – Broin II Cases,” was settled in the middle of trial during negotiations concerning a possible nation-wide settlement of claims similar to those underlying the State Settlement Agreements.
The federal Engle Progeny cases likewise presented exceptional circumstances not present in the state Engle Progeny cases or elsewhere. All of the federal Engle Progeny cases subject to the settlement were pending in the same court, were coordinated by the same judge, and involved the same sets of plaintiffs’ lawyers. Moreover, RJR Tobacco settled only after approximately 90% of the federal Engle Progeny cases otherwise had been resolved. A discussion of the Engle Progeny cases and the settlement of the federal Engle Progeny cases is set forth below under “— Litigation Affecting the Cigarette Industry – Engle and Engle Progeny Cases.”
In 2010, RJR Tobacco entered into a comprehensive agreement with the Canadian federal, provincial and territorial governments, which resolved all civil claims related to the movement of contraband tobacco products in Canada during the period 1985 through 1999 that the Canadian governments could assert against RJR Tobacco and its affiliates. These claims involved different theories of recovery than the other tobacco-related litigation claims pending against the Reynolds Defendants.
Also, in 2004, RJR Tobacco and B&W separately settled the antitrust case DeLoach v. Philip Morris Cos., Inc., which was brought by a unique class of plaintiffs: a class of all tobacco growers and tobacco allotment holders. The plaintiffs asserted that the defendants conspired to fix the price of tobacco leaf and to destroy the federal government’s tobacco quota and price support program. Despite legal defenses they believed to be valid, RJR Tobacco and B&W separately settled this case to avoid a long and contentious trial with the tobacco growers. The DeLoach case involved different types of plaintiffs and different theories of recovery under the antitrust laws than the other tobacco-related litigation claims pending against the Reynolds Defendants.
Finally, as discussed under “— Litigation Affecting the Cigarette Industry – State Settlement Agreements—Enforcement and Validity; Adjustments,” RJR Tobacco, B&W and Lorillard Tobacco each has settled certain cases brought by states concerning the enforcement of State Settlement Agreements. Despite legal defenses believed to be valid, these cases were settled to avoid further contentious litigation with the states involved. These enforcement actions involved alleged breaches of State Settlement Agreements based on specific actions taken by particular defendants. Accordingly, any future enforcement actions involving State Settlement Agreements will be reviewed by RJR Tobacco on the merits and should not be affected by the settlement of prior enforcement cases.
98
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Even though RAI’s management continues to believe that the loss of particular pending tobacco-related litigation claims against Reynolds Defendants, when viewed on an individual case-by-case basis, is not probable or estimable (except for certain Engle Progeny and Filter cases described below), the possibility of material losses related to such litigation is more than remote. Litigation is subject to many uncertainties, and generally, it is not possible to predict the outcome of any particular litigation pending against Reynolds Defendants, or to reasonably estimate the amount or range of any possible loss.
Although Reynolds Defendants believe that they have valid bases for appeals of adverse verdicts in their pending cases and valid defenses to all actions and intend to defend them vigorously as described above, it is possible that there could be further adverse developments in pending cases, and that additional cases could be decided unfavorably against Reynolds Defendants. Determinations of liability or adverse rulings in such cases or in similar cases involving other cigarette manufacturers as defendants, even if such judgments are not final, could have a material adverse effect on the litigation against Reynolds Defendants and could encourage the commencement of additional tobacco-related litigation. Reynolds Defendants also may enter into settlement discussions in some cases, if they believe it is in their best interests to do so. In addition, a number of political, legislative, regulatory and other developments relating to the tobacco industry and cigarette smoking have received wide media attention. These developments may negatively affect the outcomes of tobacco-related legal actions and encourage the commencement of additional similar litigation.
Although it is impossible to predict the outcome of such events on pending litigation and the rate new lawsuits may be filed against Reynolds Defendants, a significant increase in litigation or in adverse outcomes for tobacco defendants, or difficulties in obtaining the bonding required to stay execution of judgments on appeal, could have a material adverse effect on any or all of these entities. Moreover, notwithstanding the quality of defenses available to Reynolds Defendants in litigation matters, it is possible that RAI’s results of operations, cash flows or financial position could be materially adversely affected by the ultimate outcome of certain pending litigation or future claims against Reynolds Defendants.
Litigation Affecting the Cigarette Industry
Table of Contents
|
Page |
99 |
|
102 |
|
103 |
|
104 |
|
120 |
|
120 |
|
124 |
|
125 |
|
State Settlement Agreements—Enforcement and Validity; Adjustments |
130 |
134 |
Introduction. In connection with the B&W business combination, RJR Tobacco agreed to indemnify B&W and its affiliates against, among other things, certain litigation liabilities, costs and expenses incurred by B&W or its affiliates arising out of the U.S. cigarette and tobacco business of B&W. Also, as a result of the Lorillard Tobacco Merger, Lorillard Tobacco was merged into RJR Tobacco with RJR Tobacco being the surviving entity, Lorillard Tobacco ceasing to exist, and RJR Tobacco succeeding to Lorillard Tobacco’s liabilities, including Lorillard Tobacco’s litigation liabilities, costs and expenses. Although Lorillard Tobacco no longer exists as a result of the Lorillard Tobacco Merger, it will remain as a named party in cases pending on the date of the Lorillard Tobacco Merger until courts grant motions to substitute RJR Tobacco for Lorillard Tobacco or the claims are dismissed. The cases discussed below include cases brought against RJR Tobacco, Lorillard Tobacco and their affiliates and indemnitees, including RAI, RJR, B&W and Lorillard. Cases brought against SFNTC and RJR Vapor also are discussed.
During the fourth quarter of 2016, 23 tobacco-related cases were served against Reynolds Defendants. On December 31, 2016, there were, subject to the exclusions described immediately below, 304 cases pending against Reynolds Defendants: 287 in the United States and 17 in Canada, as compared with 268 total cases on December 31, 2015. Of the U.S. cases pending on December 31, 2016, 34 are pending in federal court, 252 in state court and one in tribal court, primarily in the following states: Illinois (52 cases); Maryland (52 cases); Florida (27 cases); New York (21 cases); Missouri (19 cases); Massachusetts (18 cases); New Mexico (14
99
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
cases); and California (12 cases). The U.S. case number excludes the approximately 564 individual smoker cases pending in West Virginia state court as a consolidated action, 2,822 Engle Progeny cases, involving approximately 3,645 individual plaintiffs, and 2,406 Broin II cases, pending in the United States against RJR Tobacco, Lorillard Tobacco or certain other Reynolds Defendants.
The following table lists the categories of the U.S. tobacco-related cases pending against Reynolds Defendants as of December 31, 2016, and the increase or decrease from the number of cases pending against Reynolds Defendants as of September 30, 2016, as reported in RAI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016, filed with the U.S. Securities and Exchange Commission, referred to as the SEC, on October 19, 2016, and a cross-reference to the discussion of each case type.
Case Type |
|
U.S. Case Numbers as of December 31, 2016 |
|
|
Change in Number of Cases Since September 30, 2016 Increase/(Decrease) |
|
|
|
Individual Smoking and Health |
|
|
132 |
|
|
7 |
|
|
West Virginia IPIC (Number of Plaintiffs)* |
|
1 (approx. 564) |
|
|
No change |
|
|
|
Engle Progeny (Number of Plaintiffs)** |
|
2,822 (approx. 3,645) |
|
|
(66) (110) |
|
|
|
Broin II |
|
|
2,406 |
|
|
(15) |
|
|
Class Action |
|
|
25 |
|
|
1 |
|
|
Filter Cases |
|
|
78 |
|
|
4 |
|
|
Health-Care Cost Recovery |
|
|
2 |
|
|
No change |
|
|
State Settlement Agreements—Enforcement and Validity; Adjustments |
|
|
28 |
|
|
No change |
|
|
Other Litigation and Developments |
|
|
21 |
|
|
No change |
|
|
* |
Includes as one case the approximately 564 cases pending as a consolidated action In Re: Tobacco Litigation Individual Personal Injury Cases , sometimes referred to as West Virginia IPIC cases, described below. The West Virginia IPIC cases have been separated from the Individual Smoking and Health cases for reporting purposes. |
** |
The Engle Progeny cases have been separated from the Individual Smoking and Health cases for reporting purposes. The number of cases will fluctuate as cases are dismissed or if any of the dismissed cases are appealed. |
The Florida state court class-action case, Engle v. R. J. Reynolds Tobacco Co. , and the related cases commonly referred to as Engle Progeny cases have attracted significant attention. After the Florida Supreme Court’s 2006 ruling that members of the formerly certified class could file individual actions, roughly 10,000 claims or actions were filed in Florida state or federal courts before the deadline set by the Florida Supreme Court. No new or additional such claims may be filed. As reflected in the table above, 2,822 Engle Progeny cases were pending as of December 31, 2016, that included claims asserted on behalf of 3,645 plaintiffs. Following an agreement to settle most Engle Progeny cases that remained pending in federal courts in the first quarter of 2015, nearly all Engle Progeny cases currently pending are in Florida state courts. Since 2009, there have been over 200 Engle Progeny trials in Florida state or federal courts involving RJR Tobacco or Lorillard Tobacco. As described more fully immediately below in “— Scheduled Trials ” and “— Trial Results ,” additional Engle Progeny cases involving RJR Tobacco are being tried and set for trial on an ongoing basis. Juries in Engle Progeny cases have awarded substantial amounts in compensatory and punitive damage awards, many of which currently are at various stages in the appellate process. RJR Tobacco and Lorillard Tobacco also have paid substantial amounts in compensatory and punitive damage awards in Engle Progeny cases. For a detailed description of these cases, see “— Engle and Engle Progeny cases” below.
In November 1998, the major U.S. cigarette manufacturers, including RJR Tobacco, B&W and Lorillard Tobacco, entered into the MSA with 46 U.S. states, Washington, D.C. and certain U.S. territories and possessions. These cigarette manufacturers previously settled four other cases, brought on behalf of Mississippi, Florida, Texas and Minnesota, by separate agreements with each state. These State Settlement Agreements:
|
• |
settled all health-care cost recovery actions brought by, or on behalf of, the settling jurisdictions; |
|
• |
released the major U.S. cigarette manufacturers from various additional present and potential future claims; |
|
• |
imposed future payment obligations in perpetuity on RJR Tobacco, B&W, Lorillard Tobacco and other major U.S. cigarette manufacturers; and |
|
• |
placed significant restrictions on their ability to market and sell cigarettes and smokeless tobacco products. |
100
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Payments under the State Settlement Agreements are subject to various adjustments for, among other things, the volume of cigarettes sold, relative market share, operating profit and inflation. See “— Health-Care Cost Recovery Cases — State Settlement Agreements” below for a detailed discussion of the State Settlement Agreements, including RAI’s operating subsidiaries’ monetary obligations under these agreements. RJR Tobacco records the allocation of settlement charges as products are shipped.
Scheduled Trials. Trial schedules are subject to change, and many cases are dismissed before trial. There are 49 cases, exclusive of Engle Progeny cases, scheduled for trial as of December 31, 2016 through December 31, 2017 , for RJR Tobacco, B&W, Lorillard Tobacco or their affiliates and indemnitees: six individual smoking and health cases, 34 Filter Cases, five Broin II cases and four other non-smoking and health cases. There are also approximately 115 Engle Progeny cases against RJR Tobacco, B&W and/or Lorillard Tobacco set for trial through December 31, 2017. It is not known how many of these cases will actually be tried.
Trial Results. From January 1, 2014 through December 31, 2016, 124 individual smoking and health, Engle Progeny, Filter and health-care cost recovery cases in which RJR Tobacco, B&W and/or Lorillard Tobacco were defendants were tried, including nine trials for cases where mistrials were declared in the original proceedings. Verdicts in favor of RJR Tobacco, B&W and Lorillard Tobacco and, in some cases, other defendants, were returned in 60 cases, tried in Florida (39), California (1) and New Jersey (1). There were also 19 mistrials in Florida. Verdicts in favor of the plaintiffs were returned in 57 cases tried in Florida, and one in California. Four cases in Florida were dismissed during trial. One case in Florida was a retrial only as to the amount of damages. In another case in Florida, the jury entered a partial verdict that did not include compensatory or punitive damages, and post-trial motions are pending.
In the fourth quarter of 2016, 11 Engle Progeny cases in which RJR Tobacco and/or Lorillard Tobacco was a defendant were tried:
|
• |
In Wallace v. R. J. Reynolds Tobacco Co. , the court declared a mistrial due to weather delays and juror unavailability. |
|
• |
In Konzelman v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found the decedent 15% at fault and RJR Tobacco 85% at fault, and awarded approximately $8.8 million in compensatory damages and $20 million in punitive damages. |
|
• |
In Maloney v. R. J. Reynolds Tobacco Co. , the court declared a mistrial due to the jury’s inability to reach a unanimous verdict. |
|
• |
In Johnston v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found the decedent 10% at fault and RJR Tobacco 90% at fault, and awarded $7.5 million in compensatory damages and $14 million in punitive damages. |
|
• |
In Ledo v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found the decedent 51% at fault and RJR Tobacco 49% at fault, and awarded $6 million in compensatory damages. |
|
• |
In Howles v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found RJR Tobacco 50% at fault and the remaining defendant 50% at fault, and awarded $4 million in compensatory damages and, against each defendant, $3 million in punitive damages. |
|
• |
In Kloppenburg v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of RJR Tobacco. |
|
• |
In Ford v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found the plaintiff 85% at fault and RJR Tobacco 15% at fault, and awarded approximately $1.02 million in compensatory damages. Punitive damages were not awarded. |
|
• |
In Stanley Martin v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found the decedent 32% at fault, RJR Tobacco 22% at fault and the remaining defendant 46% at fault, and awarded approximately $5.41 million in compensatory damages and $200,000 in punitive damages against RJR Tobacco and $450,000 in punitive damages against the remaining defendant. |
|
• |
In Dubinsky v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the defendants, including RJR Tobacco. |
|
• |
In Pardue v. R. J. Reynolds Tobacco Co. , the jury returned a verdict in favor of the plaintiff, found the decedent 25% at fault, RJR Tobacco 50% at fault, and the remaining defendant 25% at fault, and awarded approximately $5.9 million in compensatory damages and, against each defendant, $6.75 million in punitive damages. |
For a detailed description of the above-described cases, see “— Engle and Engle Progeny Cases” below.
101
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
In the fourth quarter of 2016 , no non- Engle Progeny individual smoking and health cases, in which RJR Tobacco, B&W and/or Lorillard Tobacco was a defendant, were tried.
In the fourth quarter of 2016, no Filter cases, in which RJR Tobacco and/or Lorillard Tobacco was a defendant, were tried.
For information on the verdicts in the Engle Progeny cases that have been tried and remain pending as of December 31, 2016, in which verdicts have been returned against RJR Tobacco, Lorillard Tobacco or B&W, or all three, see the Engle Progeny cases charts at “— Engle and Engle Progeny Cases” below. The following chart reflects the verdicts in the non- Engle Progeny smoking and health cases, health-care cost recovery cases or Filter Cases that have been tried and remain pending as of December 31, 2016, in which verdicts have been returned against RJR Tobacco, B&W or Lorillard Tobacco, or all three.
Date of Verdict |
|
Case Name/Type |
|
Jurisdiction |
|
Verdict |
August 17, 2006 |
|
United States v. Philip Morris USA, Inc. [Governmental Health-Care Cost Recovery] |
|
U.S. District Court, District of Columbia, (Washington, D.C.) |
|
RJR Tobacco, B&W and Lorillard Tobacco were found liable for civil RICO claims; were enjoined from using certain brand descriptors and from making certain misrepresentations; and were ordered to make corrective communications on five subjects, including smoking and health and addiction, to reimburse the U.S. Department of Justice appropriate costs associated with the lawsuit, and to maintain document web sites. |
May 26, 2010 |
|
Izzarelli v. R. J. Reynolds Tobacco Co. [Individual] |
|
U.S. District Court, District of Connecticut, (Bridgeport, CT) |
|
$13.76 million in compensatory damages; 58% of fault assigned to RJR Tobacco, which reduced the award to $7.98 million against RJR Tobacco; $3.97 million in punitive damages. |
September 13, 2013 |
|
DeLisle v. A. W. Chesterton Co. [Filter] |
|
Circuit Court, Broward County, (Ft. Lauderdale, FL) |
|
$8 million in compensatory damages; 44% of fault assigned to Lorillard Tobacco, which reduced the award to $3.52 million against Lorillard Tobacco. |
July 30, 2014 |
|
Major v. Lorillard Tobacco Co. [Individual] |
|
Superior Court, Los Angeles County, (Los Angeles, CA) |
|
$17.74 million in compensatory damages; 17% of fault assigned to Lorillard Tobacco, which reduced the award to $3.78 million against Lorillard Tobacco. |
July 8, 2015 |
|
Larkin v. R. J. Reynolds Tobacco Co. [Individual] |
|
Circuit Court, Miami-Dade County, (Miami, FL) |
|
$4.96 million in compensatory damages; 62% of fault assigned to RJR Tobacco; $8.5 million in punitive damages. Comparative fault did not apply to the final judgment. |
For information on the post-trial status of individual smoking and health cases, the governmental health-care cost recovery case and the Filter Cases, see “— Individual Smoking and Health Cases,” “— Health-Care Cost Recovery Cases – U.S. Department of Justice Case,” and “— Filter Cases,” respectively, below.
Individual Smoking and Health Cases
As of December 31, 2016, 132 individual cases were pending in the United States against RJR Tobacco, B&W (as RJR Tobacco’s indemnitee), Lorillard Tobacco or all three. This category of cases includes smoking and health cases alleging personal injuries caused by tobacco use or exposure brought by or on behalf of individual plaintiffs based on theories of negligence, strict liability, breach of express or implied warranty, and violations of state deceptive trade practices or consumer protection statutes. The plaintiffs seek to recover compensatory damages, attorneys’ fees and costs, and punitive damages. The category does not include the Broin II, Engle Progeny, Filter Cases or West Virginia IPIC cases discussed below. One of the individual cases is brought by or on behalf of an individual or his/her survivors alleging personal injury as a result of exposure to environmental tobacco smoke, referred to as ETS.
Below is a description of the non- Engle Progeny individual smoking and health cases against RJR Tobacco, B&W, and/or Lorillard Tobacco that went to trial or were decided during the period from January 1, 2016 to December 31, 2016, or remained on appeal as of December 31, 2016.
On May 26, 2010, in Izzarelli v. R. J. Reynolds Tobacco Co . (U.S.D.C. D. Conn., filed 1999), the jury awarded the plaintiff $13.76 million in compensatory damages on the negligence and strict liability claims, found RJR Tobacco 58% at fault and the plaintiff 42% at fault, and found that the plaintiff was entitled to punitive damages. The plaintiff sought to recover damages for
102
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
personal injuries allegedly sustained as a result of unsafe and unreasonably dangerous cigarette products and for economic losses she sustained as a result of supposed unfair trade practices . On December 5, 2010, the district court (1) awarded the plaintiff $3.97 million in punitive damages, (2) entered a judgment of $11.95 million, and (3) granted the plaintiff $15.8 million in offer of judgment interest through that date and, going forward, approximately $4,000 per day until entry of an amended judgment. In March 2011, the district court entered an amended judgment of approximately $28.1 million. RJR Tobacco appealed to the U.S. Court of Appeals for the Second Circuit, referred to as the Second Circuit, and the plaintiff cross appealed. In September 2013, the Second Circuit certified a question of Connecticut law to the Connecticut Supreme Court, which was answered on April 26, 2016. On July 7, 2016, the Second Circuit ordered another round of briefing to be submitted in the Izzarelli appeal after the Connecticut Supreme Court answered certified questions of Connecticut law in the Bifolck v. Philip Morris, Inc case. In a decision released on December 29, 2016, the Connecticut Supreme Court answered the questions in Bifolck . Briefing in Izzarelli will be completed on February 10, 2017.
On July 30, 2014, in Major v. Lorillard Tobacco Co. (Super. Ct. Los Angeles County, Cal., filed 2011), the jury awarded the plaintiff approximately $17.74 million in compensatory damages on the negligence and strict liability claims and found the plaintiff 50% at fault, Lorillard Tobacco 17% at fault, and RJR Tobacco and another manufacturer collectively 33% at fault. Punitive damages were not at issue. RJR Tobacco and the other manufacturer had been dismissed prior to trial. The plaintiffs alleged that as a result of the use of the defendants’ products and exposure to asbestos, the decedent, William Major, suffered from lung cancer, and sought an unspecified amount of damages. In August 2014, the trial court entered an initial final judgment of approximately $3.9 million against Lorillard Tobacco. On July 1, 2015, the trial court entered an amended final judgment in the amount of approximately $3.78 million in compensatory damages, approximately $135,000 in costs, approximately $1.9 million in prejudgment interest, and post-judgment interest from August 25, 2014 in the amount of approximately $1,100 per day. Lorillard Tobacco appealed from the original and amended judgments, which appeals have been consolidated, and posted a supersedeas bond in the amount of approximately $9.1 million. On October 20, 2015, the appellate court granted RJR Tobacco’s motion to substitute itself for Lorillard Tobacco. Briefing is underway.
On July 8, 2015, in Larkin v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2002) the jury awarded the plaintiff approximately $4.96 million in compensatory damages on the strict liability and intentional tort claims, found RJR Tobacco 62% at fault and the decedent 38% at fault, and awarded $8.5 million in punitive damages. The plaintiff alleged that as a result of using the defendant’s products, the decedent suffered from mouth and lung cancer, and sought an unspecified amount of compensatory and punitive damages. In July 2015, the trial court entered judgment in the amount of approximately $13.46 million. On March 22, 2016, the trial court granted RJR Tobacco’s motion for a new trial on claims of defective product and damages only and denied the remaining post-trial motions. The new trial has not been scheduled. In April 2016, RJR Tobacco appealed to the Third District Court of Appeal, referred to as DCA, and the plaintiff cross appealed. Briefing is underway.
On February 8, 2016, in Pooshs v. Philip Morris USA, Inc. (U.S.D.C. N.D. Cal., filed 2004) the jury returned a verdict in favor of the defendants, including RJR Tobacco. The plaintiff alleged that as a result of using the defendants’ products, the plaintiff suffers from lung cancer. Final judgment was entered on February 9, 2016. The plaintiff filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit on March 9, 2016. The case has been stayed through March 27, 2017, pending a decision in Major , described above.
In re: Tobacco Litigation Individual Personal Injury Cases (Cir. Ct. Ohio County, W. Va., filed beginning in 1999), is a series of roughly 1,200 individual cases asserting claims against Philip Morris USA Inc., Lorillard Tobacco, RJR Tobacco, B&W and The American Tobacco Company based on alleged personal injuries . The cases were consolidated for a Phase I trial on various defense conduct issues, to be followed in Phase II by individual trials of remaining claims. On May 15, 2013, the Phase I jury found that defendants’ cigarettes were not defectively designed; defendants’ cigarettes were not defective due to a failure to warn before July 1, 1969; defendants were not negligent, did not breach warranties, and did not engage in conduct warranting punitive damages; and defendants’ ventilated filter cigarettes manufactured and sold between 1964 and July 1, 1969 were defective for a failure to instruct. In November 2014, the West Virginia Supreme Court affirmed the verdict. On June 8, 2015, the U.S. Supreme Court denied the plaintiffs’ petition for writ of certiorari. On the same date, the trial court issued an order finding that only 30 plaintiffs are alleged to have smoked ventilated filter cigarettes in the relevant period. On October 9, 2015, the trial court outlined the procedures for resolving the claims of the 30 Phase II plaintiffs, which claims will focus on whether plaintiffs blocked cigarette vents and, if so, whether blocking proximately caused their alleged injuries. Five cases were selected to be the first claims tried, and they were tentatively scheduled to be tried beginning on May 1, 2017 . In June 2016, the court granted the defendants’ motion to compel and required the plaintiffs to file additional expert disclosures necessary to attempt to proceed with their claims. The court will set a revised discovery and trial schedule after the expert disclosures are tested for admissibility, and it pushed the tentative trial date to May 2018.
In addition to the foregoing claims, various plaintiffs in 1999 and 2000 asserted claims against retailers and distributors. Those claims were severed and stayed pending the outcome of Phase I. Also, 41 plaintiffs asserted smokeless tobacco claims against various
103
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
smokeless manufacturers, including 14 claims against certain Reynolds Defendants. Those claims were severed from IPIC in 2001, and the plaintiffs took no action to prosecute the claims. They now seek to activate their smokeless claims. On January 25, 2017, the trial court denied the defendants’ motion to dismiss those claims as abandoned. The plaintiffs are now free to move forward with their claims.
In July 1998, trial began in Engle v. R. J. Reynolds Tobacco Co., a then-certified class action filed in Circuit Court, Miami-Dade County, Florida , against U.S. cigarette manufacturers, including RJR Tobacco, B&W, Lorillard Tobacco, Philip Morris USA Inc., and others. The then-certified class consisted of Florida citizens and residents, and their survivors, who suffered from smoking-related diseases that first manifested between May 5, 1990, and November 21, 1996, and were caused by an addiction to cigarettes. In July 1999, the jury in Phase I found against RJR Tobacco, B&W, Lorillard Tobacco and the other defendants on common issues relating to the defendants’ conduct, general causation, the addictiveness of cigarettes, and entitlement to punitive damages.
On July 14, 2000, the jury in Phase II awarded the class a total of approximately $145 billion in punitive damages, which were apportioned $36.3 billion to RJR Tobacco, $17.6 billion to B&W, and $16.3 billion to Lorillard Tobacco. The defendants appealed.
On December 21, 2006, the Florida Supreme Court prospectively decertified the class and set aside the jury’s Phase II punitive damages award. But the court preserved certain of the jury’s Phase I findings, including that cigarettes can cause certain diseases, nicotine is addictive, and defendants placed defective cigarettes on the market, breached duties of care, concealed health-related information, and conspired. The court also authorized former class members to file individual lawsuits within one year, and it stated that the preserved findings would have res judicata effect in those actions.
In the year after the Florida Supreme Court’s Engle decision, putative class members filed thousands of individual actions against RJR Tobacco, B&W, Lorillard Tobacco, Philip Morris USA Inc., and the other Engle defendants, which actions commonly are referred to as Engle Progeny cases. As of December 31, 2016, 2,809 Engle Progeny cases were pending in state courts, and 13 Engle Progeny cases were pending in federal court against RJR Tobacco, B&W and/or Lorillard Tobacco. Those cases include claims by or on behalf of approximately 3,645 plaintiffs. As of December 31, 2016, RJR Tobacco also was aware of nine additional Engle Progeny cases that have been filed but not served. The number of pending cases fluctuates for a variety of reasons, including voluntary and involuntary dismissals. Voluntary dismissals include cases in which a plaintiff accepts an “offer of judgment,” referred to in Florida statutes as “proposals for settlement,” from RJR Tobacco, Lorillard Tobacco and/or RJR Tobacco’s affiliates and indemnitees. An offer of judgment, if rejected by the plaintiff, preserves RJR Tobacco’s and Lorillard Tobacco’s right to recover attorneys’ fees under Florida law in the event of a verdict favorable to RJR Tobacco or Lorillard Tobacco. Such offers are sometimes made through court-ordered mediations.
At the beginning of the Engle Progeny litigation, a central issue was the proper use of the preserved Engle findings. RJR Tobacco has argued that use of the Engle findings to establish individual elements of progeny claims (such as defect, negligence and concealment) is a violation of federal due process. In 2013, however, both the Florida Supreme Court and the U.S. Court of Appeals for the Eleventh Circuit, referred to as the Eleventh Circuit, rejected that argument. As noted below, the Eleventh Circuit, this time sitting en banc , recently heard argument on this issue again. In addition to this global due process argument, RJR Tobacco and Lorillard Tobacco raise many other factual and legal defenses as appropriate in each case. These defenses may include, among other things, arguing that the plaintiff is not a proper member of the Engle class, that the plaintiff did not rely on any statements by any tobacco company, that the trial was conducted unfairly, that some or all claims are preempted or barred by applicable statutes of limitation, or that any injury was caused by the smoker’s own conduct. In Hess v. Philip Morris USA Inc. and Russo v. Philip Morris USA Inc. , decided on April 2, 2015, the Florida Supreme Court held that, in Engle Progeny cases, the defendants cannot raise a statute of repose defense to claims for concealment or conspiracy. On April 8, 2015, in Graham v. R. J. Reynolds Tobacco Co. , the Eleventh Circuit held that federal law impliedly preempts use of the preserved Engle findings to establish claims for strict liability or negligence. On January 21, 2016, the Eleventh Circuit granted the plaintiff’s motion for rehearing en banc and vacated the panel decision. On March 23, 2016, the Eleventh Circuit requested briefing on the issues of whether plaintiff’s claims are preempted and, if not, whether the defendants’ due process rights are violated. Oral argument occurred on June 21, 2016. A decision is pending. On January 6, 2016, in Marotta v. R. J. Reynolds Tobacco Co. , the Fourth DCA, disagreed with the Graham panel decision and held that federal law does not impliedly preempt any tort claims against cigarette manufacturers, including those of Engle Progeny plaintiffs. The Florida Supreme Court has accepted jurisdiction in Marotta, and oral argument occurred on November 1, 2016. A decision is pending.
In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applied to all Engle Progeny cases in the aggregate. In May 2011, Florida removed the provision that would have allowed the bond cap to expire on December 31, 2012. The bond cap for any given individual Engle Progeny case varies depending on the number of judgments on appeal at a given time, but never exceeds $5 million per case for appeals within the Florida state court system. The legislation, which became effective
104
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
in June 2009 and 2011, applied to judgments entered after the original 2009 effective date. Bills are pending in the Florida legislature that would repeal the $200 million bond cap applicable to Engle Progeny cases.
During 2015, RJR Tobacco and Lorillard Tobacco, together with Philip Morris USA Inc., settled virtually all of the Engle Progeny cases then pending against them in federal district court. The total amount of the settlement was $100 million divided as follows: RJR Tobacco - $42.5 million; Philip Morris USA Inc. - $42.5 million; and Lorillard Tobacco - $15 million. The settlement covered more than 400 federal progeny cases but did not cover 12 federal progeny cases previously tried to verdict and currently pending on post-trial motions or appeal; and 2 federal progeny cases filed by different lawyers from the ones who negotiated the settlement for the plaintiffs. Between August 3, 2015 and January 4, 2016, RJR Tobacco and Philip Morris USA Inc. removed 39 Engle Progeny cases from state to federal courts in Florida. These cases were not part of the settlement described above and were all remanded back to state court.
One hundred twenty Engle Progeny cases have been tried in Florida state and federal courts since the beginning of 2014 through December 31, 2016, and additional state court trials are scheduled for 2017. Since the beginning of 2014 through December 31, 2016, RJR Tobacco or Lorillard Tobacco has paid judgments in 37 Engle Progeny cases. Those payments totaled $297.8 million and included $216.9 million for compensatory or punitive damages and $80.9 million for attorneys’ fees and statutory interest. In addition, accruals for compensatory and punitive damages and attorneys’ fees and statutory interest for Starr-Blundell , Buonomo, and Ward (for attorneys’ fees and interest only) were recorded in RAI’s consolidated balance sheet as of December 31, 2016. The following chart reflects the details of accrued compensatory and punitive damages related to Starr-Blundell and Buonomo.
Plaintiff Case Name |
|
RJR Tobacco Allocation of Fault |
|
|
Lorillard Tobacco Allocation of Fault |
|
|
Compensatory Damages (as adjusted) (1) |
|
|
Punitive Damages |
|
|
Appeal Status |
||||
Starr-Blundell |
|
|
10% |
|
|
|
— |
|
|
$ |
50,000 |
|
|
$ |
— |
|
|
First DCA, per curiam , reversed and remanded its May 29, 2015 opinion to the trial court for reconsideration in light of the decision in Soffer |
Buonomo |
|
|
77.5% |
|
|
|
— |
|
|
|
4,060,000 |
|
|
|
25,000,000 |
|
|
Fourth DCA affirmed the amended final judgment, per curiam ; RJR Tobacco's motion for rehearing was denied on October 27, 2016; deadline for RJR Tobacco to file a petition for writ of certiorari with the U.S. Supreme Court is March 26, 2017 |
Totals |
|
|
|
|
|
|
|
|
|
$ |
4,110,000 |
|
|
$ |
25,000,000 |
|
|
|
(1) |
Compensatory damages are adjusted to reflect the reduction that may be required by the allocation of fault. Punitive damages are not adjusted and reflect the amount of the final judgment(s) signed by the trial court judge(s). The amounts listed above do not include attorneys’ fees or statutory interest of approximately $13.3 million or approximately $1.6 million in attorneys’ fees and statutory interest in Ward . |
105
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The following chart lists judgments in all other individual Engle Progeny cases pending as of December 31, 2016, in which a verdict or judgment has been returned against RJR Tobacco, B&W, and/or Lorillard Tobacco and the verdict or judgment has not been set aside on appeal. No liability for any of these cases has been recorded in RAI’s consolidated balance sheet as of December 31, 2016. This chart does not include the mistrials or verdicts returned in favor of RJR Tobacco, B&W, and/or Lorillard Tobacco.
Plaintiff Case Name |
|
RJR Tobacco Allocation of Fault |
|
|
Lorillard Tobacco Allocation of Fault |
|
|
Compensatory Damages (as adjusted) (1) |
|
|
Punitive Damages |
|
|
Appeal Status |
||||
Putney |
|
|
30% |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
2,500,000 |
|
|
Fourth DCA reinstated the punitive damages awards of $2.5 million each against RJR Tobacco and the remaining defendant; court's opinion that previously granted remittitur of the compensatory damages awards still stands; remanded to trial court for further proceedings |
Andy Allen |
|
|
24% |
|
|
|
— |
|
|
|
2,475,000 |
|
|
|
7,756,000 |
|
|
Pending – First DCA |
Calloway |
|
|
27% |
|
|
|
18% |
|
|
|
— |
|
|
|
— |
|
|
Fourth DCA granted rehearing en banc and substituted a new opinion, ordered a new trial based on improper argument; the plaintiff filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court on October 21, 2016; decision is pending |
James Smith |
|
|
55% |
|
|
|
— |
|
|
|
600,000 |
|
(2) |
|
20,000 |
|
|
Pending – Eleventh Circuit |
Evers |
|
|
60% |
|
|
|
9% |
|
|
|
2,950,000 |
|
|
|
12,360,000 |
|
|
Second DCA reinstated punitive damage award of $12.36 million the trial court had set aside; the verdict was reinstated on remand; a subsequent appeal is pending in the Second DCA |
Schoeff |
|
|
75% |
|
|
|
— |
|
|
|
7,875,000 |
|
|
|
— |
|
|
Pending – Florida Supreme Court |
Marotta |
|
|
58% |
|
|
|
— |
|
|
|
3,480,000 |
|
|
|
— |
|
|
Pending – Florida Supreme Court |
Searcy |
|
|
30% |
|
|
|
— |
|
|
|
500,000 |
|
(2) |
|
1,670,000 |
|
|
Pending – Eleventh Circuit |
Earl Graham |
|
|
20% |
|
|
|
— |
|
|
|
550,000 |
|
|
|
— |
|
|
Eleventh Circuit held that federal law impliedly preempts claims for strict liability and negligence based on the defect and negligence findings from Engle ; plaintiff's motion for rehearing en banc was granted; oral argument occurred on June 21, 2016; decision is pending |
Skolnick |
|
|
30% |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Fourth DCA set aside judgment and ordered a partial new trial |
Grossman |
|
|
75% |
|
|
|
— |
|
|
|
11,514,000 |
|
|
|
22,500,000 |
|
|
Fourth DCA ordered award of compensatory damages reduced to reflect comparative fault, but otherwise affirmed; RJR Tobacco filed a motion for rehearing on February 6, 2017; decision is pending |
Gafney |
|
|
33% |
|
|
|
33% |
|
|
|
— |
|
|
|
— |
|
|
Fourth DCA reversed the judgment and remanded for a new trial; Florida Supreme Court declined to accept jurisdiction; new trial has not been scheduled |
Burkhart |
|
|
25% |
|
|
|
10% |
|
|
|
3,500,000 |
|
(2) |
|
1,750,000 |
|
|
Pending – Eleventh Circuit |
Bakst (Odom) |
|
|
75% |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Fourth DCA reversed the judgment of the trial court and remanded the case for a new trial on damages only; motion for rehearing was filed on January 9, 2017 |
Robinson |
|
|
71% |
|
|
|
— |
|
|
|
16,900,000 |
|
|
|
16,900,000 |
|
|
Pending – First DCA |
Harris |
|
|
15% |
|
|
|
10% |
|
|
|
1,100,000 |
|
(2) |
|
— |
|
|
Post-trial motions are pending (3) |
Irimi |
|
|
15% |
|
|
|
15% |
|
|
|
— |
|
|
|
— |
|
|
Pending – Fourth DCA |
106
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
|
3% |
|
|
|
7% |
|
|
|
137,000 |
|
|
|
— |
|
|
Second DCA affirmed the final judgment; defendants filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court on September 8, 2016; Florida Supreme Court stayed proceedings pending disposition of Marotta |
|
Kerrivan |
|
|
31% |
|
|
|
— |
|
|
|
6,046,660 |
|
(2) |
|
9,600,000 |
|
|
Post-trial motions are pending (3) |
Schleider |
|
|
70% |
|
|
|
— |
|
|
|
14,700,000 |
|
|
|
— |
|
|
Pending – Third DCA |
Perrotto |
|
|
20% |
|
|
|
6% |
|
|
|
1,063,000 |
|
|
|
— |
|
|
Plaintiff's motion for a new trial granted as to punitive damages; new trial scheduled for June 5, 2017 |
Ellen Gray |
|
|
50% |
|
|
|
— |
|
|
|
3,000,000 |
|
|
|
— |
|
|
Post-trial motions are pending (3) |
Sowers |
|
|
50% |
|
|
|
— |
|
|
|
2,125,000 |
|
|
|
— |
|
|
Post-trial motions are pending (3) |
Caprio |
|
|
20% |
|
|
|
10% |
|
|
|
167,700 |
|
|
|
— |
|
|
Appeal in the Fourth DCA dismissed; pending in trial court |
Zamboni |
|
|
30% |
|
|
|
— |
|
|
|
102,000 |
|
|
|
— |
|
|
Final judgment has not been entered |
Pollari |
|
|
43% |
|
|
|
— |
|
|
|
4,250,000 |
|
|
|
1,500,000 |
|
|
Pending – Fourth DCA |
Gore |
|
|
23% |
|
|
|
— |
|
|
|
460,000 |
|
|
|
— |
|
|
Pending – Fourth DCA |
Ryan |
|
|
65% |
|
|
|
— |
|
|
|
13,975,000 |
|
|
|
25,000,000 |
|
|
Pending – Fourth DCA |
Hardin |
|
|
13% |
|
|
|
— |
|
|
|
100,880 |
|
|
|
— |
|
|
Third DCA remanded the case for a new trial on punitive damages for the non-intentional tort claims; new trial has not been scheduled |
McCoy |
|
|
25% |
|
|
|
20% |
|
|
|
670,000 |
|
|
|
6,000,000 |
|
|
Pending – Fourth DCA |
Block |
|
|
50% |
|
|
|
— |
|
|
|
463,000 |
|
|
|
800,000 |
|
|
Pending – Fourth DCA |
Lewis |
|
|
25% |
|
|
|
— |
|
|
|
187,500 |
|
|
|
— |
|
|
Pending – Fifth DCA |
Cooper |
|
|
40% |
|
|
|
— |
|
|
|
1,200,000 |
|
|
|
— |
|
|
Pending – Fourth DCA |
Duignan |
|
|
30% |
|
|
|
— |
|
|
|
2,690,000 |
|
(2) |
|
2,500,000 |
|
|
Pending – Second DCA |
O'Hara |
|
|
85% |
|
|
|
— |
|
|
|
14,700,000 |
|
|
|
20,000,000 |
|
|
Pending – First DCA |
Marchese |
|
|
22.5% |
|
|
|
— |
|
|
|
225,000 |
|
|
|
250,000 |
|
|
Pending – Fourth DCA |
Barbose |
|
|
42.5% |
|
|
|
— |
|
|
|
5,000,000 |
|
(2) |
|
500,000 |
|
|
Pending – Second DCA |
Monroe |
|
|
58% |
|
|
|
— |
|
|
|
6,380,000 |
|
|
|
— |
|
|
Pending – First DCA |
Ledoux |
|
|
47% |
|
|
|
— |
|
|
|
5,000,000 |
|
(2) |
|
12,500,000 |
|
|
Pending – Third DCA |
Ewing |
|
|
2% |
|
|
|
— |
|
|
|
4,800 |
|
|
|
— |
|
|
Post-trial motions denied; final judgment has not been entered |
Ahrens |
|
|
44% |
|
|
|
— |
|
|
|
5,800,000 |
|
(2) |
|
2,500,000 |
|
|
Pending – Second DCA |
Turner |
|
|
80% |
|
|
|
— |
|
|
|
2,400,000 |
|
|
|
10,000,000 |
|
|
Pending – Fourth DCA |
Enochs |
|
|
66% |
|
|
|
— |
|
|
|
13,860,000 |
|
|
|
6,250,000 |
|
|
Pending – Fourth DCA |
Dion |
|
|
75% |
|
|
|
— |
|
|
|
12,000,000 |
|
(2) |
|
30,000 |
|
|
Pending – Second DCA |
Nally |
|
|
75% |
|
|
|
— |
|
|
|
6,000,000 |
|
(2) |
|
12,000,000 |
|
|
Pending – Second DCA |
McCabe |
|
|
30% |
|
|
|
— |
|
|
|
1,500,000 |
|
|
|
6,500,000 |
|
|
Post-trial motions are pending (3) |
Sermons |
|
|
5% |
|
|
|
— |
|
|
|
3,250 |
|
|
|
17,075 |
|
|
Post-trial motions are pending (3) |
Mathis |
|
|
55% |
|
|
|
— |
|
|
|
5,000,000 |
|
(2) |
|
— |
|
|
Pending – Third DCA |
Oshinsky-Blacker |
|
|
25% |
|
|
|
— |
|
|
|
1,539,000 |
|
|
|
2,000,000 |
|
|
Post-trial motions are pending (3) |
Sherry Smith |
|
|
65% |
|
|
|
— |
|
|
|
3,000,000 |
|
(2) |
|
— |
|
|
Pending – Fifth DCA |
Prentice |
|
|
40% |
|
|
|
— |
|
|
|
2,560,000 |
|
|
|
— |
|
|
Post-trial motions are pending (3) |
Konzelman |
|
|
85% |
|
|
|
— |
|
|
|
7,476,000 |
|
|
|
20,000,000 |
|
|
Pending – Fourth DCA |
Ledo |
|
|
49% |
|
|
|
— |
|
|
|
2,940,000 |
|
|
|
— |
|
|
Post-trial motions are pending (3) |
Johnston |
|
|
90% |
|
|
|
— |
|
|
|
6,750,000 |
|
|
|
14,000,000 |
|
|
Post-trial motions are pending (3) |
Howles |
|
|
50% |
|
|
|
— |
|
|
|
2,000,000 |
|
|
|
3,000,000 |
|
|
Pending – Fourth DCA |
Ford |
|
|
15% |
|
|
|
— |
|
|
|
153,430 |
|
|
|
— |
|
|
Post-trial motions are pending (3) |
Martin |
|
|
22% |
|
|
|
— |
|
|
|
1,190,400 |
|
|
|
200,000 |
|
|
Post-trial motions are pending (3) |
Pardue |
|
|
50% |
|
|
|
— |
|
|
|
3,923,000 |
|
(2) |
|
6,750,000 |
|
|
Post-trial motions are pending (3) |
Totals |
|
|
|
|
|
|
|
|
|
$ |
212,186,620 |
|
|
$ |
227,353,075 |
|
|
|
107
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
(2) |
The court did not apply comparative fault in the final judgment. |
(3) |
Should the pending post-trial motions be denied, RJR Tobacco will likely file a notice of appeal with the appropriate appellate court. |
As reflected in the preceding chart, as of December 31, 2016, verdicts or judgments in favor of Engle Progeny plaintiffs have been entered and remain outstanding against RJR Tobacco or Lorillard Tobacco totaling $212,186,620 in compensatory damages (as adjusted) and $227,353,075 in punitive damages, which is a combined total of $439,539,695. These verdicts or judgments are at various stages in the post-trial or appellate process. RJR Tobacco believes that RJR Tobacco and Lorillard Tobacco have valid defenses in these cases, including case-specific issues beyond the due process issue discussed above, and, as described in more detail above in “— Accounting for Tobacco-Related Litigation Contingencies,” RJR Tobacco and its affiliates vigorously defend smoking and health claims, including Engle Progeny cases.
Should RJR Tobacco or Lorillard Tobacco not prevail in any particular individual Engle Progeny case or determine that in any individual Engle Progeny case an unfavorable outcome has become probable and the amount can be reasonably estimated, a loss would be recognized, which could have a material adverse effect on the results of operations, cash flows and financial position of RAI. This position on loss recognition for Engle Progeny cases as of December 31, 2016, is consistent with RAI’s and RJR Tobacco’s historic position on loss recognition for other smoking and health litigation. It is the policy of RJR Tobacco to record any loss concerning litigation at such time as an unfavorable outcome becomes probable and the amount can be reasonably estimated on an individual case-by-case basis.
Below is a description of the Engle Progeny cases against RJR Tobacco, B&W, and/or Lorillard Tobacco that went to trial or were decided during the period from January 1, 2016 to December 31, 2016, or remained on appeal as of December 31, 2016, listed chronologically by the date of the verdict. In each case, the plaintiff: (1) alleged that the smoker was addicted to nicotine in cigarettes and, as a result of that addiction, suffered or died from one or more smoking-related diseases; (2) asserted claims based on theories of negligence, strict liability, and intentional tort; and (3) sought to recover unspecified compensatory damages, as well as attorneys’ fees and costs. The plaintiffs in most, but not all, cases also sought to recover punitive damages.
On April 13, 2010, in Putney v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), a jury in Phase I of the trial returned a verdict for the plaintiff. On April 26, 2010, the jury in Phase II of the trial found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $15.1 million in compensatory damages; found the decedent 35% at fault, RJR Tobacco 30% at fault and the remaining defendants collectively 35% at fault; and awarded $2.5 million in punitive damages against each of RJR Tobacco and one of the remaining defendants. In August 2010, the trial court entered final judgment against RJR Tobacco in the amount of $4.5 million in compensatory damages and $2.5 million in punitive damages. In December 2010, the trial court entered an amended final judgment to provide that interest would run from April 26, 2010. In June 2013, the Fourth DCA held that the trial court erred in denying the defendants’ motion for remittitur of the compensatory damages for loss of consortium and in striking the defendants’ statute of repose affirmative defenses. As a result, the Fourth DCA reversed and remanded for further proceedings. After its April 2, 2015, ruling in Hess v. Philip Morris USA Inc. that Engle Progeny defendants cannot raise a statute of repose defense to claims for concealment or conspiracy, the Florida Supreme Court, on February 1, 2016, accepted jurisdiction in Putney , quashed the Fourth DCA’s decision and reinstated the verdict. On March 15, 2016, the Florida Supreme Court granted the defendants’ motion for clarification in an order stating that remand was for reconsideration only on the issue of the statute of repose. On August 31, 2016, t he Fourth DCA entered a new opinion following remand from the Florida Supreme Court. The court reinstated the punitive damages awards of $2.5 million each against RJR Tobacco and the remaining defendant. The court’s opinion that previously granted remittitur of the compensatory damages awards still stands. The matter is remanded to the trial court for further proceedings.
On April 21, 2010, in Grossman v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), the jury, in Phase I of a retrial that followed a mistrial, returned a verdict for the plaintiff. On April 29, 2010, the jury in Phase II of the retrial found for the plaintiff on the strict liability claim and for RJR Tobacco on the negligence, warranty, and intentional tort claims; awarded $1.9 million in compensatory damages; found RJR Tobacco 25% at fault, the decedent 70% at fault, and the decedent’s spouse 5% at fault; and did not reach the issue of entitlement to punitive damages. In June 2010, the trial court entered final judgment against RJR Tobacco in the amount of approximately $484,000 in compensatory damages. In June 2012, the Fourth DCA affirmed the trial court’s judgment, but remanded for a new trial on all Phase II issues. On July 31, 2013, the jury in the second retrial found for the plaintiff on the intentional tort claims, awarded $15.35 million in compensatory damages, found the decedent 25% at fault and RJR Tobacco 75% at fault, and awarded $22.5 million in punitive damages. The trial court entered final judgment in August 2013 and did not include a reduction for comparative fault. RJR Tobacco appealed, posted a supersedeas bond in the amount of $5 million, and the plaintiff cross appealed. On January 4, 2017, the Fourth DCA ordered the award of compensatory damages be reduced to reflect the comparative
108
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
fault allocation assigned by the jury, but otherwise affirmed the final judgment. RJR Tobacco filed a motion for rehearing on February 6, 2017. A decision is pending.
On May 20, 2010, in Buonomo v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $5.2 million in compensatory damages; found RJR Tobacco 77.5% at fault and the decedent 22.5% at fault; and awarded $25 million in punitive damages. In accordance with a Florida statute, the trial court later reduced the punitive damage award to $15.7 million – three times the compensatory damages award of $5.2 million and entered final judgment in the amount of $4.06 million in compensatory damages and $15.7 million in punitive damages. In September 2013, the Fourth DCA affirmed the judgment and damages award to the plaintiff on strict liability and negligence, held that the trial court was not bound to hold punitive damages at three times compensatory damages, and reversed the judgment entered for the plaintiff on the claims for fraudulent concealment and conspiracy to commit fraud by concealment due to the erroneous striking of RJR Tobacco’s statute of repose defense. As a result, the punitive damages award was set aside and remanded for a new trial. In October 2014, the trial court found that the original $25 million punitive damages award was not excessive and would be reinstated if the plaintiff prevails on the repose issue and, in April 2015, entered an amended judgment against RJR Tobacco in the amount of approximately $29.1 million from which RJR Tobacco appealed. After its April 2, 2015, ruling in Hess v. Philip Morris USA Inc. that Engle Progeny defendants cannot raise a statute of repose defense to claims for concealment or conspiracy, the Florida Supreme Court, on January 26, 2016, accepted jurisdiction in Buonomo , quashed the Fourth DCA’s decision, and reinstated the jury verdict. RJR Tobacco’s motion for clarification was denied on March 21, 2016. In the appeal of the amended final judgment, on September 22, 2016, the Fourth DCA affirmed the amended final judgment, per curiam . RJR Tobacco’s motion for rehearing was denied in October 2016. The deadline for RJR Tobacco to file a petition for writ of certiorari with the U.S. Supreme Court is March 26, 2017.
On October 15, 2010, in Frazier v. Philip Morris USA Inc . (Cir. Ct. Miami-Dade County, Fla., filed 2007), a case now known as Russo v. Philip Morris USA Inc. , a jury found for the defendants based on the statute of limitations. In February 2011, the trial court entered final judgment for the defendants. In April 2012, the Third DCA reversed the trial court’s judgment, directed entry of judgment in the plaintiff’s favor and ordered a new trial. On April 2, 2015, the Florida Supreme Court, in its ruling in Hess v. Philip Morris USA Inc. , approved the decision of the Third DCA. On April 23, 2015, the jury found for the defendants, including RJR Tobacco, on the issue of addiction causation, and the trial court entered final judgment for the defendants in May 2015. In June 2015, the plaintiff appealed to the Third DCA, and the defendants cross appealed. On October 19, 2016, the Third DCA affirmed the final judgment of the trial court. The plaintiff did not seek further review.
On April 26, 2011, in Andy Allen v. R. J. Reynolds Tobacco Co . (Cir. Ct. Duval County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $6 million in compensatory damages; found RJR Tobacco 45% at fault, the decedent 40% at fault, and the remaining defendant 15% at fault; and awarded $17 million in punitive damages against each defendant. The trial court entered final judgment against RJR Tobacco in the amount of $19.7 million in May 2011 and, in October 2011, entered a remittitur of the punitive damages to $8.1 million. In May 2013, the First DCA reversed and remanded the case for a new trial. On November 24, 2014, the jury in the retrial found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $3.1 million in compensatory damages; found the decedent 70% at fault, RJR Tobacco 24% at fault, and the remaining defendant to be 6% at fault; and found that the plaintiff was entitled to punitive damages. On November 26, 2014, the jury awarded approximately $7.75 million in punitive damages against each defendant. In August 2015, the trial court entered final judgment against RJR Tobacco and the remaining defendant, jointly and severally, in the amount of approximately $3.1 million in compensatory damages and $7.75 million in punitive damages from each defendant. In September 2015, the defendants filed a notice of appeal to the First DCA, and RJR Tobacco posted a supersedeas bond in the amount of approximately $2.5 million. Oral argument occurred on November 2, 2016. A decision is pending.
On May 17, 2012, in Calloway v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $20.5 million in compensatory damages; found the decedent 20.5% at fault, RJR Tobacco 27% at fault, Lorillard Tobacco 18% at fault, and the remaining defendants collectively 34.5% at fault; and found that the plaintiff was entitled to punitive damages. On May 31, 2012, the jury awarded punitive damages in the amount of $17.25 million against RJR Tobacco, $12.6 million against Lorillard Tobacco, and $25 million collectively against the remaining defendants. The trial court later determined that the jury’s apportionment of comparative fault did not apply to the compensatory damages award and, in August 2012, entered final judgment. On January 6, 2016, the Fourth DCA reversed the fraudulent concealment and conspiracy claims, reversed the punitive damages award, and remanded the case for a new trial on those issues. On September 23, 2016, the Fourth DCA, sitting en banc, reversed the judgment in its entirety and remanded the case for a new trial. The new trial has not been scheduled. The plaintiff filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court on October 21, 2016. A decision is pending.
On October 17, 2012, in James Smith v. R. J. Reynolds Tobacco Co . (U.S.D.C. M.D. Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $600,000 in compensatory damages; found the
109
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
decedent 45% at fault and RJR Tobacco 55% at fault; and found that the plaintiff was entitled to punitive damages. On October 18, 2012, the jury awarded $20,000 in punitive damages. The trial court entered final judgment against RJR Tobacco in the amount of $620,000. RJR Tobacco appealed to the Eleventh Circuit and posted a supersedeas bond in the amount of approximately $620,000. Oral argument occurred on October 17, 2014. A decision is pending .
On February 11, 2013, in Evers v. R. J. Reynolds Tobacco Co. (Cir. Ct. Hillsborough County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $3.23 million in compensatory damages; found the decedent 31% at fault, RJR Tobacco 60% at fault and Lorillard Tobacco 9% at fault; and found that the plaintiff was entitled to punitive damages from RJR Tobacco but not from Lorillard Tobacco. On February 12, 2013, the jury awarded $12.36 million in punitive damages against RJR Tobacco. In March 2013, the trial court granted the defendants’ post-trial motions for directed verdict on fraudulent concealment, conspiracy and punitive damages and set aside the $12.36 million punitive damages award. The trial court entered final judgment in the amount of $1.77 million against RJR Tobacco and approximately $266,000 against Lorillard Tobacco. On November 6, 2015, the Second DCA concluded that the trial court erred in granting the defendants’ motion for directed verdict on claims for fraud by concealment and conspiracy to commit fraud by concealment, and reversed and reinstated the jury’s verdict on those two claims. As a result, the punitive damages award was reinstated. On remand, the jury’s verdict was reinstated. On March 14, 2016, the trial court entered an amended final judgment against RJR Tobacco in the amount of $2.95 million in compensatory damages and $12.36 million in punitive damages. In April 2016, RJR Tobacco appealed to the Second DCA and posted a supersedeas bond in the amount of $5 million. Oral argument occurred on February 7, 2017. A decision is pending.
On February 13, 2013, in Schoeff v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $10.5 million in compensatory damages; found the decedent 25% at fault and RJR Tobacco 75% at fault; and found that the plaintiff was entitled to punitive damages. On February 14, 2013, the jury awarded $30 million in punitive damages. In April 2013, the trial court entered final judgment against RJR Tobacco in the amount of $7.88 million in compensatory damages and $30 million in punitive damages. On November 4, 2015, the Fourth DCA reversed the punitive damages portion of the final judgment and remanded the case to the trial court, directing the trial court to grant RJR Tobacco’s motion for remittitur and, if RJR Tobacco does not agree with the remitted amount, to hold a new trial on punitive damages. On May 26, 2016, the Florida Supreme Court accepted jurisdiction of the case. Oral argument is scheduled for March 8, 2017.
On March 20, 2013, in Marotta v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), the jury, in a retrial following a mistrial, found for the plaintiff on the strict liability claim and for RJR Tobacco on the negligence and intentional tort claims, awarded $6 million in compensatory damages, found the decedent 42% at fault and RJR Tobacco 58% at fault, and did not reach the issue of entitlement to punitive damages. The trial court later entered final judgment against RJR Tobacco in the amount of $3.48 million. On January 6, 2016, the Fourth DCA affirmed, disagreeing with the Eleventh Circuit panel decision in Graham , discussed below, regarding whether the plaintiff’s claims are preempted. On March 8, 2016, the Florida Supreme Court accepted jurisdiction of the case. Oral argument occurred on November 1, 2016. A decision is pending.
On April 1, 2013, in Searcy v. R. J. Reynolds Tobacco Co . (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $6 million in compensatory damages; found the decedent 40% at fault, RJR Tobacco 30% at fault and the remaining defendant 30% at fault; and awarded $10 million in punitive damages against each defendant. The trial court later entered final judgment against RJR Tobacco in the amount of $6 million in compensatory damages and $10 million in punitive damages. In September 2013, the trial court granted the defendants’ motion for a new trial, or in the alternative, reduction or remittitur of the damages awarded to the extent it sought remittitur of the damages. The compensatory damage award was remitted to $1 million, and the punitive damage award was remitted to $1.67 million against each defendant. The plaintiff filed a notice of acceptance of remittitur in November 2013, and the trial court issued an amended final judgment. The defendants appealed to the Eleventh Circuit, and RJR Tobacco posted a supersedeas bond in the amount of approximately $2.2 million. Oral argument occurred on October 17, 2014. A decision is pending.
On May 2, 2013, in David Cohen v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $2.06 million in compensatory damages; found the decedent 40% at fault, RJR Tobacco 30% at fault, Lorillard Tobacco 20% at fault and the remaining defendant 10% at fault; and did not reach the issue of entitlement to punitive damages. In May 2013, the trial court entered final judgment against RJR Tobacco in the amount of $617,000 and against Lorillard Tobacco in the amount of approximately $411,000. In July 2013, the court granted the defendants’ motion for a new trial due to the plaintiff’s improper arguments during closing. The new trial date has not been scheduled. The plaintiff filed a notice of appeal to the Fourth DCA, and the defendants filed a notice of cross appeal. On September 7, 2016, the Fourth DCA affirmed the trial court’s order granting RJR Tobacco’s motion for a new trial. The plaintiff filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court on October 10, 2016. A decision is pending.
110
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
On May 23, 2013, in Earl Graham v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $2.75 million in compensatory damages; found the decedent 70% at fault, RJR Tobacco 20% at fault, and the remaining defendant 10% at fault, and did not reach the issue of entitlement to punitive damages. In May 2013, the trial court entered final judgment against RJR Tobacco in the amount of $550,000. On April 8, 2015, the Eleventh Circuit reversed and ordered entry of judgment for RJR Tobacco. The Eleventh Circuit held that federal law impliedly preempts claims for strict liability and negligence based on the defect and negligence findings from Engle . On January 21, 2016, the plaintiff’s motion for rehearing en banc was granted, and the panel’s decision was vacated. On March 23, 2016, the Eleventh Circuit requested briefing on the issues of whether plaintiff’s claims are preempted and, if not, whether the defendants’ due process rights are violated. Oral argument occurred on June 21, 2016. A decision is pending.
On June 4, 2013, in Starr-Blundell v. R. J. Reynolds Tobacco Co. (Cir. Ct. Duval County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $500,000 in compensatory damages; found the decedent 80% at fault, RJR Tobacco 10% at fault and the remaining defendant 10% at fault; and did not reach the issue of entitlement to punitive damages. In November 2013, the trial court entered final judgment in the amount of $50,000 against each defendant. On May 29, 2015, the First DCA affirmed the final judgment of the trial court, per curiam . On June 29, 2015, the plaintiff filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court. On May 24, 2016, the Florida Supreme Court accepted jurisdiction of the case, quashed the decision of the First DCA, and remanded the case for reconsideration in light of Soffer . On September 6, 2016, the First DCA, per curiam , reversed and remanded its May 29, 2015 opinion to the trial court for reconsideration in light of the decision in Soffer . The trial court is considering the parties’ submissions regarding next steps in the case.
On June 14, 2013, in Skolnick v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $2.56 million in compensatory damages; found the decedent 40% at fault, RJR Tobacco 30% at fault and the remaining defendant 30% at fault; and did not reach the issue of entitlement to punitive damages. In July 2013, the trial court entered final judgment against RJR Tobacco in the amount of $766,500. On July 15, 2015, the Fourth DCA set aside the judgment and ordered a partial new trial finding that the strict liability and negligence claims, on which the plaintiff had prevailed, were barred by a prior settlement entered into by the plaintiff in a separate action. The Fourth DCA also held that the plaintiff’s concealment and conspiracy claims, on which the defendants had prevailed, must be re-tried due to an erroneous jury instruction on the statute of repose. The new trial has not been scheduled .
On September 20, 2013, in Gafney v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $5.8 million in compensatory damages; found the decedent 34% at fault, RJR Tobacco 33% at fault and Lorillard Tobacco 33% at fault; and did not reach the issue of entitlement to punitive damages. In September 2013, the trial court entered final judgment against RJR Tobacco in the amount of $1.9 million and against Lorillard Tobacco in the amount of $1.9 million. On March 23, 2016, the Fourth DCA reversed the judgment of the trial court and remanded for a new trial due to improper comments made to the jury during plaintiff’s counsel’s closing arguments. In August 2016, the Florida Supreme Court declined to accept jurisdiction of the case. The new trial has not been scheduled.
On February 27, 2014, in Banks v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $0 in compensatory damages; found the decedent 85% at fault, RJR Tobacco 15% at fault, and the remaining defendant 0% at fault; and did not reach the issue of entitlement to punitive damages. In May 2014, the trial court entered final judgment in favor of RJR Tobacco and the other defendant. The plaintiff appealed to the Fourth DCA, and the defendants cross appealed. On October 20, 2016, the Fourth DCA affirmed the judgment of the trial court, per curiam . The plaintiff did not seek further review.
On May 15, 2014, in Burkhart v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $5 million in compensatory damages; found the plaintiff 50% at fault, RJR Tobacco 25% at fault, Lorillard Tobacco 10% at fault and the remaining defendant 15% at fault; and found that the plaintiff was entitled to punitive damages. On May 16, 2014, the jury awarded punitive damages of $1.25 million against RJR Tobacco, $500,000 against Lorillard Tobacco, and $750,000 against the remaining defendant. In June 2014, the trial court entered final judgment without a reduction for comparative fault. The defendants appealed to the Eleventh Circuit. Oral argument occurred on September 29, 2015. A decision is pending.
On June 23, 2014, in Bakst v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a case now known as Odom v. R. J. Reynolds Tobacco Co. , a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded approximately $6 million in compensatory damages; found the decedent 25% at fault and RJR Tobacco 75% at fault; and found that the plaintiff was entitled to punitive damages. On June 23, 2014, the jury awarded $14 million in punitive damages. The
111
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
trial court later entered final judgment against RJR Tobacco in the amount of $4.5 million in compensatory damages and $14 million in punitive damages. RJR Tobacco appealed to the Fourth DCA and posted a supersedeas bond in the amount of $5 million. On November 30, 2016, the Fourth DCA reversed the trial court’s judgment and remanded the case with directions that the trial court grant the motion for remittitur or order a new trial on damages only. RJR Tobacco filed a motion for rehearing on January 9, 2017, requesting that the Fourth DCA grant rehearing or withdraw the section of its opinion addressing the propriety of the plaintiff’s closing argument or grant rehearing en banc on the improper argument issue. A decision is pending.
On July 17, 2014, in Robinson v. R. J. Reynolds Tobacco Co. (Cir. Ct. Escambia County, Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $16.9 million in compensatory damages; found the decedent 29.5% at fault and RJR Tobacco 70.5% at fault; and found that the plaintiff was entitled to punitive damages. On July 18, 2014, the jury awarded $23.6 billion in punitive damages. In July 2014, the trial court entered partial judgment on compensatory damages against RJR Tobacco in the amount of $16.9 million. On January 27, 2015, the trial court remitted the punitive damages award to approximately $16.9 million. In February 2015, RJR Tobacco filed an objection to the remitted award of punitive damages and a demand for a new trial on damages. The trial court granted a new trial on the amount of punitive damages only. The new trial on punitive damages has been stayed pending RJR Tobacco’s appeal to the First DCA of the partial judgment of compensatory damages and of the order granting a new trial on the amount of punitive damages only. RJR Tobacco posted a supersedeas bond in the amount of $5 million. Briefing on the merits is complete. Oral argument occurred on May 24, 2016. A decision is pending.
On July 31, 2014, in Harris v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $400,000 in compensatory damages for the wrongful death claim and $1.3 million in compensatory damages for the survival claim; allocated fault to the decedent (60% survival/70% wrongful death), RJR Tobacco (15% survival/10% wrongful death), Lorillard Tobacco (10% survival/10% wrongful death), and the remaining defendant (15% survival/10% wrongful death), and found that the plaintiff was not entitled to punitive damages. In December 2014, the trial court entered final judgment. Post-trial motions are pending, but in April 2015, the court stayed all post-trial proceedings pending resolution of the petition for en banc consideration in Graham , described above.
On August 27, 2014, in Wilcox v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $7 million in compensatory damages; found the decedent 30% at fault and RJR Tobacco 70% at fault; and found that the plaintiff was entitled to punitive damages. On August 28, 2014, the jury awarded $8.5 million in punitive damages. In September 2014, final judgment was entered against RJR Tobacco in the amount of $4.9 million in compensatory damages and $8.5 million in punitive damages. RJR Tobacco appealed to the Third DCA and posted a supersedeas bond in the amount of $5 million. On July 27, 2016, the Third DCA affirmed the final judgment, per curiam . After further evaluation of the case, RJR Tobacco paid approximately $17 million in satisfaction of the judgment on October 27, 2016.
On August 28, 2014, in Irimi v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and certain intentional tort claims and for one or more defendants on certain intentional tort claims; awarded approximately $3.1 million in compensatory damages; found the decedent 70% at fault, RJR Tobacco 14.5% at fault, Lorillard Tobacco 14.5% at fault and the remaining defendant 1% at fault; and did not reach the issue of entitlement to punitive damages. The trial court entered final judgment against each of RJR Tobacco and Lorillard Tobacco in the amount of approximately $453,000 and against the remaining defendant in the amount of approximately $31,000. On January 29, 2015, the court granted the defendants’ motion for a new trial. The plaintiff appealed to the Fourth DCA, and the defendants cross appealed. Briefing is complete. Oral argument has not been scheduled.
On October 10, 2014, in Lourie v. R. J. Reynolds Tobacco Co. (Cir. Ct. Hillsborough County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded approximately $1.37 million in compensatory damages; found the decedent 63% at fault, RJR Tobacco 3% at fault, Lorillard Tobacco 7% at fault and the remaining defendant 27% at fault; and found that the plaintiff was not entitled to punitive damages. The trial court later entered final judgment. The defendants appealed to the Second DCA in November 2014. RJR Tobacco posted a supersedeas bond in the amount of approximately $41,000, and Lorillard Tobacco posted a supersedeas bond in the amount of $96,000. On August 10, 2016, the Second DCA affirmed the final judgment. The defendants filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court on September 8, 2016. On September 9, 2016, the Florida Supreme Court stayed proceedings pending disposition of Marotta v. R. J. Reynolds Tobacco Co., described above.
On October 20, 2014, in Kerrivan v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $15.8 million in compensatory damages; found the plaintiff 19% at fault, RJR Tobacco 31% at fault and the remaining defendant 50% at fault; and found that the plaintiff was entitled to punitive damages. On October 22, 2014, the jury awarded $9.6 million in punitive damages against RJR Tobacco and $15.7 million against the remaining defendant. In November 2014, the trial court entered final judgment. RJR Tobacco filed its post-trial motions on December
112
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
11, 2014. In May 2015, the trial court deferred briefing and directed the parties to notify the court when the mandate has been issued in Graham or Searcy , described above.
On November 5, 2014, in Bishop v. R. J. Reynolds Tobacco Co. (Cir. Ct. Orange County, Fla., filed 2007), a jury found that the decedent was not a class member, which resulted in a verdict for the defendants, including RJR Tobacco. In November 2014, the trial court entered final judgment. The plaintiff appealed to the Fifth DCA, and the defendants cross appealed. On September 27, 2016, the Fifth DCA affirmed the final judgment, per curiam . The plaintiff did not seek further review.
On November 18, 2014, in Schleider v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and certain intentional tort claims and for RJR Tobacco on certain intentional tort claims, awarded $21 million in compensatory damages, found the decedent 30% at fault and RJR Tobacco 70% at fault, and found that the plaintiff was not entitled to punitive damages. In June 2015, the trial court entered final judgment against RJR Tobacco in the amount of $14.7 million. RJR Tobacco appealed to the Third DCA and posted a supersedeas bond in the amount of $5 million. Briefing is underway.
On November 21, 2014, in Perrotto v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $4.1 million in compensatory damages; found the decedent 49% at fault, RJR Tobacco 20% at fault, Lorillard Tobacco 6% at fault and the remaining defendant 25% at fault; and did not reach the issue of entitlement to punitive damages. Final judgment was entered against RJR Tobacco in the amount of approximately $ 818,000 and against Lorillard Tobacco in the amount of approximately $245,000. In May 2016, the court granted the plaintiff’s motion for a new trial on punitive damages but denied it in all other respects. The new trial is scheduled to begin June 5, 2017.
On December 19, 2014, in Haliburton v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2008), a jury found that the plaintiff’s claims were time-barred, which resulted in a verdict for RJR Tobacco. On April 14, 2015, the trial court entered final judgment in favor of RJR Tobacco. The plaintiff appealed to the Fourth DCA, and RJR Tobacco cross appealed. Briefing is complete. On December 1, 2016, the Fourth DCA entered an order dispensing with oral argument. A decision is pending.
On January 29, 2015, in Ellen Gray v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for RJR Tobacco on the intentional tort claims, awarded $6 million in compensatory damages, and found the decedent 50% at fault and RJR Tobacco 50% at fault. Although the jury ignored an instruction on the verdict form and found that the plaintiff was entitled to punitive damages, there was no punitive damage award. In February 2015, the trial court entered final judgment against RJR Tobacco in the amount of $3 million. Post-trial motions are pending. On June 10, 2015, the court granted RJR Tobacco’s motion to stay the case pending resolution of the petition for en banc consideration in Graham , described above.
On February 10, 2015, in Hecht v. R. J. Reynolds Tobacco Co . (U.S.D.C. M.D. Fla., filed 2008), a jury found that the plaintiff’s claims were time-barred, which resulted in a verdict in favor of RJR Tobacco. Post-trial proceedings have been stayed until resolution of the petition for en banc consideration in Graham , described above. However, the trial court entered final judgment in favor of RJR Tobacco on January 7, 2016. On February 2, 2016, the plaintiff appealed to the Eleventh Circuit. Oral argument occurred on January 26, 2017. A decision is pending.
On February 11, 2015, in Sowers v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for RJR Tobacco on the intentional tort claims, awarded $4.25 million in compensatory damages, found the decedent 50% at fault and RJR Tobacco 50% at fault, and did not reach the issue of entitlement to punitive damages. On February 12, 2015, the trial court entered final judgment against RJR Tobacco in the amount of approximately $2.13 million. Post-trial motions are pending. On April 17, 2015, the court stayed post-trial proceedings until resolution of the petition for en banc consideration in Graham , described above.
On February 24, 2015, in Caprio v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), a jury advised the trial court that it could not reach a unanimous verdict, but the trial court directed the jury to complete the verdict form on those individual verdict questions where there was unanimous agreement. In the partially completed verdict, the jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; found the plaintiff 40% at fault, RJR Tobacco 20% at fault, Lorillard Tobacco 10% at fault, and the remaining defendants 30% at fault; and awarded $559,000 in economic damages. The jury did not answer the verdict form questions relating to noneconomic damages and entitlement to punitive damages. In May 2015, the court denied the defendants’ motion for a mistrial and advised that it accepted the questions answered by the jurors as a partial verdict. A new trial will be held on the remaining issues, including comparative fault allocation. The defendants appealed to the Fourth DCA. On January 22, 2017, the defendants dismissed their appeal. The case remains pending in the trial court.
113
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
On February 26, 2015, in Zamboni v. R. J. Reynolds Tobacco Co. (U.S.D.C. M.D. Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded the plaintiff $340,000 in compensatory damages; found the decedent 60% at fault, RJR Tobacco 30% at fault and the remaining defendant 10% at fault; and did not reach the issue of entitlement to punitive damages. Post-trial motions are pending. The court stayed the case pending resolution of the petition for en banc consideration in Graham , described above.
On March 23, 2015, in Pollari v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $10 million in compensatory damages; found the decedent 15% at fault, RJR Tobacco 42.5% at fault and the remaining defendant 42.5% at fault; and found that the plaintiff was entitled to punitive damages. On March 25, 2015, the jury awarded $1.5 million in punitive damages against each defendant. The trial court later entered final judgment against the defendants in the amount of $10 million in compensatory damages and, against each defendant, $1.5 million in punitive damages. On January 12, 2016, the trial court entered a second amended final judgment against RJR Tobacco that awarded $4.25 million in compensatory damages and $1.5 million in punitive damages. The defendants appealed to the Fourth DCA, RJR Tobacco posted a supersedeas bond in the amount of $2.5 million, and the plaintiff cross appealed. Briefing is complete. Oral argument has not been scheduled.
On March 26, 2015, in Gore v. R. J. Reynolds Tobacco Co . (Cir. Ct. Indian River County, Fla., filed 2008), a jury, in a retrial following a mistrial, found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $2 million in compensatory damages; found the decedent 54% at fault, RJR Tobacco 23% at fault and the remaining defendant 23% at fault; and found that the plaintiff was not entitled to punitive damages. In September 2015, the trial court entered final judgment against RJR Tobacco and the remaining defendant, each in the amount of $460,000. RJR Tobacco posted a supersedeas bond in the amount of $460,000 in September 2015, and in October 2015, the defendants appealed to the Fourth DCA, and the plaintiff cross appealed. Briefing is underway.
On April 17, 2015, in Ryan v. R. J. Reynolds Tobacco Co . (Cir. Ct. Broward County, Fla., filed 2007), a jury, in a retrial following a mistrial, found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $21.5 million in compensatory damages; found the plaintiff 35% at fault and RJR Tobacco 65% at fault; and found that the plaintiff was entitled to punitive damages. On April 21, 2015, the jury awarded $25 million in punitive damages. In May 2015, the trial court entered final judgment against RJR Tobacco in the amount of $21.5 million in compensatory damages and $25 million in punitive damages. On April 29, 2016, the court entered an amended final judgment against RJR Tobacco in the amount of approximately $14 million in compensatory damages and $25 million in punitive damages. RJR Tobacco filed a notice of appeal to the Fourth DCA and posted a supersedeas bond in the amount of $5 million on May 27, 2016. The plaintiff filed a notice of cross appeal on June 13, 2016. Briefing is underway.
On June 18, 2015, in Hardin v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for RJR Tobacco on the intentional tort claims, awarded $776,000 in compensatory damages, found the decedent 87% at fault and RJR Tobacco 13% at fault, and found that the plaintiff was not entitled to punitive damages. In June 2015, the trial court entered final judgment against RJR Tobacco in the amount of $100,880. Post-trial motions were denied in January 2016. The plaintiff appealed to the Third DCA, and RJR Tobacco cross appealed. Oral argument occurred on December 7, 2016. On December 21, 2016, the Third DCA remanded the case for a new trial limited to the issue of punitive damages for the plaintiff’s non-intentional tort claims. Otherwise, the final judgment was affirmed. Neither party sought further review. The new trial has not been scheduled.
On July 13, 2015, in McCoy v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $1.5 million in compensatory damages; found the decedent 35% at fault, RJR Tobacco 25% at fault, Lorillard Tobacco 20% at fault and the remaining defendant 20% at fault; and found that the plaintiff was entitled to punitive damages. On July 17, 2015, the jury awarded $3 million in punitive damages against each defendant. In August 2015, the trial court entered final judgment against RJR Tobacco, RJR Tobacco as successor-by-merger to Lorillard Tobacco, and the remaining defendant, jointly and severally, in the amount of $1.5 million in compensatory damages and, against each of them, $3 million in punitive damages. On January 4, 2016, the trial court entered an amended final judgment in the amount of $370,000 in compensatory damages and $3 million in punitive damages against RJR Tobacco, $300,000 in compensatory damages and $3 million in punitive damages against RJR Tobacco as successor-by-merger to Lorillard Tobacco, and $300,000 in compensatory damages and $3 million in punitive damages against the remaining defendant. RJR Tobacco appealed to the Fourth DCA and posted a supersedeas bond in the amount of approximately $3.35 million, and the plaintiff filed a notice of cross appeal. Briefing is underway.
On July 29, 2015, in Collar v. R. J. Reynolds Tobacco Co. (Cir. Ct. Indian River County, Fla., filed 2008), a jury found that the plaintiff was not a class member, which resulted in a verdict for the defendants, including RJR Tobacco. In September 2015, the trial
114
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
court entered final judgment. The plaintiff appealed to the Fourth DCA, and the defendants cross appealed. Oral argument is scheduled for March 22, 2017.
On August 6, 2015, in Block v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded approximately $1.03 million in compensatory damages; found the decedent 50% at fault and RJR Tobacco 50% at fault; and found that the plaintiff was entitled to punitive damages. On August 7, 2015, the jury awarded $800,000 in punitive damages. In September 2015, the trial court entered final judgment against RJR Tobacco in the amount of approximately $926,000 in compensatory damages and $800,000 in punitive damages. On December 9, 2015, the trial court granted RJR Tobacco’s motion to alter or amend the judgment in part in light of the Fourth DCA’s decision in Schoeff v. R. J. Reynolds Tobacco Co. , described above, finding that the intentional tort exception in Section 768.81, Florida Statutes, does not apply to the fraud and conspiracy claims brought by Engle Progeny plaintiffs. As a result, an amended final judgment was entered in the amount of approximately $463,000 in compensatory damages and $800,000 in punitive damages. RJR Tobacco appealed to the Fourth DCA and posted a supersedeas bond in the amount of approximately $1.3 million, and the plaintiff filed a notice of cross appeal. Briefing is complete. On February 3, 2017, the Fourth DCA entered an order dispensing with oral argument. A decision is pending.
On September 1, 2015, in Lewis v. R. J. Reynolds Tobacco Co . (Cir. Ct. Volusia County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for RJR Tobacco on the intentional tort claims, awarded $750,000 in compensatory damages, found the decedent 75% at fault and RJR Tobacco 25% at fault, and found that the plaintiff was not entitled to punitive damages. Final judgment was entered against RJR Tobacco in the amount of $187,500 in March 2016. RJR Tobacco appealed to the Fifth DCA and posted a supersedeas bond in the amount of $187,500. Briefing is complete. Oral argument has not been scheduled.
On September 8, 2015, in Cooper v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $4.5 million in compensatory damages; found the plaintiff 50% at fault, RJR Tobacco 40% at fault and the remaining defendant 10% at fault; and did not reach the issue of entitlement to punitive damages. Post-trial motions were denied on December 2, 2015. In February 2016, the trial court entered final judgment against RJR Tobacco in the amount of approximately $1.2 million. The defendants appealed to the Fourth DCA, and the plaintiff cross appealed. RJR Tobacco posted a supersedeas bond in the amount of approximately $1.2 million. Briefing is complete. Oral argument has not been scheduled.
On September 10, 2015, in Duignan v. R. J. Reynolds Tobacco Co. (Cir. Ct. Pinellas County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $6 million in compensatory damages; found the decedent 33% at fault, RJR Tobacco 30% at fault, and the remaining defendant 37% at fault; and found that the plaintiff was entitled to punitive damages. On September 11, 2015, the jury awarded $2.5 million in punitive damages against RJR Tobacco and $3.5 million in punitive damages against the remaining defendant. The trial court later entered final judgment against RJR Tobacco and the remaining defendant in the amount of $6 million in compensatory damages and $2.5 million in punitive damages against RJR Tobacco and $3.5 million in punitive damages against the remaining defendant. The defendants appealed to the Second DCA, and RJR Tobacco posted a supersedeas bond in the amount of approximately $2.3 million. Oral argument occurred on December 5, 2016. A decision is pending.
On September 10, 2015, in O’Hara v. R. J. Reynolds Tobacco Co. (Cir. Ct. Escambia County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $14.7 million in compensatory damages; found the decedent 15% at fault and RJR Tobacco 85% at fault; and found that the plaintiff was entitled to punitive damages. On September 11, 2015, the jury awarded $20 million in punitive damages. In September 2015, the trial court entered final judgment against RJR Tobacco in the amount of $14.7 million in compensatory damages and $20 million in punitive damages. RJR Tobacco appealed to the First DCA and posted a supersedeas bond in the amount of $5 million. Briefing is complete. Oral argument has not been scheduled.
On September 22, 2015, in Suarez v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2008), a jury found that the decedent was not a class member, which resulted in a verdict for the defendants, including RJR Tobacco. In November 2015, the trial court entered final judgment. The plaintiff appealed to the Third DCA, and the defendants cross appealed. On October 19, 2016, the Third DCA affirmed the judgment of the trial court, per curiam . On October 27, 2016, the plaintiff filed a motion for a written opinion and certification to the Florida Supreme Court. A decision is pending.
On October 2, 2015, in Marchese v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $1 million in compensatory damages; found the decedent 55% at fault, RJR Tobacco 22.5% at fault, and the remaining defendant 22.5% at fault; and found that the plaintiff was entitled to punitive damages. On October 6, 2015, the jury awarded $250,000 in punitive damages against each defendant. Final judgment was entered on November 5, 2015. On May 17, 2016, an amended final judgment was entered in the amount of $450,000 in
115
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
compensatory damages against RJR Tobacco and the remaining defendant, jointly and severally, and $250,000 in punitive damages against each defendant. RJR Tobacco appealed to the Fourth DCA and posted a supersedeas bond in the amount of $475,000. Briefing is underway.
On November 17, 2015, in Barbose v. R. J. Reynolds Tobacco Co. (Cir. Ct. Pasco County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $10 million in compensatory damages, found the decedent 15% at fault, RJR Tobacco 42.5% at fault and the remaining defendant 42.5% at fault; and found that the plaintiff was entitled to punitive damages. On November 18, 2015, the jury awarded $500,000 in punitive damages against each of RJR Tobacco and the other defendant. The defendants appealed to the Second DCA, and RJR Tobacco posted a supersedeas bond in the amount of $2.5 million. Briefing is complete. Oral argument has not been scheduled.
On November 20, 2015, in Fanali v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2008), a jury found that cigarette smoking was not a legal cause of the decedent’s coronary artery disease and death, which resulted in a verdict for RJR Tobacco. On December 17, 2015, the trial court entered final judgment in favor of RJR Tobacco. The plaintiff appealed to the Fourth DCA, and RJR Tobacco cross appealed. Briefing is complete. Oral argument has not been scheduled.
On November 23, 2015, in Shulman v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found that the plaintiff was not a class member, which resulted in a verdict for the defendants, including RJR Tobacco. In December 2015, the trial court entered final judgment. The plaintiff appealed to the Fourth DCA, and the defendants cross appealed. On August 11, 2016, the Fourth DCA affirmed the final judgment, per curiam . The plaintiff did not seek further review.
On November 24, 2015, in Green v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2007), a jury found that the plaintiff does not have chronic obstructive pulmonary disease, which resulted in a verdict for RJR Tobacco. Post-trial motions were denied on March 23, 2016. On April 4, 2016, final judgment was entered in favor of RJR Tobacco. The plaintiff appealed to the Third DCA, and RJR Tobacco cross appealed. Briefing is underway.
On December 9, 2015, in Monroe v. R. J. Reynolds Tobacco Co. (Cir. Ct. Gadsden County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims and for RJR Tobacco on the intentional tort claims, awarded $11 million in compensatory damages, found the plaintiff 42% at fault and RJR Tobacco 58% at fault, and did not reach the issue of entitlement to punitive damages. On December 31, 2015, the trial court entered final judgment against RJR Tobacco in the amount of $6.38 million in compensatory damages. Post-trial motions were denied on March 30, 2016. RJR Tobacco appealed to the First DCA and posted a supersedeas bond in the amount of $5 million. Oral argument is scheduled for March 7, 2017.
On December 18, 2015, in Ledoux v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $10 million in compensatory damages; found the decedent 6% at fault, RJR Tobacco 47% at fault and the remaining defendant 47% at fault; and found that the plaintiff was entitled to punitive damages. On December 22, 2015, the jury awarded $12.5 million in punitive damages against each defendant. The trial court later entered final judgment against the defendants, jointly and severally, in the amount of $10 million in compensatory damages and, against each defendant, $12.5 million in punitive damages. Post-trial motions were denied in February 2016. The defendants appealed to the Third DCA, and RJR Tobacco posted a supersedeas bond in the amount of $5 million. On May 27, 2016, RJR Tobacco filed a rider amending the supersedeas bond reducing the amount from $5 million to $2.5 million. Briefing is underway.
On January 26, 2016, in Ewing v. R. J. Reynolds Tobacco Co. (Cir. Ct. Escambia County, Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for the defendants on the intentional tort claims; awarded $240,000 in compensatory damages; found the decedent 98% at fault, RJR Tobacco 2% at fault and the remaining defendant 0% at fault, and did not reach the issue of entitlement to punitive damages. Post-trial motions were denied on February 25, 2016. Final judgment has not been entered.
On February 12, 2016, in Ahrens v. R. J. Reynolds Tobacco Co. (Cir. Ct. Pinellas County, Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $9 million in compensatory damages; found the decedent 32% at fault, RJR Tobacco 44% at fault, and the remaining defendant 24% at fault; and found that the plaintiff was entitled to punitive damages. On February 13, 2016, the jury awarded $2.5 million in punitive damages against each defendant. In February 2016, the trial court entered final judgment. Post-trial motions were denied on March 31, 2016. On April 13, 2016, RJR Tobacco appealed to the Second DCA and posted a supersedeas bond in the amount of $2.5 million. Briefing is complete. Oral argument has not been scheduled.
On March 8, 2016, in Gamble v. R. J. Reynolds Tobacco Co. (Cir. Ct. Duval County, Fla., filed 2008), a jury found for the plaintiff on class membership, but found for RJR Tobacco on addiction causation, which resulted in a verdict for RJR Tobacco. Post-
116
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
trial motions were denied on May 31, 2016. Final judgment was entered in favor of RJR Tobacco on June 9, 2016. The plaintiff appealed to the First DCA on July 8, 2016. Briefing is underway.
On April 7, 2016, in Davis v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2008), a jury found for the plaintiff on class membership, but found for RJR Tobacco on addiction causation, which resulted in a verdict for RJR Tobacco. On August 17, 2016, the court granted the plaintiff’s motion for a new trial. RJR Tobacco filed a notice of appeal to the Third DCA on August 25, 2016. Briefing is underway.
On April 21, 2016, in Turner v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $3 million in compensatory damages; found the decedent 20% at fault and RJR Tobacco 80% at fault; and found that the plaintiff was entitled to punitive damages. On April 22, 2016, the jury awarded $10 million in punitive damages. The court denied the defendant’s post-trial motions and entered judgment against RJR Tobacco in the amount of $2.4 million in compensatory damages and $10 million in punitive damages. In July 2016, RJR Tobacco filed a notice of appeal to the Fourth DCA and posted a supersedeas bond in the amount of $5 million. The plaintiff filed a notice of cross appeal in August 2016. Briefing is underway.
On April 26, 2016, in Enochs v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $21 million in compensatory damages; found the decedent 22% at fault, RJR Tobacco 66% at fault and the remaining defendant 12% at fault; and found that the plaintiff was entitled to punitive damages. On April 27, 2016, the jury awarded $6.25 million in punitive damages against each defendant. Final judgment was entered against RJR Tobacco in the amount of approximately $13.9 million in compensatory damages and $6.25 million in punitive damages on May 9, 2016. Post-trial motions were denied on May 20, 2016. The defendants appealed to the Fourth DCA, and RJR Tobacco posted a supersedeas bond in the amount of approximately $3.5 million. Briefing is underway.
On May 11, 2016, in Dion v. R. J. Reynolds Tobacco Co. (Cir. Ct. Sarasota County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $12 million in compensatory damages; found the decedent 25% at fault and RJR Tobacco 75% at fault; and found that the plaintiff was entitled to punitive damages. On May 12, 2016, the jury awarded $30,000 in punitive damages. Post-trial motions were denied on July 14, 2016. On August 9, 2016, RJR Tobacco filed a notice of appeal to the Second DCA and posted a supersedeas bond in the amount of $5 million. Briefing is underway.
On May 16, 2016, in Nally v. R. J. Reynolds Tobacco Co. (Cir. Ct. Polk County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $6 million in compensatory damages; found the decedent 25% at fault and RJR Tobacco 75% at fault; and found that the plaintiff was entitled to punitive damages. On May 17, 2016, the jury awarded $12 million in punitive damages. Final judgment was entered against RJR Tobacco in the amount of $6 million in compensatory damages and $12 million in punitive damages on May 25, 2016. Post-trial motions were denied on August 15, 2016. In September 2016, RJR Tobacco filed a notice of appeal to the Second DCA and posted a supersedeas bond in the amount of $5 million. Briefing is underway.
On May 19, 2016, in McCabe v. R. J. Reynolds Tobacco Co . (Cir. Ct. Hillsborough County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims, awarded $5 million in compensatory damages, found the decedent 70% at fault and RJR Tobacco 30% at fault, and found that the plaintiff was entitled to punitive damages. On May 20, 2016, the jury awarded $6.5 million in punitive damages. Post-trial motions are pending.
On May 31, 2016, in Durrance v. R. J. Reynolds Tobacco Co. (Cir. Ct. Highlands County, Fla., filed 2007), the court declared a mistrial due to a medical emergency. Retrial began on January 23, 2017.
On June 21, 2016, in Mooney v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2008), a jury found that the decedent’s addiction to nicotine was not a legal cause of her death, which resulted in a verdict for the defendants, including RJR Tobacco. The plaintiff’s post-trial motions were denied on November 4, 2016.
On July 1, 2016, in Sermons v. Philip Morris USA Inc. (Cir. Ct. Duval County, Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims; awarded $65,000 in compensatory damages; found the decedent 80% at fault, RJR Tobacco 5% at fault, and the remaining defendant 15% at fault; and found that the plaintiff was entitled to punitive damages. On July 6, 2016, the jury awarded $17,075 in punitive damages against RJR Tobacco and $51,225 in punitive damages against the remaining defendant. Post-trial motions are pending.
On July 19, 2016, in Varner v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence and strict liability claims; found that RJR Tobacco’s cigarettes were not a legal cause of the decedent’s
117
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
disease, which resulted in a verdict for RJR Tobacco; awarded $1.5 million in compensatory damages; found the decedent 75% at fault and the remaining defendant 25% at fault; and found that the plaintiff was not entitled to punitive damages. Final judgment was entered in favor of RJR Tobacco and against the remaining defendant in the amount of $375,000 in July 2016. The remaining defendant’s post-trial motions were denied on December 21, 2016.
On August 5, 2016, in Morales v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2007), the court declared a mistrial because a death in a juror’s family prevented the juror from deliberating. The new trial was scheduled for January 9, 2017, but has since been removed from the trial calendar.
On August 15, 2016, in Mathis v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $5 million in compensatory damages; found the decedent 45% at fault and RJR Tobacco 55% at fault; and found that the plaintiff was not entitled to punitive damages. Final judgment was entered on August 17, 2016. Post-trial motions were denied on October 24, 2016. RJR Tobacco filed a notice of appeal to the Third DCA and posted a supersedeas bond in the amount of $5 million on November 18, 2016. Briefing is underway.
On August 18, 2016, in Wilkins v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2007), a jury found that the decedent was not a class member, which resulted in a verdict for RJR Tobacco. Final judgment was entered in favor of RJR Tobacco on November 16, 2016. The plaintiff filed a notice of appeal to the Third DCA on December 16, 2016, and RJR Tobacco filed a notice of cross appeal on December 21, 2016. Briefing is underway.
On August 25, 2016, in Coursey v. R. J. Reynolds Tobacco Co. (Cir. Ct. Volusia County, Fla., filed 2007), a jury found that the decedent was not a class member, which resulted in a verdict for RJR Tobacco. The trial court denied post-trial motions and entered judgment in RJR Tobacco’s favor on September 27, 2016. On October 27, 2016, the plaintiff filed a notice of appeal to the Fifth DCA. RJR Tobacco filed a notice of cross appeal on November 8, 2016. Briefing is underway.
On September 6, 2016, in Hackimer v. R. J. Reynolds Tobacco Co . (Cir. Ct. Palm Beach County, Fla., filed 2007), a jury found that the deceased smoker knew or should have known of his chronic obstructive pulmonary disease before May 5, 1990, and, for that reason, the claims were barred by the statute of limitations, which resulted in a verdict for RJR Tobacco. Post-trial motions were denied on December 20, 2016. On January 4, 2017, final judgment was entered in favor of RJR Tobacco. The plaintiff filed a notice of appeal to the Fourth DCA on February 1, 2017. Briefing is underway.
On September 22, 2016, in Oshinsky-Blacker v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $6.15 million in compensatory damages; found the decedent 15% at fault, RJR Tobacco 25% at fault, and the remaining defendant 60% at fault; and found that the plaintiff was entitled to punitive damages. On September 23, 2016, the jury awarded $2 million in punitive damages against RJR Tobacco and $1 million in punitive damages against the remaining defendant. Post-trial motions are pending. Final judgment has not been entered.
On September 23, 2016, in Sherry Smith v. R. J. Reynolds Tobacco Co . (Cir. Ct. Volusia County, Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $3 million in compensatory damages; found the decedent 35% at fault and RJR Tobacco 65% at fault; and found that the plaintiff was not entitled to punitive damages. Post-trial motions were denied on December 14, 2016, and final judgment was entered against RJR Tobacco in the amount of $3 million. In January 2017, RJR Tobacco filed a notice of appeal to the Fifth DCA and posted a supersedeas bond in the amount of $3 million. Briefing is underway.
On September 28, 2016, in Prentice v. R. J. Reynolds Tobacco Co. (Cir. Ct. Duval County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $6.4 million in compensatory damages; found the decedent 60% at fault and RJR Tobacco 40% at fault; and found that the plaintiff was entitled to punitive damages. On September 29, 2016, the jury awarded $0 in punitive damages. Post-trial motions are pending.
On October 10, 2016, in Wallace v. R. J. Reynolds Tobacco Co. (Cir. Ct. Brevard County, Fla., filed 2007), the court declared a mistrial due to weather delays and juror unavailability. A new trial date has not been scheduled.
On October 24, 2016, in Konzelman v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded approximately $8.8 million in compensatory damages; found the decedent 15% at fault and RJR Tobacco 85% at fault; and found that the plaintiff was entitled to punitive damages. On October 26, 2016, the jury awarded $20 million in punitive damages. On December 1, 2016, post-trial motions were denied and the trial court entered final judgment against RJR Tobacco in the amount of approximately $7.48 million in compensatory damages and $20 million in punitive damages. RJR Tobacco filed a notice of appeal to the Fourth DCA and posted a supersedeas
118
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
bond in the amount of $5 million on December 22, 2016. The plaintiff filed a notice of cross appeal on January 2, 2017. Briefing is underway.
On November 1, 2016, in Maloney v. R. J. Reynolds Tobacco Co. (Cir. Ct. Lee County, Fla., filed 2007), the court declared a mistrial due to the jury’s inability to reach a unanimous verdict. The new trial is scheduled for July 5, 2017.
On November 2, 2016, in Johnston v. R. J. Reynolds Tobacco Co. (Cir. Ct. Sarasota County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded $7.5 million in compensatory damages; found the decedent 10% at fault and RJR Tobacco 90% at fault; and found that the plaintiff was entitled to punitive damages. On November 5, 2016, the jury awarded $14 million in punitive damages. Final judgment was entered against RJR Tobacco in the amount of $6.75 million in compensatory damages and $14 million in punitive damages on November 28, 2016. Post-trial motions are pending.
On November 3, 2016, in Ledo v. R. J. Reynolds Tobacco Co. (Cir. Ct. Miami-Dade County, Fla., filed 2008), a jury found for the plaintiff on the negligence and strict liability claims and for RJR Tobacco on the intentional tort claims; awarded $6 million in compensatory damages; found the decedent 51% at fault and RJR Tobacco 49% at fault; and found that the plaintiff was entitled to punitive damages. After receiving the verdict, the trial court granted a directed verdict in favor of RJR Tobacco on entitlement to punitive damages. Final judgment was entered against RJR Tobacco in the amount of $2.94 million in compensatory damages on December 22, 2016. Post-trial motions are pending.
On November 10, 2016, in Howles v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability and intentional tort claims; awarded $4 million in compensatory damages; found RJR Tobacco 50% at fault and the remaining defendant 50% at fault; and found that the plaintiff was entitled to punitive damages. On November 14, 2016, the jury awarded $3 million in punitive damages against RJR Tobacco and $3 million against the remaining defendant. Final judgment was entered against RJR Tobacco in the amount of $2 million in compensatory damages and $3 million in punitive damages against RJR Tobacco. Post-trial motions were denied on December 5, 2016. On December 30, 2016, the defendants filed a joint notice of appeal to the Fourth DCA. Briefing is underway.
On November 14, 2016, in Kloppenburg v. R. J. Reynolds Tobacco Co. (Cir. Ct. Collier County, Fla., filed 2007), a jury found that the plaintiff knew or should have known of her chronic obstructive pulmonary disease before May 5, 1990, and, for that reason, the claims were barred by the statute of limitations, which resulted in a verdict for RJR Tobacco. Final judgment was entered in favor of RJR Tobacco on November 29, 2016. The plaintiff’s post-trial motions were denied on December 1, 2016. The plaintiff did not seek further review.
On November 16, 2016, in Ford v. R. J. Reynolds Tobacco Co. (Cir. Ct. Palm Beach County, Fla., filed 2008), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded approximately $1.02 million in compensatory damages; found the plaintiff 85% at fault and RJR Tobacco 15% at fault; and found that the plaintiff was not entitled to punitive damages. Post-trial motions are pending.
On November 16, 2016, in Stanley Martin v. R. J. Reynolds Tobacco Co. (Cir. Ct. Broward County, Fla., filed 2007), a jury found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded approximately $5.41 million in compensatory damages; found the decedent 32% at fault, RJR Tobacco 22% at fault and the remaining defendant 46% at fault; and found that the plaintiff was entitled to punitive damages. On November 18, 2016, the jury awarded $200,000 in punitive damages against RJR Tobacco and $450,000 against the remaining defendant. Post-trial motions are pending.
On December 16, 2016, in Dubinsky v. R. J. Reynolds Tobacco Co. (Cir. Ct. Brevard County, Fla., filed 2008), a jury found that the decedent was not a class member, which resulted in a verdict for the defendants, including RJR Tobacco. Post-trial motions are pending.
On December 16, 2016, in Pardue v. R. J. Reynolds Tobacco Co. (Cir. Ct. Alachua County, Fla., filed 2008), a jury, in a retrial following a mistrial, found for the plaintiff on the negligence, strict liability, and intentional tort claims; awarded approximately $5.9 million in compensatory damages; found the decedent 25% at fault, RJR Tobacco 50% at fault, and the remaining defendant 25% at fault; and found that the plaintiff was entitled to punitive damages. On December 19, 2016, the jury awarded $6.75 million in punitive damages against RJR Tobacco and $6.75 million in punitive damages against the remaining defendant. Final judgment was entered against RJR Tobacco in the amount of approximately $5.9 million in compensatory damages (jointly and severally with the remaining defendant) and, against each defendant, $6.75 million in punitive damages on December 29, 2016. Post-trial motions are pending.
119
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Broin v. Philip Morris, Inc. (Cir. Ct. Miami-Dade County, Fla., filed 1991), was a class action brought on behalf of flight attendants alleged to have suffered from diseases or ailments caused by exposure to ETS in airplane cabins. In October 1997, RJR Tobacco, Lorillard Tobacco, B&W and other cigarette manufacturer defendants settled Broin , agreeing to pay a total of $300 million in three annual $100 million installments, allocated among the companies by market share, to fund research on the early detection and cure of diseases associated with tobacco smoke. It also required those companies to pay a total of $49 million for the plaintiffs’ counsel’s fees and expenses. RJR Tobacco’s portion of these payments was approximately $86 million; Lorillard Tobacco’s was approximately $57 million; and B&W’s was approximately $31 million. The settlement agreement, among other things, limits the types of claims class members may bring and eliminates claims for punitive damages. The settlement agreement also provides that, in individual cases by class members that are referred to as Broin II lawsuits, the defendant will bear the burden of proof with respect to whether ETS can cause certain specifically enumerated diseases, referred to as “general causation.” With respect to all other liability issues, including whether an individual plaintiff’s disease was caused by his or her exposure to ETS in airplane cabins, referred to as “specific causation,” individual plaintiffs will bear the burden of proof. On September 7, 1999, the Florida Supreme Court approved the settlement.
As of December 31, 2016, there were 2,406 Broin II lawsuits pending in Florida. There have been no Broin II trials since 2007.
Overview. As of December 31, 2016, 25 class-action cases, excluding the shareholder case described below, were pending in the United States against Reynolds Defendants. These class actions seek recovery for personal injuries allegedly caused by cigarette smoking or, in some cases, for economic damages allegedly incurred by cigarette or e-cigarette purchasers.
In 1996, the Fifth Circuit Court of Appeals in Castano v. American Tobacco Co. overturned the certification of a nation-wide class of persons whose claims related to alleged addiction to tobacco products, finding that the district court failed to properly assess variations in the governing state laws and whether common issues predominated over individual issues. Since the Fifth Circuit’s ruling in Castano , few smoker class-action complaints have been certified or, if certified, have survived on appeal. Eighteen federal courts, including two courts of appeals, and most state courts that have considered the issue have rejected class certification in such cases. Apart from Castano , only two smoker class actions have been certified by a federal court – In re Simon (II) Litigation and Schwab [McLaughlin] v. Philip Morris USA Inc. , both of which were filed in the U.S. District Court for the Eastern District of New York and were later decertified.
Class-action suits based on claims that class members are at a greater risk of injury or injured by the use of tobacco or exposure to ETS, or claims that seek primarily economic damages are pending against RJR Tobacco, Lorillard Tobacco, or their affiliates or indemnitees in state or federal courts in California, Florida, Illinois, Louisiana, Missouri, New Mexico, New York, North Carolina and West Virginia. All pending class-action cases are discussed below.
The pending class actions against RJR Tobacco or its affiliates or indemnitees include four cases alleging that the use of the term “lights” constitutes unfair and deceptive trade practices under state law or violates federal RICO. Such suits are pending in state courts in Illinois and Missouri and are discussed below under “— ‘Lights’ Cases.”
E-cigarette class-action cases are pending against RJR Vapor, RAI, and other RAI affiliates in California state and federal courts. In general, the plaintiffs allege that RJR Vapor, Lorillard Tobacco, and other RAI affiliates made false and misleading claims that e-cigarettes are less hazardous than other cigarette products or failed to disclose that e-cigarettes expose users to certain substances. The cases are typically filed pursuant to state consumer protection and related statutes and seek recovery of economic damages and are discussed below under “—E-Cigarette Cases.”
Several class actions relating to claims in advertising and promotional materials for SFNTC’s NATURAL AMERICAN SPIRIT brand cigarettes are pending in federal courts. In general, these plaintiffs allege that use of the words “natural,” “additive-free,” or “organic” in NATURAL AMERICAN SPIRIT advertising and promotional materials suggests that those cigarettes are less harmful than other cigarettes and, for that reason, violated state consumer protection statutes or amounted to fraud or a negligent or intentional misrepresentation. These cases are discussed below under “—No Additive/Natural Claim Cases.”
Additional class actions relating to alleged personal injuries purportedly caused by use of cigarettes or exposure to ETS are pending. These cases are discussed below under “— Other Class Actions.”
120
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Finally, certain third-party payers have filed health-care cost recovery actions in the form of class actions. These cases are discussed separately below under “— Health-Care Cost Recovery Cases.”
“ Lights ” Cases .
As noted above, four “lights” class-action cases are pending against RJR Tobacco or B&W, two in Illinois state court and two in Missouri state court. The classes in these cases generally seek to recover compensatory and punitive damages, injunctive and other forms of relief, and attorneys’ fees and costs from RJR Tobacco and/or B&W. In general, the plaintiffs allege that RJR Tobacco or B&W made false and misleading claims that “lights” cigarettes were lower in tar and nicotine and/or were less hazardous or less mutagenic than other cigarettes. The cases typically are filed pursuant to state consumer protection and related statutes.
The seminal “lights” class-action case is Price v. Philip Morris, Inc . (Cir. Ct. Madison County, Ill., filed 2000), an action filed against the predecessor of Philip Morris USA Inc., referred to as Philip Morris. In March 2003, the trial court entered judgment against Philip Morris in the amount of $7.1 billion in compensatory damages and $3 billion in punitive damages. In December 2005, the Illinois Supreme Court issued an opinion reversing and remanding with instructions to dismiss the case. On December 5, 2006, the Illinois Supreme Court issued its mandate, and the trial court entered a judgment of dismissal later in December 2006. In multiple filings since December 2008, the Price plaintiffs have argued that the U.S. Supreme Court’s decision in Good v. Altria Group, Inc . rejected the basis upon which the Illinois Supreme Court had reversed the Price trial court’s 2003 judgment and, on that basis, have attempted to reinstate that judgment. In April 2014, the intermediate appellate court reinstated the trial court’s 2003 judgment. In November 2015, the Illinois Supreme Court (1) vacated the lower courts’ judgments, (2) dismissed the case without prejudice to allow the plaintiffs to file a motion to have the Illinois Supreme Court recall its December 5, 2006, mandate that had reversed the trial court’s 2003 judgment, and (3) directed entry of a judgment of dismissal. The plaintiffs then moved in the Illinois Supreme Court to have that court recall its December 5, 2006 mandate. On January 11, 2016, the Illinois Supreme Court denied the plaintiffs’ motion. The plaintiffs filed a petition for writ of certiorari with the U.S. Supreme Court on January 22, 2016, which was denied on June 20, 2016.
In Turner v. R. J. Reynolds Tobacco Co. (Cir. Ct. Madison County, Ill., filed 2000), the trial court certified a class of purchasers of RJR Tobacco “lights” cigarettes in November 2001. In November 2003, the Illinois Supreme Court granted RJR Tobacco’s motion for a stay pending the court’s final appeal decision in the Price case described above . The stay subsequently expired, and the court accordingly scheduled a series of status conferences, all of which were continued by agreement of the parties. The next status conference is scheduled for February 22, 2017.
In Howard v. Brown & Williamson Tobacco Corp. (Cir. Ct. Madison County, Ill., filed 2000), the trial court certified a class of purchasers of B&W “lights” cigarettes in December 2001. In June 2003, the trial judge issued an order staying all proceedings pending resolution of the Price case described above. In August 2005, the Illinois Fifth District Court of Appeals affirmed the Circuit Court’s stay order. There is currently no activity in the case.
In Collora v. R. J. Reynolds Tobacco Co. (Cir. Ct. City of St. Louis, Mo., filed 2000), the trial court certified a class of purchasers of RJR Tobacco “lights” cigarettes in December 2003. A status conference is scheduled for June 5, 2017.
In Black v. Brown & Williamson Tobacco Corp. (Cir. Ct. City of St. Louis, Mo., filed 2000), a putative class action filed on behalf of a class of purchasers of B&W “lights” cigarettes, a status conference is scheduled for June 5, 2017.
In the event RJR Tobacco and its affiliates or indemnitees lose one or more of the pending “lights” class-action suits, RJR Tobacco, depending upon the amount of any damages ordered, could face difficulties in its ability to pay the judgment or obtain any bond required to stay execution of the judgment which could have a material adverse effect on RJR Tobacco’s, and consequently RAI’s, results of operations, cash flows or financial position.
E-Cigarette Cases .
In In re Fontem US, Inc. Consumer Class Action Litig. (U.S.D.C. C.D. Cal., filed 2015), the plaintiffs brought a class action against RAI, Lorillard, another RAI affiliate, and two other defendants on behalf of putative classes of California, New York, and Illinois purchasers of blu brand e-cigarettes. This action results from the consolidation of two actions – Diek v. Lorillard Tobacco Co. and Whitney v. ITG Brands, LLC. The plaintiffs allege that certain advertising, marketing and packaging materials for blu brand e-cigarettes made deceptive claims, omitted material information, or failed to contain required disclosures. On behalf of one or more of the classes, the plaintiffs seek injunctive relief, equitable relief, and compensatory and punitive damages under California Civil Code §1,750 et seq ., California Business & Professions Code §17,200 et seq ., California Business and Professions Code §17,500 et seq ., New York General Business Law § 349, and Illinois Consumer Fraud And Deceptive Business Practices Act § 505/1 et seq. Pursuant
121
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
to the terms of the asset purchase agreement relating to the Divestiture, RAI tendered the defense of the now-consolidated Diek and Whitney actions to, and sought indemnification for those actions from, ITG. Pursuant to the terms, limitations and conditions of the asset purchase agreement relating to the Divestiture, ITG agreed to defend and indemnify RAI and its affiliates against losses arising from the operation of the blu brand e-cigarette business. On May 20, 2016, the trial court stayed the matter pending the Ninth Circuit Court of Appeals’ rulings in Briseno v. ConAgra Foods, Inc. (decided January 3, 2017), Jones v. ConAgra Foods, Inc. (pending), and Brazil v. Dole Packaged Foods, LLC (decided September 30, 2016). The stay did not apply to finalizing the pleadings and related briefing. On May 23, 2016, the plaintiffs filed a second amended consolidated complaint, which the defendants moved to dismiss. On November 1, 2016, the trial court granted the defendants’ motion to dismiss in substantial part, finding that federal law preempted all of the plaintiffs’ claims except those based on alleged violations of California’s Proposition 65 under California’s Business and Professions Code §17,200 et seq . On November 21, 2016, the plaintiffs moved for reconsideration of the trial court’s November 1, 2016 order. The trial court scheduled a hearing on the plaintiffs’ motion for reconsideration for February 13, 2017.
In Harris v. R. J. Reynolds Vapor Co. (U.S.D.C. N.D. Cal., filed 2015), the plaintiff brought a class action against RJR Vapor on behalf of a putative class of purchasers of VUSE e-cigarettes. The plaintiff alleges that RJR Vapor failed to advise users that they potentially could be exposed to formaldehyde and acetaldehyde. The plaintiff asserts failure to warn claims under California’s Proposition 65, as well as California Business & Professions Code § 17,200 et seq . and California Civil Code § 1,750 et seq . and seeks declaratory relief, restitution, disgorgement, injunctive relief and damages. RJR Vapor moved to dismiss contending, among other things, that plaintiff’s action was governed in its entirety by Proposition 65 and that the plaintiff failed to give the 60-day pre-suit notice required by Proposition 65, requiring that the entire case be dismissed with prejudice. The motion to dismiss was argued on March 2, 2016. On September 30, 2016, the court granted RJR Vapor’s motion to dismiss but provided the plaintiff leave to amend. The plaintiff filed a second amended complaint on October 31, 2016, and RJR Vapor has again moved to dismiss. Oral argument occurred on January 19, 2017. A decision is pending.
In Center for Environmental Health v. NJoy, Inc. (Super. Ct. Alameda County, Cal., filed 2015), the plaintiff brought an action against RJR Vapor and several other e-cigarette manufacturers asserting violations of Proposition 65 for not disclosing that electronic cigarettes, including VUSE, allegedly expose consumers to formaldehyde and acetaldehyde. The plaintiff sought civil penalties, injunctive relief, attorneys’ fees, and costs. RJR Vapor filed an answer on December 29, 2015. RJR Vapor denied any and all liability and reached an agreement to resolve the claims for $94,750. The court approved the settlement agreement on October 25, 2016.
No Additive/Natural/Organic Claim Cases .
Following the FDA’s August 27, 2015, warning letter to SFNTC relating to the use of the words “natural” and “additive-free” in the labeling, advertising and promotional materials for NATURAL AMERICAN SPIRIT brand cigarettes, plaintiffs purporting to bring claims on behalf of themselves and others have filed putative nationwide and/or state-specific class actions against SFNTC and, in some instances, RAI. A total of 16 such actions have been filed in nine U.S. district courts. Each of these cases is discussed below. In various combinations, plaintiffs in these cases generally allege violations of state deceptive and unfair trade practice statutes, and claim state common law fraud, negligent misrepresentation, and unjust enrichment based on the use of descriptors such as “natural,” “organic” and “100% additive-free” in the marketing, labeling, advertising, and promotion of SFNTC’s NATURAL AMERICAN SPIRIT brand cigarettes. The actions seek various categories of recovery, including economic damages, injunctive relief (including medical monitoring and cessation programs), interest, restitution, disgorgement, treble and punitive damages, and attorneys’ fees and costs.
On January 6, 2016, the plaintiffs in one action filed a motion before the U.S. Judicial Panel on Multidistrict Litigation (“JPML”) to consolidate these actions before one district court for pretrial purposes. On April 11, 2016, the JPML ordered that these cases be consolidated for pretrial purposes before Judge James O. Browning in the U.S. District Court for the District of New Mexico, referred to as the transferee court, and the then-pending and later-filed cases now are consolidated for pretrial purposes in that court. The cases that were filed in or transferred for pretrial purposes to the transferee court are as follows:
|
• |
Sproule v. Santa Fe Natural Tobacco Co., Inc . (U.S.D.C. S.D. Fla., filed 2015), is an action against SFNTC and RAI on behalf of a putative nationwide class of purchasers of Natural American Spirit brand cigarettes. |
|
• |
Brattain v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. N.D. Cal., filed 2015), is an action against SFNTC and RAI on behalf of a putative class of California purchasers of Natural American Spirit brand cigarettes. |
|
• |
Rothman v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. S.D.N.Y., filed 2015), is an action against SFNTC and RAI on behalf of a putative class of New York purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Dunn v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. D.N.M., filed 2015), is an action against SFNTC on behalf of a putative nationwide class (and Minnesota subclass) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
122
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
• |
Haksal v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. D.N.M., filed 2015), is an action against SFNTC and RAI on behalf of a putative nationwide class (and California, Illinois, Minnesota, and New Mexico subclasses) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Cuebas v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. S.D.N.Y., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class (and New York subclass) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Okstad v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. M.D. Fla., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class and sixteen putative state-based subclasses (Alabama, California, Colorado, Florida, Georgia, Iowa, Illinois, Maryland, Maine, North Carolina, New Jersey, Ohio, Oregon, Pennsylvania, Texas and Wisconsin subclasses) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Ruggiero v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. D.D.C., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class (and Maryland subclass) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Waldo v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. M.D. Fla., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class (and Florida subclass) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Grandison v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. E.D.N.Y., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class (and California, Florida and New York subclasses) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Gudmundson v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. V.I., filed 2016), is an action against SFNTC and RAI on behalf of a putative class of U.S. Virgin Islands purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
LeCompte v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. D.N.M., filed 2016), is an action against SFNTC and RAI on behalf of a putative class of California purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
White v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. D.N.M., filed 2016), is an action against SFNTC on behalf of a putative nationwide class of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Johnston v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. S.D Fla., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class (and Florida subclass) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Cole v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. M.D. N.C., filed 2016), is an action against SFNTC and RAI on behalf of a putative nationwide class (and North Carolina subclass) of purchasers of NATURAL AMERICAN SPIRIT brand cigarettes. |
|
• |
Hebert v. Santa Fe Natural Tobacco Co., Inc. (U.S.D.C. M.D. N.C., filed 2016), is an action against SFNTC, RAI and RJR Tobacco on behalf of a putative class of purchasers in California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New Mexico, New York, Ohio and Washington of NATURAL AMERICAN SPIRIT cigarettes, and a nationwide putative class of NATURAL AMERICAN SPIRIT brand menthol cigarette purchasers (and subclass of such purchasers in California, Colorado, Florida, Illinois and New Mexico). |
The transferee court entered a scheduling order requiring the plaintiffs to file a consolidated amended complaint. On September 19, 2016, the plaintiffs filed a consolidated amended complaint naming SFNTC, RAI, and RJR Tobacco as defendants. That complaint alleges violations of 12 states’ deceptive and unfair trade practices statutes – California, Colorado, Florida, Illinois, Massachusetts, Michigan, North Carolina, New Jersey, New Mexico, New York, Ohio, and West Virginia – based on the use of descriptors such as “natural,” “organic” and “100% additive-free” in the marketing, labeling, advertising, and promotion of SFNTC’s NATURAL AMERICAN SPIRIT brand cigarettes. It also asserts unjust enrichment claims under those 12 states’ laws and asserts breach of express warranty claims on behalf of a national class of NATURAL AMERICAN SPIRIT menthol purchasers. The state deceptive and unfair trade practice statutory and unjust enrichment claims are brought on behalf of state-specific classes in the 12 states listed above and, in some instances, state-specific subclasses. The consolidated amended complaint seeks class certification, payment for class notice, injunctive relief, monetary damages, prejudgment interest, statutory damages, restitution, and attorneys’ fees and costs. On November 18, 2016, the defendants filed a motion to dismiss, and a hearing on that motion is scheduled for March 22, 2017. On January 12, 2017, the plaintiffs filed a second consolidated amended class action complaint. The transferee court’s scheduling order,
123
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
as amended, provides for the plaintiffs to file a motion for class certification by April 3, 2018, and a hearing on the class certification motion on July 13-14, 2018.
On November 7, 2016, a public health advocacy organization filed Breathe DC v. Santa Fe Natural Tobacco Co., Inc . (D.C. Super. Ct.), an action against SFNTC, RAI and RJR Tobacco based on allegations relating to the labeling, advertising and promotional materials for NATURAL AMERICAN SPIRIT brand cigarettes that are similar to the allegations in the actions consolidated for pre-trial purposes in the U.S. District Court for the District of New Mexico transferee court described immediately above. The complaint seeks injunctive and other non-monetary relief, but does not seek monetary damages. On December 6, 2016, the defendants removed the action to the U.S. District Court for the District of Columbia and, on December 7, 2016, filed a notice with the JPML to have the action transferred to the transferee court. On December 7, 2016, the plaintiff moved in the U.S. District Court for the District of Columbia to remand the action to the Superior Court for the District of Columbia. On December 9, 2016, the JPML conditionally ordered that the case be transferred to the transferee court. On December 20, 2016, the U.S. District Court for the District of Columbia issued an order stating that it will rule on the plaintiff’s motion to remand before the JPML considers the plaintiff’s motion to vacate the conditional transfer order.
Other Class Actions.
In Young v. American Tobacco Co., Inc. (Cir. Ct. Orleans Parish, La., filed 1997), the plaintiff brought a class action against U.S. cigarette manufacturers, including RJR Tobacco and B&W, and parent companies of U.S. cigarette manufacturers, including RJR, on behalf of a putative class of Louisiana residents who, though not themselves cigarette smokers, allegedly suffered injury as a result of exposure to ETS from cigarettes manufactured by defendants. The plaintiffs seek to recover an unspecified amount of compensatory and punitive damages. In March 2016, the court entered an order staying the case, including all discovery, pending the completion of the smoking cessation program ordered by the court in Scott v. The American Tobacco Co .
In Parsons v. A C & S, Inc. (Cir. Ct. Ohio County, W. Va., filed 1998), the plaintiff brought a class action against asbestos manufacturers, U.S. cigarette manufacturers, including RJR Tobacco, B&W, Lorillard Tobacco, and parent companies of U.S. cigarette manufacturers, including RJR and Lorillard, on behalf of a putative class of persons who allegedly have personal injury claims arising from their exposure to respirable asbestos fibers and cigarette smoke. The plaintiff seeks to recover $1 million in compensatory and punitive damages individually for her purported injuries and an unspecified amount for the class in compensatory and punitive damages. In December 2000, three defendants, Nitral Liquidators, Inc., Desseaux Corporation of North America and Armstrong World Industries, filed bankruptcy petitions in the U.S. Bankruptcy Court for the District of Delaware, In re Armstrong World Industries, Inc. Pursuant to section 362(a) of the Bankruptcy Code, Parsons is automatically stayed with respect to all defendants who filed for bankruptcy. The case remains pending against the other defendants, including RJR Tobacco and Lorillard Tobacco, but it has long been dormant.
In Jones v. American Tobacco Co., Inc. (Cir. Ct., Jackson County, Mo., filed 1998), the plaintiff filed a class action against the major U.S. cigarette manufacturers, including RJR Tobacco, B&W, Lorillard Tobacco, and parent companies of U.S. cigarette manufacturers, including RJR and Lorillard, on behalf of a putative class of Missouri tobacco product users and purchasers who allegedly became addicted to nicotine. The plaintiffs seek an unspecified amount of compensatory and punitive damages. There is currently no activity in this case.
Claims have been brought against Lorillard Tobacco and Lorillard by individuals who seek damages resulting from their alleged exposure to asbestos fibers that were incorporated into filter material used in one brand of cigarettes manufactured by a predecessor to Lorillard Tobacco for a limited period of time ending more than 50 years ago. As of December 31, 2016, Lorillard Tobacco and/or Lorillard was a defendant in 78 Filter Cases. Since January 1, 2013, Lorillard Tobacco and RJR Tobacco have paid, or have reached agreement to pay, a total of approximately $47.6 million in settlements to resolve 175 claims asserted in Filter Cases.
Pursuant to the terms of a 1952 agreement between P. Lorillard Company and H&V Specialties Co., Inc. (the manufacturer of the filter material), Lorillard Tobacco is required to indemnify Hollingsworth & Vose for legal fees, expenses, judgments and resolutions in cases and claims alleging injury from finished products sold by P. Lorillard Company that contained the filter material.
On September 13, 2013, the jury in a Filter Case, DeLisle v. A. W. Chesterton Co. (Cir. Ct. Broward County, Fla., filed 2012), found for the plaintiffs on the negligence and strict liability claims; awarded the plaintiffs $8 million in compensatory damages; and found Lorillard Tobacco 22% at fault, Hollingsworth & Vose 22% at fault, and the other defendants 56% at fault. Punitive damages were not at issue. On November 6, 2013, the trial court entered final judgment against Lorillard Tobacco in the amount of $3.52 million. Lorillard Tobacco appealed to the Fourth DCA. On September 14, 2016, the Fourth DCA ordered a new trial because the trial
124
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
court erred in admitting certain expert testimony and concluded that the $8 million compensatory damages award should have been remitted. The plaintiffs filed a motion for rehearing or rehearing en banc, which was denied by the Fourth DCA on November 9, 2016. The plaintiffs filed an application for discretionary review by the Florida Supreme Court on December 6, 2016. The Florida Supreme Court has issued a stay of the proceedings in that court pending its disposition of a pending application for review in another case. The matter has not been stayed in the trial court, and post-appeal motions are pending to vacate the final judgment and discharge the surety bonds. The plaintiffs have filed both a stay motion in the Florida Supreme Court and a motion to recall the mandate in the Fourth DCA, which motions are presently pending.
Health-Care Cost Recovery Cases
Health-care cost recovery cases have been brought by a variety of plaintiffs. Other than certain governmental actions, these cases largely have been unsuccessful on remoteness grounds, which means that one who pays an injured person’s medical expenses is legally too remote to maintain an action against the person allegedly responsible for the injury.
As of December 31, 2016, two health-care cost recovery cases were pending in the United States against RJR Tobacco, B&W, Lorillard Tobacco, or all three, as discussed below after the discussion of the State Settlement Agreements. A limited number of claimants have filed suit against RJR Tobacco, one of its affiliates, and other tobacco industry defendants to recover funds for health care, medical and other assistance paid by foreign provincial governments in treating their citizens. For additional information on these cases, see “— International Cases” below.
State Settlement Agreements. In June 1994, the Mississippi Attorney General brought an action, Moore v. American Tobacco Co. , against various industry members, including RJR Tobacco, B&W and Lorillard Tobacco. This case was brought on behalf of the state to recover state funds paid for health care and other assistance to state citizens suffering from diseases and conditions allegedly related to tobacco use. Most other states, through their attorneys general or other state agencies, sued RJR Tobacco, B&W, Lorillard Tobacco and other U.S. cigarette manufacturers based on similar theories. The cigarette manufacturer defendants, including RJR Tobacco, B&W and Lorillard Tobacco, settled the first four of these cases scheduled for trial — Mississippi, Florida, Texas and Minnesota — by separate agreements with each such state.
On November 23, 1998, the major U.S. cigarette manufacturers, including RJR Tobacco, B&W and Lorillard Tobacco, entered into the Master Settlement Agreement with attorneys general representing the remaining 46 states, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa and the Northern Marianas. Effective on November 12, 1999, the MSA settled all the health-care cost recovery actions brought by, or on behalf of, the settling jurisdictions and released various additional present and future claims.
In the settling jurisdictions, the MSA released RJR Tobacco, B&W, Lorillard Tobacco, and their affiliates and indemnitees, including RAI and Lorillard, from:
|
• |
all claims of the settling states and their respective political subdivisions and other recipients of state health-care funds, relating to past conduct arising out of the use, sale, distribution, manufacture, development, advertising, marketing or health effects of, the exposure to, or research, statements or warnings about, tobacco products; and |
|
• |
all monetary claims of the settling states and their respective political subdivisions and other recipients of state health-care funds, relating to future conduct arising out of the use of or exposure to, tobacco products that have been manufactured in the ordinary course of business. |
Set forth below is the unadjusted tobacco industry settlement payment schedule (in millions) for 2014 and thereafter:
|
|
2014 |
|
|
2015 |
|
|
2016 and thereafter |
|
|||
First Four States’ Settlements: (1) |
|
|
|
|
|
|
|
|
|
|
|
|
Mississippi Annual Payment |
|
$ |
136 |
|
|
$ |
136 |
|
|
$ |
136 |
|
Florida Annual Payment |
|
|
440 |
|
|
|
440 |
|
|
|
440 |
|
Texas Annual Payment |
|
|
580 |
|
|
|
580 |
|
|
|
580 |
|
Minnesota Annual Payment |
|
|
204 |
|
|
|
204 |
|
|
|
204 |
|
Master Settlement Agreement: |
|
|
|
|
|
|
|
|
|
|
|
|
Annual Payments (1) |
|
|
8,004 |
|
|
|
8,004 |
|
|
|
8,004 |
|
Total |
|
$ |
9,364 |
|
|
$ |
9,364 |
|
|
$ |
9,364 |
|
125
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
RAI’s operating subsidiaries expenses and payments under the State Settlement Agreements for 2014, 2015 and 2016 and the projected expenses and payments for 2017 and thereafter (in millions) are set forth below. (1)(2)
|
|
2014 |
|
|
2015 |
|
|
2016 |
|
|
2017 |
|
2018 and thereafter |
|
||||
Settlement expenses |
|
$ |
1,917 |
|
|
$ |
2,403 |
|
|
$ |
2,727 |
|
|
— |
|
|
— |
|
Settlement cash payments |
|
$ |
1,985 |
|
|
$ |
2,166 |
|
|
$ |
3,042 |
|
|
— |
|
|
— |
|
Projected settlement expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
$>3,000 |
|
$>3,000 |
|
|
Projected settlement cash payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
$>2,700 |
|
$>3,000 |
|
(1) |
Subject to adjustments for changes in sales volume, inflation, operating profit and other factors. Payments are allocated among the companies on the basis of relative market share or other methods. For further information, see “— State Settlement Agreements—Enforcement and Validity; Adjustments” below. |
(2) |
The amounts above reflect the impact of the Term Sheet and the NY State Settlement described below under “— State Settlement Agreements—Enforcement and Validity; Adjustments – Partial Settlement of Certain NPM Adjustment Claims.” |
The State Settlement Agreements also contain provisions restricting the marketing of tobacco products. Among these provisions are restrictions or prohibitions on the use of cartoon characters, brand-name sponsorships, apparel and other merchandise, outdoor and transit advertising, payments for product placement, free sampling and lobbying. Furthermore, the State Settlement Agreements required the dissolution of three industry-sponsored research and trade organizations.
The State Settlement Agreements have materially adversely affected RJR Tobacco’s shipment volumes. RAI believes that these settlement obligations may materially adversely affect the results of operations, cash flows or financial position of RAI and RJR Tobacco in future periods. The degree of the adverse impact will depend, among other things, on the rate of decline in U.S. cigarette sales in the premium and value categories, RJR Tobacco’s share of the domestic premium and value cigarette categories, and the effect of any resulting cost advantage of manufacturers not subject to the State Settlement Agreements.
U.S. Department of Justice Case.
In United States v. Philip Morris USA Inc. (U.S.D.C. D.D.C., filed 1999) , the U.S. Department of Justice brought an action against RJR Tobacco, B&W, Lorillard Tobacco and other tobacco companies seeking (1) recovery of federal funds expended in providing health care to smokers who developed alleged smoking-related diseases pursuant to the Medical Care Recovery Act and Medicare Secondary Payer provisions of the Social Security Act and (2) equitable relief under the civil provisions of RICO, including disgorgement of roughly $280 billion in profits the government contended were earned as a consequence of a purported racketeering “enterprise.” In September 2000, the district court dismissed the government’s Medical Care Recovery Act and Medicare Secondary Payer claims. In February 2005, the U.S. Court of Appeals for the D.C. Circuit, referred to as the D.C. Circuit, ruled that disgorgement was not an available remedy.
On August 17, 2006, after a non-jury bench trial, the district court found certain defendants, including RJR Tobacco, B&W and Lorillard Tobacco, had violated RICO, but did not impose any direct financial penalties. The district court instead enjoined RJR Tobacco, Lorillard Tobacco and the other defendants from committing future racketeering acts, participating in certain trade organizations, making misrepresentations concerning smoking and health and youth marketing, and using certain brand descriptors such as “low tar,” “light,” “ultra light,” “mild” and “natural.” The district court also ordered RJR Tobacco, Lorillard Tobacco and the other defendants to issue “corrective communications” on five subjects, including smoking and health and addiction, and to comply with further undertakings, including maintaining web sites of historical corporate documents and disseminating certain marketing information on a confidential basis to the government. In addition, the district court placed restrictions on the defendants’ ability to dispose of certain assets for use in the United States, unless the transferee agrees to abide by the terms of the district court’s order, and ordered certain defendants to reimburse the U.S. Department of Justice its taxable costs incurred in connection with the case.
Defendants, including RJR Tobacco, B&W, and Lorillard Tobacco, appealed, the government cross appealed, and the defendants moved in the district court for clarification and a stay pending appeal. After the district court denied the defendants’ motion to stay, the D.C. Circuit granted a stay in October 2006.
The district court then granted the motion for clarification in part and denied it in part. With respect to the meaning and applicability of the general injunctive relief of the August 2006 order, the district court denied the motion for clarification. With respect to the request for clarification as to the scope of the provisions in the order prohibiting the use of descriptors and requiring
126
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
corrective statements at retail point of sale, the district court granted the motion and also ruled that the provisions prohibiting the use of express or implied health messages or descriptors do apply to the actions of the defendants taken outside of the United States.
In May 2009, the D.C. Circuit largely affirmed both the finding of liability against the tobacco defendants and the remedial order, including the denial of additional remedies, but vacated the order and remanded for further proceedings as to the following four discrete issues:
|
• |
the issue of the extent of B&W’s control over tobacco operations was remanded for further fact finding and clarification; |
|
• |
the remedial order was vacated to the extent that it binds all defendants’ subsidiaries and was remanded to the district court for determination as to whether inclusion of the subsidiaries and which of the subsidiaries satisfy Rule 65(d) of the Federal Rules of Civil Procedure; |
|
• |
the D.C. Circuit held that the provision found in paragraph four of the injunction, concerning the use of any express or implied health message or health descriptor for any cigarette brand, should not be read to govern overseas sales. The issue was remanded to the district court with instructions to reformulate it so as to exempt foreign activities that have no substantial, direct and foreseeable domestic effects; and |
|
• |
the remedial order was vacated regarding “point of sale” displays and remanded for the district court to evaluate and make due provisions for the rights of innocent persons, either by abandoning this part of the remedial order or re-crafting a new version reflecting the rights of third parties. |
In June 2010, the U.S. Supreme Court denied all parties’ petitions for writ of certiorari.
Post-remand proceedings are underway. On December 22, 2010, the district court dismissed B&W from the litigation. In November 2012, the trial court entered an order setting forth the text of the corrective statements and directed the parties to engage in discussions with the Special Master to implement them. After extensive mediation led the parties to an implementation agreement, the district court entered an implementation order on June 2, 2014. The defendants filed a consolidated appeal challenging both the content of the court-ordered statements and the requirement that those statements be published in redundant media. On May 22, 2015, the D.C. Circuit reversed the corrective statements order in part, affirmed in part, and remanded to the district court for further proceedings. On October 1, 2015, the district court ordered the parties to propose new corrective-statements preambles. On February 8, 2016, the district court entered an order adopting the government’s proposed corrective-statements preamble. The parties then mediated, per the district court’s order, changes to the implementation order necessitated by the new preamble. On April 19, 2016, the district court accepted the parties’ mediated agreement on implementation and entered a superseding consent order with respect to implementation. The superseding consent order stays implementation of the corrective statements until the exhaustion of appeals from the orders establishing the text of those statements and governing implementation details. On April 7, 2016, the defendants and the post-judgment parties regarding remedies noticed an appeal to the D.C. Circuit from the order adopting the government’s proposed corrective-statement preambles. On May 6, 2016, the defendants and post-judgment parties regarding remedies noticed an appeal to the D.C. Circuit from the superseding consent order. On June 7, 2016, the D.C. Circuit granted the unopposed motion of the defendants and the post-judgment parties regarding remedies to consolidate the two appeals. Briefing in the consolidated appeals concluded in late December 2016, and oral argument is scheduled for February 17, 2017. Additionally, RJR Tobacco appealed the district court’s May 28, 2015, order requiring RJR Tobacco to televise an additional set of corrective statements on behalf of B&W. On November 1, 2016, the D.C. Circuit upheld the order. In light of the corrective-statements implementation requirements, $20 million has been accrued for the estimated costs of the corrective communications and is included in the consolidated balance sheet as of December 31, 2016.
Native American Tribe Case.
As of December 31, 2016, one Native American tribe case was pending before a tribal court against RJR Tobacco, B&W and Lorillard Tobacco, Crow Creek Sioux Tribe v. American Tobacco Co. (Tribal Ct., Crow Creek Sioux, S.D., filed 1997). The plaintiffs seek to recover actual and punitive damages, restitution, funding of a clinical cessation program, funding of a corrective public education program, and disgorgement of unjust profits from sales to minors. The plaintiffs claim that the defendants are liable under the following theories: unlawful marketing and targeting of minors, contributing to the delinquency of minors, unfair and deceptive acts or practices, unreasonable restraint of trade and unfair method of competition, negligence, negligence per se, conspiracy and restitution of unjust enrichment. The case is dormant.
127
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Each of the ten Canadian provinces has filed a health-care cost recovery action against Canadian and non-Canadian tobacco-related entities, including RJR Tobacco and one of its affiliates. In these actions, which are described below, each of the Canadian provinces seeks to recover for health care, medical and other assistance paid and to be paid for treating tobacco-related disease. Pursuant to the terms of the 1999 sale of RJR Tobacco’s international tobacco business, RJR Tobacco has tendered the defense of these actions to JTI. Subject to a reservation of rights, JTI has assumed the defense of RJR Tobacco and its affiliate in these actions.
|
• |
British Columbia (British Columbia Sup. Ct., Vancouver Registry, filed 1997) - In 1997, British Columbia enacted a statute creating a civil cause of action against tobacco-related entities for the provincial government to recover the costs of health-care benefits incurred for insured British Columbia residents resulting from tobacco-related disease. An initial action brought pursuant to the statute against Canadian and non-Canadian tobacco-related entities, including RJR Tobacco and certain of its affiliates, was dismissed in February 2000 when the British Columbia Supreme Court ruled that the legislation was unconstitutional. British Columbia then enacted a revised statute, pursuant to which an action was filed in January 2001 against many of the same defendants, including RJR Tobacco and one of its affiliates. In that action, the British Columbia government seeks to recover the present value of its total expenditures for health-care benefits provided for insured persons resulting from tobacco-related disease or the risk of tobacco-related disease caused by alleged breaches of duty by the manufacturers, the present value of its estimated total expenditures for health-care benefits that reasonably could be expected to be provided for those insured persons resulting from tobacco-related disease or the risk of tobacco-related disease in the future, court ordered interest, and costs, or in the alternative, special or increased costs. The government alleges that the defendants are liable under the British Columbia statute by reason of their “tobacco related wrongs,” which are alleged to include: selling defective products, failure to warn, sale of cigarettes to children and adolescents, strict liability, deceit and misrepresentation, violation of trade practice and competition acts, concerted action, and joint liability. RJR Tobacco and its affiliate filed statements of defense in January 2007. Pretrial discovery is ongoing. |
|
• |
New Brunswick (Ct. of Queen’s Bench of New Brunswick, Jud. Dist. Fredericton, filed 2008) - This claim is brought pursuant to New Brunswick legislation enacted in 2008 that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed statements of defense in March 2010. Pretrial discovery is ongoing. |
|
• |
Ontario (Ontario Super. Ct. Justice, Toronto, filed 2009) - This claim is brought pursuant to Ontario legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability, although the government also asserted claims based on the illegal importation of cigarettes, which claims were deleted in an amended statement of claim filed in August 2010. RJR Tobacco and its affiliate filed statements of defense in April 2016. |
|
• |
Newfoundland and Labrador (Sup. Ct. Newfoundland and Labrador, St. John’s, filed 2011) - This claim is brought pursuant to Newfoundland and Labrador legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed statements of defense in May 2016. |
|
• |
Manitoba (Ct. of Queen’s Bench, Winnipeg Jud. Centre, filed 2012) - This claim is brought pursuant to Manitoba legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed statements of defense in September 2014. Pre-trial discovery is ongoing. |
|
• |
Quebec (Super. Ct. Quebec, Dist. Montreal, filed 2012) - This claim is brought pursuant to Quebec legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages being sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed defenses in December 2014. Pretrial discovery is ongoing. |
|
• |
Saskatchewan (Ct. of Queen’s Bench, Jud. Centre Saskatoon, filed 2012) - This claim is brought pursuant to Saskatchewan legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed statements of defense in February 2015. |
|
• |
Alberta (Ct. of Queen’s Bench, Alberta Jud. Centre of Calgary, filed 2012) - This claim is brought pursuant to Alberta legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed statements of defense in March 2016. |
128
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
• |
Nova Scotia (Sup. Ct. Nova Scotia, Halifax, filed 2015) - This claim is brought pursuant to Nova Scotia legislation that is substantially similar to the revised British Columbia statute described above. It seeks recovery of essentially the same types of damages sought in the British Columbia action based on analogous theories of liability. RJR Tobacco and its affiliate filed statements of defense in July 2015. |
Seven putative class actions, which are described below, have been filed against various Canadian and non-Canadian tobacco-related entities, including RJR Tobacco and one of its affiliates, in Canadian provincial courts. In these cases, the plaintiffs allege claims based on fraud, fraudulent concealment, breach of warranty, breach of warranty of merchantability, and of fitness for a particular purpose, failure to warn, design defects, negligence, breach of a “special duty” to children and adolescents, conspiracy, concert of action, unjust enrichment, market share liability, and violations of various trade practices and competition statutes. The plaintiffs seek recovery on behalf of proposed classes of persons allegedly suffering from tobacco-related disease as a result of smoking defendants’ cigarettes and seek recovery of compensatory and punitive damages, restitution, recovery of government health-care benefits, interest, and costs. Pursuant to the terms of the 1999 sale of RJR Tobacco’s international tobacco business, RJR Tobacco has tendered the defense of these seven actions to JTI. Subject to a reservation of rights, JTI has assumed the defense of RJR Tobacco and its current or former affiliates in these actions. Plaintiffs’ counsel have been actively pursuing only Bourassa , the action pending in British Columbia, at this time.
|
• |
In Kunka v. Canadian Tobacco Manufacturers’ Council (Ct. of Queen’s Bench, Winnipeg Jud. Centre, filed 2009), the plaintiff seeks compensatory and punitive damages on behalf of a proposed class of persons who purchased or smoked defendants’ cigarettes and suffered, or currently suffer, from tobacco-related disease, as well as restitution of profits and reimbursement of government expenditure for health-care benefits allegedly caused by the use of tobacco products. |
|
• |
In Dorion v. Canadian Tobacco Manufacturers’ Council (Ct. of Queen’s Bench, Alberta Jud. Centre of Calgary – filed 2009), the plaintiff seeks compensatory and punitive damages on behalf of a proposed class of persons who purchased or smoked defendants’ cigarettes and suffered, or currently suffer, from tobacco-related disease, as well as restitution of profits and reimbursement of government expenditure for health-care benefits allegedly caused by the use of tobacco products. |
|
• |
In Semple v. Canadian Tobacco Manufacturers’ Council (Sup. Ct. Nova Scotia, Halifax, filed 2009), the plaintiff seeks compensatory and punitive damages on behalf of a proposed class comprised of persons who purchased or smoked defendants’ cigarettes for the period from January 1, 1954, to the expiry of the opt-out period as set by the court and suffered, or currently suffer, from tobacco-related disease, as well as restitution of profits and reimbursement of government expenditure for health-care costs allegedly caused by the use of tobacco products. |
|
• |
In Adams v. Canadian Tobacco Manufacturers’ Council (Ct. of Queen’s Bench, Jud. Centre of Regina, filed 2009), the plaintiff seeks compensatory and punitive damages on behalf of a proposed class of persons who were alive on July 10, 2009, and suffered, or currently suffer, from chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after having smoked a minimum of 25,000 of defendants’ cigarettes, as well as disgorgement of revenues earned by the defendants. RJR Tobacco and its affiliate have brought a motion challenging the jurisdiction of the Saskatchewan court. |
|
• |
In Bourassa v. Imperial Tobacco Canada Ltd. (Sup. Ct. of British Columbia, Victoria Registry, filed 2010), the plaintiff seeks compensatory and punitive damages on behalf of a proposed class of persons who were alive on June 12, 2007, and suffered, or currently suffer, from chronic respiratory diseases, after having smoked a minimum of 25,000 of defendants’ cigarettes, as well as disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. RJR Tobacco and its affiliate have filed a challenge to the jurisdiction of the British Columbia court. The plaintiff filed a motion for certification in April 2012, and filed affidavits in support in August 2013. An amended claim was filed in December 2014. |
|
• |
In McDermid v. Imperial Tobacco Canada Ltd. (Sup. Ct. of British Columbia, Victoria Registry, filed 2010), the plaintiff seeks compensatory and punitive damages on behalf of a proposed class of persons who were alive on June 12, 2007, and suffered, or currently suffer, from heart disease, after having smoked a minimum of 25,000 of defendants’ cigarettes, as well as disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. RJR Tobacco and its affiliate have filed a challenge to the jurisdiction of the British Columbia court. |
129
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
2007, and suffered, or currently suffer, from chronic obstructive pulmonary disease, heart disease, or cancer, after having smoked a minimum of 25,000 of defendants’ cigarettes, as well as restitution of profits, and reimbursement of government expenditure for health-care benefits allegedly caused by the use of tobacco products. |
State Settlement Agreements— Enforcement and Validity; Adjustments
As of December 31, 2016, there were 28 cases concerning the enforcement, validity or interpretation of the State Settlement Agreements in which RJR Tobacco, B&W or Lorillard Tobacco is a party. This number includes those cases, discussed below, relating to disputed payments under the State Settlement Agreements.
In May 2006, the State of Florida filed a motion, in the Circuit Court of the Fifteenth Judicial Circuit, in and for Palm Beach County, Florida, to enforce the Florida settlement agreement, referred to as the Florida Settlement Agreement, for an accounting by Brown & Williamson Holdings, Inc., and for an Order of Contempt. The State asserted that B&W failed to report in its net operating profit on its shipments, cigarettes manufactured by B&W under contract for Star Tobacco or its parent, Star Scientific, Inc. The State is seeking approximately $12.4 million in additional payments under the Florida Settlement Agreement, as well as $17.0 million in interest payments. This matter is currently in the discovery phase.
On January 18, 2017, the State of Florida filed a motion to enjoin ITG as a defendant and to enforce the Florida Settlement Agreement. The State’s motion seeks payment under the Florida Settlement Agreement with respect to the four brands (WINSTON, SALEM, KOOL and MAVERICK) that were sold to ITG in the Divestiture. Under the asset purchase agreement relating to the Divestiture (and related documents), ITG was to assume responsibility with respect to these brands. Since the closing of the Divestiture and the transfer of these brands to it, ITG has not made settlement payments to the State with respect to these brands. The State’s motion asserts that it “is presently owed more than $45 million and will continue to suffer annual losses of approximately $30 million absent the Court’s enforcement of the Settlement Agreement….” The State’s motion seeks, among other things, an order from the court declaring that RJR Tobacco and ITG are in breach of the Florida Settlement Agreement and are required, jointly and severally, to make annual payments to the State under the Florida Settlement Agreement with respect to the brands transferred to ITG in the Divestiture.
Also on January 18, 2017, Philip Morris USA, Inc. filed a motion to enforce the Florida Settlement Agreement. Philip Morris USA, Inc.’s motion asserted that RJR Tobacco and ITG have breached the Florida Settlement Agreement by failing to comply with the obligations under the Florida Settlement Agreement with respect to the transferred brands. Philip Morris USA, Inc.’s motion asserts that RJR Tobacco and ITG have “…deprived the State…of over $40 million in settlement payments and improperly shifted millions of the remaining settlement payment obligations from themselves to Philip Morris USA, Inc., amounts that will increase greatly going forward absent intervention by [the] Court.” Philip Morris USA, Inc.’s motion seeks various forms of relief to modify the settlement payment calculations to address the issues raised in its motion.
On January 27, 2017, RJR Tobacco filed a motion asserting that ITG failed to use its reasonable best efforts to join the Florida Settlement Agreement and breached the asset purchase agreement relating to the Divestiture. Accordingly, RJR Tobacco filed a motion for leave to allow a supplemental pleading for breach by ITG of its obligations regarding joinder into the Florida Settlement Agreement.
NPM Adjustment Claims. The MSA includes an adjustment that potentially reduces the annual payment obligations of RJR Tobacco, Lorillard Tobacco and the other PMs. Certain requirements, collectively referred to as the Adjustment Requirements, must be satisfied before the NPM Adjustment for a given year is available:
|
• |
an Independent Auditor must determine that the PMs have experienced a market share loss, beyond a triggering threshold, to those manufacturers that do not participate in the MSA, such non-participating manufacturers referred to as NPMs; and |
|
• |
in a binding arbitration proceeding, a firm of independent economic consultants must find that the disadvantages of the MSA were a significant factor contributing to the loss of market share. This finding is known as a significant factor determination. |
When the Adjustment Requirements are satisfied, the MSA provides that the NPM Adjustment applies to reduce the annual payment obligation of the PMs. However, an individual settling state may avoid its share of the NPM Adjustment if it had in place and diligently enforced during the entirety of the relevant year a “Qualifying Statute” that imposes escrow obligations on NPMs that are comparable to what the NPMs would have owed if they had joined the MSA. In such event, the state’s share of the NPM Adjustment is reallocated to other settling states, if any, that did not have in place and diligently enforce a Qualifying Statute.
130
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
NPM Adjustment Claim for 2003. For 2003, the Adjustment Requirements were satisfied. As a result, based on revised numbers calculated by the Independent Auditor, RJR Tobacco placed approximately $615 million , and Lorillard Tobacco placed approximately $109 million, of its 2006 and 2007 MSA payments into a disputed payments account, in accordance with a procedure established by the MSA.
As a result of this action, 37 of the settling states filed legal proceedings in their respective MSA courts seeking declaratory orders that they diligently enforced their Qualifying Statutes during 2003 and/or orders compelling RJR Tobacco and the other PMs that placed money in the disputed payments account to pay the disputed amounts to the settling states. In response, RJR Tobacco and other PMs, pursuant to the MSA’s arbitration provisions, moved to compel arbitration of the parties’ dispute concerning the 2003 NPM Adjustment, including the states’ diligent enforcement claims, before an arbitration panel consisting of three retired federal court judges. The settling states opposed these motions, arguing, among other things, that the issue of diligent enforcement must be resolved by MSA courts in each of the 52 settling states and territories.
Forty-seven of the 48 courts that addressed the question whether the dispute concerning the 2003 NPM Adjustment is arbitrable ruled that arbitration was required under the MSA. The Montana Supreme Court ruled that the State of Montana did not agree to arbitrate the question of whether it diligently enforced a Qualifying Statute. Subsequently, Montana and the PMs reached an agreement whereby the PMs agreed not to contest Montana’s claim that it diligently enforced the Qualifying Statute during 2003.
In January 2009, RJR Tobacco and certain other PMs entered into an Agreement Regarding Arbitration, referred to as the Arbitration Agreement, with 45 of the MSA settling states (representing approximately 90% of the allocable share of the settling states) pursuant to which those states agreed to participate in a multistate arbitration of issues related to the 2003 NPM Adjustment. Under the Arbitration Agreement, the signing states had their ultimate liability, if any, with respect to the 2003 NPM Adjustment reduced by 20%, and RJR Tobacco and the other PMs that placed their share of the disputed 2005 NPM Adjustment (discussed below) into the disputed payments account, without releasing or waiving any claims, authorized the release of those funds to the settling states.
The arbitration panel contemplated by the MSA and the Arbitration Agreement, referred to as the Arbitration Panel, was selected, and proceedings before the panel with respect to the 2003 NPM Adjustment claim began in July 2010. Following the completion of document and deposition discovery, on November 3, 2011, RJR Tobacco and the other PMs advised the Arbitration Panel that they were not contesting the “diligent enforcement” of 12 states and the four U.S. territories with a combined allocable share of less than 14%. The “diligent enforcement” of the remaining 33 settling states, the District of Columbia and Puerto Rico was contested and became the subject of further proceedings. A common issues hearing was held in April 2012, and state specific evidentiary hearings with respect to the contested states were initiated.
As a result of the partial settlement of certain NPM Adjustment claims, as described in more detail below, as well as the earlier decisions not to contest the diligent enforcement of 12 states, two of which are participants in the partial settlement, and the four U.S. territories, only 15 contested settling states required state specific diligent enforcement rulings. State specific evidentiary hearings were completed in May 2013.
In September 2013, the Arbitration Panel issued rulings with respect to the 15 remaining contested states. The Arbitration Panel ruled that six states – Indiana, Kentucky, Maryland, Missouri, New Mexico and Pennsylvania (collectively representing approximately 14.68% allocable share) – had not diligently enforced their Qualifying Statutes in 2003. Each of these six states filed motions to vacate and/or modify the diligent enforcement rulings on the 2003 NPM Adjustment claim. The status as to each of these states is as follows:
|
• |
Indiana and Kentucky (representing approximately 3.80% allocable share) subsequently joined the partial settlement of certain NPM Adjustment claims, as described in more detail below. Indiana participated in a joint motion to stay indefinitely further proceedings on the motions it had filed to vacate the settlement and to modify the adverse diligent enforcement ruling against it. Similarly, Kentucky has joined in a stipulation by the parties filed with the court in that state to stay further proceedings on its motions, but that stipulation has not yet been signed by the court. |
|
• |
Pennsylvania dropped its challenge to the finding of non-diligence entered against it. However, the state court in Pennsylvania entered an order that modified the judgment reduction method that had been adopted by the Arbitration Panel, which reduced RJR Tobacco’s and Lorillard Tobacco’s recovery from this state by $54.0 million and $9.5 million, respectively. Upon appeal, in April 2015, the intermediate appellate court in Pennsylvania upheld the trial court ruling. The Pennsylvania Supreme Court declined to take the industry’s appeal of that ruling. RJR Tobacco filed a petition for writ of certiorari with the U.S. Supreme Court on April 21, 2016. On October 11, 2016, the U.S. Supreme Court denied RJR Tobacco’s petition for writ of certiorari. |
131
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
reduced RJR Tobacco’s and Lorillard Tobacco’s recovery from this state by $21.4 million and $3.8 million, respectively. Upon appeal, in September 2015, the intermediate appellate court in Missouri reversed the trial court ruling. Missouri is appealing that ruling to the Missouri Supreme Court. The appeal is fully briefed, and oral argument on the appeal was held on November 8, 2016. A decision is pending. |
|
• |
Maryland dropped its challenge to the finding of non-diligence entered against it. Maryland’s motion challenging the judgment reduction method adopted by the Arbitration Panel was denied by its state court. Upon appeal, in October 2015, the intermediate appellate court in Maryland reversed the trial court, the effect of which was to reduce RJR Tobacco’s and Lorillard Tobacco’s recovery from this state by a total of $21.2 million and $3.7 million, respectively. The Maryland Supreme Court declined to take the industry’s appeal of that ruling. RJR Tobacco filed a petition for writ of certiorari with the U.S. Supreme Court on June 22, 2016. On October 11, 2016, the U.S. Supreme Court denied RJR Tobacco’s petition for writ of certiorari. |
|
• |
New Mexico filed motions challenging the finding of non-diligence and seeking a modification of the judgment reduction method adopted by the Arbitration Panel. The New Mexico trial court denied the state’s motion to vacate the finding of non-diligence, but granted the state’s motion challenging the judgment reduction method that had been adopted by the Arbitration Panel, which reduced RJR Tobacco’s and Lorillard Tobacco’s recovery from this state by $5.6 million and $1 million, respectively. RJR Tobacco has appealed the court’s ruling on the judgment reduction method. The State did not appeal the trial court’s denial of its motion to vacate the finding on non-diligence. |
As noted above, the effect from the four non-diligent states, Pennsylvania, Missouri, Maryland and New Mexico, no longer challenging the findings of non-diligence entered against them by the Arbitration Panel was that a certain portion of the potential recovery from these four states was probable and reasonably estimable. Consequently, $6 million and $93 million was recognized as a reduction of cost of products sold in RAI’s consolidated statement of income for the year ended December 31, 2016 and 2015, respectively. Therefore, RJR Tobacco now estimates that the maximum remaining amount of its claim and Lorillard Tobacco’s claim with respect to the 2003 NPM Adjustment claim is $27 million and $5 million, respectively, plus any applicable interest and earnings. Until such time as the various remaining state motions challenging the rulings of the Arbitration Panel have been resolved, including any necessary appeals, uncertainty exists as to the timing, process and amount of RJR Tobacco’s ultimate recovery with respect to its remaining share of the 2003 NPM Adjustment claim and, accordingly, no additional amounts for the remaining four non-diligent states have been recognized in RAI’s consolidated financial statements as of December 31, 2016.
NPM Adjustment Claims for 2004- 2015 . From 2006 to 2008, proceedings (including significant factor arbitrations before an independent economic consulting firm) were initiated with respect to the NPM Adjustment for 2004, 2005 and 2006. Ultimately, the Adjustment Requirements were satisfied with respect to each of these NPM Adjustments.
In subsequent years, RJR Tobacco, Lorillard Tobacco, certain other PMs and the settling states entered into three separate agreements, covering fiscal years 2007 to 2009, fiscal years 2010 to 2012 and fiscal years 2013 to 2014, respectively, wherein the settling states would not contest that the disadvantages of the MSA were “a significant factor contributing to” the market share loss experienced by the PMs in those years. The stipulation pertaining to each of the years covered by the three agreements became effective in February of the year a final determination by the firm of independent economic consultants would otherwise have been expected if the issue had been arbitrated on the merits. RJR Tobacco and the PMs paid certain amounts into the States’ Antitrust/Consumer Protection Tobacco Enforcement Fund established under Section VIII(c) of the MSA for each year covered by these agreements, with RJR Tobacco paying approximately 47% and Lorillard Tobacco paying approximately 20% of such amounts.
132
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Based on the payment calculations of the Independent Auditor and the agreements described above regarding the significant factor determinations, the Adjustment Requirements have been satisfied with respect to the NPM Adjustments for fiscal years 2007 to 2013. Determination of satisfaction of the Adjustment Requirements for 2014 has not been made. The approximate maximum principal amounts of RJR Tobacco’s and Lorillard Tobacco’s shares of the disputed NPM Adjustments for the years 2004 through 2014 (in millions) , as currently calculated by the Independent Auditor, and the remaining amounts after the settlements of certain NPM Adjustments claims (see below), are as follows (1) :
|
|
RJR Tobacco |
|
|
Lorillard Tobacco |
|
||||||||||
Volume Year |
|
Disputed |
|
|
Remaining after settlements |
|
|
Disputed |
|
|
Remaining after settlements |
|
||||
2004 |
|
$ |
562 |
|
|
$ |
210 |
|
|
$ |
111 |
|
|
$ |
41 |
|
2005 |
|
|
445 |
|
|
|
166 |
|
|
|
76 |
|
|
|
29 |
|
2006 |
|
|
419 |
|
|
|
156 |
|
|
|
73 |
|
|
|
27 |
|
2007 |
|
|
435 |
|
|
|
166 |
|
|
|
83 |
|
|
|
32 |
|
2008 |
|
|
468 |
|
|
|
179 |
|
|
|
104 |
|
|
|
40 |
|
2009 |
|
|
472 |
|
|
|
180 |
|
|
|
107 |
|
|
|
41 |
|
2010 |
|
|
470 |
|
|
|
179 |
|
|
|
119 |
|
|
|
46 |
|
2011 |
|
|
422 |
|
|
|
161 |
|
|
|
88 |
|
|
|
34 |
|
2012 |
|
|
428 |
|
|
|
163 |
|
|
|
96 |
|
|
|
37 |
|
2013 |
|
|
455 |
|
|
|
173 |
|
|
|
91 |
|
|
|
35 |
|
2014 |
|
|
430 |
|
|
|
164 |
|
|
|
92 |
|
|
|
36 |
|
(1) |
The amounts shown above do not include the interest or earnings thereon to which RJR Tobacco and Lorillard Tobacco believe they would be entitled under the MSA. |
In addition to the above, SFNTC’s portion of the disputed NPM Adjustments for the years 2004 through 2014 is approximately $67 million and the remaining amount after the settlements is approximately $26 million.
The 2015 volume year NPM Adjustments for RJR Tobacco, Lorillard Tobacco and SFNTC are $481 million, $41 million and $18 million, respectively.
The 2004 NPM Adjustment proceeding is underway before two overlapping panels, with one panel hearing the issues with respect to five states and the other panel hearing the issues as to the remaining states that will be part of the arbitration. A case management order governing the arbitration was entered on June 14, 2016. Under the timing established by that case management order, it is expected that discovery in the arbitration proceedings will be completed by the end of the second quarter of 2017 and that a hearing on common issues will take place before the end of the third quarter of 2017. State specific evidentiary hearings are expected to begin in the fourth quarter of 2017 and will likely conclude by the end of the third quarter of 2018. Diligent enforcement rulings from the panels are likely by the end of the fourth quarter of 2018. RJR Tobacco’s and Lorillard Tobacco’s remaining claim with respect to 2004 is approximately $251 million.
Missouri has obtained an order from the Missouri court of appeals for a separate state specific arbitration of the diligent enforcement issue, although that ruling is on appeal. Also, in the context of the 2003 NPM Adjustment proceedings, Montana obtained a ruling from the Montana Supreme Court that the issue of diligent enforcement under the MSA must be heard before that state’s MSA court. Finally, New Mexico and the four U.S. territories have been asked to join the 2004 NPM Adjustment Arbitration, but have not yet done so.
Due to the uncertainty over the final resolution of the 2004-2015 NPM Adjustment claims asserted by RJR Tobacco (including Lorillard Tobacco claims) and SFNTC, no assurances can be made related to the amounts, if any, that will be realized or any amounts (including interest) that will be owed, except as described below related to the partial settlement of certain NPM Adjustment claims.
Settlement/Partial Settlement of Certain NPM Adjustment Claims. In November 2012, RJR Tobacco, certain other PMs and certain settling states entered into a Term Sheet that set forth terms on which accrued and potential NPM Adjustment claims for 2003 through 2014 could be resolved. The Term Sheet also set forth a restructured NPM Adjustment process to be applied on a going-forward basis, starting with the 2013 volume year. The Term Sheet was provided to all of the MSA settling states for their review and consideration. A total of 17 states, the District of Columbia and Puerto Rico, collectively representing approximately 42% allocable share, joined the proposed settlement. RJR Tobacco and the other PMs indicated that they were prepared to go forward with the proposed settlement with that level of jurisdictional participation.
133
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The Term Sheet provided that the Arbitration Panel in place to deal with the 2003 NPM Adjustment (and other NPM Adjustment-related matters) must review the proposed settlement and enter an appropriate order to confirm for the Independent Auditor that it should implement, as necessary, the terms of the settlement agreement.
In March 2013, the Arbitration Panel entered a Stipulated Partial Settlement and Award, referred to as the Award, reflecting the financial terms of the Term Sheet. Shortly thereafter, the Independent Auditor issued a notice indicating that it intended to implement the financial provisions of the Term Sheet, and also issued various revised payment calculations pertaining to payment years 2009 through 2012 and final calculations pertaining to payment year 2013 that reflected implementation of the financial provisions of the Term Sheet.
Subsequently in 2013, Oklahoma, Connecticut and South Carolina joined the Term Sheet. Efforts by two states, Colorado and Ohio, to obtain injunctions to prevent implementation of the Award were unsuccessful that year.
In June 2014, Kentucky and Indiana, both of which were among the states found “non-diligent” by the Arbitration Panel, joined the Term Sheet on financial terms more favorable to the industry than those agreed to by the original signatory states. Twenty-four jurisdictions have joined the settlement representing approximately 49.87% allocable share.
On October 20, 2015, RJR Tobacco and certain other PMs (including SFNTC) entered into the NY Settlement Agreement with the State of New York to settle certain claims related to the NPM Adjustment. The NY Settlement Agreement resolves NPM Adjustment claims related to payment years from 2004 through 2014 and puts in place a new method to determine future adjustments from 2015 forward as to New York. With the addition of New York’s allocable share of 12.76%, RJR Tobacco has resolved the 2004 through 2014 NPM Adjustments with 25 jurisdictions, representing approximately 62.63% allocable share.
On February 8, 2016, Missouri conditionally joined the Term Sheet on financial terms more favorable to the industry than those received by the original signatory states. Various provisions regarding the timing of credits to be received by RJR Tobacco and the other PMs and disbursements to Missouri from the Disputed Payments Account are also set forth in the conditional joinder. Missouri’s joinder was conditioned upon the enactment by the Missouri legislature of Allocable Share Repeal legislation in Missouri with an effective date making such legislation applicable to NPM cigarettes sold in Missouri beginning no later than August 28, 2016. This condition was not satisfied, and thus the conditional joinder was terminated.
For additional information related to the Term Sheet, the NY Settlement Agreement and the 2003 NPM Adjustment, see “— Cost of Products Sold” in note 1.
Other Litigation and Developments
JTI Claims for Indemnification . By a purchase agreement dated March 9, 1999, amended and restated as of May 11, 1999, referred to as the 1999 Purchase Agreement, RJR and RJR Tobacco sold its international tobacco business to JTI. Under the 1999 Purchase Agreement, RJR and RJR Tobacco retained certain liabilities relating to the international tobacco business sold to JTI. Under its reading of the indemnification provisions of the 1999 Purchase Agreement, JTI has requested indemnification for damages allegedly arising out of these retained liabilities. As previously reported, a number of the indemnification claims between the parties relating to the activities of Northern Brands in Canada have been resolved. The other matters for which JTI has requested indemnification for damages under the indemnification provisions of the 1999 Purchase Agreement are described below:
|
• |
In a letter dated March 31, 2006, counsel for JTI stated that JTI would be seeking indemnification under the 1999 Purchase Agreement for any damages it may incur or may have incurred arising out of a Southern District of New York grand jury investigation, a now-terminated Eastern District of North Carolina grand jury investigation, and various actions filed by the European Community and others in the U.S. District Court for the Eastern District of New York, referred to as the EDNY, against RJR Tobacco and certain of its affiliates on November 3, 2000, August 6, 2001, and (as discussed in greater detail below) October 30, 2002, and against JTI on January 11, 2002. |
134
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
an unsuccessful motion to dismiss the action as barred by the statute of limitations were ultimately denied on November 4, 2016. Certification proceedings are pending. |
|
• |
Finally, JTI has advised RJR and RJR Tobacco of its view that, under the terms of the 1999 Purchase Agreement, RJR and RJR Tobacco are liable for approximately $1.85 million related to a judgment entered in 1998, plus interest and costs, in an action filed in Brazil by Lutz Hanneman, a former employee of a former RJR Tobacco subsidiary. RJR and RJR Tobacco deny that they are liable for this judgment under the terms of the 1999 Purchase Agreement. |
Although RJR and RJR Tobacco recognize that, under certain circumstances, they may have these and other unresolved indemnification obligations to JTI under the 1999 Purchase Agreement, RJR and RJR Tobacco disagree with JTI as to (1) what circumstances relating to any such matters may give rise to indemnification obligations by RJR and RJR Tobacco, and (2) the nature and extent of any such obligation. RJR and RJR Tobacco have conveyed their position to JTI, and the parties have agreed to resolve their differences at a later time.
European Community. In European Community v. RJR Nabisco, Inc. (U.S.D.C. E.D.N.Y., filed 2002), the European Community and several of its member states allege that RJR, RJR Tobacco and other currently and formerly related companies engaged in money laundering and other conduct violating civil RICO and a variety of common laws. The plaintiffs also allege that the defendants manufactured cigarettes that were eventually sold in Iraq in violation of U.S. sanctions. The plaintiffs seek compensatory, punitive and treble damages among other types of relief. On February 15, 2010, the defendants moved to dismiss, and the action has been stayed and largely inactive since then while the parties have litigated that motion. On March 8, 2011, the district court granted the defendants’ motion in part and dismissed the plaintiffs’ RICO claims. On May 13, 2011, the district court granted the remaining portion of the defendants’ motion and dismissed the plaintiffs’ state-law claims based on the court’s lack of subject matter jurisdiction. The plaintiffs appealed to the Second Circuit.
On April 29, 2014, the Second Circuit vacated and remanded in a decision concluding that (1) as pled, the RICO claims are within the scope of the RICO statute, and (2) the federal court has subject matter jurisdiction over the state-law claims. The defendants sought rehearing and rehearing en banc . On August 20, 2014, the Second Circuit denied panel rehearing and issued an amended opinion that, in addition to adhering to the earlier opinion, held that a civil RICO cause of action extends to extraterritorial injuries. The U.S. Supreme Court granted certiorari and, on June 20, 2016, reversed the Second Circuit’s decision and ordered the dismissal of the plaintiffs’ RICO damages claims, finding that RICO civil causes of action extend only to domestic injuries, which claims the plaintiffs had abandoned. The court also held that any private RICO claims for equitable relief must also rest on domestic injuries but reserved decision on whether the plaintiffs had alleged such claims. The court’s decision does not affect the plaintiffs’ common-law claims. After remand, the district court entered an order allowing the plaintiffs to file an amended complaint by October 24, 2016, which later was extended indefinitely. Once the amended complaint is filed, the parties have been directed to submit a joint briefing schedule for the defendants’ anticipated motion to dismiss. Further, the district court stayed discovery until ten days after entry of an order deciding the defendants’ anticipated motion to dismiss.
Fontem Patent Litigation . On April 4, 2016, a case was filed in federal court, Fontem Ventures B.V. and Fontem Holdings 1 B.V. v. R. J. Reynolds Vapor Company (U.S.D.C. C.D. Cal.), which alleges that VUSE products infringe four patents owned by Fontem purportedly directed to e-cigarettes. On May 3, 2016, Fontem filed a second complaint asserting that the VUSE products infringe two additional Fontem patents purportedly directed to e-cigarettes. On June 22, 2016, Fontem filed a third complaint asserting that the VUSE products infringe one additional Fontem patent purportedly directed to e-cigarettes. RJR Vapor filed an answer in the first case on June 27, 2016, and an amended answer on July 25, 2016. RJR Vapor also filed answers in the second and third cases on July 25, 2016. On June 29, 2016, RJR Vapor filed a motion to transfer the three cases to the Middle District of North Carolina, which was granted on August 8, 2016. The cases are now pending in the Middle District of North Carolina.
Also, RJR Vapor has filed petitions for inter partes review against six of the seven asserted patents. Two of the petitions have been granted, two denied, and the others are still pending decision.
FDA Litigation. On February 25, 2011, RJR Tobacco, Lorillard and Lorillard Tobacco jointly filed a lawsuit, Lorillard, Inc. v. U.S. Food and Drug Administration , in the U.S. District Court for the District of Columbia, challenging the composition of TPSAC which had been established by the FDA under the Family Smoking Prevention and Tobacco Control Act, referred to as the FDA Tobacco Act. The complaint alleges that certain members of the TPSAC and certain members of its Constituents Subcommittee have financial and appearance conflicts of interest that are disqualifying under federal ethics law and regulations, and that the TPSAC is not “fairly balanced,” as required by the Federal Advisory Committee Act, referred to as FACA. In March 2011, the plaintiffs filed an amended complaint, which added an additional claim, based on a nonpublic meeting of members of the TPSAC, in violation of the FACA. The court granted the plaintiffs’ unopposed motion to file a second amended complaint adding a count addressing the FDA’s refusal to produce all documents generated by the TPSAC and its subcommittee in preparation of the menthol report. On July 21,
135
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
2014, the court granted the plaintiffs’ summary judgment motions finding that three members of the TPSAC Committee had impermissible conflicts of interest. As relief, the court ordered the FDA to reconstitute the committee in conformance with the law and enjoined the agency from using or relying on the TPSAC’s 2011 Menthol Report. On September 18, 2014, the FDA appealed the decision to the D.C. Circuit. On January 15, 2016, the appellate court reversed the decision of the district court, finding that the plaintiffs did not have standing to challenge appointments of certain TPSAC members. Under the appellate court’s order, the three former committee members can serve once again on the TPSAC and FDA can rely on the TPSAC menthol report. On May 9, 2016, the plaintiffs’ petition for rehearing or rehearing en banc was denied. On May 18, 2016, the appellate court issued a mandate vacating the injunction that had barred use of the TPSAC menthol report and had ordered reconstitution of the TPSAC.
For a detailed description of the FDA Tobacco Act, see “— Governmental Activity” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Part II, Item 7.
Smokeless Tobacco Litigation
In 1999, when the IPIC litigation was first filed, the named defendants included manufacturers of smokeless products, including Conwood Company, LLC (now known as American Snuff Company, LLC) and others. When the IPIC plaintiffs filed discovery responses in IPIC listing the products they used, 41 of them listed a smokeless product. Six of those 41 plaintiffs listed a brand owned by American Snuff (Levi Garrett). Seven listed a brand (Beechnut) once manufactured by Lorillard Tobacco (now manufactured by National Tobacco Company). On December 3, 2001, the IPIC court severed all smokeless claims and all smokeless defendants from IPIC. There was no order staying the case during IPIC. In the ensuing 15 years, the plaintiffs in the severed cases did nothing to pursue the cases. The plaintiffs now seek to activate various smokeless claims, including certain plaintiffs whose cases were dismissed in IPIC after severance of the smokeless claims and whose claims are not counted in the 41 claims described above. After a status conference on July 11, 2016, the court set a schedule for briefing the issue of whether the severed claims should be dismissed because of the prolonged inaction in the case. On January 25, 2017, the trial court denied the defendants’ motion to dismiss those claims as abandoned. The plaintiffs are now free to move forward with their claims.
Tobacco Buyout Legislation
In 2004, legislation was passed eliminating the U.S. Government’s tobacco production controls and price support program. The buyout of tobacco quota holders provided for in the Fair and Equitable Tobacco Reform Act, referred to as FETRA, was funded by a direct quarterly assessment on every tobacco product manufacturer and importer, on a market-share basis measured on volume to which federal excise tax was applied. The aggregate cost of the buyout to the industry was approximately $9.9 billion, including approximately $9.6 billion payable to quota tobacco holders and growers through industry assessments over ten years, into 2014, and approximately $290 million for the liquidation of quota tobacco stock. RAI’s operating subsidiaries recorded the FETRA assessment on a quarterly basis as cost of goods sold. RAI’s operating subsidiaries’ overall share of the buyout approximated $2.5 billion prior to the deduction of permitted offsets under the MSA. The FETRA assessment expired in September 2014.
ERISA Litigation
In May 2002, in Tatum v. The R.J.R. Pension Investment Committee of the R. J. Reynolds Tobacco Company Capital Investment Plan , an employee of RJR Tobacco filed a class-action suit in the U.S. District Court for the Middle District of North Carolina, alleging that the defendants, RJR, RJR Tobacco, the RJR Employee Benefits Committee and the RJR Pension Investment Committee, violated the Employee Retirement Income Security Act of 1974, referred to as ERISA. The actions about which the plaintiff complains stem from a decision made in 1999 by RJR Nabisco Holdings Corp., subsequently renamed Nabisco Group Holdings Corp., referred to as NGH, to spin off RJR, thereby separating NGH’s tobacco business and food business. As part of the spin-off, the 401(k) plan for the previously related entities had to be divided into two separate plans for the now separate tobacco and food businesses. The plaintiff contends that the defendants breached their fiduciary duties to participants of the RJR 401(k) plan when the defendants removed the stock funds of the companies involved in the food business, NGH and Nabisco Holdings Corp., referred to as Nabisco, as investment options from the RJR 401(k) plan approximately six months after the spin-off. The plaintiff asserts that a November 1999 amendment (the “1999 Amendment”) that eliminated the NGH and Nabisco funds from the RJR 401(k) plan on January 31, 2000, contained sufficient discretion for the defendants to have retained the NGH and Nabisco funds after January 31, 2000, and that the failure to exercise such discretion was a breach of fiduciary duty. In his complaint, the plaintiff requests, among other things, that the court require the defendants to pay as damages to the RJR 401(k) plan an amount equal to the subsequent appreciation that was purportedly lost as a result of the liquidation of the NGH and Nabisco funds.
In July 2002, the defendants filed a motion to dismiss, which the court granted in December 2003. In December 2004, the U.S. Court of Appeals for the Fourth Circuit reversed the dismissal of the complaint, holding that the 1999 Amendment did contain sufficient discretion for the defendants to have retained the NGH and Nabisco funds as of February 1, 2000, and remanded the case for
136
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
further proceedings. The court granted the plaintiff leave to file an amended complaint and denied all pending motions as moot. In April 2007, the defendants moved to dismiss the amended complaint. The court granted the motion in part and denied it in part, dismissing all claims against the RJR Employee Benefits Committee and the RJR Pension Investment Committee. The plaintiff filed a motion for class certification, which the court granted in September 2008.
A non-jury trial was held in January and February 2010. On February 25, 2013, the district court dismissed the case with prejudice, finding that a hypothetical prudent fiduciary could have made the same decision and thus the plan’s loss was not caused by the procedural prudence which the court found to have existed. On August 4, 2014, the Fourth Circuit Court of Appeals, referred to as Fourth Circuit, reversed, holding that the district court applied the wrong standard when it held that the defendants did not cause any loss to the plan, determined the test was whether a hypothetical prudent fiduciary would have made the same decision and remanded the case back to the district court to apply the “would have standard.” On February 18, 2016, the district court dismissed the case with prejudice, finding that the defendants have shown by a preponderance of the evidence that a fiduciary acting with prudence would have divested the NGH and Nabisco Funds at the time and in the manner that the defendants did. On March 17, 2016, the plaintiff appealed arguing that the district court erred in finding that a hypothetical prudent fiduciary would have divested the NGH and Nabisco Funds at the same time and in the same manner as RJR. Briefing before the Fourth Circuit is complete. Oral argument occurred on January 25, 2017. A decision is pending.
Environmental Matters
RAI and its subsidiaries are subject to federal, state and local environmental laws and regulations concerning the discharge, storage, handling and disposal of hazardous or toxic substances. Such laws and regulations provide for significant fines, penalties and liabilities, sometimes without regard to whether the owner or operator of the property or facility knew of, or was responsible for, the release or presence of hazardous or toxic substances. In addition, third parties may make claims against owners or operators of properties for personal injuries and property damage associated with releases of hazardous or toxic substances. In the past, RJR Tobacco has been named a potentially responsible party with third parties under the Comprehensive Environmental Response, Compensation and Liability Act with respect to several superfund sites. RAI and its subsidiaries are not aware of any current environmental matters that are expected to have a material adverse effect on the business, results of operations or financial position of RAI or its subsidiaries.
RAI and its operating subsidiaries believe that climate change is an environmental issue primarily driven by carbon dioxide emissions from the use of energy. RAI’s operating subsidiaries are working to reduce carbon dioxide emissions by minimizing the use of energy where cost effective, minimizing waste to landfills and increasing recycling. Climate change is not viewed by RAI’s operating subsidiaries as a significant direct economic risk to their businesses, but rather an indirect risk involving the potential for a longer-term general increase in the cost of doing business. Regulatory changes are difficult to predict, but the current regulatory risks to the business of RAI’s operating subsidiaries with respect to climate change are relatively low. Financial impacts will be driven more by the cost of natural gas and electricity. Efforts are made to anticipate the effect of increases in fuel costs directly impacting RAI’s operating subsidiaries by evaluating natural gas usage and market conditions. Occasionally forward contracts are purchased, limited to a two-year period, for natural gas. In addition, RAI’s operating subsidiaries are continually evaluating energy conservation measures and energy efficient equipment to mitigate impacts of increases in energy costs, and adopting or utilizing such measures and equipment where appropriate.
Regulations promulgated by the EPA and other governmental agencies under various statutes have resulted in, and likely will continue to result in, substantial expenditures for pollution control, waste treatment or handling, facility modification and similar activities. RAI and its subsidiaries are engaged in a continuing program to comply with federal, state and local environmental laws and regulations, and dependent upon the probability of occurrence and reasonable estimation of cost, accrue or disclose any material liability. Although it is difficult to reasonably estimate the portion of capital expenditures or other costs attributable to compliance with environmental laws and regulations, RAI does not expect such expenditures or other costs to have a material adverse effect on the business, results of operations, cash flows or financial position of RAI or its subsidiaries.
Shareholder Case
RAI, the members of the RAI board of directors and BAT have been named as defendants in a putative class-action lawsuit captioned Corwin v. British American Tobacco PLC , et al ., brought in North Carolina state court, referred to as the North Carolina Action, by a person identifying himself as a shareholder of RAI. The North Carolina Action was initiated on August 8, 2014, and an amended complaint was filed on November 7, 2014. The amended complaint generally alleges, among other things, that the members of the RAI board of directors breached their fiduciary duties to RAI shareholders by approving the BAT Share Purchase and the sharing of technology with BAT, as well as that there were various conflicts of interest in the transaction. More specifically, the amended complaint alleges that (1) RAI aided and abetted the alleged breaches of fiduciary duties by its board of directors and (2)
137
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
BAT was a controlling shareholder of RAI and, as a consequence, owed other RAI shareholders fiduciary duties in connection with the BAT Share Purchase. The North Carolina Action seeks injunctive relief, damages and reimbursement of costs, among other remedies. On January 2, 2015, the plaintiff in the North Carolina Action filed a motion for a preliminary injunction seeking to enjoin temporarily the RAI shareholder meeting and votes scheduled for January 28, 2015. RAI and the RAI board of directors timely opposed that motion prior to a hearing that was scheduled to occur on January 16, 2015.
RAI believed that the North Carolina Action was without merit and that no further disclosure was necessary to supplement the Joint Proxy Statement/Prospectus under applicable laws. However, to eliminate certain burdens, expenses and uncertainties, on January 17, 2015, RAI and the director defendants in the North Carolina Action entered into the North Carolina Memorandum of Understanding regarding the settlement of the disclosure claims asserted in that lawsuit. The North Carolina Memorandum of Understanding outlines the terms of the parties’ agreement in principle to settle and release the disclosure claims which were or could have been asserted in the North Carolina Action. In consideration of the partial settlement and release, RAI agreed to make certain supplemental disclosures to the Joint Proxy Statement/Prospectus, which it did on January 20, 2015. On August 4, 2015, the trial court granted the defendants’ motions to dismiss all of the remaining non-disclosure claims. The plaintiff appealed. On February 17, 2016, the trial court approved the partial settlement, including the plaintiff’s unopposed request for $415,000 in attorneys’ fees and costs. The partial settlement did not affect the consideration paid to Lorillard shareholders in connection with the Lorillard Merger. On December 20, 2016, the North Carolina Court of Appeals affirmed the trial court’s dismissal of the claims against RAI and RAI’s Board of Directors on the grounds that the plaintiff could not state a direct claim against RAI’s Board of Directors for breach of fiduciary duties. The Court of Appeals reversed the dismissal of the claims against BAT. On January 4, 2017, BAT filed a motion for rehearing en banc of the Court of Appeals’ opinion, which was denied on February 2, 2017.
Other Contingencies
JTI Indemnities . In connection with the sale of the international tobacco business to JTI, pursuant to the 1999 Purchase Agreement, RJR and RJR Tobacco agreed to indemnify JTI against:
|
• |
any liabilities, costs and expenses arising out of the imposition or assessment of any tax with respect to the international tobacco business arising prior to the sale, other than as reflected on the closing balance sheet; |
|
• |
any liabilities, costs and expenses that JTI or any of its affiliates, including the acquired entities, may incur after the sale with respect to any of RJR’s or RJR Tobacco’s employee benefit and welfare plans; and |
|
• |
any liabilities, costs and expenses incurred by JTI or any of its affiliates arising out of certain activities of Northern Brands. |
As described above in “— Litigation Affecting the Cigarette Industry – Other Litigation and Developments – JTI Claims for Indemnification,” RJR Tobacco has received claims for indemnification from JTI, and several of these have been resolved. Although RJR and RJR Tobacco recognize that, under certain circumstances, they may have other unresolved indemnification obligations to JTI under the 1999 Purchase Agreement, RJR and RJR Tobacco disagree what circumstances described in such claims give rise to any indemnification obligations by RJR and RJR Tobacco and the nature and extent of any such obligation. RJR and RJR Tobacco have conveyed their position to JTI, and the parties have agreed to resolve their differences at a later date.
In connection with the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks to JTI Holding, along with the international companies that distribute and market the brand outside the United States, pursuant to the 2015 Purchase Agreement, SFNTC, R. J. Reynolds Global Products, Inc., and R. J. Reynolds Tobacco B.V. agreed to indemnify JTI Holding against, among other things, any liabilities, costs, and expenses relating to actions:
|
• |
commenced on or before (1) January 13, 2019, to the extent relating to alleged personal injuries, and (2) in all other cases, January 13, 2021; |
|
• |
brought by (1) a governmental authority to enforce legislation implementing European Union Directive 2001/37/EC or European Directive 2014/40/EU or (2) consumers or a consumer association; and |
|
• |
arising out of any statement or claim (1) made on or before January 13, 2016, (2) by any company sold to JTI Holding in the transaction, (3) concerning NATURAL AMERICAN SPIRIT brand products consumed or intended to be consumed outside of the United States and (4) that the NATURAL AMERICAN SPIRIT brand product is natural, organic, or additive free. |
ITG Indemnity . In the purchase agreement relating to the Divestiture, RAI agreed to defend and indemnify, subject to certain conditions and limitations, ITG in connection with claims relating to the purchase or use of one or more of the WINSTON, KOOL,
138
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
SALEM, or MAVERICK cigarette brands on or before June 12, 2015, as well as in actions filed before June 13, 2023, relating to the purchase or use of one or more of the WINSTON, KOOL, SALEM, or MAVERICK cigarette brands. In the purchase agreement relating to the Divestiture, ITG agreed to defend and indemnify, subject to certain conditions and limitations, RAI and its affiliates in connection with claims relating to the purchase or use of blu brand e-cigarettes. ITG also agreed to defend and indemnify, subject to certain conditions and limitations, RAI and its affiliates in actions filed after June 12, 2023, relating to the purchase or use of one or more of the WINSTON, KOOL, SALEM, or MAVERICK cigarette brands after June 12, 2015.
Loews Indemnity . In 2008, Loews Corporation, referred to as Loews, entered into an agreement with Lorillard, Lorillard Tobacco, and certain of their affiliates, which agreement is referred to as the Separation Agreement. In the Separation Agreement, Lorillard agreed to indemnify Loews and its officers, directors, employees and agents against all costs and expenses arising out of third party claims (including, without limitation, attorneys’ fees, interest, penalties and costs of investigation or preparation of defense), judgments, fines, losses, claims, damages, liabilities, taxes, demands, assessments, and amounts paid in settlement based on, arising out of or resulting from, among other things, Loews’s ownership of or the operation of Lorillard and its assets and properties, and its operation or conduct of its businesses at any time prior to or following the separation of Lorillard and Loews (including with respect to any product liability claims). Loews is a defendant in three pending product liability actions, each of which is a putative class action. Pursuant to the Separation Agreement, Lorillard is required to indemnify Loews for the amount of any losses and any legal or other fees with respect to such cases. Following the closing of the Lorillard Merger, RJR Tobacco assumed Lorillard’s obligations under the Separation Agreement as was required under the Separation Agreement.
Indemnification of Distributors and Retailers. RJR Tobacco, Lorillard Tobacco, SFNTC, American Snuff Co. and RJR Vapor have entered into agreements to indemnify certain distributors and retailers from liability and related defense costs arising out of the sale or distribution of their products. Additionally, SFNTC has entered into an agreement to indemnify a supplier from liability and related defense costs arising out of the sale or use of SFNTC’s products. The cost has been, and is expected to be, insignificant. RJR Tobacco, SFNTC, American Snuff Co. and RJR Vapor believe that the indemnified claims are substantially similar in nature and extent to the claims that they are already exposed to by virtue of their having manufactured those products.
Except as otherwise noted above, RAI is not able to estimate the maximum potential amount of future payments, if any, related to these indemnification obligations.
Lease Commitments
RAI has operating lease agreements that are primarily for automobiles, office space, warehouse space and equipment. The majority of these leases expire within the next five years and some contain renewal or purchase options and escalation clauses or restrictions to subleases. Total rent expense was $27 million, $26 million and $25 million for 2016, 2015 and 2014, respectively.
Future minimum lease payments as of December 31, 2016 (in millions) were as follows:
|
|
Noncancellable Operating Leases |
|
|
2017 |
|
$ |
20 |
|
2018 |
|
|
3 |
|
2019 |
|
|
2 |
|
2020 |
|
|
1 |
|
2021 |
|
|
1 |
|
Total |
|
$ |
27 |
|
Note 14 — Shareholders’ Equity
RAI’s authorized capital stock at December 31, 2016 and 2015, consisted of 100 million shares of preferred stock, par value $.01 per share, and 3.2 billion shares of common stock, par value $.0001 per share. Four million shares of the preferred stock are designated as Series A Junior Participating Preferred Stock, none of which is issued or outstanding. The Series A Junior Participating Preferred Stock will rank junior as to dividends and upon liquidation to all other series of RAI preferred stock, unless specified otherwise. Also, of the preferred stock, one million shares are designated as Series B Preferred Stock, all of which are issued and outstanding. The Series B Preferred Stock ranks senior upon liquidation, but not with respect to dividends, to all other series of RAI capital stock, unless specified otherwise. As a part of the B&W business combination, RJR is the holder of the outstanding Series B
139
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Preferred Stock. In each of 2016, 2015 and 2014, RAI declared $43 million in dividends to RJR with respect to the Series B Preferred Stock.
RAI’s board of directors declared the following quarterly cash dividends per share of RAI common stock in 2016, 2015 and 2014:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
First |
|
$ |
0.42 |
|
|
$ |
0.335 |
|
|
$ |
0.335 |
|
Second |
|
|
0.42 |
|
|
|
0.335 |
|
|
|
0.335 |
|
Third |
|
|
0.46 |
|
|
|
0.360 |
|
|
|
0.335 |
|
Fourth |
|
|
0.46 |
|
|
|
0.360 |
|
|
|
0.335 |
|
Accumulated Other Comprehensive Income (Loss)
The components of accumulated other comprehensive loss, net of tax, were as follows:
|
|
Retirement Benefits |
|
|
Long-Term Investments |
|
|
Hedging Instruments |
|
|
Cumulative Translation Adjustment and Other |
|
|
Total |
|
|||||
Balance at December 31, 2014 |
|
$ |
(294 |
) |
|
$ |
(14 |
) |
|
$ |
(12 |
) |
|
$ |
(44 |
) |
|
$ |
(364 |
) |
Other comprehensive income before reclassifications |
|
|
(78 |
) |
|
|
— |
|
|
|
— |
|
|
|
(25 |
) |
|
|
(103 |
) |
Amounts reclassified from accumulated other comprehensive income (loss) |
|
|
128 |
|
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
129 |
|
Net current-period other comprehensive income |
|
|
50 |
|
|
|
— |
|
|
|
1 |
|
|
|
(25 |
) |
|
|
26 |
|
Balance at December 31, 2015 |
|
|
(244 |
) |
|
|
(14 |
) |
|
|
(11 |
) |
|
|
(69 |
) |
|
|
(338 |
) |
Other comprehensive income before reclassifications |
|
|
(18 |
) |
|
|
— |
|
|
|
— |
|
|
|
(17 |
) |
|
|
(35 |
) |
Amounts reclassified from accumulated other comprehensive income (loss) |
|
|
7 |
|
|
|
14 |
|
|
|
11 |
|
|
|
27 |
|
|
|
59 |
|
Net current-period other comprehensive income |
|
|
(11 |
) |
|
|
14 |
|
|
|
11 |
|
|
|
10 |
|
|
|
24 |
|
Balance at December 31, 2016 |
|
$ |
(255 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(59 |
) |
|
$ |
(314 |
) |
140
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the consolidated statements of income for the years ended December 31, 2016, 2015 and 2014, were as follows:
|
|
Amounts Reclassified |
|
|
|
|||||||||
Components |
|
2016 |
|
|
2015 |
|
|
2014 |
|
|
Affected Line Item |
|||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
(20 |
) |
|
$ |
(20 |
) |
|
$ |
(21 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
(19 |
) |
|
|
(19 |
) |
|
|
(18 |
) |
|
Selling, general and administrative expenses |
Settlement cost |
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
Selling, general and administrative expenses |
MTM adjustment |
|
|
21 |
|
|
|
120 |
|
|
|
205 |
|
|
Cost of products sold |
MTM adjustment |
|
|
24 |
|
|
|
126 |
|
|
|
247 |
|
|
Selling, general and administrative expenses |
|
|
|
8 |
|
|
|
207 |
|
|
|
413 |
|
|
Operating income |
Deferred taxes |
|
|
(1 |
) |
|
|
(79 |
) |
|
|
(162 |
) |
|
Provision for income taxes |
Net of tax |
|
|
7 |
|
|
|
128 |
|
|
|
251 |
|
|
Net income |
Long-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Realized loss, net on long-term investments |
|
|
24 |
|
|
|
— |
|
|
|
— |
|
|
Other (income) expense, net |
Deferred taxes |
|
|
(10 |
) |
|
|
— |
|
|
|
— |
|
|
Provision for income taxes |
Net of tax |
|
|
14 |
|
|
|
— |
|
|
|
— |
|
|
Net income |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forward starting interest rate contracts |
|
|
16 |
|
|
|
— |
|
|
|
— |
|
|
Other (income) expense, net |
Amortization of realized loss |
|
|
1 |
|
|
|
2 |
|
|
|
2 |
|
|
Interest and debt expense |
|
|
|
17 |
|
|
|
2 |
|
|
|
2 |
|
|
Income from continuing operations before income taxes |
Deferred taxes |
|
|
(6 |
) |
|
|
(1 |
) |
|
|
(1 |
) |
|
Provision for income taxes |
Net of tax |
|
|
11 |
|
|
|
1 |
|
|
|
1 |
|
|
Net income |
Cumulative translation adjustment and other: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derecognition of cumulative translation adjustment |
|
|
27 |
|
|
|
— |
|
|
|
— |
|
|
Gain on divestitures |
Total reclassifications |
|
$ |
59 |
|
|
$ |
129 |
|
|
$ |
252 |
|
|
Net income |
Share Repurchases and Other
In November 2011, RAI, B&W and BAT entered into Amendment No. 3 to the governance agreement dated as of July 30, 2004, as amended, referred to as the Governance Agreement, pursuant to which RAI has agreed that, so long as the beneficial ownership interest of BAT and its subsidiaries in RAI has not dropped below 25%, if RAI issues shares of its common stock or any other RAI equity security to certain designated persons, including its directors, officers or employees, then RAI will repurchase a number of shares of outstanding RAI common stock so that the number of outstanding shares of RAI common stock are not increased, and the beneficial ownership interest of BAT and its subsidiaries in RAI is not decreased, by such issuance after taking into account such repurchase. During 2016, RAI repurchased and cancelled 1,817,846 shares of RAI common stock for $93 million in accordance with the Governance Agreement.
Restricted stock units granted in March 2013, May 2015, September 2014 and January 2016 under the Amended and Restated Omnibus Incentive Compensation Plan, referred to as the Omnibus Plan, vested in March 2016, May 2016, September 2016 and December 2016, respectively, and were settled with the issuance of 2,938,567 shares of RAI common stock. In addition, during the year ended December 31, 2016, at a cost of $58 million, RAI purchased 1,146,978 shares of RAI common stock that were forfeited and cancelled with respect to tax liabilities associated with restricted stock units vesting under the Omnibus Plan.
On July 25, 2016, the board of directors of RAI authorized the repurchase, from time to time, on or before December 31, 2018, of up to $2 billion of outstanding shares of RAI common stock in open-market or privately negotiated transactions, referred to as the Share Repurchase Program. The purchases are subject to prevailing market and business conditions, and the program may be terminated or suspended at any time. In connection with the Share Repurchase Program, B&W and Louisville Securities Limited, referred to as LSL, wholly owned subsidiaries of BAT, entered into an agreement, referred to as the Share Repurchase Agreement, with RAI, pursuant to which BAT and its subsidiaries will participate in the Share Repurchase Program on a basis approximately proportionate with BAT and its subsidiaries’ ownership of RAI’s common stock. During 2016, RAI repurchased 1,565,698 shares of
141
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
RAI common stock for $75 million in accordance with the Share Repurchase Program. The Merger Agreement places restrictions on RAI ’s ability to repurchase its common stock. As a result, RAI does not expect to make repurchases under the Share Repurchase Program while the Merger Agreement is in effect.
Due to RAI’s incorporation in North Carolina, which does not recognize treasury shares, the shares repurchased were cancelled at the time of repurchase.
Changes in RAI common stock outstanding were as follows:
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Shares outstanding at beginning of year |
|
|
1,427,341,341 |
|
|
|
1,062,567,026 |
|
|
|
1,076,106,048 |
|
Omnibus Plan tax shares repurchased and cancelled |
|
|
(1,146,978 |
) |
|
|
(1,111,835 |
) |
|
|
(1,108,084 |
) |
Omnibus Plan shares issued from vesting of restricted stock units |
|
|
2,938,567 |
|
|
|
2,870,927 |
|
|
|
2,936,588 |
|
Issuance of additional shares as Lorillard Merger Consideration |
|
|
— |
|
|
|
209,413,694 |
|
|
|
— |
|
Issuance of additional shares for BAT Share Purchase |
|
|
— |
|
|
|
155,360,518 |
|
|
|
— |
|
Shares repurchased and cancelled |
|
|
(3,383,544 |
) |
|
|
(1,822,197 |
) |
|
|
(15,431,526 |
) |
Equity incentive award plan shares issued |
|
|
75,569 |
|
|
|
63,208 |
|
|
|
64,000 |
|
Shares outstanding at end of year |
|
|
1,425,824,955 |
|
|
|
1,427,341,341 |
|
|
|
1,062,567,026 |
|
As of December 31, 2016, RAI had two stock plans, the Equity Incentive Award Plan for Directors of RAI, referred to as the EIAP, and the Omnibus Plan.
Under the EIAP, RAI currently provides grants of deferred stock units to eligible directors on a quarterly and annual basis, with the annual grant being made generally on the date of RAI’s annual shareholders’ meeting. Prior to September 13, 2012, upon election to RAI’s board of directors, an eligible director received an initial grant of 3,500 deferred stock units under the EIAP. After September 13, 2012, grants are no longer made to directors upon their initial election to the board of directors, but eligible directors initially elected to RAI’s board of directors after such date on a date other than the annual meeting date, and who, therefore, are not eligible to receive the annual stock award for such year, now receive a pro rata portion of the annual award upon election. Directors may elect to receive shares of common stock in lieu of their initial and annual grants of deferred stock units. A maximum of 4,000,000 shares, subject to anti-dilution adjustments, of common stock may be issued under this plan, of which 1,904,424 shares were available for grant as of December 31, 2016. Deferred stock units granted under the EIAP have a value equal to, and bear dividend equivalents at the same rate as, one share of RAI common stock, and have no voting rights. The dividends are paid as additional units in an amount equal to the number of shares of RAI common stock that could be purchased with the dividends on the date of payment. Generally, distribution of a director’s deferred stock units will be made on January 2 following his or her last year of service on the board; however, for all grants made under the EIAP after December 31, 2007, a director may elect to receive his or her deferred stock units on the later of January 2 of a specified year or January 2 following his or her last year of service on the board. At the election of a director, distribution may be made in one lump sum or in up to ten annual installments. A director is paid in cash for the units granted quarterly and in common stock for the units granted initially and annually, unless the director elects to receive cash for the initial and annual grants. Cash payments are based on the average closing price of RAI common stock during December of the year preceding payment. Compensation expense related to the EIAP was $14 million, $15 million and $10 million during 2016, 2015 and 2014, respectively.
Awards to key employees under the Omnibus Plan may be in the form of cash awards, incentive or non-incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units or other awards. Subject to adjustments as set forth in the Omnibus Plan, the number of shares of RAI common stock that may be issued with respect to awards under the Omnibus Plan will not exceed 76,000,000 shares in the aggregate. Upon retirement, a holder’s grant under the Omnibus Plan generally vests on a pro rata basis for the portion of the vesting service period that has elapsed, thereby maintaining an appropriate approximation of forfeitures related to retirement.
142
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Information regarding restricted stock unit awards outstanding as of December 31, 2016, under the Omnibus Plan was as follows:
Grant Year |
|
Number of Shares Granted |
|
|
Grant Price Per Share |
|
|
Vesting Date |
|
Number of Shares Cancelled and Vested |
|
|
Cumulative Dividends Per Share |
|
|
Ending Date of Performance Period |
||||
Three-year grants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014 |
|
|
2,098,696 |
|
|
$ |
26.645 |
|
|
March 3, 2017 |
|
|
504,776 |
|
|
$ |
4.02 |
|
|
December 31, 2016 |
2014 |
|
|
51,814 |
|
|
$ |
29.365 |
|
|
March 3, 2017 |
|
|
— |
|
|
$ |
3.02 |
|
|
December 31, 2016 |
2015 |
|
|
1,386,180 |
|
|
$ |
37.940 |
|
|
March 2, 2018 |
|
|
169,217 |
|
|
$ |
4.02 |
|
|
December 31, 2017 |
2015 |
|
|
17,196 |
|
|
$ |
36.300 |
|
|
March 2, 2018 |
|
|
— |
|
|
$ |
4.02 |
|
|
December 31, 2017 |
2016 |
|
|
1,071,544 |
|
|
$ |
50.490 |
|
|
March 1, 2019 |
|
|
83,454 |
|
|
$ |
5.04 |
|
|
December 31, 2018 |
2016 |
|
|
4,898 |
|
|
$ |
50.130 |
|
|
March 1, 2019 |
|
|
— |
|
|
$ |
4.62 |
|
|
December 31, 2018 |
2016 |
|
|
1,727 |
|
|
$ |
51.030 |
|
|
March 1, 2019 |
|
|
— |
|
|
$ |
4.20 |
|
|
December 31, 2018 |
2016 |
|
|
4,581 |
|
|
$ |
50.550 |
|
|
March 1, 2019 |
|
|
— |
|
|
$ |
4.20 |
|
|
December 31, 2018 |
2016 |
|
|
21,249 |
|
|
$ |
55.100 |
|
|
March 1, 2019 |
|
|
— |
|
|
$ |
3.78 |
|
|
December 31, 2018 |
2016 |
|
|
1,366 |
|
|
$ |
56.040 |
|
|
March 1, 2019 |
|
|
— |
|
|
$ |
3.36 |
|
|
December 31, 2018 |
One-year grant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
|
|
164,841 |
|
|
$ |
56.040 |
|
|
May 1, 2017 |
|
|
— |
|
|
$ |
1.68 |
|
|
April 30, 2017 |
Other grants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014 |
|
|
74,266 |
|
|
$ |
29.365 |
|
|
September 30, 2018 |
|
|
— |
|
|
N/A |
|
|
N/A |
|
2016 |
|
|
23,605 |
|
|
$ |
46.930 |
|
|
December 15, 2017 |
|
|
— |
|
|
N/A |
|
|
N/A |
|
2016 |
|
|
16,094 |
|
|
$ |
46.930 |
|
|
December 15, 2018 |
|
|
— |
|
|
N/A |
|
|
N/A |
|
2016 |
|
|
10,551 |
|
|
$ |
55.100 |
|
|
December 15, 2017 |
|
|
— |
|
|
N/A |
|
|
N/A |
|
2016 |
|
|
10,550 |
|
|
$ |
55.100 |
|
|
December 15, 2018 |
|
|
— |
|
|
N/A |
|
|
N/A |
Three-Year Grants and Other Grants
The grant date fair value was based on the per share closing price of RAI common stock on the date of grant. The actual number of shares granted is fixed. As an equity-based grant, compensation expense includes the vesting period lapsed. There were no shares issued during 2016 with respect to awards outstanding as of December 31, 2016. All outstanding grants will be settled exclusively in RAI common stock.
Upon settlement, each grantee of the three-year grants will receive a number of shares of RAI’s common stock equal to the product of the number of vested units and a percentage up to 150% based on the average RAI annual incentive award plan score over the three-year period ending on December 31 of the year prior to the vesting date. The other grants do not contain a performance measure.
One-Year Grant
The actual number of shares granted is fixed. As an equity-based grant, compensation expense will take into account the vesting period lapsed and will be calculated based on the per share closing price of RAI common stock as of the end of each quarter, which was $56.04 as of December 31, 2016. There were no shares issued during 2016 with respect to awards outstanding as of December 31, 2016. All outstanding grants will be settled exclusively in RAI common stock.
Upon settlement, the grantee will receive a number of shares of RAI’s common stock equal to the product of the number of vested units and a percentage up to 200% based on the overall performance of RAI and its subsidiaries during the one-year performance period beginning May 1, 2016, and ending April 30, 2017, against RAI’s 2016 annual incentive award program metrics and other performance factors.
Restricted Stock Unit Dividends
Dividends paid on shares of RAI common stock will accumulate on the restricted stock units and be paid to the grantee on the vesting date. If RAI fails to pay its shareholders cumulative dividends of at least the amounts shown above, then each award will be reduced by an amount equal to three times the percentage of the dividend underpayment, up to a maximum reduction of 50%. Dividends are accrued on the grants and included in other current liabilities, based on the vesting date of less than one year, and in
143
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
other noncurrent liabilities, based on the vesting date of greater than one year, in the consolidated balance sheets as of December 31, 2016 and 2015.
The changes in the number of RAI restricted stock units during 2016 were as follows:
|
|
Number of Stock Units |
|
|
Weighted Average Grant Date Fair Value Per Share |
|
||
Outstanding at beginning of year |
|
|
5,147,400 |
|
|
$ |
28.42 |
|
Granted |
|
|
1,354,611 |
|
|
|
51.15 |
|
Forfeited |
|
|
(224,490 |
) |
|
|
39.21 |
|
Vested |
|
|
(2,075,810 |
) |
|
|
25.11 |
|
Outstanding at end of year |
|
|
4,201,711 |
|
|
|
36.81 |
|
Total compensation expense related to stock-based compensation and the related tax benefits recognized in selling, general and administrative expenses in the consolidated statements of income as of December 31, were as follows:
Grant/Type |
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
2011 restricted stock units |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3 |
|
2012 restricted stock units |
|
|
— |
|
|
|
3 |
|
|
|
14 |
|
2013 restricted stock units |
|
|
3 |
|
|
|
20 |
|
|
|
15 |
|
2014 restricted stock units |
|
|
20 |
|
|
|
32 |
|
|
|
24 |
|
2015 restricted stock units |
|
|
30 |
|
|
|
24 |
|
|
|
— |
|
2016 restricted stock units |
|
|
24 |
|
|
|
— |
|
|
|
— |
|
Total compensation expense |
|
$ |
77 |
|
|
$ |
79 |
|
|
$ |
56 |
|
Total related tax benefits |
|
$ |
27 |
|
|
$ |
28 |
|
|
$ |
20 |
|
The amounts related to the unvested Omnibus Plan restricted stock unit grants included in the consolidated balance sheets as of December 31, were as follows:
|
|
2016 |
|
|
2015 |
|
||
Other current liabilities |
|
$ |
10 |
|
|
$ |
10 |
|
Other noncurrent liabilities |
|
|
7 |
|
|
|
8 |
|
Paid-in capital |
|
|
111 |
|
|
|
110 |
|
As of December 31, 2016, there were $63 million of unrecognized compensation costs related to restricted stock units, calculated at the grant-date price, which are expected to be recognized over a weighted-average period of 1.7 years. The excess tax benefits related to stock-based compensation were $28 million, $17 million and $12 million in 2016, 2015 and 2014, respectively.
There are no outstanding options under the EIAP or the Omnibus Plan, and as a result there was no share option activity during 2016 and 2015.
144
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Equity compensation plan information as of December 31, 2016, was as follows:
Plan Category |
|
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
|
|
|
Weighted Average Exercise Price of Outstanding Options, Warrants and Rights |
|
|
Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) |
|
|||
|
|
(a) |
|
|
|
(b) |
|
|
(c) |
|
|||
Equity Compensation Plans Approved by Security Holders |
|
|
6,317,451 |
|
(2) |
|
$ |
— |
|
|
|
62,307,352 |
|
Equity Compensation Plans Not Approved by Security Holders (1) |
|
|
— |
|
|
|
|
— |
|
|
|
1,904,424 |
|
Total |
|
|
6,317,451 |
|
(2) |
|
|
— |
|
|
|
64,211,776 |
|
(1) |
The EIAP was approved by RJR’s sole shareholder, Nabisco Group Holdings Corp., prior to RJR’s spin-off on June 15, 1999. |
(2) |
Consists of restricted stock units. These restricted stock units represent the maximum number of shares to be awarded under the best-case targets, and accordingly, may overstate expected dilution. |
Pension and Postretirement Benefit Plans
RAI sponsors a number of non-contributory defined benefit pension plans covering certain employees of RAI and its subsidiaries. RAI and a subsidiary provide health and life insurance benefits for certain retired employees of RAI and its subsidiaries and their dependents. These benefits are generally no longer provided to employees hired on or after January 1, 2004.
The changes in benefit obligations and plan assets, as well as the funded status of these plans at December 31 were as follows:
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Change in benefit obligations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Obligations at beginning of year |
|
$ |
6,738 |
|
|
$ |
6,389 |
|
|
$ |
1,210 |
|
|
$ |
1,251 |
|
Service cost |
|
|
16 |
|
|
|
26 |
|
|
|
2 |
|
|
|
2 |
|
Interest cost |
|
|
295 |
|
|
|
275 |
|
|
|
49 |
|
|
|
50 |
|
Actuarial (gain) loss |
|
|
95 |
|
|
|
(270 |
) |
|
|
(12 |
) |
|
|
(120 |
) |
Merger |
|
|
— |
|
|
|
756 |
|
|
|
— |
|
|
|
111 |
|
Benefits paid |
|
|
(434 |
) |
|
|
(431 |
) |
|
|
(87 |
) |
|
|
(84 |
) |
Settlements |
|
|
(36 |
) |
|
|
(7 |
) |
|
|
— |
|
|
|
— |
|
Obligations at end of year |
|
$ |
6,674 |
|
|
$ |
6,738 |
|
|
$ |
1,162 |
|
|
$ |
1,210 |
|
Change in plan assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at beginning of year |
|
$ |
5,351 |
|
|
$ |
5,309 |
|
|
$ |
241 |
|
|
$ |
259 |
|
Actual return on plan assets |
|
|
432 |
|
|
|
(131 |
) |
|
|
10 |
|
|
|
(1 |
) |
Employer contributions |
|
|
335 |
|
|
|
18 |
|
|
|
66 |
|
|
|
67 |
|
Merger |
|
|
— |
|
|
|
593 |
|
|
|
— |
|
|
|
— |
|
Benefits paid |
|
|
(434 |
) |
|
|
(431 |
) |
|
|
(87 |
) |
|
|
(84 |
) |
Settlements |
|
|
(36 |
) |
|
|
(7 |
) |
|
|
— |
|
|
|
— |
|
Fair value of plan assets at end of year |
|
$ |
5,648 |
|
|
$ |
5,351 |
|
|
$ |
230 |
|
|
$ |
241 |
|
Funded status |
|
$ |
(1,026 |
) |
|
$ |
(1,387 |
) |
|
$ |
(932 |
) |
|
$ |
(969 |
) |
For the pension benefit plans, the benefit obligation is the projected benefit obligation. For the postretirement benefit plans, the benefit obligation is the accumulated postretirement benefit obligation.
145
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
As of December 31, 2016, the improvement in pension benefits funded status is primarily due to employer contributions, updated mortality and other assumptions and higher return on plan assets partially offset by the decrease in the discount rate .
As of December 31, 2016, the improvement in postretirement benefits funded status is primarily due to updated mortality and health-care claims assumptions offset by the decrease in the discount rate.
As of December 31, 2015, the decline in pension benefits funded status is primarily a result of the acquired plans from the Lorillard Merger, lower return on plan assets, and updated assumptions offset by the increase in the discount rate.
As of December 31, 2015, the improvement in postretirement benefits funded status is primarily a result of the increase in the discount rate and updated assumptions offset by the acquired plans from the Lorillard Merger.
The changes in net actuarial (gain) loss impacted the funded status as follows:
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Net actuarial (gain) loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in discount rate |
|
$ |
266 |
|
|
$ |
(287 |
) |
|
$ |
38 |
|
|
$ |
(37 |
) |
Change in mortality table |
|
|
(101 |
) |
|
|
(128 |
) |
|
|
(14 |
) |
|
|
(21 |
) |
Actual return on plan assets |
|
|
(432 |
) |
|
|
131 |
|
|
|
(10 |
) |
|
|
1 |
|
Expected return on plan assets |
|
|
372 |
|
|
|
373 |
|
|
|
12 |
|
|
|
12 |
|
Other |
|
|
(69 |
) |
|
|
145 |
|
|
|
(37 |
) |
|
|
(62 |
) |
Net actuarial (gain) loss |
|
$ |
36 |
|
|
$ |
234 |
|
|
$ |
(11 |
) |
|
$ |
(107 |
) |
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Amounts recognized in the consolidated balance sheets consist of: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued benefit — other current liabilities |
|
$ |
(11 |
) |
|
$ |
(10 |
) |
|
$ |
(78 |
) |
|
$ |
(81 |
) |
Accrued benefit — long-term retirement benefits |
|
|
(1,015 |
) |
|
|
(1,377 |
) |
|
|
(854 |
) |
|
|
(888 |
) |
Net amount recognized |
|
|
(1,026 |
) |
|
|
(1,387 |
) |
|
|
(932 |
) |
|
|
(969 |
) |
Accumulated other comprehensive loss |
|
|
616 |
|
|
|
636 |
|
|
|
(146 |
) |
|
|
(183 |
) |
Net amounts recognized in the consolidated balance sheets |
|
$ |
(410 |
) |
|
$ |
(751 |
) |
|
$ |
(1,078 |
) |
|
$ |
(1,152 |
) |
Amounts included in accumulated other comprehensive loss were as follows as of December 31:
|
|
2016 |
|
|
2015 |
|
||||||||||||||||||
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
|
Total |
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
|
Total |
|
||||||
Prior service cost (credit) |
|
$ |
7 |
|
|
$ |
(95 |
) |
|
$ |
(88 |
) |
|
$ |
10 |
|
|
$ |
(137 |
) |
|
$ |
(127 |
) |
Net actuarial (gain) loss |
|
|
609 |
|
|
|
(51 |
) |
|
|
558 |
|
|
|
626 |
|
|
|
(46 |
) |
|
|
580 |
|
Deferred income taxes |
|
|
(256 |
) |
|
|
41 |
|
|
|
(215 |
) |
|
|
(262 |
) |
|
|
53 |
|
|
|
(209 |
) |
Accumulated other comprehensive loss |
|
$ |
360 |
|
|
$ |
(105 |
) |
|
$ |
255 |
|
|
$ |
374 |
|
|
$ |
(130 |
) |
|
$ |
244 |
|
146
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Changes in accumulated other comprehensive loss were as follows:
|
|
2016 |
|
|
2015 |
|
||||||||||||||||||
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
|
Total |
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
|
Total |
|
||||||
Net actuarial (gain) loss |
|
$ |
36 |
|
|
$ |
(11 |
) |
|
$ |
25 |
|
|
$ |
234 |
|
|
$ |
(107 |
) |
|
$ |
127 |
|
Amortization of prior service cost (credit) |
|
|
(3 |
) |
|
|
42 |
|
|
|
39 |
|
|
|
(3 |
) |
|
|
42 |
|
|
|
39 |
|
Prior service cost (credit) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
(1 |
) |
Settlement cost |
|
|
(2 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
(1 |
) |
MTM adjustment |
|
|
(51 |
) |
|
|
6 |
|
|
|
(45 |
) |
|
|
(246 |
) |
|
|
— |
|
|
|
(246 |
) |
Deferred income tax (benefit) expense |
|
|
6 |
|
|
|
(12 |
) |
|
|
(6 |
) |
|
|
6 |
|
|
|
26 |
|
|
|
32 |
|
Change in accumulated other comprehensive loss |
|
$ |
(14 |
) |
|
$ |
25 |
|
|
$ |
11 |
|
|
$ |
(10 |
) |
|
$ |
(40 |
) |
|
$ |
(50 |
) |
The pension MTM adjustment expense in 2016 is primarily a result of a decrease in the discount rate and was partially offset by pension asset return gains of $432 million versus an expected return of $372 million and updated mortality and other assumptions. The postretirement MTM adjustment gain in 2016 is primarily a result of updated mortality and health-care claims assumptions and was partially offset by a decrease in the discount rate.
The MTM adjustment expense in 2015 is primarily a result of pension asset return losses of $131 million versus an expected return of $373 million and was partially offset by an increase in the discount rate.
In March 2010, the Patient Protection Affordable Care Act, referred to as the PPACA, as amended by the Health Care and Reconciliation Act of 2010, was signed into law. The PPACA mandates health-care reforms with staggered effective dates from 2010 to 2018. The additional postretirement liability resulting from the material impacts of the PPACA have been included in the accumulated postretirement benefit obligation at December 31, 2016 and 2015. Given the complexity of the PPACA and the extended time period in which implementation is expected to occur, further adjustments to the accumulated postretirement benefit obligation may be necessary in the future.
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Weighted-average assumptions used to determine benefit obligations at December 31: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate |
|
|
4.16 |
% |
|
|
4.54 |
% |
|
|
4.12 |
% |
|
|
4.47 |
% |
Rate of compensation increase |
|
|
4.00 |
% |
|
|
4.00 |
% |
|
|
— |
|
|
|
— |
|
The measurement date used for all plans was December 31.
Pension plans experiencing accumulated benefit obligations, which represent benefits earned to date, in excess of plan assets are summarized below:
|
|
December 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
Projected benefit obligation |
|
$ |
6,674 |
|
|
$ |
6,738 |
|
Accumulated benefit obligation |
|
|
6,625 |
|
|
|
6,684 |
|
Plan assets |
|
|
5,648 |
|
|
|
5,351 |
|
147
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
The components of the total benefit cost (income) and assumptions are set forth below:
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
||||||||||||||||||
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
||||||
Service cost |
|
$ |
16 |
|
|
$ |
26 |
|
|
$ |
21 |
|
|
|
2 |
|
|
|
2 |
|
|
$ |
2 |
|
Interest cost |
|
|
295 |
|
|
|
275 |
|
|
|
266 |
|
|
|
49 |
|
|
|
50 |
|
|
|
53 |
|
Expected return on plan assets |
|
|
(372 |
) |
|
|
(373 |
) |
|
|
(360 |
) |
|
|
(12 |
) |
|
|
(12 |
) |
|
|
(12 |
) |
Amortization of prior service cost (credit) |
|
|
3 |
|
|
|
3 |
|
|
|
3 |
|
|
|
(42 |
) |
|
|
(42 |
) |
|
|
(42 |
) |
Settlements |
|
|
2 |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
MTM adjustment |
|
|
51 |
|
|
|
246 |
|
|
|
420 |
|
|
|
(6 |
) |
|
|
— |
|
|
|
32 |
|
Total benefit cost (income) |
|
$ |
(5 |
) |
|
$ |
178 |
|
|
$ |
350 |
|
|
$ |
(9 |
) |
|
$ |
(2 |
) |
|
$ |
33 |
|
The estimated amortization of prior service cost for the pension plans is expected to be $3 million during 2017. The estimated amortization of prior service credit for the postretirement plans is expected to be $36 million during 2017.
|
|
Pension Benefits |
|
|
Postretirement Benefits |
|
||||||||||||||||||
|
|
2016 |
|
|
2015 (1) |
|
|
2014 |
|
|
2016 |
|
|
2015 (1) |
|
|
2014 |
|
||||||
Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate |
|
|
4.54 |
% |
|
|
4.14 |
% |
|
|
4.92 |
% |
|
|
4.47 |
% |
|
|
4.12 |
% |
|
|
4.87 |
% |
Expected long-term return on plan assets |
|
|
6.82 |
% |
|
|
6.83 |
% |
|
|
7.13 |
% |
|
|
4.60 |
% |
|
|
4.85 |
% |
|
|
4.85 |
% |
Rate of compensation increase |
|
|
4.00 |
% |
|
|
4.00 |
% |
|
|
4.00 |
% |
|
|
— |
|
|
|
— |
|
|
|
— |
|
(1) |
Determined as of the beginning of year and adjusted for the Lorillard Merger in 2015. |
Additional information relating to RAI’s significant postretirement plans is as follows:
|
|
2016 |
|
|
2015 |
|
||
Weighted-average health-care cost trend rate assumed for the following year |
|
|
7.00 |
% |
|
|
7.00 |
% |
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate) |
|
|
5.00 |
% |
|
|
5.00 |
% |
Year that the rate reaches the ultimate trend rate |
|
|
2025 |
|
|
|
2020 |
|
Assumed health-care cost trend rates have a significant effect on the amounts reported for the health-care plans. A one-percentage-point change in assumed health-care cost trend rates would have had the following effects at December 31, 2016:
|
|
1-Percentage Point Increase |
|
|
1-Percentage Point Decrease |
|
||
Effect on total of service and interest cost components |
|
$ |
2 |
|
|
$ |
(2 |
) |
Effect on benefit obligation |
|
|
58 |
|
|
|
(49 |
) |
During 2017, RAI expects to contribute $111 million to its pension plans and $78 million to its postretirement plans.
148
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Estimated future benefit payments:
|
|
|
|
|
|
Postretirement Benefits |
|
|||||||||
Year |
|
Pension Benefits |
|
|
Gross Projected Benefit Payments Before Medicare Part D Subsidies |
|
|
Expected Medicare Part D Subsidies |
|
|
Net Projected Benefit Payments After Medicare Part D Subsidies |
|
||||
2017 |
|
$ |
447 |
|
|
$ |
105 |
|
|
$ |
(2 |
) |
|
$ |
103 |
|
2018 |
|
|
443 |
|
|
|
90 |
|
|
|
(2 |
) |
|
|
88 |
|
2019 |
|
|
439 |
|
|
|
87 |
|
|
|
(2 |
) |
|
|
85 |
|
2020 |
|
|
436 |
|
|
|
85 |
|
|
|
(2 |
) |
|
|
83 |
|
2021 |
|
|
431 |
|
|
|
83 |
|
|
|
(2 |
) |
|
|
81 |
|
2022-2026 |
|
|
2,082 |
|
|
|
386 |
|
|
|
(11 |
) |
|
|
375 |
|
Pension and Postretirement Assets
RAI generally uses a hypothetical bond matching analysis to determine the discount rate. The discount rate modeling process involves selecting a portfolio of high quality corporate bonds whose cash flows, via coupons and maturities, match the projected cash flows of the obligations.
The overall expected long-term rate of return on asset assumptions for pension and postretirement assets are based on: (1) the target asset allocation for plan assets, (2) long-term capital markets forecasts for asset classes employed, and (3) excess return expectations of active management to the extent asset classes are actively managed.
Plan assets are invested using active investment strategies and multiple investment management firms. Managers within each asset class cover a range of investment styles and approaches and are combined in a way that controls for capitalization, style bias, and interest rate exposures, while focusing primarily on security selection as a means to add value. Risk is controlled through diversification among asset classes, managers, investment styles and securities. Risk is further controlled both at the manager and asset class level by assigning excess return and tracking error targets against related benchmark indices. Investment manager performance is evaluated against these targets.
RAI employs a risk mitigation strategy, which seeks to balance pension plan returns with a reasonable level of funded status volatility. Based on this framework, the asset allocation has two primary components. The first component is the “hedging portfolio,” which uses extended duration fixed income holdings and derivatives to match a portion of the interest rate risk associated with the benefit obligations, thereby reducing expected funded status volatility. The second component is the “return seeking portfolio,” which is designed to enhance portfolio returns. The return seeking portfolio is broadly diversified across asset classes.
Allowable investment types include domestic equity, international equity, global equity, emerging market equity, fixed income, real assets, private equity, absolute return and commodities. The range of allowable investment types utilized for pension assets provides enhanced returns and more widely diversifies the plan. Domestic equities are composed of common stocks of large, medium and small companies. International equities include equity securities issued by companies domiciled outside the United States and in depository receipts, which represent ownership of securities of non-U.S. companies. Global equities include a combination of both domestic and international equities. Emerging market equities are comprised of stocks that are domiciled in less developed, fast growing countries. Fixed income includes corporate debt obligations, fixed income securities issued or guaranteed by the U.S. government, and to a lesser extent by non-U.S. governments, mortgage backed securities, high yield securities, asset backed securities, municipal bonds and dollar-denominated obligations issued in the United States by non-U.S. banks and corporations. Real assets consist of publicly traded real estate investment trust securities, private real estate investments and private energy investments. Private equity consists of the unregistered securities of private and public companies. Absolute return investments are diversified portfolios utilizing multiple strategies that invest primarily in public securities, including equities and fixed income. Commodities utilize futures contracts to invest in a variety of energy, metal and agricultural goods.
For pension assets, futures and forward contracts are used for portfolio rebalancing and to approach fully invested portfolio positions. Otherwise, a small number of investment managers employ limited use of derivatives, including futures contracts, options on futures, forward contracts and interest rate swaps in place of direct investment in securities to gain efficient exposure to markets.
149
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
RAI’s pension and postretirement plans asset allocations at December 31, 2016 and 2015, by asset category were as follows:
|
|
Pension Plans |
|
|||||||||||||
|
|
2016 Target (1) |
|
|
2016 |
|
|
2015 Target (1) |
|
|
2015 |
|
||||
Asset Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic equities |
|
|
10 |
% |
|
|
12 |
% |
|
|
10 |
% |
|
|
10 |
% |
International equities |
|
|
8 |
% |
|
|
8 |
% |
|
|
8 |
% |
|
|
7 |
% |
Global equities |
|
|
9 |
% |
|
|
12 |
% |
|
|
9 |
% |
|
|
11 |
% |
Emerging market equities |
|
|
3 |
% |
|
|
2 |
% |
|
|
3 |
% |
|
|
2 |
% |
Fixed income |
|
|
53 |
% |
|
|
53 |
% |
|
|
53 |
% |
|
|
53 |
% |
Absolute return |
|
|
6 |
% |
|
|
7 |
% |
|
|
6 |
% |
|
|
8 |
% |
Private equity |
|
|
2 |
% |
|
|
2 |
% |
|
|
2 |
% |
|
|
2 |
% |
Real assets |
|
|
5 |
% |
|
|
4 |
% |
|
|
5 |
% |
|
|
5 |
% |
Commodities |
|
|
4 |
% |
|
|
— |
|
|
|
4 |
% |
|
|
2 |
% |
Total |
|
|
100 |
% |
|
|
100 |
% |
|
|
100 |
% |
|
|
100 |
% |
|
|
Postretirement Plans |
|
|||||||||||||
|
|
2016 Target (1) |
|
|
2016 |
|
|
2015 Target (1) |
|
|
2015 |
|
||||
Asset Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic equities |
|
|
21 |
% |
|
|
22 |
% |
|
|
21 |
% |
|
|
20 |
% |
International equities |
|
|
21 |
% |
|
|
20 |
% |
|
|
21 |
% |
|
|
21 |
% |
Fixed income |
|
|
55 |
% |
|
|
51 |
% |
|
|
55 |
% |
|
|
54 |
% |
Cash and other |
|
|
3 |
% |
|
|
7 |
% |
|
|
3 |
% |
|
|
5 |
% |
Total |
|
|
100 |
% |
|
|
100 |
% |
|
|
100 |
% |
|
|
100 |
% |
(1) |
Allows for a rebalancing range of up to 5 percentage points around target asset allocations. |
RAI’s pension and postretirement plan assets, excluding uninvested cash and unsettled trades, carried at fair value on a recurring basis as of December 31, 2016 and 2015, were as follows (1) :
|
|
2016 |
|
|
2015 |
|
||||||||||||||||||||||||||
Pension Plans |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||||||
Asset Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic equities |
|
$ |
457 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
457 |
|
|
$ |
410 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
410 |
|
Global equities |
|
|
635 |
|
|
|
— |
|
|
|
— |
|
|
|
635 |
|
|
|
585 |
|
|
|
— |
|
|
|
— |
|
|
|
585 |
|
International equities |
|
|
137 |
|
|
|
— |
|
|
|
— |
|
|
|
137 |
|
|
|
144 |
|
|
|
— |
|
|
|
— |
|
|
|
144 |
|
Real assets |
|
|
23 |
|
|
|
— |
|
|
|
— |
|
|
|
23 |
|
|
|
21 |
|
|
|
— |
|
|
|
— |
|
|
|
21 |
|
Agency bonds |
|
|
— |
|
|
|
29 |
|
|
|
— |
|
|
|
29 |
|
|
|
— |
|
|
|
18 |
|
|
|
— |
|
|
|
18 |
|
Asset backed securities |
|
|
— |
|
|
|
52 |
|
|
|
1 |
|
|
|
53 |
|
|
|
— |
|
|
|
90 |
|
|
|
3 |
|
|
|
93 |
|
Corporate bonds |
|
|
— |
|
|
|
1,797 |
|
|
|
1 |
|
|
|
1,798 |
|
|
|
— |
|
|
|
1,718 |
|
|
|
1 |
|
|
|
1,719 |
|
Government bonds |
|
|
— |
|
|
|
78 |
|
|
|
— |
|
|
|
78 |
|
|
|
— |
|
|
|
91 |
|
|
|
— |
|
|
|
91 |
|
High yield fixed income |
|
|
— |
|
|
|
20 |
|
|
|
— |
|
|
|
20 |
|
|
|
— |
|
|
|
19 |
|
|
|
— |
|
|
|
19 |
|
Mortgage backed securities |
|
|
— |
|
|
|
75 |
|
|
|
— |
|
|
|
75 |
|
|
|
— |
|
|
|
41 |
|
|
|
— |
|
|
|
41 |
|
Municipal bonds |
|
|
— |
|
|
|
201 |
|
|
|
— |
|
|
|
201 |
|
|
|
— |
|
|
|
201 |
|
|
|
— |
|
|
|
201 |
|
Treasuries |
|
|
— |
|
|
|
554 |
|
|
|
— |
|
|
|
554 |
|
|
|
— |
|
|
|
550 |
|
|
|
— |
|
|
|
550 |
|
Cash equivalents and other |
|
|
28 |
|
|
|
332 |
|
|
|
2 |
|
|
|
362 |
|
|
|
33 |
|
|
|
90 |
|
|
|
2 |
|
|
|
125 |
|
Total investments in the fair value hierarchy |
|
$ |
1,280 |
|
|
$ |
3,138 |
|
|
$ |
4 |
|
|
|
4,422 |
|
|
$ |
1,193 |
|
|
$ |
2,818 |
|
|
$ |
6 |
|
|
|
4,017 |
|
Investments measured at net asset value (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,282 |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
5,672 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
5,299 |
|
150
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
|
2016 |
|
|
2015 |
|
||||||||||||||||||||||||||
Postretirement Plans |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||||||
Asset Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term bonds |
|
$ |
8 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
8 |
|
|
$ |
13 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
13 |
|
Cash equivalents and other |
|
|
— |
|
|
|
7 |
|
|
|
— |
|
|
|
7 |
|
|
|
— |
|
|
|
6 |
|
|
|
— |
|
|
|
6 |
|
Total investments in the fair value hierarchy |
|
$ |
8 |
|
|
$ |
7 |
|
|
$ |
— |
|
|
|
15 |
|
|
$ |
13 |
|
|
$ |
6 |
|
|
$ |
— |
|
|
|
19 |
|
Investments measured at net asset value (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
205 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
216 |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
220 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
235 |
|
(1) |
See note 1 for additional information on the fair value hierarchy. |
(2) |
Prior-year amounts were reclassified in accordance with the adoption of ASU 2015-07. |
For the years ended December 31, 2016 and 2015, there were no transfers among the fair value hierarchy levels.
At December 31, 2016 and 2015, the fair value of pension and postretirement assets classified as Level 1 was determined using a combination of third party pricing services for certain domestic equities, global equities, international equities, real assets and cash equivalents and other.
At December 31, 2016 and 2015, the fair value of pension and postretirement assets classified as Level 2 was determined using a combination of third party pricing services for certain agency bonds, asset backed securities, corporate bonds, government bonds, high yield fixed income, mortgage backed securities, municipal bonds, treasuries and cash equivalents and other.
The fair value of assets classified as asset backed securities, corporate bonds and other, classified as Level 3, was determined primarily using an income approach that utilized cash flow models and benchmarking strategies. This approach utilized inputs, including market-based interest rate curves, corporate credit spreads and corporate ratings. Additionally, unobservable factors incorporated into these models included default probability assumptions, potential recovery, discount rates and other entity specific factors.
In instances where the plans have invested in commingled pools, the net asset value was used as the practical expedient and no adjustments were made to the provided fair value. This approach utilized the net asset value of the underlying investment fund adjusted by the investment manager for restrictions or illiquidity of the disposition of the interest, if any, valuations provided by the fund’s cash flows, and the rights and obligations of the ownership interest of the fund.
Transfers of pension and postretirement plan assets in and out of Level 3 during 2016, by asset category were as follows (1) :
|
|
Balance as of January 1, 2016 |
|
|
Purchases, Sales, Issuances and Settlements (net) |
|
|
Realized Gains (Losses) |
|
|
Unrealized Gains (Losses) |
|
|
Transferred From Other Levels |
|
|
Balance as of December 31, 2016 |
|
||||||
Asset backed securities |
|
$ |
3 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(2 |
) |
|
$ |
— |
|
|
$ |
1 |
|
Corporate bonds |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Other |
|
|
2 |
|
|
|
— |
|
|
|
(28 |
) |
|
|
28 |
|
|
|
— |
|
|
|
2 |
|
Total |
|
$ |
6 |
|
|
$ |
— |
|
|
$ |
(28 |
) |
|
$ |
26 |
|
|
$ |
— |
|
|
$ |
4 |
|
Transfers of pension and postretirement plan assets in and out of Level 3 during 2015, by asset category were as follows (1) :
|
|
Balance as of January 1, 2015 |
|
|
Purchases, Sales, Issuances and Settlements (net) |
|
|
Realized Gains (Losses) |
|
|
Unrealized Gains (Losses) |
|
|
Transferred From Other Levels |
|
|
Balance as of December 31, 2015 |
|
||||||
Asset backed securities |
|
$ |
3 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3 |
|
Corporate bonds |
|
|
2 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Other |
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
Total |
|
$ |
7 |
|
|
$ |
(1 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
6 |
|
(1) |
See note 1 for additional information on the fair value hierarchy. |
151
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
RAI sponsors qualified defined contribution plans. The expense related to these plans was $41 million in 2016, $40 million in 2015 and $37 million in 2014. Included in the plans is a non-leveraged employee stock ownership plan, which holds shares of the Reynolds Stock Fund. Participants can elect to contribute to the fund. Dividends paid on shares are reflected as a reduction of equity. All shares are considered outstanding for earnings per share computations.
RAI’s reportable operating segments are RJR Tobacco, Santa Fe and American Snuff. The RJR Tobacco segment consists of the primary operations of R. J. Reynolds Tobacco Company. The Santa Fe segment consists of the primary operations of SFNTC. The American Snuff segment consists of the primary operations of American Snuff Co. Included in All Other, among other RAI subsidiaries, are RJR Vapor, Niconovum USA, Inc., Niconovum AB, and until their sale on January 13, 2016, SFRTI and various foreign subsidiaries affiliated with SFRTI. The segments were identified based on how RAI’s chief operating decision maker allocates resources and assesses performance. Certain of RAI’s operating subsidiaries have entered into intercompany agreements for products or services with other subsidiaries. As a result, certain activities of an operating subsidiary may be included in a different segment of RAI.
RAI’s largest reportable operating segment, RJR Tobacco, is the second largest tobacco company in the United States. Its brands include three of the top four best-selling cigarettes in the United States: NEWPORT, CAMEL and PALL MALL. These brands, and its other brands, including DORAL, MISTY and CAPRI, are manufactured in a variety of styles and marketed in the United States. As part of its total tobacco strategy, RJR Tobacco also offers a smoke-free tobacco product, CAMEL Snus. RJR Tobacco manages contract manufacturing of cigarette and tobacco products through arrangements with BAT affiliates, and manages the export of tobacco products to U.S. territories, U.S. duty-free shops and U.S. overseas military bases. RJR Tobacco also manages the super-premium cigarettes, DUNHILL and STATE EXPRESS 555, which are licensed from BAT. For additional information regarding related parties, see note 18.
Santa Fe manufactures and markets super-premium cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand in the United States.
American Snuff is the second largest smokeless tobacco products manufacturer in the United States. American Snuff’s primary brands include its largest selling moist snuff brands, GRIZZLY and KODIAK.
RJR Vapor is a marketer of digital vapor cigarettes, manufactured on its behalf by RJR Tobacco, under the VUSE brand name in the United States. Niconovum USA, Inc. and Niconovum AB are marketers of nicotine replacement therapy products in the United States and Sweden, respectively, under the ZONNIC brand name.
SFRTI and various foreign subsidiaries affiliated with SFRTI distributed the NATURAL AMERICAN SPIRIT brand outside the United States. On January 13, 2016, RAI, through the Sellers, completed the sale of the international rights to the NATURAL AMERICAN SPIRIT brand name and associated trademarks, along with the international companies that distributed and marketed the brand outside the United States to JTI Holding, in an all-cash transaction of approximately $5 billion and recognized a pre-tax gain of approximately $4.9 billion. See note 3 for additional information.
Intersegment revenues and items below the operating income line of the consolidated statements of income are not presented by segment, since they are excluded from the measure of segment profitability reviewed by RAI’s chief operating decision maker. Additionally, information about total assets by segment is not reviewed by RAI’s chief operating decision maker and therefore is not disclosed.
152
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco |
|
$ |
10,314 |
|
|
$ |
8,634 |
|
|
$ |
6,767 |
|
Santa Fe |
|
|
973 |
|
|
|
818 |
|
|
|
658 |
|
American Snuff |
|
|
914 |
|
|
|
855 |
|
|
|
783 |
|
All Other |
|
|
302 |
|
|
|
368 |
|
|
|
263 |
|
Consolidated net sales |
|
$ |
12,503 |
|
|
$ |
10,675 |
|
|
$ |
8,471 |
|
Operating income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco (1)(2) |
|
$ |
4,922 |
|
|
$ |
3,359 |
|
|
$ |
2,173 |
|
Santa Fe |
|
|
546 |
|
|
|
449 |
|
|
|
337 |
|
American Snuff (2) |
|
|
541 |
|
|
|
502 |
|
|
|
438 |
|
All Other (3) |
|
|
(145 |
) |
|
|
(265 |
) |
|
|
(234 |
) |
Gain on divestitures |
|
|
4,861 |
|
|
|
3,181 |
|
|
|
— |
|
Corporate Expense (2) |
|
|
(156 |
) |
|
|
(273 |
) |
|
|
(183 |
) |
Consolidated operating income |
|
$ |
10,569 |
|
|
$ |
6,953 |
|
|
$ |
2,531 |
|
Cash capital expenditures: |
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco |
|
$ |
130 |
|
|
$ |
84 |
|
|
$ |
53 |
|
Santa Fe |
|
|
12 |
|
|
|
16 |
|
|
|
7 |
|
American Snuff |
|
|
22 |
|
|
|
10 |
|
|
|
12 |
|
All Other |
|
|
42 |
|
|
|
64 |
|
|
|
132 |
|
Consolidated capital expenditures |
|
$ |
206 |
|
|
$ |
174 |
|
|
$ |
204 |
|
Depreciation and amortization expense: |
|
|
|
|
|
|
|
|
|
|
|
|
RJR Tobacco |
|
$ |
77 |
|
|
$ |
71 |
|
|
$ |
65 |
|
Santa Fe |
|
|
4 |
|
|
|
3 |
|
|
|
3 |
|
American Snuff |
|
|
16 |
|
|
|
17 |
|
|
|
17 |
|
All Other |
|
|
26 |
|
|
|
31 |
|
|
|
21 |
|
Consolidated depreciation and amortization expense |
|
$ |
123 |
|
|
$ |
122 |
|
|
$ |
106 |
|
Reconciliation to income from continuing operations before income taxes: |
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated operating income (1)(2)(3) |
|
$ |
10,569 |
|
|
$ |
6,953 |
|
|
$ |
2,531 |
|
Interest and debt expense |
|
|
626 |
|
|
|
570 |
|
|
|
286 |
|
Interest income |
|
|
(8 |
) |
|
|
(6 |
) |
|
|
(3 |
) |
Other (income) expense, net |
|
|
260 |
|
|
|
5 |
|
|
|
(14 |
) |
Income from continuing operations before income taxes |
|
$ |
9,691 |
|
|
$ |
6,384 |
|
|
$ |
2,262 |
|
(1) |
Includes NPM Adjustment credits of $388 million, $293 million and $341 million for RJR Tobacco for the years ended December 31, 2016, 2015 and 2014, respectively. |
(2) |
Includes MTM adjustment expense of $42 million for RJR Tobacco and $3 million for Corporate Expense for the year ended December 31, 2016. Includes MTM adjustment expense of $229 million for RJR Tobacco, $1 million for American Snuff and $16 million for Corporate Expense and All Other for the year ended December 31, 2015. Includes MTM adjustment expense of $422 million for RJR Tobacco, $4 million for American Snuff and $26 million for Corporate Expense and All Other for the year ended December 31, 2014. |
(3) |
Includes $99 million of asset impairment and exit charges for the year ended December 31, 2015. See note 6. |
Sales to McLane Company, Inc., a distributor, constituted approximately 28% of RAI’s consolidated revenue in each of 2016 and 2015 and 31% in 2014. Sales to Core-Mark International, Inc., a distributor, represented approximately 14%, 10% and 11% of RAI’s consolidated revenue in 2016, 2015 and 2014, respectively. McLane Company, Inc. and Core-Mark International, Inc. are customers of RJR Tobacco, Santa Fe and American Snuff. No other customer accounted for 10% or more of RAI’s consolidated revenue during those periods.
RAI’s operating subsidiaries’ sales to foreign countries, primarily to related parties, for the years ended December 31, 2016, 2015 and 2014 were $351 million, $482 million and $497 million, respectively.
153
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Note 18 — Related P arty Transactions
RAI and RAI’s operating subsidiaries engage in transactions with affiliates of BAT. BAT, through wholly owned subsidiaries, beneficially owns approximately 42% of RAI’s outstanding common stock. The following is a summary of balances and transactions with such BAT affiliates as of and for the years ended December 31:
|
|
2016 |
|
|
2015 |
|
||
Current Balances: |
|
|
|
|
|
|
|
|
Accounts receivable, related party |
|
$ |
113 |
|
|
$ |
38 |
|
Due to related party |
|
|
7 |
|
|
|
9 |
|
Deferred revenue, related party |
|
|
66 |
|
|
|
33 |
|
Other current liabilities |
|
|
— |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
Long-term Balances: |
|
|
|
|
|
|
|
|
Long-term deferred revenue, related party |
|
$ |
39 |
|
|
$ |
— |
|
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|||
Significant Transactions: |
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
226 |
|
|
$ |
259 |
|
|
$ |
311 |
|
Purchases |
|
|
21 |
|
|
|
38 |
|
|
|
28 |
|
BAT Share Purchase |
|
|
— |
|
|
|
4,673 |
|
|
|
— |
|
Share repurchase agreements |
|
|
32 |
|
|
|
— |
|
|
|
155 |
|
Research and development services billings |
|
|
1 |
|
|
|
3 |
|
|
|
4 |
|
RJR Tobacco sells contract-manufactured cigarettes, tobacco leaf and processed tobacco to BAT affiliates. In December 2012, RJR Tobacco entered into an amendment to its contract manufacturing agreement (relating to the production of cigarettes to be sold in Japan) with a BAT affiliate, which amendment, among other things, requires either party to provide three years’ notice to the other party to terminate the agreement without cause, with any such notice to be given no earlier than January 1, 2016. On January 4, 2016, RJR Tobacco received written notice from a BAT affiliate terminating that contract manufacturing agreement effective January 5, 2019. In July 2016, RJR Tobacco further amended the contract manufacturing agreement with a BAT affiliate to permit an early transition of the cigarette production covered by the agreement to BAT facilities over several months beginning in the fourth quarter of 2016. The amendment provides for a BAT affiliate to make a payment to RJR Tobacco of $89.6 million, in exchange for RJR Tobacco’s commitment to provide contingent manufacturing capacity to a BAT affiliate through December 31, 2018. Of this amount, $40.2 million was recorded as current deferred revenue and $38.9 million was recorded as long-term deferred revenue in RAI’s consolidated balance sheet as of December 31, 2016. The first installment of $7.4 million was received in September 2016. The second installment of $82.2 million is due on or before March 31, 2017. RJR Tobacco will recognize the income ratably from the effective date of the amendment to December 31, 2018. Net sales to BAT affiliates, primarily cigarettes, represented approximately 2% of RAI’s total net sales in each of 2016 and 2015, and 4% in 2014.
RJR Tobacco recorded deferred sales revenue relating to leaf sold to BAT affiliates that had not been delivered as of December 31, in each of 2016, 2015 and 2014, given that RJR Tobacco has a legal right to bill the BAT affiliates. Leaf sales revenue to BAT affiliates is recognized when the product is shipped to the customer.
RAI’s operating subsidiaries also purchase unprocessed leaf at market prices, and import cigarettes at prices not to exceed manufacturing costs plus 10%, from BAT affiliates.
RJR Tobacco performs certain research and development for BAT affiliates pursuant to a joint technology sharing agreement entered into as a part of the B&W business combination. These services were billed to BAT affiliates and were recorded in RJR Tobacco’s selling, general and administrative expenses, net of associated costs.
In January 2016, prior to the sale of the international rights to the NATURAL AMERICAN SPIRIT brand to JTI, SFRTI paid $6 million to a BAT affiliate pursuant to a contract manufacturing agreement, whereby the BAT affiliate agreed to contract manufacture certain tobacco products for SFRTI. The $6 million fee paid to amend the contract was recognized within selling, general and administrative expenses in the consolidated statements of income.
In connection with the Share Repurchase Program, B&W and LSL, wholly owned subsidiaries of BAT, entered into the Share Repurchase Agreement on July 25, 2016, with RAI, pursuant to which BAT and its subsidiaries will participate in the Share
154
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Repurchase Program on a basis approximately proportionate with BAT and its subsidiaries’ ownership of RAI common stock. Under the Share Repurchase Agreement, RAI repurchased 660,385 shares of RAI common stock for $32 million from BAT and its subsidiaries during the year ended December 31, 2016. The Merger Agreement places restrictions on RAI’ s ability to repurchase its common stock. As a result, RAI does not expect to make repurchases under the Share Repurchase Program while the Merger Agreement is in effect.
On June 12, 2015, RAI and BAT completed the BAT Share Purchase in connection with the Lorillard Merger and Divestiture. For additional information, see note 2.
In December 2015, RJR Tobacco and Nicoventures Holdings Limited, a subsidiary of BAT, signed a definitive vapor technology-sharing and licensing agreement, pursuant to which the companies collaborate on the development of next generation vapor products.
For information regarding the BAT Merger, see note 22.
Note 19 — RAI Guaranteed, Unsecured Notes — Condensed Consolidating Financial Statements
The following condensed consolidating financial statements relate to the guaranties of RAI’s $12.7 billion aggregate principal amount of unsecured notes. See note 12 for additional information relating to these notes. Certain of RAI’s direct, wholly owned subsidiaries and certain of its indirectly owned subsidiaries have fully and unconditionally, and jointly and severally, guaranteed these notes. The following condensed consolidating financial statements include: the accounts and activities of RAI, the parent issuer; RJR, RJR Tobacco, SFNTC, American Snuff Co. and certain of RAI’s other subsidiaries, the Guarantors; other direct and indirect subsidiaries of RAI that are not Guarantors; and elimination adjustments.
155
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Income
(Dollars in Millions)
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
For the Year Ended December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
— |
|
|
$ |
12,209 |
|
|
$ |
198 |
|
|
$ |
(130 |
) |
|
$ |
12,277 |
|
Net sales, related party |
|
|
— |
|
|
|
226 |
|
|
|
— |
|
|
|
— |
|
|
|
226 |
|
Net sales |
|
|
— |
|
|
|
12,435 |
|
|
|
198 |
|
|
|
(130 |
) |
|
|
12,503 |
|
Cost of products sold |
|
|
— |
|
|
|
4,787 |
|
|
|
185 |
|
|
|
(131 |
) |
|
|
4,841 |
|
Selling, general and administrative expenses |
|
|
41 |
|
|
|
1,721 |
|
|
|
167 |
|
|
|
2 |
|
|
|
1,931 |
|
Gain on divestitures |
|
|
— |
|
|
|
(4,843 |
) |
|
|
(16 |
) |
|
|
(2 |
) |
|
|
(4,861 |
) |
Amortization expense |
|
|
— |
|
|
|
22 |
|
|
|
1 |
|
|
|
— |
|
|
|
23 |
|
Operating income (loss) |
|
|
(41 |
) |
|
|
10,748 |
|
|
|
(139 |
) |
|
|
1 |
|
|
|
10,569 |
|
Interest and debt expense |
|
|
619 |
|
|
|
81 |
|
|
|
9 |
|
|
|
(83 |
) |
|
|
626 |
|
Interest income |
|
|
(84 |
) |
|
|
(6 |
) |
|
|
(1 |
) |
|
|
83 |
|
|
|
(8 |
) |
Other (income) expense, net |
|
|
244 |
|
|
|
(30 |
) |
|
|
3 |
|
|
|
43 |
|
|
|
260 |
|
Income (loss) before income taxes |
|
|
(820 |
) |
|
|
10,703 |
|
|
|
(150 |
) |
|
|
(42 |
) |
|
|
9,691 |
|
Provision for (benefit from) income taxes |
|
|
(171 |
) |
|
|
3,840 |
|
|
|
(51 |
) |
|
|
— |
|
|
|
3,618 |
|
Equity income from subsidiaries |
|
|
6,722 |
|
|
|
4 |
|
|
|
— |
|
|
|
(6,726 |
) |
|
|
— |
|
Net income (loss) |
|
$ |
6,073 |
|
|
$ |
6,867 |
|
|
$ |
(99 |
) |
|
$ |
(6,768 |
) |
|
$ |
6,073 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
— |
|
|
$ |
10,319 |
|
|
$ |
333 |
|
|
$ |
(236 |
) |
|
$ |
10,416 |
|
Net sales, related party |
|
|
— |
|
|
|
259 |
|
|
|
— |
|
|
|
— |
|
|
|
259 |
|
Net sales |
|
|
— |
|
|
|
10,578 |
|
|
|
333 |
|
|
|
(236 |
) |
|
|
10,675 |
|
Cost of products sold |
|
|
— |
|
|
|
4,673 |
|
|
|
248 |
|
|
|
(233 |
) |
|
|
4,688 |
|
Selling, general and administrative expenses |
|
|
79 |
|
|
|
1,738 |
|
|
|
281 |
|
|
|
— |
|
|
|
2,098 |
|
Gain on divestitures |
|
|
— |
|
|
|
(3,153 |
) |
|
|
(28 |
) |
|
|
— |
|
|
|
(3,181 |
) |
Amortization expense |
|
|
— |
|
|
|
18 |
|
|
|
— |
|
|
|
— |
|
|
|
18 |
|
Asset impairment and exit charges |
|
|
— |
|
|
|
99 |
|
|
|
— |
|
|
|
— |
|
|
|
99 |
|
Operating income (loss) |
|
|
(79 |
) |
|
|
7,203 |
|
|
|
(168 |
) |
|
|
(3 |
) |
|
|
6,953 |
|
Interest and debt expense |
|
|
559 |
|
|
|
104 |
|
|
|
7 |
|
|
|
(100 |
) |
|
|
570 |
|
Interest income |
|
|
(100 |
) |
|
|
(6 |
) |
|
|
— |
|
|
|
100 |
|
|
|
(6 |
) |
Other (income) expense, net |
|
|
20 |
|
|
|
(42 |
) |
|
|
(16 |
) |
|
|
43 |
|
|
|
5 |
|
Income (loss) before income taxes |
|
|
(558 |
) |
|
|
7,147 |
|
|
|
(159 |
) |
|
|
(46 |
) |
|
|
6,384 |
|
Provision for (benefit from) income taxes |
|
|
(224 |
) |
|
|
3,417 |
|
|
|
(62 |
) |
|
|
— |
|
|
|
3,131 |
|
Equity income from subsidiaries |
|
|
3,587 |
|
|
|
46 |
|
|
|
— |
|
|
|
(3,633 |
) |
|
|
— |
|
Net income (loss) |
|
$ |
3,253 |
|
|
$ |
3,776 |
|
|
$ |
(97 |
) |
|
$ |
(3,679 |
) |
|
$ |
3,253 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
— |
|
|
$ |
8,109 |
|
|
$ |
232 |
|
|
$ |
(181 |
) |
|
$ |
8,160 |
|
Net sales, related party |
|
|
— |
|
|
|
311 |
|
|
|
— |
|
|
|
— |
|
|
|
311 |
|
Net sales |
|
|
— |
|
|
|
8,420 |
|
|
|
232 |
|
|
|
(181 |
) |
|
|
8,471 |
|
Cost of products sold |
|
|
— |
|
|
|
4,002 |
|
|
|
235 |
|
|
|
(179 |
) |
|
|
4,058 |
|
Selling, general and administrative expenses |
|
|
75 |
|
|
|
1,535 |
|
|
|
261 |
|
|
|
— |
|
|
|
1,871 |
|
Amortization expense |
|
|
— |
|
|
|
11 |
|
|
|
— |
|
|
|
— |
|
|
|
11 |
|
Operating income (loss) |
|
|
(75 |
) |
|
|
2,872 |
|
|
|
(264 |
) |
|
|
(2 |
) |
|
|
2,531 |
|
Interest and debt expense |
|
|
286 |
|
|
|
79 |
|
|
|
6 |
|
|
|
(85 |
) |
|
|
286 |
|
Interest income |
|
|
(85 |
) |
|
|
(3 |
) |
|
|
— |
|
|
|
85 |
|
|
|
(3 |
) |
Other (income) expense, net |
|
|
4 |
|
|
|
(44 |
) |
|
|
(17 |
) |
|
|
43 |
|
|
|
(14 |
) |
Income (loss) from continuing operations before income taxes |
|
|
(280 |
) |
|
|
2,840 |
|
|
|
(253 |
) |
|
|
(45 |
) |
|
|
2,262 |
|
Provision for (benefit from) income taxes |
|
|
(89 |
) |
|
|
1,004 |
|
|
|
(98 |
) |
|
|
— |
|
|
|
817 |
|
Equity income from subsidiaries |
|
|
1,661 |
|
|
|
26 |
|
|
|
— |
|
|
|
(1,687 |
) |
|
|
— |
|
Income (loss) from continuing operations |
|
|
1,470 |
|
|
|
1,862 |
|
|
|
(155 |
) |
|
|
(1,732 |
) |
|
|
1,445 |
|
Income from discontinued operations, net of tax |
|
|
— |
|
|
|
25 |
|
|
|
— |
|
|
|
— |
|
|
|
25 |
|
Net income (loss) |
|
$ |
1,470 |
|
|
$ |
1,887 |
|
|
$ |
(155 |
) |
|
$ |
(1,732 |
) |
|
$ |
1,470 |
|
156
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Comprehensive Income
(Dollars in Millions)
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
For the Year Ended December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
6,073 |
|
|
$ |
6,867 |
|
|
$ |
(99 |
) |
|
$ |
(6,768 |
) |
|
$ |
6,073 |
|
Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits |
|
|
(11 |
) |
|
|
(12 |
) |
|
|
(4 |
) |
|
|
16 |
|
|
|
(11 |
) |
Long-term investments |
|
|
14 |
|
|
|
14 |
|
|
|
— |
|
|
|
(14 |
) |
|
|
14 |
|
Hedging instruments |
|
|
11 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11 |
|
Cumulative translation adjustment and other |
|
|
10 |
|
|
|
10 |
|
|
|
13 |
|
|
|
(23 |
) |
|
|
10 |
|
Comprehensive income (loss) |
|
$ |
6,097 |
|
|
$ |
6,879 |
|
|
$ |
(90 |
) |
|
$ |
(6,789 |
) |
|
$ |
6,097 |
|
For the Year Ended December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
3,253 |
|
|
$ |
3,776 |
|
|
$ |
(97 |
) |
|
$ |
(3,679 |
) |
|
$ |
3,253 |
|
Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits |
|
|
50 |
|
|
|
50 |
|
|
|
13 |
|
|
|
(63 |
) |
|
|
50 |
|
Hedging instruments |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Cumulative translation adjustment and other |
|
|
(25 |
) |
|
|
(27 |
) |
|
|
(37 |
) |
|
|
64 |
|
|
|
(25 |
) |
Comprehensive income (loss) |
|
$ |
3,279 |
|
|
$ |
3,799 |
|
|
$ |
(121 |
) |
|
$ |
(3,678 |
) |
|
$ |
3,279 |
|
For the Year Ended December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
1,470 |
|
|
$ |
1,887 |
|
|
$ |
(155 |
) |
|
$ |
(1,732 |
) |
|
$ |
1,470 |
|
Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits |
|
|
(277 |
) |
|
|
(271 |
) |
|
|
(1 |
) |
|
|
272 |
|
|
|
(277 |
) |
Long-term investments |
|
|
2 |
|
|
|
2 |
|
|
|
— |
|
|
|
(2 |
) |
|
|
2 |
|
Hedging instruments |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Cumulative translation adjustment and other |
|
|
(34 |
) |
|
|
(34 |
) |
|
|
(48 |
) |
|
|
82 |
|
|
|
(34 |
) |
Comprehensive income (loss) |
|
$ |
1,162 |
|
|
$ |
1,584 |
|
|
$ |
(204 |
) |
|
$ |
(1,380 |
) |
|
$ |
1,162 |
|
157
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the consolidating statement of income for the year ended December 31, 2016, were as follows:
Components |
|
Amount Reclassified |
|
|
Affected Line Item |
|||||||||||||||||
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|
|
|||||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
— |
|
|
$ |
(20 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(20 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
— |
|
|
|
(19 |
) |
|
|
— |
|
|
|
— |
|
|
|
(19 |
) |
|
Selling, general and administrative expenses |
Settlement cost |
|
|
— |
|
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Selling, general and administrative expenses |
MTM adjustment |
|
|
— |
|
|
|
21 |
|
|
|
— |
|
|
|
— |
|
|
|
21 |
|
|
Cost of products sold |
MTM adjustment |
|
|
4 |
|
|
|
26 |
|
|
|
(6 |
) |
|
|
— |
|
|
|
24 |
|
|
Selling, general and administrative expenses |
|
|
|
4 |
|
|
|
10 |
|
|
|
(6 |
) |
|
|
— |
|
|
|
8 |
|
|
Operating income (loss) |
Deferred taxes |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
4 |
|
|
|
9 |
|
|
|
(6 |
) |
|
|
— |
|
|
|
7 |
|
|
Net income (loss) |
Long-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Realized loss, net on long-term investments |
|
|
— |
|
|
|
24 |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
|
Other (income) expense, net |
Deferred taxes |
|
|
— |
|
|
|
(10 |
) |
|
|
— |
|
|
|
— |
|
|
|
(10 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
— |
|
|
|
14 |
|
|
|
— |
|
|
|
— |
|
|
|
14 |
|
|
Net income (loss) |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forward starting interest rate contracts |
|
|
16 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
16 |
|
|
Other (income) expense, net |
Amortization of realized loss |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
Interest and debt expense |
Deferred taxes |
|
|
(6 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
11 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11 |
|
|
Net income (loss) |
Cumulative translation adjustment and other: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derecognition of cumulative translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
27 |
|
|
|
— |
|
|
|
27 |
|
|
Gain on divestitures |
Equity income from subsidiaries |
|
|
44 |
|
|
|
21 |
|
|
|
— |
|
|
|
(65 |
) |
|
|
— |
|
|
Equity income from subsidiaries |
Total reclassifications |
|
$ |
59 |
|
|
$ |
44 |
|
|
$ |
21 |
|
|
$ |
(65 |
) |
|
$ |
59 |
|
|
Net income (loss) |
158
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the consolidating statement of income for the year ended December 31, 2015, were as follows:
Components |
|
Amount Reclassified |
|
|
Affected Line Item |
|||||||||||||||||
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|
|
|||||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
— |
|
|
$ |
(20 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(20 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
— |
|
|
|
(19 |
) |
|
|
— |
|
|
|
— |
|
|
|
(19 |
) |
|
Selling, general and administrative expenses |
MTM adjustment |
|
|
— |
|
|
|
120 |
|
|
|
— |
|
|
|
— |
|
|
|
120 |
|
|
Cost of products sold |
MTM adjustment |
|
|
5 |
|
|
|
121 |
|
|
|
— |
|
|
|
— |
|
|
|
126 |
|
|
Selling, general and administrative expenses |
|
|
|
5 |
|
|
|
202 |
|
|
|
— |
|
|
|
— |
|
|
|
207 |
|
|
Operating income (loss) |
Deferred taxes |
|
|
(1 |
) |
|
|
(78 |
) |
|
|
— |
|
|
|
— |
|
|
|
(79 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
4 |
|
|
|
124 |
|
|
|
— |
|
|
|
— |
|
|
|
128 |
|
|
Net income (loss) |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of realized loss |
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Interest and debt expense |
Deferred taxes |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
Net income (loss) |
Equity income from subsidiaries |
|
|
124 |
|
|
|
— |
|
|
|
— |
|
|
|
(124 |
) |
|
|
— |
|
|
Equity income from subsidiaries |
Total reclassifications |
|
$ |
129 |
|
|
$ |
124 |
|
|
$ |
— |
|
|
$ |
(124 |
) |
|
$ |
129 |
|
|
Net income (loss) |
159
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the consolidating statement of income for the year ended December 31, 2014, were as follows:
Components |
|
Amount Reclassified |
|
|
Affected Line Item |
|||||||||||||||||
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|
|
|||||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
— |
|
|
$ |
(21 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(21 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
— |
|
|
|
(18 |
) |
|
|
— |
|
|
|
— |
|
|
|
(18 |
) |
|
Selling, general and administrative expenses |
MTM adjustment |
|
|
— |
|
|
|
205 |
|
|
|
— |
|
|
|
— |
|
|
|
205 |
|
|
Cost of products sold |
MTM adjustment |
|
|
10 |
|
|
|
236 |
|
|
|
1 |
|
|
|
— |
|
|
|
247 |
|
|
Selling, general and administrative expenses |
|
|
|
10 |
|
|
|
402 |
|
|
|
1 |
|
|
|
— |
|
|
|
413 |
|
|
Operating income (loss) |
Deferred taxes |
|
|
(4 |
) |
|
|
(158 |
) |
|
|
— |
|
|
|
— |
|
|
|
(162 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
6 |
|
|
|
244 |
|
|
|
1 |
|
|
|
— |
|
|
|
251 |
|
|
Net income (loss) |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of realized loss |
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Interest and debt expense |
Deferred taxes |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
Net income (loss) |
Equity income from subsidiaries |
|
|
245 |
|
|
|
— |
|
|
|
— |
|
|
|
(245 |
) |
|
|
— |
|
|
Equity income from subsidiaries |
Total reclassifications |
|
$ |
252 |
|
|
$ |
244 |
|
|
$ |
1 |
|
|
$ |
(245 |
) |
|
$ |
252 |
|
|
Net income (loss) |
160
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Cash Flows
(Dollars in Millions)
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
For the Year Ended December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from (used in) operating activities |
|
$ |
(413 |
) |
|
$ |
3,162 |
|
|
$ |
(234 |
) |
|
$ |
(1,235 |
) |
|
$ |
1,280 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
— |
|
|
|
(211 |
) |
|
|
(7 |
) |
|
|
12 |
|
|
|
(206 |
) |
Proceeds from settlement of investments |
|
|
— |
|
|
|
266 |
|
|
|
— |
|
|
|
— |
|
|
|
266 |
|
Proceeds from divestitures |
|
|
5,015 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,015 |
|
Return of intercompany investments |
|
|
2,274 |
|
|
|
26 |
|
|
|
— |
|
|
|
(2,300 |
) |
|
|
— |
|
Contributions to intercompany investments |
|
|
(16 |
) |
|
|
— |
|
|
|
— |
|
|
|
16 |
|
|
|
— |
|
Other, net |
|
|
193 |
|
|
|
24 |
|
|
|
— |
|
|
|
(214 |
) |
|
|
3 |
|
Net cash flows from (used in) investing activities |
|
|
7,466 |
|
|
|
105 |
|
|
|
(7 |
) |
|
|
(2,486 |
) |
|
|
5,078 |
|
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(2,369 |
) |
|
|
(1,152 |
) |
|
|
(28 |
) |
|
|
1,180 |
|
|
|
(2,369 |
) |
Repurchase of common stock |
|
|
(226 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(226 |
) |
Repayments of long-term debt |
|
|
(415 |
) |
|
|
(85 |
) |
|
|
— |
|
|
|
— |
|
|
|
(500 |
) |
Early extinguishment of debt |
|
|
(3,642 |
) |
|
|
(8 |
) |
|
|
— |
|
|
|
— |
|
|
|
(3,650 |
) |
Premiums paid for early extinguishment of debt |
|
|
(206 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
(207 |
) |
Proceeds from termination of interest rate swaps |
|
|
— |
|
|
|
66 |
|
|
|
— |
|
|
|
— |
|
|
|
66 |
|
Debt issuance costs and financing fees |
|
|
(8 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
28 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
28 |
|
Dividends paid on preferred stock |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
Distribution of equity |
|
|
— |
|
|
|
(2,274 |
) |
|
|
(26 |
) |
|
|
2,300 |
|
|
|
— |
|
Receipt of equity |
|
|
— |
|
|
|
— |
|
|
|
16 |
|
|
|
(16 |
) |
|
|
— |
|
Other, net |
|
|
(21 |
) |
|
|
(360 |
) |
|
|
167 |
|
|
|
214 |
|
|
|
— |
|
Net cash flows from (used in) financing activities |
|
|
(6,902 |
) |
|
|
(3,814 |
) |
|
|
129 |
|
|
|
3,721 |
|
|
|
(6,866 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
|
|
— |
|
|
|
(8 |
) |
Net change in cash and cash equivalents |
|
|
151 |
|
|
|
(547 |
) |
|
|
(120 |
) |
|
|
— |
|
|
|
(516 |
) |
Cash and cash equivalents at beginning of year |
|
|
575 |
|
|
|
1,544 |
|
|
|
448 |
|
|
|
— |
|
|
|
2,567 |
|
Cash and cash equivalents at end of year |
|
$ |
726 |
|
|
$ |
997 |
|
|
$ |
328 |
|
|
$ |
— |
|
|
$ |
2,051 |
|
161
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Cash Flows
(Dollars in Millions)
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
For the Year Ended December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from (used in) operating activities |
|
$ |
(2,279 |
) |
|
$ |
3,219 |
|
|
$ |
6 |
|
|
$ |
(750 |
) |
|
$ |
196 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
— |
|
|
|
(160 |
) |
|
|
(12 |
) |
|
|
(2 |
) |
|
|
(174 |
) |
Proceeds from settlement of investments |
|
|
— |
|
|
|
332 |
|
|
|
— |
|
|
|
— |
|
|
|
332 |
|
Acquisition, net of cash acquired |
|
|
(18,278 |
) |
|
|
1,001 |
|
|
|
57 |
|
|
|
— |
|
|
|
(17,220 |
) |
Proceeds from divestitures |
|
|
7,056 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,056 |
|
Return of intercompany investments |
|
|
185 |
|
|
|
— |
|
|
|
— |
|
|
|
(185 |
) |
|
|
— |
|
Other, net |
|
|
10 |
|
|
|
22 |
|
|
|
— |
|
|
|
(31 |
) |
|
|
1 |
|
Net cash flows from (used in) investing activities |
|
|
(11,027 |
) |
|
|
1,195 |
|
|
|
45 |
|
|
|
(218 |
) |
|
|
(10,005 |
) |
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(1,583 |
) |
|
|
(709 |
) |
|
|
— |
|
|
|
709 |
|
|
|
(1,583 |
) |
Repurchase of common stock |
|
|
(124 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(124 |
) |
Proceeds from BAT Share Purchase |
|
|
4,673 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,673 |
|
Issuance of long-term debt |
|
|
8,975 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,975 |
|
Repayments of long-term debt |
|
|
(450 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(450 |
) |
Debt issuance costs and financing fees |
|
|
(70 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(70 |
) |
Borrowings under revolving credit facility |
|
|
1,400 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,400 |
|
Repayments of borrowings under revolving credit facility |
|
|
(1,400 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,400 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
17 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
17 |
|
Dividends paid on preferred stock |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
Distribution of equity |
|
|
— |
|
|
|
(185 |
) |
|
|
— |
|
|
|
185 |
|
|
|
— |
|
Other, net |
|
|
2,384 |
|
|
|
(2,445 |
) |
|
|
30 |
|
|
|
31 |
|
|
|
— |
|
Net cash flows from (used in) financing activities |
|
|
13,779 |
|
|
|
(3,339 |
) |
|
|
30 |
|
|
|
968 |
|
|
|
11,438 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
— |
|
|
|
— |
|
|
|
(28 |
) |
|
|
— |
|
|
|
(28 |
) |
Net change in cash and cash equivalents |
|
|
473 |
|
|
|
1,075 |
|
|
|
53 |
|
|
|
— |
|
|
|
1,601 |
|
Cash and cash equivalents at beginning of year |
|
|
102 |
|
|
|
469 |
|
|
|
395 |
|
|
|
— |
|
|
|
966 |
|
Cash and cash equivalents at end of year |
|
$ |
575 |
|
|
$ |
1,544 |
|
|
$ |
448 |
|
|
$ |
— |
|
|
$ |
2,567 |
|
162
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Cash Flows
(Dollars in Millions)
|
|
Parent |
|
|
|
|
|
|
Non- |
|
|
|
|
|
|
|
|
|
||
|
|
Issuer |
|
|
Guarantors |
|
|
Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
For the Year Ended December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from (used in) operating activities |
|
$ |
1,277 |
|
|
$ |
1,865 |
|
|
$ |
(179 |
) |
|
$ |
(1,340 |
) |
|
$ |
1,623 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
— |
|
|
|
(265 |
) |
|
|
(94 |
) |
|
|
155 |
|
|
|
(204 |
) |
Proceeds from termination of joint venture |
|
|
— |
|
|
|
— |
|
|
|
35 |
|
|
|
— |
|
|
|
35 |
|
Proceeds from settlement of investments |
|
|
— |
|
|
|
4 |
|
|
|
— |
|
|
|
— |
|
|
|
4 |
|
Return of intercompany investments |
|
|
165 |
|
|
|
— |
|
|
|
— |
|
|
|
(165 |
) |
|
|
— |
|
Contributions to intercompany investments |
|
|
(32 |
) |
|
|
— |
|
|
|
— |
|
|
|
32 |
|
|
|
— |
|
Other, net |
|
|
250 |
|
|
|
35 |
|
|
|
126 |
|
|
|
(451 |
) |
|
|
(40 |
) |
Net cash flows from (used in) investing activities |
|
|
383 |
|
|
|
(226 |
) |
|
|
67 |
|
|
|
(429 |
) |
|
|
(205 |
) |
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(1,411 |
) |
|
|
(1,301 |
) |
|
|
— |
|
|
|
1,301 |
|
|
|
(1,411 |
) |
Repurchase of common stock |
|
|
(440 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(440 |
) |
Borrowings under revolving credit facility |
|
|
1,000 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,000 |
|
Repayments of borrowings under revolving credit facility |
|
|
(1,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,000 |
) |
Debt issuance costs and financing fees |
|
|
(79 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(79 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
12 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
12 |
|
Dividends paid on preferred stock |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
Distribution of equity |
|
|
— |
|
|
|
(165 |
) |
|
|
— |
|
|
|
165 |
|
|
|
— |
|
Receipt of equity |
|
|
— |
|
|
|
— |
|
|
|
32 |
|
|
|
(32 |
) |
|
|
— |
|
Other, net |
|
|
(41 |
) |
|
|
(400 |
) |
|
|
149 |
|
|
|
292 |
|
|
|
— |
|
Net cash flows from (used in) financing activities |
|
|
(2,002 |
) |
|
|
(1,866 |
) |
|
|
181 |
|
|
|
1,769 |
|
|
|
(1,918 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
— |
|
|
|
— |
|
|
|
(34 |
) |
|
|
— |
|
|
|
(34 |
) |
Net change in cash and cash equivalents |
|
|
(342 |
) |
|
|
(227 |
) |
|
|
35 |
|
|
|
— |
|
|
|
(534 |
) |
Cash and cash equivalents at beginning of year |
|
|
444 |
|
|
|
696 |
|
|
|
360 |
|
|
|
— |
|
|
|
1,500 |
|
Cash and cash equivalents at end of year |
|
$ |
102 |
|
|
$ |
469 |
|
|
$ |
395 |
|
|
$ |
— |
|
|
$ |
966 |
|
163
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Balance Sheets
(Dollars in Millions)
|
|
Parent Issuer |
|
|
Guarantors |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
726 |
|
|
$ |
997 |
|
|
$ |
328 |
|
|
$ |
— |
|
|
$ |
2,051 |
|
Accounts receivable |
|
|
— |
|
|
|
62 |
|
|
|
4 |
|
|
|
— |
|
|
|
66 |
|
Accounts receivable, related party |
|
|
— |
|
|
|
113 |
|
|
|
— |
|
|
|
— |
|
|
|
113 |
|
Other receivables |
|
|
63 |
|
|
|
3,572 |
|
|
|
17 |
|
|
|
(3,642 |
) |
|
|
10 |
|
Inventories |
|
|
— |
|
|
|
1,604 |
|
|
|
43 |
|
|
|
(2 |
) |
|
|
1,645 |
|
Other current assets |
|
|
112 |
|
|
|
238 |
|
|
|
— |
|
|
|
3 |
|
|
|
353 |
|
Total current assets |
|
|
901 |
|
|
|
6,586 |
|
|
|
392 |
|
|
|
(3,641 |
) |
|
|
4,238 |
|
Property, plant and equipment, net |
|
|
2 |
|
|
|
1,314 |
|
|
|
32 |
|
|
|
— |
|
|
|
1,348 |
|
Trademarks and other intangible assets, net of accumulated amortization |
|
|
— |
|
|
|
29,432 |
|
|
|
14 |
|
|
|
(2 |
) |
|
|
29,444 |
|
Goodwill |
|
|
— |
|
|
|
15,976 |
|
|
|
16 |
|
|
|
— |
|
|
|
15,992 |
|
Long-term intercompany notes receivable |
|
|
1,390 |
|
|
|
148 |
|
|
|
— |
|
|
|
(1,538 |
) |
|
|
— |
|
Investment in subsidiaries |
|
|
36,865 |
|
|
|
333 |
|
|
|
— |
|
|
|
(37,198 |
) |
|
|
— |
|
Other assets and deferred charges |
|
|
80 |
|
|
|
52 |
|
|
|
37 |
|
|
|
(96 |
) |
|
|
73 |
|
Total assets |
|
$ |
39,238 |
|
|
$ |
53,841 |
|
|
$ |
491 |
|
|
$ |
(42,475 |
) |
|
$ |
51,095 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1 |
|
|
$ |
213 |
|
|
$ |
7 |
|
|
$ |
— |
|
|
$ |
221 |
|
Tobacco settlement accruals |
|
|
— |
|
|
|
2,498 |
|
|
|
— |
|
|
|
— |
|
|
|
2,498 |
|
Due to related party |
|
|
— |
|
|
|
7 |
|
|
|
— |
|
|
|
— |
|
|
|
7 |
|
Deferred revenue, related party |
|
|
— |
|
|
|
66 |
|
|
|
— |
|
|
|
— |
|
|
|
66 |
|
Current maturities of long-term debt |
|
|
448 |
|
|
|
53 |
|
|
|
— |
|
|
|
— |
|
|
|
501 |
|
Dividends payable on common stock |
|
|
656 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
656 |
|
Other current liabilities |
|
|
3,767 |
|
|
|
871 |
|
|
|
40 |
|
|
|
(3,642 |
) |
|
|
1,036 |
|
Total current liabilities |
|
|
4,872 |
|
|
|
3,708 |
|
|
|
47 |
|
|
|
(3,642 |
) |
|
|
4,985 |
|
Long-term intercompany notes payable |
|
|
148 |
|
|
|
900 |
|
|
|
490 |
|
|
|
(1,538 |
) |
|
|
— |
|
Long-term debt (less current maturities) |
|
|
12,404 |
|
|
|
260 |
|
|
|
— |
|
|
|
— |
|
|
|
12,664 |
|
Long-term deferred income taxes, net |
|
|
— |
|
|
|
9,700 |
|
|
|
— |
|
|
|
(93 |
) |
|
|
9,607 |
|
Long-term retirement benefits (less current portion) |
|
|
59 |
|
|
|
1,767 |
|
|
|
43 |
|
|
|
— |
|
|
|
1,869 |
|
Long-term deferred revenue, related party |
|
|
— |
|
|
|
39 |
|
|
|
— |
|
|
|
— |
|
|
|
39 |
|
Other noncurrent liabilities |
|
|
44 |
|
|
|
176 |
|
|
|
— |
|
|
|
— |
|
|
|
220 |
|
Shareholders’ equity |
|
|
21,711 |
|
|
|
37,291 |
|
|
|
(89 |
) |
|
|
(37,202 |
) |
|
|
21,711 |
|
Total liabilities and shareholders’ equity |
|
$ |
39,238 |
|
|
$ |
53,841 |
|
|
$ |
491 |
|
|
$ |
(42,475 |
) |
|
$ |
51,095 |
|
164
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Balance Sheets
(Dollars in Millions)
|
|
Parent |
|
|
|
|
|
|
Non- |
|
|
|
|
|
|
|
|
|
||
|
|
Issuer |
|
|
Guarantors |
|
|
Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|||||
December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
575 |
|
|
$ |
1,544 |
|
|
$ |
448 |
|
|
$ |
— |
|
|
$ |
2,567 |
|
Short-term investments |
|
|
— |
|
|
|
149 |
|
|
|
— |
|
|
|
— |
|
|
|
149 |
|
Accounts receivable |
|
|
— |
|
|
|
62 |
|
|
|
6 |
|
|
|
— |
|
|
|
68 |
|
Accounts receivable, related party |
|
|
— |
|
|
|
38 |
|
|
|
— |
|
|
|
— |
|
|
|
38 |
|
Other receivables |
|
|
70 |
|
|
|
3,459 |
|
|
|
91 |
|
|
|
(3,585 |
) |
|
|
35 |
|
Inventories |
|
|
— |
|
|
|
1,694 |
|
|
|
44 |
|
|
|
(4 |
) |
|
|
1,734 |
|
Other current assets |
|
|
116 |
|
|
|
323 |
|
|
|
129 |
|
|
|
(4 |
) |
|
|
564 |
|
Total current assets |
|
|
761 |
|
|
|
7,269 |
|
|
|
718 |
|
|
|
(3,593 |
) |
|
|
5,155 |
|
Property, plant and equipment, net |
|
|
3 |
|
|
|
1,223 |
|
|
|
29 |
|
|
|
— |
|
|
|
1,255 |
|
Trademarks and other intangible assets, net of accumulated amortization |
|
|
— |
|
|
|
29,467 |
|
|
|
— |
|
|
|
— |
|
|
|
29,467 |
|
Goodwill |
|
|
— |
|
|
|
15,976 |
|
|
|
17 |
|
|
|
— |
|
|
|
15,993 |
|
Long-term intercompany notes receivable |
|
|
1,583 |
|
|
|
169 |
|
|
|
— |
|
|
|
(1,752 |
) |
|
|
— |
|
Investment in subsidiaries |
|
|
37,151 |
|
|
|
662 |
|
|
|
— |
|
|
|
(37,813 |
) |
|
|
— |
|
Other assets and deferred charges |
|
|
189 |
|
|
|
212 |
|
|
|
38 |
|
|
|
(209 |
) |
|
|
230 |
|
Total assets |
|
$ |
39,687 |
|
|
$ |
54,978 |
|
|
$ |
802 |
|
|
$ |
(43,367 |
) |
|
$ |
52,100 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2 |
|
|
$ |
173 |
|
|
$ |
4 |
|
|
$ |
— |
|
|
$ |
179 |
|
Tobacco settlement accruals |
|
|
— |
|
|
|
2,816 |
|
|
|
— |
|
|
|
— |
|
|
|
2,816 |
|
Due to related party |
|
|
— |
|
|
|
9 |
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
Deferred revenue, related party |
|
|
— |
|
|
|
33 |
|
|
|
— |
|
|
|
— |
|
|
|
33 |
|
Current maturities of long-term debt |
|
|
420 |
|
|
|
86 |
|
|
|
— |
|
|
|
— |
|
|
|
506 |
|
Dividends payable on common stock |
|
|
514 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
514 |
|
Other current liabilities |
|
|
3,707 |
|
|
|
1,039 |
|
|
|
79 |
|
|
|
(3,591 |
) |
|
|
1,234 |
|
Total current liabilities |
|
|
4,643 |
|
|
|
4,156 |
|
|
|
83 |
|
|
|
(3,591 |
) |
|
|
5,291 |
|
Long-term intercompany notes payable |
|
|
169 |
|
|
|
1,260 |
|
|
|
323 |
|
|
|
(1,752 |
) |
|
|
— |
|
Long-term debt (less current maturities) |
|
|
16,522 |
|
|
|
327 |
|
|
|
— |
|
|
|
— |
|
|
|
16,849 |
|
Long-term deferred income taxes, net |
|
|
— |
|
|
|
9,410 |
|
|
|
— |
|
|
|
(206 |
) |
|
|
9,204 |
|
Long-term retirement benefits (less current portion) |
|
|
57 |
|
|
|
2,153 |
|
|
|
55 |
|
|
|
— |
|
|
|
2,265 |
|
Other noncurrent liabilities |
|
|
44 |
|
|
|
195 |
|
|
|
— |
|
|
|
— |
|
|
|
239 |
|
Shareholders’ equity |
|
|
18,252 |
|
|
|
37,477 |
|
|
|
341 |
|
|
|
(37,818 |
) |
|
|
18,252 |
|
Total liabilities and shareholders’ equity |
|
$ |
39,687 |
|
|
$ |
54,978 |
|
|
$ |
802 |
|
|
$ |
(43,367 |
) |
|
$ |
52,100 |
|
Note 20 — RJR Tobacco Guaranteed, Unsecured Notes — Condensed Consolidating Financial Statements
The following condensed consolidating financial statements relate to the guaranties of RJR Tobacco’s $284 million aggregate principal amount of unsecured notes, representing the Lorillard Tobacco Notes assumed by RJR Tobacco in connection with the Lorillard Tobacco Merger. RAI and RJR have fully and unconditionally, and jointly and severally, guaranteed these notes. The following condensed consolidating financial statements include: the accounts and activities of RAI, the Parent Guarantor; RJR Tobacco, the Issuer; RJR, a Guarantor; other direct and indirect subsidiaries of RAI that are not Guarantors; and elimination adjustments.
165
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Income
(Dollars in Millions)
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
||||||
For the Year Ended December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
— |
|
|
$ |
10,365 |
|
|
$ |
— |
|
|
$ |
2,229 |
|
|
$ |
(317 |
) |
|
$ |
12,277 |
|
Net sales, related party |
|
|
— |
|
|
|
226 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
226 |
|
Net sales |
|
|
— |
|
|
|
10,591 |
|
|
|
— |
|
|
|
2,229 |
|
|
|
(317 |
) |
|
|
12,503 |
|
Cost of products sold |
|
|
— |
|
|
|
4,323 |
|
|
|
— |
|
|
|
837 |
|
|
|
(319 |
) |
|
|
4,841 |
|
Selling, general and administrative expenses, net |
|
|
41 |
|
|
|
2,719 |
|
|
|
2 |
|
|
|
(834 |
) |
|
|
3 |
|
|
|
1,931 |
|
Gain on divestitures |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(4,861 |
) |
|
|
— |
|
|
|
(4,861 |
) |
Amortization expense |
|
|
— |
|
|
|
16 |
|
|
|
— |
|
|
|
7 |
|
|
|
— |
|
|
|
23 |
|
Operating income (loss) |
|
|
(41 |
) |
|
|
3,533 |
|
|
|
(2 |
) |
|
|
7,080 |
|
|
|
(1 |
) |
|
|
10,569 |
|
Interest and debt expense |
|
|
619 |
|
|
|
7 |
|
|
|
— |
|
|
|
86 |
|
|
|
(86 |
) |
|
|
626 |
|
Interest income |
|
|
(84 |
) |
|
|
(5 |
) |
|
|
(3 |
) |
|
|
(2 |
) |
|
|
86 |
|
|
|
(8 |
) |
Other (income) expense, net |
|
|
244 |
|
|
|
12 |
|
|
|
(42 |
) |
|
|
3 |
|
|
|
43 |
|
|
|
260 |
|
Income (loss) before income taxes |
|
|
(820 |
) |
|
|
3,519 |
|
|
|
43 |
|
|
|
6,993 |
|
|
|
(44 |
) |
|
|
9,691 |
|
Provision for (benefit from) income taxes |
|
|
(171 |
) |
|
|
1,247 |
|
|
|
(1 |
) |
|
|
2,543 |
|
|
|
— |
|
|
|
3,618 |
|
Equity income from subsidiaries |
|
|
6,722 |
|
|
|
850 |
|
|
|
3,142 |
|
|
|
— |
|
|
|
(10,714 |
) |
|
|
— |
|
Net income |
|
$ |
6,073 |
|
|
$ |
3,122 |
|
|
$ |
3,186 |
|
|
$ |
4,450 |
|
|
$ |
(10,758 |
) |
|
$ |
6,073 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
— |
|
|
$ |
8,714 |
|
|
$ |
— |
|
|
$ |
2,039 |
|
|
$ |
(337 |
) |
|
$ |
10,416 |
|
Net sales, related party |
|
|
— |
|
|
|
259 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
259 |
|
Net sales |
|
|
— |
|
|
|
8,973 |
|
|
|
— |
|
|
|
2,039 |
|
|
|
(337 |
) |
|
|
10,675 |
|
Cost of products sold |
|
|
— |
|
|
|
4,277 |
|
|
|
— |
|
|
|
746 |
|
|
|
(335 |
) |
|
|
4,688 |
|
Selling, general and administrative expenses, net |
|
|
79 |
|
|
|
2,318 |
|
|
|
3 |
|
|
|
(302 |
) |
|
|
— |
|
|
|
2,098 |
|
(Gain) loss on divestitures |
|
|
— |
|
|
|
1,887 |
|
|
|
— |
|
|
|
(5,068 |
) |
|
|
— |
|
|
|
(3,181 |
) |
Amortization expense |
|
|
— |
|
|
|
12 |
|
|
|
— |
|
|
|
6 |
|
|
|
— |
|
|
|
18 |
|
Asset impairment and exit charges |
|
|
— |
|
|
|
99 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
99 |
|
Operating income (loss) |
|
|
(79 |
) |
|
|
380 |
|
|
|
(3 |
) |
|
|
6,657 |
|
|
|
(2 |
) |
|
|
6,953 |
|
Interest and debt expense |
|
|
559 |
|
|
|
20 |
|
|
|
— |
|
|
|
94 |
|
|
|
(103 |
) |
|
|
570 |
|
Interest income |
|
|
(100 |
) |
|
|
(5 |
) |
|
|
(4 |
) |
|
|
— |
|
|
|
103 |
|
|
|
(6 |
) |
Other (income) expense, net |
|
|
20 |
|
|
|
2 |
|
|
|
(43 |
) |
|
|
(17 |
) |
|
|
43 |
|
|
|
5 |
|
Income (loss) before income taxes |
|
|
(558 |
) |
|
|
363 |
|
|
|
44 |
|
|
|
6,580 |
|
|
|
(45 |
) |
|
|
6,384 |
|
Provision for (benefit from) income taxes |
|
|
(224 |
) |
|
|
928 |
|
|
|
— |
|
|
|
2,427 |
|
|
|
— |
|
|
|
3,131 |
|
Equity income from subsidiaries |
|
|
3,587 |
|
|
|
3,732 |
|
|
|
3,185 |
|
|
|
— |
|
|
|
(10,504 |
) |
|
|
— |
|
Net income |
|
$ |
3,253 |
|
|
$ |
3,167 |
|
|
$ |
3,229 |
|
|
$ |
4,153 |
|
|
$ |
(10,549 |
) |
|
$ |
3,253 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
— |
|
|
$ |
6,728 |
|
|
$ |
— |
|
|
$ |
1,701 |
|
|
$ |
(269 |
) |
|
$ |
8,160 |
|
Net sales, related party |
|
|
— |
|
|
|
311 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
311 |
|
Net sales |
|
|
— |
|
|
|
7,039 |
|
|
|
— |
|
|
|
1,701 |
|
|
|
(269 |
) |
|
|
8,471 |
|
Cost of products sold |
|
|
— |
|
|
|
3,641 |
|
|
|
— |
|
|
|
686 |
|
|
|
(269 |
) |
|
|
4,058 |
|
Selling, general and administrative expenses |
|
|
75 |
|
|
|
1,629 |
|
|
|
6 |
|
|
|
161 |
|
|
|
— |
|
|
|
1,871 |
|
Amortization expense |
|
|
— |
|
|
|
4 |
|
|
|
— |
|
|
|
7 |
|
|
|
— |
|
|
|
11 |
|
Operating income (loss) |
|
|
(75 |
) |
|
|
1,765 |
|
|
|
(6 |
) |
|
|
847 |
|
|
|
— |
|
|
|
2,531 |
|
Interest and debt expense |
|
|
286 |
|
|
|
21 |
|
|
|
— |
|
|
|
67 |
|
|
|
(88 |
) |
|
|
286 |
|
Interest income |
|
|
(85 |
) |
|
|
(2 |
) |
|
|
(3 |
) |
|
|
(1 |
) |
|
|
88 |
|
|
|
(3 |
) |
Other (income) expense, net |
|
|
4 |
|
|
|
1 |
|
|
|
(45 |
) |
|
|
(17 |
) |
|
|
43 |
|
|
|
(14 |
) |
Income (loss) from continuing operations before income taxes |
|
|
(280 |
) |
|
|
1,745 |
|
|
|
42 |
|
|
|
798 |
|
|
|
(43 |
) |
|
|
2,262 |
|
Provision for (benefit from) income taxes |
|
|
(89 |
) |
|
|
627 |
|
|
|
(1 |
) |
|
|
280 |
|
|
|
— |
|
|
|
817 |
|
Equity income from subsidiaries |
|
|
1,661 |
|
|
|
279 |
|
|
|
1,425 |
|
|
|
— |
|
|
|
(3,365 |
) |
|
|
— |
|
Net income from continuing operations |
|
|
1,470 |
|
|
|
1,397 |
|
|
|
1,468 |
|
|
|
518 |
|
|
|
(3,408 |
) |
|
|
1,445 |
|
Income from discontinued operations, net of tax |
|
|
— |
|
|
|
25 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
25 |
|
Net income |
|
$ |
1,470 |
|
|
$ |
1,422 |
|
|
$ |
1,468 |
|
|
$ |
518 |
|
|
$ |
(3,408 |
) |
|
$ |
1,470 |
|
166
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Comprehensive Income
(Dollars in Millions)
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
||||||
For the Year Ended December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
6,073 |
|
|
$ |
3,122 |
|
|
$ |
3,186 |
|
|
$ |
4,450 |
|
|
$ |
(10,758 |
) |
|
$ |
6,073 |
|
Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits |
|
|
(11 |
) |
|
|
(6 |
) |
|
|
(10 |
) |
|
|
(5 |
) |
|
|
21 |
|
|
|
(11 |
) |
Long-term investments |
|
|
14 |
|
|
|
14 |
|
|
|
14 |
|
|
|
— |
|
|
|
(28 |
) |
|
|
14 |
|
Hedging instruments |
|
|
11 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11 |
|
Cumulative translation adjustment and other |
|
|
10 |
|
|
|
7 |
|
|
|
10 |
|
|
|
10 |
|
|
|
(27 |
) |
|
|
10 |
|
Comprehensive income |
|
$ |
6,097 |
|
|
$ |
3,137 |
|
|
$ |
3,200 |
|
|
$ |
4,455 |
|
|
$ |
(10,792 |
) |
|
$ |
6,097 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
3,253 |
|
|
$ |
3,167 |
|
|
$ |
3,229 |
|
|
$ |
4,153 |
|
|
$ |
(10,549 |
) |
|
$ |
3,253 |
|
Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits |
|
|
50 |
|
|
|
39 |
|
|
|
51 |
|
|
|
12 |
|
|
|
(102 |
) |
|
|
50 |
|
Hedging instruments |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Cumulative translation adjustment and other |
|
|
(25 |
) |
|
|
(25 |
) |
|
|
(25 |
) |
|
|
(26 |
) |
|
|
76 |
|
|
|
(25 |
) |
Comprehensive income |
|
$ |
3,279 |
|
|
$ |
3,181 |
|
|
$ |
3,255 |
|
|
$ |
4,139 |
|
|
$ |
(10,575 |
) |
|
$ |
3,279 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,470 |
|
|
$ |
1,422 |
|
|
$ |
1,468 |
|
|
$ |
518 |
|
|
$ |
(3,408 |
) |
|
$ |
1,470 |
|
Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retirement benefits |
|
|
(277 |
) |
|
|
(259 |
) |
|
|
(261 |
) |
|
|
(11 |
) |
|
|
531 |
|
|
|
(277 |
) |
Long-term investments |
|
|
2 |
|
|
|
2 |
|
|
|
2 |
|
|
|
— |
|
|
|
(4 |
) |
|
|
2 |
|
Hedging instruments |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Cumulative translation adjustment and other |
|
|
(34 |
) |
|
|
(32 |
) |
|
|
(32 |
) |
|
|
(33 |
) |
|
|
97 |
|
|
|
(34 |
) |
Comprehensive income |
|
$ |
1,162 |
|
|
$ |
1,133 |
|
|
$ |
1,177 |
|
|
$ |
474 |
|
|
$ |
(2,784 |
) |
|
$ |
1,162 |
|
167
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the condensed consolidating statement of income for the year ended December 31, 2016, were as follows:
Components |
|
Amounts Reclassified |
|
|
Affected Line Item |
|||||||||||||||||||||
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|
|
||||||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
— |
|
|
$ |
(20 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(20 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
— |
|
|
|
(19 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(19 |
) |
|
Selling, general and administrative expenses, net |
Settlement cost |
|
|
— |
|
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Selling, general and administrative expenses, net |
MTM adjustment |
|
|
— |
|
|
|
21 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
21 |
|
|
Cost of products sold |
MTM adjustment |
|
|
4 |
|
|
|
21 |
|
|
|
2 |
|
|
|
(3 |
) |
|
|
— |
|
|
|
24 |
|
|
Selling, general and administrative expenses, net |
|
|
|
4 |
|
|
|
5 |
|
|
|
2 |
|
|
|
(3 |
) |
|
|
— |
|
|
|
8 |
|
|
Operating income (loss) |
Deferred taxes |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
4 |
|
|
|
4 |
|
|
|
2 |
|
|
|
(3 |
) |
|
|
— |
|
|
|
7 |
|
|
Net income |
Long-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Realized loss, net on long-term investments |
|
|
— |
|
|
|
24 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
|
Other (income) expense, net |
Deferred taxes |
|
|
— |
|
|
|
(10 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
— |
|
|
|
14 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14 |
|
|
Net income |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forward starting interest rate contracts |
|
|
16 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
16 |
|
|
Other (income) expense, net |
Amortization of realized loss |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
Interest and debt expense |
Deferred taxes |
|
|
(6 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
11 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11 |
|
|
Net income |
Cumulative translation adjustment and other: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derecognition of cumulative translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
27 |
|
|
|
— |
|
|
|
27 |
|
|
Gain on divestitures |
Equity income from subsidiaries |
|
|
44 |
|
|
|
27 |
|
|
|
39 |
|
|
|
— |
|
|
|
(110 |
) |
|
|
— |
|
|
Equity income from subsidiaries |
Total reclassifications |
|
$ |
59 |
|
|
$ |
45 |
|
|
$ |
41 |
|
|
$ |
24 |
|
|
$ |
(110 |
) |
|
$ |
59 |
|
|
Net income |
168
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the condensed consolidating statement of income for the year ended December 31, 2015, were as follows:
Components |
|
Amounts Reclassified |
|
|
Affected Line Item |
|||||||||||||||||||||
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|
|
||||||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
— |
|
|
$ |
(19 |
) |
|
$ |
— |
|
|
$ |
(1 |
) |
|
$ |
— |
|
|
$ |
(20 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
— |
|
|
|
(17 |
) |
|
|
(1 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
(19 |
) |
|
Selling, general and administrative expenses, net |
MTM adjustment |
|
|
— |
|
|
|
119 |
|
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
120 |
|
|
Cost of products sold |
MTM adjustment |
|
|
5 |
|
|
|
110 |
|
|
|
3 |
|
|
|
8 |
|
|
|
— |
|
|
|
126 |
|
|
Selling, general and administrative expenses, net |
|
|
|
5 |
|
|
|
193 |
|
|
|
2 |
|
|
|
7 |
|
|
|
— |
|
|
|
207 |
|
|
Operating income (loss) |
Deferred taxes |
|
|
(1 |
) |
|
|
(74 |
) |
|
|
(1 |
) |
|
|
(3 |
) |
|
|
— |
|
|
|
(79 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
4 |
|
|
|
119 |
|
|
|
1 |
|
|
|
4 |
|
|
|
— |
|
|
|
128 |
|
|
Net income |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of realized loss |
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Interest and debt expense |
Deferred taxes |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
Net income |
Equity income from subsidiaries |
|
|
124 |
|
|
|
— |
|
|
|
118 |
|
|
|
— |
|
|
|
(242 |
) |
|
|
— |
|
|
Equity income from subsidiaries |
Total reclassifications |
|
$ |
129 |
|
|
$ |
119 |
|
|
$ |
119 |
|
|
$ |
4 |
|
|
$ |
(242 |
) |
|
$ |
129 |
|
|
Net income |
169
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Details about the reclassifications out of accumulated other comprehensive loss and the affected line items in the condensed consolidating statement of income for the year ended December 31, 2014, were as follows:
Components |
|
Amounts Reclassified |
|
|
Affected Line Item |
|||||||||||||||||||||
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
|
|
||||||
Retirement benefits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost |
|
$ |
— |
|
|
$ |
(20 |
) |
|
$ |
— |
|
|
$ |
(1 |
) |
|
$ |
— |
|
|
$ |
(21 |
) |
|
Cost of products sold |
Amortization of prior service cost |
|
|
— |
|
|
|
(17 |
) |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
(18 |
) |
|
Selling, general and administrative expenses |
MTM adjustment |
|
|
— |
|
|
|
195 |
|
|
|
— |
|
|
|
10 |
|
|
|
— |
|
|
|
205 |
|
|
Cost of products sold |
MTM adjustment |
|
|
10 |
|
|
|
228 |
|
|
|
4 |
|
|
|
5 |
|
|
|
— |
|
|
|
247 |
|
|
Selling, general and administrative expenses |
|
|
|
10 |
|
|
|
386 |
|
|
|
4 |
|
|
|
13 |
|
|
|
— |
|
|
|
413 |
|
|
Other (income) expense, net |
Deferred taxes |
|
|
(4 |
) |
|
|
(152 |
) |
|
|
(1 |
) |
|
|
(5 |
) |
|
|
— |
|
|
|
(162 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
6 |
|
|
|
234 |
|
|
|
3 |
|
|
|
8 |
|
|
|
— |
|
|
|
251 |
|
|
Net income |
Hedging instruments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of realized loss |
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Interest and debt expense |
Deferred taxes |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Provision for (benefit from) income taxes |
Net of tax |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
Net income |
Equity income from subsidiaries |
|
|
245 |
|
|
|
— |
|
|
|
234 |
|
|
|
— |
|
|
|
(479 |
) |
|
|
— |
|
|
Equity income from subsidiaries |
Total reclassifications |
|
$ |
252 |
|
|
$ |
234 |
|
|
$ |
237 |
|
|
$ |
8 |
|
|
$ |
(479 |
) |
|
$ |
252 |
|
|
Net income |
170
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Cash Flows
(Dollars in Millions)
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
||||||
For the Year Ended December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from (used in) operating activities |
|
$ |
(413 |
) |
|
$ |
2,462 |
|
|
$ |
1,918 |
|
|
$ |
827 |
|
|
$ |
(3,514 |
) |
|
$ |
1,280 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
— |
|
|
|
(143 |
) |
|
|
— |
|
|
|
(75 |
) |
|
|
12 |
|
|
|
(206 |
) |
Proceeds from settlement of investments |
|
|
— |
|
|
|
266 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
266 |
|
Proceeds from divestitures |
|
|
5,015 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,015 |
|
Return of intercompany investments |
|
|
2,274 |
|
|
|
508 |
|
|
|
1,473 |
|
|
|
— |
|
|
|
(4,255 |
) |
|
|
— |
|
Contributions to intercompany investments |
|
|
(16 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
16 |
|
|
|
— |
|
Other, net |
|
|
193 |
|
|
|
3 |
|
|
|
17 |
|
|
|
21 |
|
|
|
(231 |
) |
|
|
3 |
|
Net cash flows from (used in) from investing activities |
|
|
7,466 |
|
|
|
634 |
|
|
|
1,490 |
|
|
|
(54 |
) |
|
|
(4,458 |
) |
|
|
5,078 |
|
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(2,369 |
) |
|
|
(1,752 |
) |
|
|
(1,152 |
) |
|
|
(555 |
) |
|
|
3,459 |
|
|
|
(2,369 |
) |
Repurchase of common stock |
|
|
(226 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(226 |
) |
Repayments of long-term debt |
|
|
(415 |
) |
|
|
(85 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(500 |
) |
Early extinguishment of debt |
|
|
(3,642 |
) |
|
|
(8 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(3,650 |
) |
Premiums paid for early extinguishment of debt |
|
|
(206 |
) |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(207 |
) |
Proceeds from termination of interest rate swaps |
|
|
— |
|
|
|
66 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
66 |
|
Debt issuance costs and financing fees |
|
|
(8 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
28 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
28 |
|
Dividends paid on preferred stock |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
Distribution of equity |
|
|
— |
|
|
|
(1,455 |
) |
|
|
(2,274 |
) |
|
|
(526 |
) |
|
|
4,255 |
|
|
|
— |
|
Receipt of equity |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
16 |
|
|
|
(16 |
) |
|
|
— |
|
Other, net |
|
|
(21 |
) |
|
|
— |
|
|
|
— |
|
|
|
(210 |
) |
|
|
231 |
|
|
|
— |
|
Net cash flows used in financing activities |
|
|
(6,902 |
) |
|
|
(3,235 |
) |
|
|
(3,426 |
) |
|
|
(1,275 |
) |
|
|
7,972 |
|
|
|
(6,866 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
|
|
— |
|
|
|
(8 |
) |
Net change in cash and cash equivalents |
|
|
151 |
|
|
|
(139 |
) |
|
|
(18 |
) |
|
|
(510 |
) |
|
|
— |
|
|
|
(516 |
) |
Cash and cash equivalents at beginning of period |
|
|
575 |
|
|
|
809 |
|
|
|
19 |
|
|
|
1,164 |
|
|
|
— |
|
|
|
2,567 |
|
Cash and cash equivalents at end of period |
|
$ |
726 |
|
|
$ |
670 |
|
|
$ |
1 |
|
|
$ |
654 |
|
|
$ |
— |
|
|
$ |
2,051 |
|
171
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Statements of Cash Flows
(Dollars in Millions)
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
||||||
For the Year Ended December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from (used in) operating activities |
|
$ |
(2,279 |
) |
|
$ |
2,924 |
|
|
$ |
549 |
|
|
$ |
422 |
|
|
$ |
(1,420 |
) |
|
$ |
196 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
— |
|
|
|
(99 |
) |
|
|
— |
|
|
|
(73 |
) |
|
|
(2 |
) |
|
|
(174 |
) |
Proceeds from settlement of investments |
|
|
— |
|
|
|
332 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
332 |
|
Acquisition, net of cash acquired |
|
|
(18,278 |
) |
|
|
523 |
|
|
|
— |
|
|
|
535 |
|
|
|
— |
|
|
|
(17,220 |
) |
Proceeds from divestitures |
|
|
7,056 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,056 |
|
Return of intercompany investments |
|
|
185 |
|
|
|
11 |
|
|
|
344 |
|
|
|
— |
|
|
|
(540 |
) |
|
|
— |
|
Other, net |
|
|
10 |
|
|
|
1 |
|
|
|
17 |
|
|
|
21 |
|
|
|
(48 |
) |
|
|
1 |
|
Net cash flows from (used in) investing activities |
|
|
(11,027 |
) |
|
|
768 |
|
|
|
361 |
|
|
|
483 |
|
|
|
(590 |
) |
|
|
(10,005 |
) |
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(1,583 |
) |
|
|
(461 |
) |
|
|
(709 |
) |
|
|
(209 |
) |
|
|
1,379 |
|
|
|
(1,583 |
) |
Repurchase of common stock |
|
|
(124 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(124 |
) |
Proceeds from BAT Share Purchase |
|
|
4,673 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,673 |
|
Issuance of long-term debt |
|
|
8,975 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,975 |
|
Repayments of long-term debt |
|
|
(450 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(450 |
) |
Debt issuance costs and financing fees |
|
|
(70 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(70 |
) |
Borrowings under revolving credit facility |
|
|
1,400 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,400 |
|
Repayments of borrowings under revolving credit facility |
|
|
(1,400 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,400 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
17 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
17 |
|
Dividends paid on preferred stock |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
Distribution of equity |
|
|
— |
|
|
|
(344 |
) |
|
|
(185 |
) |
|
|
(11 |
) |
|
|
540 |
|
|
|
— |
|
Other, net |
|
|
2,384 |
|
|
|
(2,405 |
) |
|
|
— |
|
|
|
(27 |
) |
|
|
48 |
|
|
|
— |
|
Net cash flows from (used in) financing activities |
|
|
13,779 |
|
|
|
(3,210 |
) |
|
|
(894 |
) |
|
|
(247 |
) |
|
|
2,010 |
|
|
|
11,438 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(28 |
) |
|
|
— |
|
|
|
(28 |
) |
Net change in cash and cash equivalents |
|
|
473 |
|
|
|
482 |
|
|
|
16 |
|
|
|
630 |
|
|
|
— |
|
|
|
1,601 |
|
Cash and cash equivalents at beginning of period |
|
|
102 |
|
|
|
327 |
|
|
|
3 |
|
|
|
534 |
|
|
|
— |
|
|
|
966 |
|
Cash and cash equivalents at end of period |
|
$ |
575 |
|
|
$ |
809 |
|
|
$ |
19 |
|
|
$ |
1,164 |
|
|
$ |
— |
|
|
$ |
2,567 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities |
|
$ |
1,277 |
|
|
$ |
1,364 |
|
|
$ |
1,424 |
|
|
$ |
524 |
|
|
$ |
(2,966 |
) |
|
$ |
1,623 |
|
Cash flows from (used in) investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
— |
|
|
|
(232 |
) |
|
|
— |
|
|
|
(127 |
) |
|
|
155 |
|
|
|
(204 |
) |
Proceeds from settlement of investments |
|
|
— |
|
|
|
2 |
|
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
4 |
|
Proceeds from termination of joint venture |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
35 |
|
|
|
— |
|
|
|
35 |
|
Return of intercompany investments |
|
|
165 |
|
|
|
105 |
|
|
|
21 |
|
|
|
— |
|
|
|
(291 |
) |
|
|
— |
|
Contribution to intercompany investments |
|
|
(32 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
32 |
|
|
|
— |
|
Other, net |
|
|
250 |
|
|
|
(8 |
) |
|
|
19 |
|
|
|
187 |
|
|
|
(488 |
) |
|
|
(40 |
) |
Net cash flows from (used in) investing activities |
|
|
383 |
|
|
|
(133 |
) |
|
|
42 |
|
|
|
95 |
|
|
|
(592 |
) |
|
|
(205 |
) |
Cash flows from (used in) financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid on common stock |
|
|
(1,411 |
) |
|
|
(1,377 |
) |
|
|
(1,301 |
) |
|
|
(250 |
) |
|
|
2,928 |
|
|
|
(1,411 |
) |
Repurchase of common stock |
|
|
(440 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(440 |
) |
Borrowings under revolving credit facility |
|
|
1,000 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,000 |
|
Repayments of borrowings under revolving credit facility |
|
|
(1,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,000 |
) |
Debt issuance costs and financing fees |
|
|
(79 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(79 |
) |
Excess tax benefit on stock-based compensation plans |
|
|
12 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
12 |
|
Dividends paid on preferred stock |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
43 |
|
|
|
— |
|
Distribution of equity |
|
|
— |
|
|
|
(21 |
) |
|
|
(165 |
) |
|
|
(105 |
) |
|
|
291 |
|
|
|
— |
|
Receipt of equity |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
32 |
|
|
|
(32 |
) |
|
|
— |
|
Other, net |
|
|
(41 |
) |
|
|
(20 |
) |
|
|
— |
|
|
|
(267 |
) |
|
|
328 |
|
|
|
— |
|
Net cash flows used in financing activities |
|
|
(2,002 |
) |
|
|
(1,418 |
) |
|
|
(1,466 |
) |
|
|
(590 |
) |
|
|
3,558 |
|
|
|
(1,918 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(34 |
) |
|
|
— |
|
|
|
(34 |
) |
Net change in cash and cash equivalents |
|
|
(342 |
) |
|
|
(187 |
) |
|
|
— |
|
|
|
(5 |
) |
|
|
— |
|
|
|
(534 |
) |
Cash and cash equivalents at beginning of period |
|
|
444 |
|
|
|
514 |
|
|
|
3 |
|
|
|
539 |
|
|
|
— |
|
|
|
1,500 |
|
Cash and cash equivalents at end of period |
|
$ |
102 |
|
|
$ |
327 |
|
|
$ |
3 |
|
|
$ |
534 |
|
|
$ |
— |
|
|
$ |
966 |
|
172
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Balance Sheets
(Dollars in Millions)
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
||||||
December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
726 |
|
|
$ |
670 |
|
|
$ |
1 |
|
|
$ |
654 |
|
|
$ |
— |
|
|
$ |
2,051 |
|
Accounts receivable |
|
|
— |
|
|
|
27 |
|
|
|
— |
|
|
|
39 |
|
|
|
— |
|
|
|
66 |
|
Accounts receivable, related party |
|
|
— |
|
|
|
113 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
113 |
|
Other receivables |
|
|
63 |
|
|
|
5 |
|
|
|
38 |
|
|
|
4,828 |
|
|
|
(4,924 |
) |
|
|
10 |
|
Inventories |
|
|
— |
|
|
|
812 |
|
|
|
— |
|
|
|
835 |
|
|
|
(2 |
) |
|
|
1,645 |
|
Other current assets |
|
|
112 |
|
|
|
195 |
|
|
|
— |
|
|
|
43 |
|
|
|
3 |
|
|
|
353 |
|
Total current assets |
|
|
901 |
|
|
|
1,822 |
|
|
|
39 |
|
|
|
6,399 |
|
|
|
(4,923 |
) |
|
|
4,238 |
|
Property, plant and equipment, net |
|
|
2 |
|
|
|
855 |
|
|
|
— |
|
|
|
491 |
|
|
|
— |
|
|
|
1,348 |
|
Trademarks and other intangible assets, net of accumulated amortization |
|
|
— |
|
|
|
317 |
|
|
|
— |
|
|
|
29,129 |
|
|
|
(2 |
) |
|
|
29,444 |
|
Goodwill |
|
|
— |
|
|
|
3,453 |
|
|
|
9,853 |
|
|
|
2,686 |
|
|
|
— |
|
|
|
15,992 |
|
Long-term intercompany notes receivable |
|
|
1,390 |
|
|
|
— |
|
|
|
73 |
|
|
|
148 |
|
|
|
(1,611 |
) |
|
|
— |
|
Investment in subsidiaries |
|
|
36,865 |
|
|
|
22,954 |
|
|
|
23,938 |
|
|
|
— |
|
|
|
(83,757 |
) |
|
|
— |
|
Other assets and deferred charges |
|
|
80 |
|
|
|
1,204 |
|
|
|
11 |
|
|
|
13 |
|
|
|
(1,235 |
) |
|
|
73 |
|
Total assets |
|
$ |
39,238 |
|
|
$ |
30,605 |
|
|
$ |
33,914 |
|
|
$ |
38,866 |
|
|
$ |
(91,528 |
) |
|
$ |
51,095 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1 |
|
|
$ |
190 |
|
|
$ |
— |
|
|
$ |
30 |
|
|
$ |
— |
|
|
$ |
221 |
|
Tobacco settlement accruals |
|
|
— |
|
|
|
2,326 |
|
|
|
— |
|
|
|
172 |
|
|
|
— |
|
|
|
2,498 |
|
Due to related party |
|
|
— |
|
|
|
7 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7 |
|
Deferred revenue, related party |
|
|
— |
|
|
|
66 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
66 |
|
Current maturities of long-term debt |
|
|
448 |
|
|
|
53 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
501 |
|
Dividends payable on common stock |
|
|
656 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
656 |
|
Other current liabilities |
|
|
3,767 |
|
|
|
1,923 |
|
|
|
2 |
|
|
|
268 |
|
|
|
(4,924 |
) |
|
|
1,036 |
|
Total current liabilities |
|
|
4,872 |
|
|
|
4,565 |
|
|
|
2 |
|
|
|
470 |
|
|
|
(4,924 |
) |
|
|
4,985 |
|
Long-term intercompany notes payable |
|
|
148 |
|
|
|
— |
|
|
|
— |
|
|
|
1,463 |
|
|
|
(1,611 |
) |
|
|
— |
|
Long-term debt (less current maturities) |
|
|
12,404 |
|
|
|
260 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
12,664 |
|
Long-term deferred income taxes, net |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10,839 |
|
|
|
(1,232 |
) |
|
|
9,607 |
|
Long-term retirement benefits (less current portion) |
|
|
59 |
|
|
|
1,651 |
|
|
|
28 |
|
|
|
131 |
|
|
|
— |
|
|
|
1,869 |
|
Long-term deferred revenue, related party |
|
|
— |
|
|
|
39 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
39 |
|
Other noncurrent liabilities |
|
|
44 |
|
|
|
153 |
|
|
|
— |
|
|
|
23 |
|
|
|
— |
|
|
|
220 |
|
Shareholders’ equity |
|
|
21,711 |
|
|
|
23,937 |
|
|
|
33,884 |
|
|
|
25,940 |
|
|
|
(83,761 |
) |
|
|
21,711 |
|
Total liabilities and shareholders’ equity |
|
$ |
39,238 |
|
|
$ |
30,605 |
|
|
$ |
33,914 |
|
|
$ |
38,866 |
|
|
$ |
(91,528 |
) |
|
$ |
51,095 |
|
173
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Condensed Consolidating Balance Sheets
(Dollars in Millions)
|
|
Parent Guarantor |
|
|
Issuer |
|
|
Guarantor |
|
|
Non- Guarantors |
|
|
Eliminations |
|
|
Consolidated |
|
||||||
December 31, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
575 |
|
|
$ |
809 |
|
|
$ |
19 |
|
|
$ |
1,164 |
|
|
$ |
— |
|
|
$ |
2,567 |
|
Short-term investments |
|
|
— |
|
|
|
149 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
149 |
|
Accounts receivable |
|
|
— |
|
|
|
48 |
|
|
|
— |
|
|
|
20 |
|
|
|
— |
|
|
|
68 |
|
Accounts receivable, related party |
|
|
— |
|
|
|
38 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
38 |
|
Other receivables |
|
|
70 |
|
|
|
30 |
|
|
|
17 |
|
|
|
4,890 |
|
|
|
(4,972 |
) |
|
|
35 |
|
Inventories |
|
|
— |
|
|
|
941 |
|
|
|
— |
|
|
|
797 |
|
|
|
(4 |
) |
|
|
1,734 |
|
Other current assets |
|
|
116 |
|
|
|
236 |
|
|
|
— |
|
|
|
212 |
|
|
|
— |
|
|
|
564 |
|
Total current assets |
|
|
761 |
|
|
|
2,251 |
|
|
|
36 |
|
|
|
7,083 |
|
|
|
(4,976 |
) |
|
|
5,155 |
|
Property, plant and equipment, net |
|
|
3 |
|
|
|
792 |
|
|
|
— |
|
|
|
460 |
|
|
|
— |
|
|
|
1,255 |
|
Trademarks and other intangible assets, net of accumulated amortization |
|
|
— |
|
|
|
346 |
|
|
|
— |
|
|
|
29,121 |
|
|
|
— |
|
|
|
29,467 |
|
Goodwill |
|
|
— |
|
|
|
3,453 |
|
|
|
9,853 |
|
|
|
2,687 |
|
|
|
— |
|
|
|
15,993 |
|
Long-term intercompany notes receivable |
|
|
1,583 |
|
|
|
— |
|
|
|
90 |
|
|
|
169 |
|
|
|
(1,842 |
) |
|
|
— |
|
Investment in subsidiaries |
|
|
37,151 |
|
|
|
23,199 |
|
|
|
24,276 |
|
|
|
— |
|
|
|
(84,626 |
) |
|
|
— |
|
Other assets and deferred charges |
|
|
189 |
|
|
|
1,711 |
|
|
|
14 |
|
|
|
9 |
|
|
|
(1,693 |
) |
|
|
230 |
|
Total assets |
|
$ |
39,687 |
|
|
$ |
31,752 |
|
|
$ |
34,269 |
|
|
$ |
39,529 |
|
|
$ |
(93,137 |
) |
|
$ |
52,100 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2 |
|
|
$ |
146 |
|
|
$ |
— |
|
|
$ |
31 |
|
|
$ |
— |
|
|
$ |
179 |
|
Tobacco settlement accruals |
|
|
— |
|
|
|
2,673 |
|
|
|
— |
|
|
|
143 |
|
|
|
— |
|
|
|
2,816 |
|
Due to related party |
|
|
— |
|
|
|
9 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
Deferred revenue, related party |
|
|
— |
|
|
|
33 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
33 |
|
Current maturities of long-term debt |
|
|
420 |
|
|
|
86 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
506 |
|
Dividends payable on common stock |
|
|
514 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
514 |
|
Other current liabilities |
|
|
3,707 |
|
|
|
2,189 |
|
|
|
31 |
|
|
|
284 |
|
|
|
(4,977 |
) |
|
|
1,234 |
|
Total current liabilities |
|
|
4,643 |
|
|
|
5,136 |
|
|
|
31 |
|
|
|
458 |
|
|
|
(4,977 |
) |
|
|
5,291 |
|
Long-term intercompany notes payable |
|
|
169 |
|
|
|
— |
|
|
|
— |
|
|
|
1,673 |
|
|
|
(1,842 |
) |
|
|
— |
|
Long-term debt (less current maturities) |
|
|
16,522 |
|
|
|
327 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
16,849 |
|
Long-term deferred income taxes, net |
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
10,892 |
|
|
|
(1,689 |
) |
|
|
9,204 |
|
Long-term retirement benefits (less current portion) |
|
|
57 |
|
|
|
2,036 |
|
|
|
30 |
|
|
|
142 |
|
|
|
— |
|
|
|
2,265 |
|
Other noncurrent liabilities |
|
|
44 |
|
|
|
182 |
|
|
|
— |
|
|
|
13 |
|
|
|
— |
|
|
|
239 |
|
Shareholders’ equity |
|
|
18,252 |
|
|
|
24,070 |
|
|
|
34,208 |
|
|
|
26,351 |
|
|
|
(84,629 |
) |
|
|
18,252 |
|
Total liabilities and shareholders’ equity |
|
$ |
39,687 |
|
|
$ |
31,752 |
|
|
$ |
34,269 |
|
|
$ |
39,529 |
|
|
$ |
(93,137 |
) |
|
$ |
52,100 |
|
174
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
Note 21 — Quarterly Results of Operations (Unaudited)
|
|
First |
|
|
Second |
|
|
Third |
|
|
Fourth |
|
||||
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
2,917 |
|
|
$ |
3,195 |
|
|
$ |
3,205 |
|
|
$ |
3,186 |
|
Gross profit (1) |
|
|
1,752 |
|
|
|
1,920 |
|
|
|
2,016 |
|
|
|
1,974 |
|
Net income (1)(2) |
|
|
3,565 |
|
|
|
796 |
|
|
|
861 |
|
|
|
851 |
|
Per share data (3) : |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
2.50 |
|
|
|
0.56 |
|
|
|
0.60 |
|
|
|
0.60 |
|
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
2.49 |
|
|
|
0.56 |
|
|
|
0.60 |
|
|
|
0.60 |
|
2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
$ |
2,057 |
|
|
$ |
2,403 |
|
|
$ |
3,161 |
|
|
$ |
3,054 |
|
Gross profit (4) |
|
|
1,207 |
|
|
|
1,319 |
|
|
|
1,757 |
|
|
|
1,704 |
|
Net income (4)(5) |
|
|
389 |
|
|
|
1,928 |
|
|
|
657 |
|
|
|
279 |
|
Per share data (3) : |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
0.36 |
|
|
|
1.70 |
|
|
|
0.46 |
|
|
|
0.20 |
|
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
0.36 |
|
|
|
1.69 |
|
|
|
0.46 |
|
|
|
0.19 |
|
(1) |
Includes NPM Adjustment credits of $91 million in the first quarter of 2016, $98 million in the second quarter of 2016, $104 million in the third quarter of 2016 and $97 million in the fourth quarter of 2016, see “— Cost of Products Sold” in note 1. The fourth quarter of 2016 includes an MTM adjustment of $21 million. |
(2) |
First quarter of 2016 reflects the impact of the sale of the international rights to the NATURAL AMERICAN SPIRIT brand. Fourth quarter of 2016 includes an additional MTM adjustment expense of $24 million for a total of $45 million. |
(3) |
Income per share is computed independently for each of the periods presented. The sum of the income per share amounts for the quarters may not equal the total for the year. |
(4) |
Includes NPM Adjustment credits of $66 million in the first quarter of 2015, $69 million in the second quarter of 2015, $76 million in the third quarter of 2015 and $86 million in the fourth quarter of 2015, see “— Cost of Products Sold” in note 1. The fourth quarter of 2015 includes an MTM adjustment expense of $120 million. |
(5) |
Second quarter of 2015 reflects the impact of the Lorillard Merger and Divestiture. Fourth quarter of 2015 includes an additional MTM adjustment expense of $126 million for a total of $246 million. |
Proposed Merger with BAT
On January 16, 2017, RAI, BAT, a subsidiary of BAT, and Merger Sub entered into the Merger Agreement pursuant to which, subject to the satisfaction or waiver of certain conditions, Merger Sub will merge with and into RAI, referred to as the BAT Merger, with RAI surviving as a wholly owned subsidiary of BAT.
The BAT Merger has been approved by the independent directors of RAI who formed a transaction committee to negotiate with BAT, given BAT’s existing ownership stake in RAI and representation on RAI’s Board, and by the Boards of Directors of both companies.
At the effective time of the BAT Merger, each share of RAI common stock (other than any shares of RAI common stock owned by BAT or any of its subsidiaries and by shareholders of RAI who have properly asserted and not lost or effectively withdrawn appraisal rights) will be converted into the right to receive 0.5260 of a BAT American Depositary Share and $29.44 in cash, without interest, and subject to adjustment to prevent dilution.
The BAT Merger is subject to customary closing conditions, including RAI and BAT shareholder approvals, including the approval of the BAT Merger by a majority of the shares of RAI common stock not owned, directly or indirectly, by BAT or its subsidiaries or any of RAI’s subsidiaries, and regulatory approvals. The Merger Agreement contains certain other termination rights for each of RAI and BAT, including the right of each party to terminate the Merger Agreement if the BAT Merger has not been completed on or before December 31, 2017, subject to an extension of five business days if, on December 31, 2017, BAT has not
175
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — continued
completed all or any portion of the financing it needs to fund the BAT Merger and the transactions contemplated by the Merger Agreement. Financing, however, is not a condition to the closing of the BAT Merger. Under certain circumstances, if the Merger Agreement is terminated, the terminating party must pay the non-terminating party a termination fee of $1 billion. In the event that the Merger Agreement is terminated due to an inability to obtain unconditional approval under the H art- S cott- R odino Antitrust Improvements Act of 1976, as amended, or any other antitrust laws, RAI will be entitled to receive a termination fee of $500 million from BAT. The BAT Merger is currently expected to close in the third quarter of 2017.
Each of RAI and BAT has made representations and warranties in the Merger Agreement. RAI and BAT each also have agreed to various covenants and agreements, including, among other things, to conduct their respective businesses in the ordinary course in all material respects during the period between the execution of the Merger Agreement and completion of the BAT Merger and not to engage in certain transactions during this period.
176
Item 9. Changes in and Disagreements with Accou ntants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Disclosure Controls and Procedures
RAI’s chief executive officer and chief financial officer have concluded that RAI’s disclosure controls and procedures were effective as of the end of the period covered by this report, based on their evaluation of these controls and procedures.
Internal Control over Financial Reporting
Limitation on the Effectiveness of Controls
Internal controls are designed to provide reasonable assurance that assets are safeguarded and transactions are properly recorded, executed and reported in accordance with management’s authorization. The effectiveness of internal controls is supported by qualified personnel and an organization structure that provides an appropriate division of responsibility and formalized procedures. Internal audit regularly monitors the adequacy and effectiveness of internal controls, including reporting to RAI’s audit committee. Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. See “Management’s Report on Internal Control over Financial Reporting” in Item 8 of Part II of this report.
Changes in Controls
There have been no changes in RAI’s internal controls over financial reporting that occurred during the fourth quarter that have materially affected, or are reasonably likely to materially affect, RAI’s internal controls over financial reporting.
None.
177
Item 10. Directors, Executive Officers and Corporate Governance
Item 10 is incorporated by reference to the following sections of RAI’s Form 10-K/A to be filed with the SEC on or before May 1, 2017, referred to as the 10-K Amendment: “The Board of Directors — Item 1: Election of Directors;” “The Board of Directors — Biographies of Board Members;” “The Board of Directors — Governance Agreement;” “The Board of Directors — Committees and Meetings of the Board of Directors — Audit and Finance Committee;” “The Board of Directors — Code of Conduct;” and “Security Ownership of Certain Beneficial Owners and Management — Section 16(a) Beneficial Ownership Reporting Compliance.” For information regarding the executive officers and certain significant employees of RAI, see “Executive Officers and Certain Significant Employees of the Registrant” in Item 1 of Part I of this report.
Item 11. Executive Compensation
Item 11 is incorporated by reference to the following sections of the 10-K Amendment: “Executive Compensation;” “Executive Compensation — Compensation Committee Report;” “The Board of Directors — Committees and Meetings of the Board of Directors — Compensation and Leadership Development Committee; Compensation Committee Interlocks and Insider Participation;” and “The Board of Directors — Director Compensation.”
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 12 is incorporated by reference to the following sections of the 10-K Amendment: “Security Ownership of Certain Beneficial Owners and Management — Stock Ownership of Principal Shareholders;” “Security Ownership of Certain Beneficial Owners and Management — Stock Ownership of Management;” and “The Board of Directors — Governance Agreement.” For information regarding securities authorized for issuance under equity compensation plans, see note 15 to consolidated financial statements in Item 8 of Part II to this report.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 13 is incorporated by reference to the following sections of the 10-K Amendment: “Certain Relationships and Related Transactions;” and “The Board of Directors — Determination of Independence of Directors.”
Item 14. Principal Accounting Fees and Services
Item 14 is incorporated by reference to the following sections of the 10-K Amendment: “Audit Matters — Audit Committee’s Audit and Non-Audit Services Pre-Approval Policy;” and “Audit Matters — Fees of Independent Registered Public Accounting Firm.”
178
Item 15. Exhibits, Financial Statement Schedules
|
(a) |
The following documents are filed as a part of this report: |
|
(1) |
Consolidated Statements of Income for the years ended December 31, 2016, 2015 and 2014. |
Consolidated Statements of Comprehensive Income for the years ended December 31, 2016, 2015 and 2014.
Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014.
Consolidated Balance Sheets as of December 31, 2016 and 2015.
Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2016, 2015 and 2014.
|
(2) |
Financial Statement Schedules have been omitted because the information required has been separately disclosed in the consolidated financial statements or notes. |
|
(3) |
See (b) below. |
|
(b) |
Exhibit Numbers 10.27 through 10.62 below are management contracts, compensatory plans or arrangements. The following exhibits are filed or furnished, as the case may be, as part of this report: |
Exhibit
|
|
|
|
|
|
2.1 |
|
Agreement and Plan of Merger, dated as of July 15, 2014, among Lorillard, Inc., Reynolds American Inc. and Lantern Acquisition Co. (incorporated by reference to Exhibit 2.1 to Reynolds American Inc.’s Form 8-K, dated July 15, 2014). |
|
|
|
2.2 |
|
Asset Purchase Agreement, dated as of July 15, 2014, among Reynolds American Inc., Lignum-2, L.L.C. and Imperial Tobacco Group PLC (incorporated by reference to Exhibit 2.2 to Reynolds American Inc.’s Form 8-K, dated July 15, 2014). |
|
|
|
2.3 |
|
Amendment No. 1 to Asset Purchase Agreement, dated May 26, 2015, by and between Reynolds American Inc. and ITG Brands, LLC (formerly known as Lignum-2, L.L.C.) and Imperial Tobacco Group PLC (incorporated by reference to Exhibit 2.3 to Reynolds American Inc.’s Form 8-K, dated May 28, 2015). |
|
|
|
2.4 |
|
Purchase Agreement, dated as of September 28, 2015, by and among Santa Fe Natural Tobacco Company, Inc., R. J. Reynolds Global Products, Inc., R. J. Reynolds Tobacco B.V., JT International Holding BV, Reynolds American Inc. and Japan Tobacco Inc. (incorporated by reference to Exhibit 2.1 to Reynolds American Inc.’s Form 8-K, dated September 28, 2015). |
|
|
|
2.5 |
|
Agreement and Plan of Merger, dated as of January 16, 2017, among British American Tobacco p.l.c., BATUS Holdings Inc., Flight Acquisition Corporation and Reynolds American Inc. (incorporated by reference to Exhibit 2.1 to Reynolds American Inc.’s Form 8-K, dated January 17, 2017). |
|
|
|
3.1 |
|
Restated Articles of Incorporation of Reynolds American Inc., effective May 5, 2016 (incorporated by reference to Exhibit 3.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed July 26, 2016). |
|
|
|
3.2 |
|
Amended and Restated Bylaws of Reynolds American Inc., dated December 1, 2016. |
|
|
|
4.1 |
|
Indenture, dated May 31, 2006, among Reynolds American Inc. and certain of its subsidiaries as guarantors and The Bank of New York Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.1 to Reynolds American Inc.’s Form 8-K dated May 31, 2006). |
|
|
|
4.2 |
|
First Supplemental Indenture, dated September 30, 2006, to Indenture, dated May 31, 2006, among Reynolds American Inc. and certain of its subsidiaries as guarantors, and The Bank of New York Trust Company, N.A., as successor to The Bank of New York, as Trustee (incorporated by reference to Exhibit 4.1 to Reynolds American Inc.’s Form 8-K dated September 30, 2006). |
|
|
|
4.3 |
|
Second Supplemental Indenture, dated February 6, 2009, to Indenture, dated May 31, 2006, as supplemented by the First Supplemental Indenture, dated September 30, 2006, among Reynolds American Inc. and certain of its subsidiaries, as guarantors, and The Bank of New York Mellon Trust Company, N.A., f/k/a The Bank of New York Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.21 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008, filed February 23, 2009). |
179
Exhibit
|
|
|
|
|
|
4.4 |
|
Third Supplemental Indenture, dated September 17, 2013, to Indenture, dated May 31, 2006, by and among Reynolds American Inc., as issuer, and certain of its subsidiaries as guarantors, and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.3 to Reynolds American Inc.’s Form 8-K, dated September 12, 2013). |
|
|
|
4.5 |
|
Fourth Supplemental Indenture, dated September 2, 2015, to Indenture dated May 31, 2006, among Reynolds American Inc. and certain of its subsidiaries as guarantors and The Bank of New York Mellon Trust Company, N.A. (incorporated by reference to Exhibit 4.1 to Reynolds American Inc.’s Form 8-K, dated August 31, 2015). |
|
|
|
4.6 |
|
Indenture, dated June 23, 2009, among Lorillard Tobacco Company, Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.1 to Lorillard, Inc.’s Form 8-K, dated June 18, 2009). |
|
|
|
4.7 |
|
First Supplemental Indenture, dated June 23, 2009, among Lorillard Tobacco Company, Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.2 to Lorillard, Inc.’s Form 8-K, dated June 18, 2009). |
|
|
|
4.8 |
|
Second Supplemental Indenture, dated April 12, 2010, among Lorillard Tobacco Company, Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.2 to Lorillard, Inc.’s Form 8-K, dated April 7, 2010). |
|
|
|
4.9 |
|
Third Supplemental Indenture, dated August 4, 2011, among Lorillard Tobacco Company, Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.2 to Lorillard, Inc.’s Form 8-K, dated August 1, 2011). |
|
|
|
4.10 |
|
Fourth Supplemental Indenture, dated August 21, 2012, among Lorillard Tobacco Company, Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.2 to Lorillard, Inc.’s Form 8-K, dated August 16, 2012). |
|
|
|
4.11 |
|
Fifth Supplemental Indenture, dated May 20, 2013, among Lorillard Tobacco Company, Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.2 to Lorillard, Inc.’s Form 8-K, dated May 15, 2013). |
|
|
|
4.12 |
|
Sixth Supplemental Indenture, dated June 12, 2015, among R. J. Reynolds Tobacco Company, Lorillard Tobacco Company, LLC, R.J. Reynolds Tobacco Holdings, Inc., Lorillard, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.7 to Reynolds American Inc.’s Form 8-K, dated June 12, 2015). |
|
|
|
4.13 |
|
Guarantee Agreement of R.J. Reynolds Tobacco Holdings, Inc., dated June 12, 2015, for the Senior Notes of Lorillard Tobacco Company, LLC (incorporated by reference to Exhibit 4.15 to Reynolds American Inc.’s Form 8-K, dated June 12, 2015). |
|
|
|
4.14 |
|
Seventh Supplemental Indenture, dated June 25, 2015, to Indenture dated June 23, 2009 (incorporated by reference to Exhibit 4.1 to Reynolds American Inc.’s Form 8-K, dated June 29, 2015). |
|
|
|
4.15 |
|
Guarantee Agreement of Reynolds American Inc., dated August 6, 2015, for the Senior Notes of R. J. Reynolds Tobacco Company (as successor obligor to Lorillard Tobacco Company, LLC (formerly known as Lorillard Tobacco Company)) (incorporated by reference to Exhibit 4.11 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed August 6, 2015). |
|
|
|
4.16 |
|
Eighth Supplemental Indenture, dated August 6, 2015, to Indenture dated June 23, 2009 (incorporated by reference to Exhibit 4.12 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed August 6, 2015). |
|
|
|
4.17 |
|
In accordance with Item 601(b)(4)(iii) of Regulation S-K, Reynolds American Inc. agrees to furnish to the SEC, upon request, a copy of each instrument that defines the rights of holders of such long-term debt not filed or incorporated by reference as an exhibit to this Annual Report on Form 10-K. |
|
|
|
10.1 |
|
Credit Agreement, dated as of December 18, 2014, among Reynolds American Inc., as Borrower, and the agents and lending institutions party thereto (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K, dated December 18, 2014). |
|
|
|
10.2 |
|
Subsidiary Guarantee Agreement, dated as of December 18, 2014, among certain subsidiaries of Reynolds American Inc. as guarantors and JPMorgan Chase Bank, N.A. as administrative agent (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K, dated December 18, 2014). |
180
Exhibit
|
|
|
|
|
|
10.3 |
|
Joinder Agreement, dated August 31, 2015, by and between Lorillard Licensing Company LLC and JP Morgan Chase Bank, N.A., as Administrative Agent, to the Subsidiary Guarantee, dated December 18, 2014 (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K, dated August 31, 2015). |
|
|
|
10.4 |
|
Notice of Extension of Maturity Date, dated October 21, 2015, by the administrative agent under the Credit Agreement, dated as of December 18, 2014, among Reynolds American Inc., as Borrower, and the agents and lending institutions party thereto (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K, dated October 21, 2015). |
|
|
|
10.5 |
|
First Amendment to Credit Agreement, dated as of October 21, 2015, to the Credit Agreement, dated as of December 18, 2014, among Reynolds American Inc., as Borrower, and the agents and lending institutions party thereto (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K, dated October 21, 2015). |
|
|
|
10.6 |
|
Request for, and Notice of, Extension of Maturity Date under the Credit Agreement (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K, dated November 4, 2016). |
|
|
|
10.7 |
|
Second Amendment to Credit Agreement, dated as of November 4, 2016, to the Credit Agreement, dated as of December 18, 2014, among Reynolds American Inc., as Borrower, and the agents and lending institutions party thereto, as amended by the First Amendment to Credit Agreement, dated October 21, 2015 (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K, dated November 4, 2016). |
|
|
|
10.8 |
|
Formation Agreement, dated as of July 30, 2004, among Brown & Williamson Tobacco Corporation (n/k/a Brown & Williamson Holdings, Inc.), Brown & Williamson U.S.A., Inc. (n/k/a R. J. Reynolds Tobacco Company) and Reynolds American Inc. (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated July 30, 2004). |
|
|
|
10.9 |
|
Governance Agreement, dated as of July 30, 2004, among British American Tobacco p.l.c., Brown & Williamson Tobacco Corporation (n/k/a Brown & Williamson Holdings, Inc.) and Reynolds American Inc. (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K dated July 30, 2004). |
|
|
|
10.10 |
|
Amendment No. 1, dated as of November 18, 2004, to the Governance Agreement, dated as of July 30, 2004, among British American Tobacco p.l.c., Brown & Williamson Holdings, Inc. and Reynolds American Inc. (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated November 18, 2004). |
|
|
|
10.11 |
|
Amendment No. 2, dated April 29, 2008, to the Governance Agreement, dated as of July 30, 2004, as amended, by and among British American Tobacco p.l.c., Brown & Williamson Holdings, Inc. and Reynolds American Inc. (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K dated April 29, 2008). |
|
|
|
10.12 |
|
Amendment No. 3, dated November 11, 2011, to the Governance Agreement, dated as of July 30, 2004, as amended, by and among British American Tobacco p.l.c., Brown & Williamson Holdings, Inc. and Reynolds American Inc. (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K dated November 14, 2011). |
|
|
|
10.13 |
|
Share Repurchase Agreement, dated July 25, 2016, by Reynolds American, Inc., Brown & Williamson Holdings, Inc. and Louisville Securities Limited (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated July 25, 2016.) |
|
|
|
10.14 |
|
Purchase Agreement dated as of March 9, 1999, as amended and restated as of May 11, 1999, among R. J. Reynolds Tobacco Company, RJR Nabisco, Inc. and Japan Tobacco Inc. (incorporated by reference to Exhibit 2.1 to R.J. Reynolds Tobacco Holdings, Inc.’s Form 8-K dated May 12, 1999). |
|
|
|
10.15 |
|
Settlement Agreement dated August 25, 1997, between the State of Florida and settling defendants in The State of Florida v. American Tobacco Co. (incorporated by reference to Exhibit 2 to R.J. Reynolds Tobacco Holdings, Inc.’s Form 8-K dated August 25, 1997). |
|
|
|
10.16 |
|
Comprehensive Settlement Agreement and Release dated January 16, 1998, between the State of Texas and settling defendants in The State of Texas v. American Tobacco Co. (incorporated by reference to Exhibit 2 to R.J. Reynolds Tobacco Holdings, Inc.’s Form 8-K dated January 16, 1998). |
|
|
|
10.17 |
|
Settlement Agreement and Release in re: The State of Minnesota v. Philip Morris, Inc., by and among the State of Minnesota, Blue Cross and Blue Shield of Minnesota and the various tobacco company defendants named therein, dated as of May 8, 1998 (incorporated by reference to Exhibit 99.1 to R.J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 30, 1998, filed May 15, 1998). |
181
Exhibit
|
|
|
|
|
|
10.18 |
|
Settlement Agreement and Stipulation for Entry of Consent Judgment in re: The State of Minnesota v. Philip Morris, Inc., by and among the State of Minnesota, Blue Cross and Blue Shield of Minnesota and the various tobacco company defendants named therein, dated as of May 8, 1998 (incorporated by reference to Exhibit 99.2 to R.J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 30, 1998, filed May 15, 1998). |
|
|
|
10.19 |
|
Form of Consent Judgment by Judge Kenneth J. Fitzpatrick, Judge of District Court in re: The State of Minnesota v. Philip Morris, Inc. (incorporated by reference to Exhibit 99.3 to R.J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 30, 1998, filed May 15, 1998). |
|
|
|
10.20 |
|
Stipulation of Amendment to Settlement Agreement and for Entry of Agreed Order dated July 2, 1998, by and among the Mississippi Defendants, Mississippi and the Mississippi Counsel in connection with the Mississippi Action (incorporated by reference to Exhibit 99.2 to R.J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 1998, filed August 14, 1998). |
|
|
|
10.21 |
|
Stipulation of Amendment to Settlement Agreement and for Entry of Consent Decree dated July 24, 1998, by and among the Texas Defendants, Texas and the Texas Counsel in connection with the Texas Action (incorporated by reference to Exhibit 99.4 to R.J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 1998, filed August 14, 1998). |
|
|
|
10.22 |
|
Stipulation of Amendment to Settlement Agreement and for Entry of Consent Decree dated September 11, 1998, by and among the State of Florida and the tobacco companies named therein (incorporated by reference to Exhibit 99.1 to R.J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 1998, filed November 12, 1998). |
|
|
|
10.23 |
|
Master Settlement Agreement, referred to as the MSA, dated November 23, 1998, between the Settling States named in the MSA and the Participating Manufacturers also named therein (incorporated by reference to Exhibit 4 to R.J. Reynolds Tobacco Holdings, Inc.’s Form 8-K dated November 23, 1998). |
|
|
|
10.24 |
|
Term Sheet agreed to by R. J. Reynolds Tobacco Company, an indirect subsidiary of Reynolds American Inc., certain other Participating Manufacturers, 17 states, the District of Columbia and Puerto Rico (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated March 12, 2013). |
|
|
|
10.25 |
|
Comprehensive Agreement, dated as of April 13, 2010, among R. J. Reynolds Tobacco Company and Her Majesty the Queen in Right of Canada and the Provinces and Territories listed on the signature pages attached thereto (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated April 16, 2010). |
|
|
|
10.26 |
|
Agreed Statement of Facts, dated as of April 13, 2010, between Her Majesty the Queen and Northern Brands International, Inc. (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K dated April 16, 2010). |
|
|
|
10.27 |
|
Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated December 1, 2016). |
|
|
|
10.28 |
|
Reynolds American Inc. 2017 Outside Directors’ Compensation Summary. |
|
|
|
10.29 |
|
Equity Incentive Award Plan for Directors of Reynolds American Inc., referred to as the EIAP (incorporated by reference to Exhibit 10.33 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed February 11, 2014). |
|
|
|
10.30 |
|
Form of Deferred Stock Unit Agreement between Reynolds American Inc. and the Director named therein, pursuant to the EIAP (incorporated by reference to Exhibit 10.32 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008, filed February 23, 2009). |
|
|
|
10.31 |
|
Form of Deferred Stock Unit Agreement between R. J. Reynolds Tobacco Holdings, Inc. and the Director named therein, pursuant to the EIAP (incorporated by reference to Exhibit 10.9 to R. J. Reynolds Tobacco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 1999, filed August 16, 1999). |
|
|
|
10.32 |
|
Deferred Compensation Plan for Directors of Reynolds American Inc. (Amended and Restated Effective November 30, 2007) (incorporated by reference to Exhibit 10.43 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed February 27, 2008). |
|
|
|
10.33 |
|
Reynolds American Inc. 2009 Omnibus Incentive Compensation Plan (incorporated by reference to Appendix A of Reynolds American Inc.’s definitive Proxy Statement on Schedule 14A filed on March 23, 2009). |
182
Exhibit
|
|
|
|
|
|
10.34 |
|
Reynolds American Inc. Amended and Restated 2009 Omnibus Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated May 12, 2014). |
|
|
|
10.35 |
|
Form of Performance Share Agreement (three-year vesting), dated March 1, 2013, between Reynolds American Inc. and the grantee named therein (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, filed April 23, 2013). |
|
|
|
10.36 |
|
Form of Performance Share Agreement (three-year vesting), dated March 3, 2014, between Reynolds American Inc. and the grantee named therein (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, filed April 23, 2014). |
|
|
|
10.37 |
|
Form of Performance Share Agreement (three-year vesting), dated March 2, 2015, between Reynolds American Inc. and the grantee named therein (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed April 20, 2015). |
|
|
|
10.38 |
|
Form of Performance Share Agreement (three-year vesting), dated March 1, 2016, between Reynolds American Inc. and the grantee named therein (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed April 26, 2016). |
|
|
|
10.39 |
|
Performance Share Agreement (one-year vesting), dated May 7, 2015, between Reynolds American Inc. and Susan M. Cameron (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed August 6, 2015). |
|
|
|
10.40 |
|
Performance Share Agreement (one-year vesting), dated May 5, 2016, between Reynolds American Inc. and Susan M. Cameron (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed July 26, 2016). |
|
|
|
10.41 |
|
Offer Letter, by and between Reynolds American Inc. and Susan M. Cameron, dated April 16, 2014 (incorporated by reference to Exhibit 10.2 to Reynolds American Inc.’s Form 8-K dated April 16, 2014). |
|
|
|
10.42 |
|
Offer Letter, by and between R. J. Reynolds Tobacco Company and Debra A. Crew, entered into September 18, 2014 (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated September 18, 2014). |
|
|
|
10.43 |
|
Offer Letter, by and between R. J. Reynolds Tobacco Company and Joseph P. Fragnito, entered into October 17, 2016 (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated October 18, 2016). |
|
|
|
10.44 |
|
Performance Share Agreement, dated October 1, 2014, between Reynolds American Inc. and Debra A. Crew (incorporated by reference to Exhibit 10.7 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed October 21, 2014). |
|
|
|
10.45 |
|
Restricted Stock Unit Agreement (retention grant), dated October 1, 2014, between Reynolds American Inc. and Debra A. Crew (incorporated by reference to Exhibit 10.8 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed October 21, 2014). |
|
|
|
10.46 |
|
Restricted Stock Unit Agreement (make-whole grant), dated October 1, 2014, between Reynolds American Inc. and Debra A. Crew (incorporated by reference to Exhibit 10.9 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed October 21, 2014). |
|
|
|
10.47 |
|
Performance Share Agreement, between Reynolds American Inc. and Joseph P. Fragnito, entered into October 17, 2016. |
|
|
|
10.48 |
|
Restricted Stock Unit Agreement (retention grant), between Reynolds American Inc. and Joseph P. Fragnito, entered into October 17, 2016. |
|
|
|
10.49 |
|
Form of Amended Letter Agreement regarding Severance Benefits and Change of Control Protections between Reynolds American Inc. and the officer named therein (incorporated by reference to Exhibit 10.67 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed February 27, 2008). |
|
|
|
10.50 |
|
Reynolds American Inc. Executive Severance Plan, as amended and restated effective May 5, 2016 (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated May 5, 2016.) |
|
|
|
10.51 |
|
Retention Trust Agreement dated May 13, 1998, by and between RJR Nabisco, Inc. and Wachovia Bank, N.A. (n/k/a Wells Fargo, N.A.) (incorporated by reference to Exhibit 10.6 to RJR Nabisco Holdings, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 1998, filed August 14, 1998). |
183
Exhibit
|
|
|
|
|
|
10.52 |
|
Amendment No. 1 to Retention Trust Agreement, dated May 13, 1998, by and between RJR Nabisco, Inc. and Wachovia Bank, N.A. (n/k/a Wells Fargo, N.A.), dated October 1, 2006 (incorporated by reference to Exhibit 10.56 to Reynolds American Inc.’s S-4 filed October 3, 2006). |
|
|
|
10.53 |
|
Amendment No. 2 to Retention Trust Agreement, dated May 13, 1998, as amended, by and between R.J. Reynolds Tobacco Holdings, Inc., as successor to RJR Nabisco, Inc., and Wachovia Bank, N.A. (n/k/a Wells Fargo, N.A.), dated January 24, 2007 (incorporated by reference to Exhibit 10.66 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, filed February 27, 2007). |
|
|
|
10.54 |
|
Amendment No. 3 to Retention Trust Agreement, dated January 7, 2016, as amended, by and between R.J. Reynolds Tobacco Holdings, Inc., as successor to RJR Nabisco, Inc., and Wachovia Bank, N.A. (n/k/a Wells Fargo, N.A.), dated January 24, 2007 (incorporated by reference to Exhibit 10.60 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed February 11, 2016). |
|
|
|
10.55 |
|
Supplemental Pension Plan for Executives of Brown & Williamson Tobacco Corporation (n/k/a Brown & Williamson Holdings, Inc.) (as amended and restated through January 1, 2012) (incorporated by reference to Exhibit 10.48 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed February 15, 2012). |
|
|
|
10.56 |
|
Form of Reynolds American Inc. Trust Agreement, by and among the executive officer named therein, J.P. Morgan Trust Company of Delaware, the trustee, as successor to United States Trust Company, N.A., and Reynolds American Inc., as administrative agent for the executive (incorporated by reference to Exhibit 10.65 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008, filed February 23, 2009). |
|
|
|
10.57 |
|
Brown & Williamson Tobacco Corporation (n/k/a Brown & Williamson Holdings, Inc.) Health Care Plan for Salaried Employees (as amended through July 29, 2004, by Amendment Nos. 1 and 2) (incorporated by reference to Exhibit 10.69 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004, filed March 9, 2005). |
|
|
|
10.58 |
|
Amendment No. 3, entered into as of December 31, 2004, to the Brown & Williamson Tobacco Corporation (n/k/a Brown & Williamson Holdings, Inc.) Health Care Plan for Salaried Employees (incorporated by reference to Exhibit 10.70 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004, filed March 9, 2005). |
|
|
|
10.59 |
|
Amendment No. 4, entered into as of April 20, 2005, to the Brown & Williamson Tobacco Corporation Health Care Plan for Salaried Employees (incorporated by reference to Exhibit 10.71 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, filed February 27, 2007). |
|
|
|
10.60 |
|
Amendment No. 5, entered into as of December 29, 2006, to the Brown & Williamson Tobacco Corporation Health Care Plan for Salaried Employees (incorporated by reference to Exhibit 10.72 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, filed February 27, 2007). |
|
|
|
10.61 |
|
Amendment No. 6, entered into as of December 19, 2011, to the Brown & Williamson Tobacco Corporation Health Care Plan for Salaried Employees (incorporated by reference to Exhibit 10.54 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed February 15, 2012). |
|
|
|
10.62 |
|
Amendment No. 7, entered into as of January 24, 2014, to the Brown & Williamson Tobacco Corporation Health Care Plan for Salaried Employees (incorporated by reference to Exhibit 10.57 to Reynolds American Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed February 11, 2014). |
|
|
|
10.63 |
|
Standard Supplier Agreement, dated August 1, 2003, as amended, by and between R. J. Reynolds Tobacco Company and Eastman Chemical Company (incorporated by reference to Exhibit 10.3 to Reynolds American Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, filed October 23, 2012). |
|
|
|
10.64 |
|
Amendment, effective January 8, 2014, to Standard Supplier Agreement among R. J. Reynolds Tobacco Company, Santa Fe Natural Tobacco Company, Inc. and Eastman Chemical Company (incorporated by reference to Exhibit 10.1 to Reynolds American Inc.’s Form 8-K dated February 10, 2014). |
|
|
|
12.1 |
|
Computation of Ratio of Earnings to Fixed Charges for each of the five years within the period ended December 31, 2016. |
|
|
|
21.1 |
|
Subsidiaries of the Registrant. |
|
|
|
23.1 |
|
Consent of Independent Registered Public Accounting Firm. |
|
|
|
31.1 |
|
Certification of Chief Executive Officer relating to RAI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. |
184
Exhibit
|
|
|
|
|
|
31.2 |
|
Certification of Chief Financial Officer relating to RAI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. |
|
|
|
32.1* |
|
Certification of Chief Executive Officer and Chief Financial Officer relating to RAI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, pursuant to Section 18 U.S.C. §1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). |
|
|
|
99.1 |
|
Arbitration Panel’s Entry of Stipulated Partial Settlement and Award, dated March 12, 2013 (incorporated by reference to Exhibit 99.2 to Reynolds American Inc.’s Form 8-K, dated March 12, 2013). |
|
|
|
101.INS |
|
XBRL instance document |
|
|
|
101.SCH |
|
XBRL taxonomy extension schema |
|
|
|
101.CAL |
|
XBRL taxonomy extension calculation linkbase |
|
|
|
101.DEF |
|
XBRL taxonomy extension definition linkbase document |
|
|
|
101.LAB |
|
XBRL taxonomy extension label linkbase |
|
|
|
101.PRE |
|
XBRL taxonomy extension presentation linkbase |
* |
Exhibit is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subjected to the liabilities of that Section. This exhibit shall not be incorporated by reference into any given registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. |
The SEC file number for Reynolds American Inc. documents filed with the SEC pursuant to the Securities Exchange Act of 1934, as amended, is 001-32258. The SEC file number for Lorillard, Inc. is 001-34097; the SEC file number for RJR Nabisco Holdings, Inc. is 001-10215; and the SEC file number for R.J. Reynolds Tobacco Holdings, Inc. is 001-06388.
185
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
REYNOLDS AMERICAN INC. (Registrant) |
||
|
|
|
|
|||
Dated: February 9, 2017 |
|
|
|
By: |
|
/S/ DEBRA A. CREW |
|
|
|
|
|
|
Debra A. Crew |
|
|
|
|
|
|
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
Signature |
|
Title |
|
Date |
|
|
|
||
/ S / DEBRA A. CREW
Debra A. Crew |
|
President, Chief Executive Officer and Director (principal executive officer) |
|
February 9, 2017 |
|
|
|
||
/ S / ANDREW D. GILCHRIST
Andrew D. Gilchrist |
|
Executive Vice President and Chief Financial Officer (principal financial officer) |
|
February 9, 2017 |
|
|
|
||
/ S / FREDERICK W. SMOTHERS
Frederick W. Smothers |
|
Senior Vice President and Chief Accounting Officer (principal accounting officer) |
|
February 9, 2017 |
|
|
|
||
/ S / SUSAN M. CAMERON
Susan M. Cameron |
|
Executive Chairman of the Board |
|
February 9, 2017 |
|
|
|
||
/ S / JEROME ABELMAN
Jerome Abelman |
|
Director |
|
February 9, 2017 |
|
|
|
|
|
/ S / JOHN A. BOEHNER
John A. Boehner |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / MARTIN D. FEINSTEIN
Martin D. Feinstein |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / LUC JOBIN
Luc Jobin |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / MURRAY S. KESSLER
Murray S. Kessler |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / HOLLY KELLER KOEPPEL
Holly Keller Koeppel |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / JEAN-MARC LEVY
Jean-Marc Levy |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / NANA MENSAH
Nana Mensah |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / LIONEL L. NOWELL III
Lionel L. Nowell III |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / RICARDO OBERLANDER
Ricardo Oberlander |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / RONALD S. ROLFE
Ronald S. Rolfe |
|
Director |
|
February 9, 2017 |
|
|
|
||
/ S / JOHN J. ZILLMER
John J. Zillmer |
|
Director |
|
February 9, 2017 |
186
Exhibit 3.2
AMENDED AND RESTATED BYLAWS
OF
REYNOLDS AMERICAN INC.
ARTICLE 1
MEETINGS OF SHAREHOLDERS
Section 1.01 Place of Meetings . Meetings of shareholders of the Reynolds American Inc. (the “Corporation”) shall be held at such time and place either within or without the State of North Carolina as shall be fixed by the Corporation’s Board of Directors (the “Board”) and designated in the notice or waiver thereof. The Board may postpone and reschedule any previously scheduled annual or special meeting of shareholders.
Section 1.02 Annual and Special Meetings . Annual meetings of shareholders shall be held at a place, if any, date and hour fixed by the Board to elect directors to the Board and to transact such other business as may properly come before the meeting. Special meetings of shareholders may be called by the persons permitted to call such meetings by the Corporation’s Articles of Incorporation.
Section 1.03 Notice . Except as otherwise provided by law or by the Articles of Incorporation, written notice shall be given to each shareholder entitled to vote at such meeting not fewer than 10 nor more than 60 days before the date of each meeting of shareholders. Such notice shall include the place, if any, date and hour of the meeting, the means of remote communications, if any, by which shareholders and proxy holders may be deemed to be present in person and vote at such meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. When a meeting is adjourned to a different date, time or place, notice need not be given of the new date, time or place if (a) the new date, time or place is announced at the meeting before adjournment, and (b) a new record date is not fixed for the adjourned meeting. If a new record date is fixed for the adjourned meeting (which must be done if the new meeting date is more than 120 days after the date of the original meeting), notice of the adjourned meeting must be given as provided in this Section 1.03 to persons who are shareholders as of the new record date.
Section 1.04 Quorum; Adjournment . Shares entitled to vote as a separate voting group may take action in a matter only if a quorum of those shares exists with respect to that matter. A majority of the votes entitled to be cast on the matter by the voting group constitutes a quorum of the voting group for action on that matter. Except as otherwise provided by law or by the Articles of Incorporation, at the opening of any meeting, such meeting may be adjourned from time to time by the vote of a majority of the votes cast on the motion to adjourn or by any officer entitled to preside at or to act as secretary of the meeting. Once a share is represented for any purpose at a meeting, it is deemed present for quorum purposes for the remainder of the meeting and for any adjournment of that meeting unless a new record date is or must be set for that adjourned meeting. Subject to the provisions of the North Carolina Business Corporation Act, at any adjourned meeting any business may be transacted that might have been transacted at the original meeting if a quorum exists with respect to the matter proposed
Section 1.05 Conduct of Meeting and Order of Business . The Chairman or, at the Chairman’s request or in the absence of the Chairman, the Chief Executive Officer, or, in the absence of the Chairman and the Chief Executive Officer, such person as shall be selected by the Board, shall act as chairman at all meetings of shareholders. The Secretary of the Corporation or, in his or her absence, an Assistant Secretary shall act as secretary at all meetings of shareholders. The chairman of the meeting shall have the right and authority to determine and maintain the rules, regulations and procedures for the proper conduct of the meeting, including but not limited to restricting entry to the meeting after it has commenced, maintaining order and the safety of those in attendance, opening and closing the polls for voting, dismissing business not properly submitted, and limiting time allowed for discussion of the business of the meeting.
Business to be conducted at annual meetings of shareholders shall be limited to that business properly submitted to the meeting either by or at the direction of the Board or by any shareholder of the Corporation who satisfies and complies with the notice requirements set forth in Section 1.06. If the chairman of the meeting shall determine that any business was not properly submitted in accordance with the terms of Section 1.06, he or she shall so declare to the meeting and the business that was not properly submitted shall not be transacted at that meeting.
Section 1.06 Advance Notice of Shareholder Proposals and Nominations . In addition to any other applicable requirements under law or under this Section 1.06, in order to properly submit any business to an annual meeting of shareholders, a shareholder must (a) be a shareholder of record or beneficially own shares of the Corporation at the time of the giving of notice provided for in this Section 1.06 and at the time of such annual meeting, (b) be entitled to vote at the annual meeting, and (c) give timely notice in writing to the Secretary of the Corporation, and include in such notice all of the information required by this Section 1.06 to be contained in such notice. The requirements of this Section 1.06 are separate from and in addition to the requirements under Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
To be timely, notice provided under this Section 1.06 must be delivered either in person or by United States certified mail, postage prepaid, and received prior to the close of business at the principal executive offices of the Corporation (a) not less than 120 days nor more than 150 days before the first anniversary of the date of the Corporation’s proxy statement released to shareholders in connection with the most recent annual meeting of shareholders or (b) if no annual meeting was held in the previous year or the date of the applicable annual meeting has been changed by more than 30 days from the date contemplated at the time of the previous year’s proxy statement, not later than the close of business on the later of (i) the tenth calendar day following the day on which the first public announcement of the date of the annual meeting was made and (ii) the date that is 90 days before the date of the applicable annual meeting In no event shall the public announcement of a postponement or adjournment of an annual meeting commence a new time period for the giving of a shareholder’s notice as described above.
Nomination of persons for election to the Board may be made by the Board or any committee designated by the Board or, in the case of an annual meeting, by any shareholder entitled to vote for the election of directors at the annual meeting of shareholders and who otherwise meets the requirements of this Section 1.06 (including, without limitation, the first sentence of Section 1.06). However, nominations other than those made by the Board or its
2
designated committee must be made in accordance with the procedures for submitting business at an annual meeting of the shareholders as set forth in this Section 1.06, and no person shall be eligible to serve as a director unless such procedures have been followed. A shareholder may nominate a person or persons for election to the Board only if written notice of such shareholder’s intent to make such nomination is given to the Secretary of the Corporation in accordance with the procedures set forth in this Section 1.06 .
A shareholder’s notice to submit business to an annual meeting of shareholders shall set forth (a) the name and address of the shareholder and any Shareholder Related Person (as hereinafter defined) covered by clauses (b), (c) and (e) below, (b) the class and number of shares of stock of the Corporation beneficially owned by such shareholder and any Shareholder Related Person, and the name in which such shares are registered on the stock transfer books of the Corporation or, if such shares are held beneficially and not of record and the shareholder has not filed a Schedule 13D or Schedule 13G with the Securities and Exchange Commission that discloses such beneficial ownership, a written statement from the record holder of such securities verifying such beneficial ownership, ( c) a description of (i) any option, warrant, convertible security, stock appreciation right or similar right with an exercise or conversion privilege or settlement payment or mechanism at a price related to any class or series of securities of the Corporation or with a value derived in whole or in part from the value of any class or series of securities of the Corporation, whether or not such instrument or right shall be subject to settlement in the underlying class or series of securities of the Corporation or otherwise (each, a “Derivative Instrument”), directly or indirectly held of record or beneficially by the shareholder or any Shareholder Related Person, (ii) any hedging, swap or other transaction or series of transactions, agreement, arrangement or understanding entered into or made, the effect or intent of which is to increase or decrease the voting power of such shareholder or any Shareholder Related Person with respect to the Corporation’s securities or to allow such shareholder or any Shareholder Related Person the opportunity to profit or share in any profit derived from any increase or decrease in the value of the Corporation’s securities, (iii) any proxy, transaction, agreement, arrangement, understanding or relationship pursuant to which such shareholder or any Shareholder Related Person has a right to vote any of the Corporation’s securities, (iv) any short interest of such shareholder or any Shareholder Related Person in any security of the Corporation (for purposes of these Bylaws, a person shall be deemed to have a short interest in a security if such person, directly or indirectly, through any contract, arrangement, understanding or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security), (v) any rights, directly or indirectly, held of record or beneficially by the shareholder or any Shareholder Related Person to dividends on the Corporation’s securities that are separated or separable from the underlying securities, (vi) any performance-related fees (other than an asset-based fee) that such shareholder or any Shareholder Related Person is entitled to based on any increase or decrease in the value of securities of the Corporation or Derivative Instruments as of the date of such notice, including, without limitation, any such interests held by members of such shareholder’s immediate family sharing the same household and (vii) all arrangements or understandings between or among the shareholder giving the notice, any Shareholder Related Person and any other person relating to the business specified in the notice, ( d ) whether either such shareholder or beneficial owner intends to deliver a proxy statement and form of proxy to the holders of at least the percentage of shares of stock of the Corporation entitled to vote that is required to approve the proposal, (e) a representation that the shareholder intends to appear at the meeting in person or by proxy to submit the business
3
specified in such notice, and if intending to appear by proxy, the name and address of the proxy, (f) any other material interest of the shareholder or any Shareholder Related Person in the business to be submitted and ( g ) a brief description of the business desired to be submitted to the annual meeting, including the complete text of any resolutions to be presented at the annual meeting, and the reasons for conducting such business at the annual meeting. In addition, the shareholder making such proposal shall promptly provide any other information reasonably requested by the Corporation. A “Shareholder Related Person” of any shareholder means (i) any person controlling, directly or indirectly, or acting in concert with, such shareholder, (ii) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such shareholder, and (iii) any person controlled by or under common control with such shareholder.
In addition to the information required above to be given by a shareholder who intends to submit business to a meeting of shareholders, if the business to be submitted is the nomination of a person or persons for election to the Board then such shareholder’s notice must also set forth, as to each person whom the shareholder proposes to nominate for election as a director, (a) the name, age, business address and, if known, residence address of such person, (b) the principal occupation or employment of such person, (c) the class and number of shares of stock of the Corporation which are beneficially owned by such person, (d) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of directors or is otherwise required by the rules and regulations of the Securities and Exchange Commission promulgated under the Exchange Act, (e) the written consent of such person to (i) be named in the proxy statement as a nominee, (ii) serve as a director if elected and (iii) provide information that the Board requests to determine whether such person qualifies as an independent director under applicable guidelines, and (f) a description of all arrangements or understandings between such shareholder or any Shareholder Related Person and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by such shareholder.
If any of the facts set forth in the notice provided pursuant to either of the two preceding paragraphs changes between the date that such notice is sent and the date of the annual meeting, the shareholder must deliver to the Secretary of the Corporation either in person or by United States certified mail, postage prepaid, and the Corporation must receive at its principal executive offices by the earlier of (a) the close of business within five (5) calendar days of the event giving rise to such change, or (b) the commencement of such annual meeting, a supplemental notice providing such revised information. Any person nominated for election as a director by the Board or any committee designated by the Board shall, upon the request of the Board or such committee, furnish to the Secretary of the Corporation all such information pertaining to such person that is required to be set forth in a shareholder’s notice of nomination.
In addition to the foregoing provisions of this Section 1.06, a shareholder who seeks to have any proposal included in the Corporation’s proxy statement also shall comply with the requirements of the Exchange Act, and the rules and regulations promulgated thereunder, including, without limitation, Regulation 14A.
For purposes of this Section 1.06, “public announcement’’ means announcement in a press release reported by the Dow Jones News Service, Associated Press or comparable national
4
news service or in a document filed by the Corporation with the Securities and Exchange Commission pursuant to the Exchange Act.
Section 1.07 Voting . If a quorum exists, in all actions of shareholders other than the election of directors or as otherwise required by law, the Articles of Incorporation or these Bylaws, action on a matter by a voting group is approved if the votes cast within the voting group favoring the action exceed the votes cast opposing the action.
The vote required for election of a director at any meeting of shareholders for the election of directors at which a quorum is present (other than a Contested Election (as defined below)) shall be the vote of a majority of the votes cast with respect to that director’s election. In a Contested Election, directors shall be elected by a plurality of the votes in accordance with § 55-7-28 (or any successor provision) of the North Carolina Business Corporation Act. For purposes of this Section, a “vote of the majority of the shares cast” means that the number of shares voted “for” a director must exceed the number of votes cast “against” that director’s election. A “Contested Election” means an election for directors at a meeting of shareholders for the election of directors at which a quorum is present for which there are more nominees for election to the Board of Directors than open directorships on the Board of Directors to be filled pursuant to that election.
A shareholder may appoint one or more proxies to vote or otherwise act for the shareholder in accordance with the North Carolina Business Corporation Act. A proxy shall be submitted to the secretary of the meeting at or prior to the time designated by the chairman of the meeting.
Section 1.08 Inspectors of Election . Prior to any meeting of shareholders, the Board may appoint one or more inspectors to act at the meeting and make a written report thereof. The Board may designate one or more persons as alternate inspectors to replace any inspector who fails to act. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath to execute faithfully the duties of inspector with strict impartiality and according to the best of his or her ability. If any inspector previously appointed shall fail to attend or refuse or be unable to serve, a substitute shall be appointed by the presiding officer.
ARTICLE 2
DIRECTORS
Section 2.01 Meetings . Regular meetings of the Board shall be held at such times and places within or without the State of North Carolina as may from time to time be fixed by the Board or as may be specified in a notice of meeting. Special meetings of the Board may be held at any time upon the call of the Chairman, the Chief Executive Officer or the President and shall be called by the Chairman, the Chief Executive Officer, the President or the Secretary if directed by the Board or at least two or more Directors. A meeting of the Board may be held without notice immediately after the annual meeting of shareholders. No notice shall be required for any regular meeting of the Board. Notice of the date, time and place of holding of each special meeting shall be given by delivering such notice at least two business days before the date of the meeting to each director by telecopy, telegraph or e-mail, personally or by telephone.
5
Any director unable to participate in person at any meeting shall be given the opportunity to participate by any means of communication by which all directors participating may simultaneously hear each other during the meeting. In addition, notwithstanding the foregoing, action may be taken by the Board without a meeting if it is taken by unanimous written consent. A director’s consent to action taken without a meeting may be in electronic form and delivered by electronic means.
Section 2.02 Quorum . Except as otherwise provided in the Articles of Incorporation, a majority of the total number of directors shall constitute a quorum for the transaction of business. If a quorum is not present at any meeting of the Board, the directors present may adjourn the meeting from time to time, without notice other than announcement at the meeting, until such a quorum is present.
Section 2.03 Committees of Directors . The Board may, by resolution adopted by a majority of the Board, designate one or more committees to have and exercise such power and authority as the Board shall specify.
No action by any committee of the Board shall be valid unless taken at a meeting for which notice has been duly given in accordance with the last sentence of the first paragraph of Section 2.01 of these Bylaws or waived by the members of such committee. Such notice shall include a description of the general nature of the business to be transacted at the meeting, and no other business may be transacted at such meeting unless all members of the committee are present and consent to the consideration of such other business.
Any committee member unable to participate in person at any meeting shall be given the opportunity to participate by any means of communication by which all committee members participating may simultaneously hear each other during the meeting. In addition, notwithstanding the foregoing, action may be taken by a committee of the Board without a meeting if it is taken by unanimous written consent. A committee member’s consent to action taken without a meeting may be in electronic form and delivered by electronic means.
Each of the committees established by the Board pursuant to this Section 2.03 shall establish such other rules and procedures for its operation and governance (consistent with the North Carolina Business Corporation Act) as it shall see fit and may seek such consultation and advice as to matters within its purview as it shall require.
Section 2.04 Chairman of the Board . The Board shall elect a Chairman of the Board from among the members of the Board. The Board shall designate the Chairman as either a Non-Executive Chairman of the Board or, in accordance with the provisions of Section 3.01 of these Bylaws, an Executive Chairman of the Board. (References in these Bylaws to the "Chairman" shall mean the Non-Executive Chairman or Executive Chairman, as designated by the Board.) The Chairman shall preside at all meetings of the Board and shall perform such other duties as may be directed by the Board or as otherwise set forth in these Bylaws.
Section 2.05 Vice Chairman of the Board . The Board may elect a Vice Chairman of the Board from among the members of the Board. If the Board has elected a Vice Chairman of
6
the Board, the Vice Chairman shall perform such duties as may be designated by the Chairman, subject to the direction of the Board.
ARTICLE 3
OFFICERS
Section 3.01 Description and Terms . The officers of the Corporation shall be, the Chief Executive Officer, the President, a Treasurer and a Secretary, who shall have the duty, among other things, to record the proceedings of the meetings of shareholders and directors in a book kept for that purpose, and such other additional officers with such titles as the Board shall determine, all of whom shall be chosen by and serve at the pleasure of the Board; provided that the Chief Executive Officer may appoint Senior Vice Presidents, Vice Presidents or Assistant Officers at his or her discretion. Without limiting the generality of the foregoing, the Board may designate the Chairman as an Executive Chairman, in which case such person shall be an officer of the Corporation and shall have, in addition to the duties set forth in these Bylaws, such powers and authority as determined by the Board. Subject to such limitations as may be imposed by the Board, the Chief Executive Officer shall have full executive power and authority with respect to the Corporation. The President, if separate from the Chief Executive Officer, shall have such powers and authority as the Chief Executive Officer may determine. If the Chief Executive Officer is absent or incapacitated, the Board or any committee designated by the Board for such purpose shall determine the person who shall have all the power and authority of the Chief Executive Officer. Other officers shall have the usual powers and shall perform all the usual duties incident to their respective offices. All officers shall be subject to the supervision and direction of the Board. The authority, duties or responsibilities of any officer (other than an Executive Chairman, if the Chairman has been so designated) of the Corporation may be suspended by the Chief Executive Officer with or without cause. Any officer may be removed by the Board with or without cause; provided that an Executive Chairman who is removed as an officer pursuant to the foregoing shall, subject to and in accordance with the provisions and limitations of the Articles of Incorporation, these Bylaws and applicable law, retain his position as a director. Subject to such limitations as the Board and the North Carolina Business Corporation Act may provide, each officer may further delegate to any other officer or any employee or agent of the Corporation such portions of his or her authority as the officer shall deem appropriate, subject to such limitations as the officer shall specify, and may revoke such authority at any time.
Section 3.02 Shareholder Consents and Proxies . The Chairman, the Chief Executive Officer, the President, the Secretary and the Treasurer, or any one of them, shall have the power and authority on behalf of the Corporation to execute any shareholders’ consents or proxies and to attend and act and vote in person or by proxy at any meetings of shareholders of any corporation in which the Corporation may own stock, and at any such meetings shall possess and may exercise any and all of the rights and powers incident to the ownership of such stock which as the owner thereof the Corporation might have possessed and executed if present. The Board by resolution from time to time may confer like powers upon any officer.
7
Section 4.01 Notices . Whenever any statute, the Articles of Incorporation or these Bylaws require notice to be given to any shareholder, such notice is to be given in writing by mail, addressed to such shareholder at his or her address as it appears on the current shareholder records of the Corporation, with postage thereon prepaid. Such notice shall be deemed to have been given when it is deposited in the United States mail. Notice to directors may be given by telegram or facsimile transmission or be delivered personally or by telephone.
Section 4.02 Indemnification . If a claim under Section 1 or 2 of Article Ninth of the Corporation’s Articles of Incorporation is not paid in full by the Corporation within 60 calendar days after a written claim has been received by the Corporation, the person claiming indemnification may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, such claimant shall be entitled to be paid also the expense of prosecuting or defending such suit. In any case, it shall be a defense to such claims that, and the Corporation shall not be obliged to advance any such expense if, the claimant has not met any applicable standard of conduct for indemnification set forth in the North Carolina Business Corporation Act or the Corporation’s Articles of Incorporation. The Corporation shall not advance any such expenses to a claimant, unless the Corporation has previously received from such claimant an unsecured undertaking to repay the amount of such expenses in the event it is determined such claimant was not entitled to indemnification. A determination by the Corporation (including by the disinterested members of its Board of Directors or an independent legal counsel approved by the Board of Directors) to the effect that the claimant has not met the applicable standard of conduct, or the failure by the Corporation (or by the disinterested members of its Board of Directors or an independent legal counsel approved by the Board of Directors) to make any such determination, shall not create a presumption that the claimant has not met the applicable standard of conduct.
Section 4.03 Fiscal Year . The fiscal year of the Corporation shall be fixed by the Board.
Section 4.04 Certificates of Stock . Any certificates which represent shares of the Corporation shall be signed by the President or a Vice President and by the Secretary or an Assistant Secretary. Any and all signatures on any such certificates, including the signatures of officers, transfer agents and registrars, may be facsimile.
Section 4.05 Exclusive Forum. Unless the Corporation consents in writing to the selection of an alternative forum, and to the fullest extent permitted by law, the sole and exclusive forum for: (a) any derivative action or proceeding brought on behalf of the Corporation; (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation's shareholders; (c) any action asserting a claim arising pursuant to any provision of the North Carolina Business Corporation Act, the Bylaws, or the Articles of Incorporation (as each may be amended from time to time); or (d) any action asserting a claim governed by the internal affairs doctrine (collectively, the “Actions ”) shall only be the state courts of North Carolina or the
8
United States District Court for the Middle District of North Carolina. Actions filed in any North Carolina state court shall be subject to designation or assignment to the North Carolina Business Court. For purposes of this Section 4.05, the Corporation has consented in writing to the forum selection provisions contained in the Governance Agreement dated as of July 30, 2004, as amended, among British American Tobacco p.l.c., Brown & Williamson Holdings, Inc. (f/k/a Brown & Williamson Tobacco Corporation), and the Corporation.
Adopted July 28, 2004
Amended February 2, 2005
Amended November 29, 2006
Amended December 4, 2008
Amended September 13, 2012
Amended May 9, 2013
Amended December 5, 2013
Amended December 1, 2016
9
Exhibit 10.28
REYNOLDS AMERICAN INC.
OUTSIDE DIRECTORS’ COMPENSATION SUMMARY
As of January 1, 2017
1. |
Fees/Expense Reimbursement |
Fees: |
• Board retainer fee of $60,000 per year. (Not paid to Non-Executive Chairman.) • Non-Executive Chairman retainer fee of $270,000 per year. • Lead Director retainer fee of $50,000 per year.
•
Committee Chair retainer fees:
$7,500 per year for the Regulatory, Sustainability and Public Policy Committee Chair. • Committee meeting attendance fees of $1,500 per meeting. (Not paid to Non-Executive Chairman.) • Board meeting attendance fees of $1,500 per meeting. (Not paid to Non-Executive Chairman.) |
Fees are payable quarterly in arrears, but may be deferred in 25% increments in cash and/or in deferred stock units until termination of active directorship or until a selected year in the future. To be tax effective, an irrevocable deferral election must be made in the year prior to the year fees would otherwise be payable. |
|
Expense Reimbursement: Directors are reimbursed for actual expenses incurred in connection with attendance at Board and committee meetings, including transportation and lodging expenses. |
2. |
Equity Incentive Award Plan |
• Annual grant of 8,000 deferred stock units (16,000 for Non-Executive Chairman) made at the time of the Annual Meeting and immediately vested. Director can elect to receive non-deferred award of 8,000 shares of RAI common stock (16,000 for Non-Executive Chairman) in lieu of deferred stock units. Upon initial election to the Board on a date other than the Annual Meeting, an independent director receives a pro rata portion of the annual grant. |
• Quarterly grants of deferred stock units on the last day of each calendar quarter. Number of deferred stock units equal to $10,000 ($20,000 for Non-Executive Chairman) divided by the average of the closing price of a share of RAI common stock (as reported on the NYSE) for each business day during the last month of such calendar quarter. |
• Annual deferred stock units paid per director’s election in cash or RAI common stock, and quarterly deferred units paid in cash only, following termination of active directorship per director’s election in either a lump sum or in up to ten annual installments. |
3. |
Life Insurance |
Option to receive $50,000 or $100,000 non-contributory coverage while an active director. Imputed income will be calculated based on director’s end-of-year age and coverage amount. |
4. |
Excess Liability Insurance |
Eligible to receive $10,000,000 in Excess Liability coverage. No cash payment required; the fair market value will be imputed income to directors each year. Policy requires that directors have at least $300,000 underlying liability limit under a homeowner’s or other personal liability policy. Directors are obligated to pay for claims up to $300,000 not covered by this policy. |
5. |
Business Travel Accident Insurance |
$500,000 non-contributory coverage while an active director. |
6. |
Matching Grants |
Match of 1:1 for Educational/Arts/Cultural/Charitable Organizations – combined $10,000 maximum. |
7. |
Director Education Programs |
• Directors may attend one outside director education program per year at RAI’s expense. • Directors are reimbursed for actual expenses incurred in connection with attendance at director education programs, including transportation and lodging expenses. |
Exhibit 10.47
REYNOLDS AMERICAN INC.
LONG-TERM INCENTIVE PROGRAM
PERFORMANCE SHARE AGREEMENT
DATE OF GRANT: oCTOBER 24, 2016
1. Grant . Pursuant to the provisions of the Reynolds American Inc. Amended and Restated 2009 Omnibus Incentive Compensation Plan (the “Plan”), Reynolds American Inc. (the “Company”), on the date set forth above, has granted to
Joseph P. Fragnito (the “Grantee”),
subject to the terms and conditions which follow and the terms and conditions of the Plan, an initial grant (the “Target Number”) of
21,249 Performance Shares.
A copy of the Plan has been provided to the Grantee and is made part of this Performance Share Agreement (this “Agreement”) with the same force and effect as if set forth in this Agreement itself. All capitalized terms used in this Agreement shall have the meaning set forth in the Plan, unless otherwise defined in this Agreement.
2. Value . Each Performance Share shall be equal in value to one share of common stock, par value $0.0001 per share, of the Company or any security or other consideration into which such share may be changed by reason of any transaction or event of the type referred to in Section 11 of the Plan (each, a “Share”).
3. Scoring. (a) Subject to the terms and conditions of this Agreement, the Performance Shares shall have a three-year performance period, consisting of the Company’s fiscal years 2016, 2017 and 2018 (the “Performance Period”), after which the number of Performance Shares earned (the “Earned Number”) will be determined as provided below, and when vested, will be paid in Shares.
(b) If the Company fails to pay to its shareholders cumulative dividends of at least $5.04 per Share (the “Dividend Threshold”) for the Performance Period (which would exclude the dividend paid on January 4, 2016, but would include the dividend paid on January 2, 2019), then the Target Number shall be reduced by an amount equal to three times the percentage of the dividend underpayment for the Performance Period, up to a maximum Target Number reduction of 50% (the “Revised Target Number”), provided that, if the Performance Shares are Assumed in connection with a Change of Control, the Dividend Threshold (and the reduction under this sentence based on the Dividend Threshold) shall not apply.
NAI-1502143967v3
(c) At the end of the Performance Period, after determining if the Dividend Threshold has been met, the Earned Number shall be determined by multiplying the Target Number, or Revised Target Number if the Dividend Threshold has not been met, by the average score for the Company under the Reynolds American Inc. Annual Incentive Award Program (such program, and any successor plan or program thereto, “AIAP”) for fiscal years 2016, 2017 and 2018; provided , however , that such three-year average score shall in no event be greater than 150%; and provided , further , that the value of the Earned Number of Performance Shares that vest as provided in Section 4 of this Agreement, and are paid as provided in Section 5 of this Agreement, shall not exceed any maximum limits set by the Board of Directors pursuant to its resolutions adopted on [February 4, 2016], or otherwise contained in the Plan.
(d) Notwithstanding anything in Section 3 of this Agreement to the contrary, in the event of a Change of Control prior to the end of the Performance Period, the “Change of Control Earned Number” shall be equal to the product of (i) the Target Number and (ii) the average of the following: (x) the score for the Company under the AIAP for each fiscal year of the Performance Period ending prior to the date of such Change of Control, and (y) a score of 100% for each fiscal year of the Performance Period ending after the date of such Change of Control.
4. Vesting. (a) Subject to the terms and conditions of this Agreement, the Earned Number (or in the event of a Change of Control prior to the end of the Performance Period in connection with which the Performance Shares are Assumed, the greatest of (i) the Earned Number, (ii) the Change of Control Earned Number, or (iii) the Target Number) of Performance Shares shall vest on March 1, 2019 (the “Normal Vesting Date”), if the Grantee remains employed by the Company or a Subsidiary on such date.
(b) Notwithstanding anything in Section 4(a) of this Agreement to the contrary but subject to the other terms of this Agreement, in the event of (i) the Grantee’s Retirement (as such term is defined below) or (ii) the Grantee’s Termination of Employment where the Grantee is eligible for and accepts severance benefits under a Company-sponsored severance plan or agreement with the Company (with eligibility for severance benefits to be determined in the sole discretion of the Company), in either case prior to the Normal Vesting Date, and in the case of clause (ii) above prior to the occurrence of a Change of Control, the number of Performance Shares that will vest on the Normal Vesting Date shall be equal to the product of (x) the Earned Number and (y) a fraction, the numerator of which shall be the number of days between the Date of Grant and the date of the Grantee’s Retirement or Termination of Employment, as applicable, and the denominator of which shall be the number of days between the Date of Grant and the Normal Vesting Date, and the remaining Performance Shares will be forfeited and cancelled on the Normal Vesting Date. For purposes of this Agreement, the term “Retirement” shall mean the Grantee’s voluntary Termination of Employment on or after his or her 65th birthday, on or after his or her 55th birthday with 10 or more years of service with the Company or a Subsidiary, or on or after his or her 50th birthday with 20 or more years of service with the Company or a Subsidiary. In addition, for purposes of applying the fraction set forth in clause (y) of the first sentence of this Section 4(b) solely in the case of the Grantee’s Retirement, if the Grantee is a level 8 through level 10 employee of the Company or a Subsidiary on the Date of Grant, the date of the Grantee’s Retirement shall be considered to be the earlier of (A) the Normal Vesting Date or (B) the first anniversary of the actual date of the Grantee’s Retirement if
|
2 |
|
(I) the Grantee notifies the Company of the Grantee’s intent to retire at least one year in advance of the Grantee’s intended date of Retirement and (II) the Grantee’s Retirement in fact occurs on the date provided by the Grantee to the Company in such notice (or such other date as is subsequently agreed to by the Grantee and the Company). The Company shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence, including the form and timing of the Grantee’s notice of the Grantee’s intent to retire. The Company’s determination of the Grantee’s eligibility for treatment under the second preceding sentence shall be final and binding on the Grantee.
(c) Notwithstanding anything in Section 4(a) of this Agreement to the contrary but subject to the other terms of this Agreement, in the event of (i) the Grantee’s death or (ii) the Grantee’s Termination of Employment due to Permanent Disability (as such term is defined below), in either case prior to both the Normal Vesting Date and the occurrence of a Change of Control, while the Grantee is an active employee of the Company or a Subsidiary, the number of Performance Shares that will vest on the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, shall be equal to the product of (x) the Target Number and (y) a fraction, the numerator of which shall be the number of days between the Date of Grant and the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, and the denominator of which shall be the number of days between the Date of Grant and the Normal Vesting Date, and the remaining Performance Shares will be forfeited, cancelled and will no longer be considered outstanding on the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable. For purposes of this Agreement, the term “Permanent Disability” shall mean that the Grantee has become eligible for and is in receipt of benefits under the Company’s Long-Term Disability Plan. In addition, for purposes of applying the fraction set forth in clause (y) of the first sentence of this Section 4(c), if the Grantee is a level 8 through level 10 employee of the Company or a Subsidiary on the Date of Grant, the date of the Grantee’s death or the date of Grantee’s Termination of Employment due to Permanent Disability, as applicable, shall be considered to be the earlier of (A) the Normal Vesting Date or (B) the first anniversary of the date of the Grantee’s death or the date of Grantee’s Termination of Employment due to Permanent Disability, as applicable, if (I) the Grantee notifies the Company of the Grantee’s intent to retire at least one year in advance of the Grantee’s intended date of Retirement and (II) the date of the Grantee’s death or the date of Grantee’s Termination of Employment due to Permanent Disability, as applicable, occurs on a date when the Grantee would have been eligible for Retirement. The Company shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence, including the form and timing of the Grantee’s notice of the Grantee’s intent to retire. The Company’s determination of the Grantee’s eligibility for treatment under the second preceding sentence shall be final and binding on the Grantee.
(d) (i) Notwithstanding anything in Section 4(a) or Section 4(b) of this Agreement to the contrary but subject to the other terms of this Agreement, in the event of a Change of Control (x) that occurs (A) prior to the Normal Vesting Date and (B) while the Performance Shares remain outstanding, and (y) in connection with which the Performance Shares are not Assumed, the number of Performance Shares that will vest on the date of such Change of Control shall be equal to the higher of (A) the Target Number or (B) the Change of Control Earned Number.
|
3 |
|
(ii) For purposes of this Agreement, the Performance Shares shall be considered “Assumed” in connection with a Change of Control if this Agreement is continued without change in connection with such Change of Control or, if this Agreement is modified or the Performance Shares are adjusted in connection with such Change of Control, the following requirements are satisfied: (w) the value of the Performance Shares is not reduced by such modification or adjustment, (x) the Performance Shares as so modified or adjusted relate to publicly traded equity securities of the Company or its successor in the Change of Control (or another entity that is affiliated with the Company or its successor following the Change of Control), (y) if the Grantee is subject to U.S. federal income tax under the Code, the tax consequences under the Code of the Performance Shares as so modified or adjusted are not less favorable to the Grantee than the tax consequences of the Performance Shares before such modification or adjustment, and (z) the other terms and conditions of the Performance Shares as so modified or adjusted are not less favorable to the Grantee than the terms and conditions of the Performance Shares before such modification or adjustment (including the provisions that would apply in the event of a subsequent Change of Control and in the event of the Grantee’s Termination of Employment) and are consistent with Sections 4(d)(iii) and (iv). The Performance Shares may be Assumed only to the extent such assumption does not result in the Performance Shares failing to comply with Section 409A of the Code. The determination of whether the conditions of this Section 4(d)(ii) are satisfied will be made by the Committee, as constituted immediately before the Change of Control, in its sole discretion.
(iii) Notwithstanding anything in Section 4(a) of this Agreement to the contrary but subject to the other terms of this Agreement, if the Performance Shares are Assumed in connection with a Change of Control and the Grantee incurs a Qualified Termination before the Normal Vesting Date and within the two year period following the Change of Control, the number of Performance Shares that shall vest upon such Qualified Termination shall be the higher of (x) the Target Number or (y) the Change of Control Earned Number.
(iv) For purposes of this Section 4(d), a “Qualified Termination” shall mean (x) a Termination of Employment in connection with which the Grantee is or would be eligible to receive severance benefits under a severance plan or agreement that the Company sponsors or is party to as of the Change of Control (based on the terms of such plan or agreement in effect immediately prior to the Change of Control), (y) the Grantee’s death or (z) the Grantee’s Termination of Employment due to Permanent Disability.
(e) Notwithstanding anything in this Agreement to the contrary but subject to the other terms of this Agreement, in the event of the Grantee’s (i) voluntary Termination of Employment (other than at Retirement or the Grantee’s Termination of Employment where the Grantee is eligible for and accepts severance benefits under a Company-sponsored severance plan or agreement with the Company), (ii) involuntary Termination of Employment where the Grantee is not eligible for severance benefits under a Company-sponsored severance plan or agreement with the Company (including, without limitation, a Termination of Employment for Cause, as such term is defined in the relevant severance plan or agreement) or (iii) involuntary Termination of Employment where the Grantee is eligible for but does not accept the severance benefits under the relevant Company-sponsored severance plan or agreement with the Company, in each case, prior to the Normal Vesting Date, the Performance Shares shall be immediately forfeited and cancelled and shall not be considered outstanding.
|
4 |
|
5. Payment. (a) Payment of vested Performance Shares shall be made only in Shares. At the Company’s sole discretion, such Shares may be issued in certificated or book-entry form.
(b) Except as set forth in Section 5(c) of this Agreement, or except under such other circumstances as the Committee deems appropriate if the Grantee is not a “Covered Employee” within the meaning of Section 162(m) of the Code, no payment of vested Performance Shares shall be made to the Grantee prior to the Normal Vesting Date. Except as otherwise provided by this Agreement, payment of vested Performance Shares shall be made as soon as practicable following the Normal Vesting Date, and in any event no later than 90 days after the Normal Vesting Date.
(c) In the event that the Performance Shares vest pursuant to Section 4(c), or pursuant to Section 4(d)(i) or Section 4(d)(iii) in connection with or following a Change of Control that constitutes a “change in control event” for purposes of Section 409A of the Code, the payment of the vested Performance Shares shall be made as soon as practicable after the applicable vesting event, and in any event no later than 90 days after the date such event occurs.
(d) Any payment to which the Grantee is entitled under this Agreement by reason of (or otherwise after) the Grantee’s death shall be made to the Grantee’s estate.
6. Termination of Employment . For purposes of this Agreement, the term “Termination of Employment” shall mean termination from active employment with the Company or a Subsidiary, a successor to the Company or a Subsidiary in a Change of Control, or another entity that is affiliated with the Company or its successor following the Change of Control; it does not mean the termination of pay and benefits at the end of a period of salary continuation (or other form of severance pay or pay in lieu of salary).
7. Dividend Equivalent Payment . At the time of the payment of any vested Performance Shares, the Grantee shall receive a cash dividend equivalent payment in an amount equal to the product of (a) the Earned Number and (b) the aggregate amount of dividends per share declared and paid to the Company’s shareholders on Shares during the period from the Date of Grant through the date of the payment of the Performance Shares, without interest (the “Actual Dividends Paid”); provided , however , that in the event that Section 4(b), 4(c) or 4(d) applies, the amount of the dividend equivalent payment to the Grantee shall be equal to the product of (i) the number of Performance Shares in which the Grantee becomes vested pursuant to Section 4(b), 4(c) or 4(d) of this Agreement, as applicable, and (ii) the Actual Dividends Paid. Notwithstanding anything in this Section 7 to the contrary, to the extent the payment of the vested Performance Shares occurs after both the date a dividend has been declared by the Company and the record date for such dividend, but prior to the dividend payment date related thereto, the amount of the Actual Dividend Paid also shall include such dividend. In the case of a dividend payment to be paid in property, the dividend payment shall be deemed to be the fair market value of the property at the time of distribution of the dividend payment to the Grantee, as determined by the Committee.
8. Rights as a Shareholder . The Grantee shall not be, nor have any of the rights or privileges of, a shareholder of the Company with respect to the Performance Shares unless and
|
5 |
|
until, and to the extent, the Performance Shares vest and Shares have been paid to the Grantee in accordance with Section 5 of this Agreement.
9. Transferability . Other than as specifically provided in this Agreement with regard to the death of the Grantee, this Agreement and any benefit provided or accruing hereunder shall not be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge; and any attempt to do so shall be void. No such benefit shall, prior to receipt thereof by the Grantee, be in any manner liable for or subject to the debts, contracts, liabilities, engagements or torts of the Grantee.
10. No Right to Employment . Neither the execution and delivery of this Agreement nor the granting of the Performance Shares evidenced by this Agreement shall constitute any agreement or understanding, express or implied, on the part of the Company or its subsidiaries to employ the Grantee for any specific period or in any specific capacity or shall prevent the Company or its subsidiaries from terminating the Grantee’s employment at any time with or without cause.
11. Application of Laws . The granting of Performance Shares under this Agreement shall be subject to all applicable laws, rules and regulations and to such approvals of any governmental agencies as may be required.
12. Notices . Any notices required to be given hereunder to the Company shall be addressed to the Corporate Secretary, Reynolds American Inc., Post Office Box 2990, Winston-Salem, NC 27102-2990 (other than any notice that the Grantee provides under Section 4(b) or Section 4(c), which shall be sent as described in the policies, procedures, rules and guidelines established by the Company pursuant to Section 4(b) and Section 4(c)), and any notice required to be given hereunder to the Grantee shall be sent to the Grantee’s address as shown on the records of the Company.
13. Taxes . Any taxes required by federal, state or local laws to be withheld by the Company in respect of the grant of Performance Shares or payment of vested Performance Shares hereunder shall be paid to the Company by the Grantee by the time such taxes are required to be paid or deposited by the Company. The Grantee hereby authorizes the necessary withholding of Performance Shares by the Company to satisfy the minimum statutory tax withholding amount prior to delivery of the vested Performance Shares.
14. Administration and Interpretation . In consideration of the grant of Performance Shares hereunder, the Grantee specifically agrees that the Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan and Agreement as are consistent therewith and to interpret or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee shall be final, conclusive, and binding upon the Grantee, the Company and all other interested persons. No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement. The Committee may delegate its interpretive authority as permitted by the provisions of the Plan.
|
6 |
|
15. Compliance with Section 409A of the Code . This Agreement is intended to comply with Section 409A of the Code and shall be construed and interpreted in accordance with such intent. If any period in which a payment under this Agreement is to be made begins and ends in two different years, the Grantee shall not have a right to designate the taxable year of payment.
16. Amendment . This Agreement is subject to the Plan, a copy of which has been provided to the Grantee. The Board of Directors and the Committee, as applicable, may amend the Plan, and the Committee may amend this Agreement, at any time in any way, except that, other than as otherwise provided by the Plan, any amendment of the Plan or this Agreement that would impair the Grantee’s rights under this Agreement may not be made without the Grantee’s written consent.
17. Litigation Assistance. (a) In addition to any other obligations of the Grantee under law or any other agreement with any Related Company, in consideration of the grant of Performance Shares hereunder, the Grantee specifically agrees that the Grantee:
(i) if requested by the Company, will personally provide reasonable assistance and cooperation to the Related Companies in activities related to the prosecution or defense of any pending or future lawsuits or claims involving any Related Company (with the Company reimbursing the Grantee for reasonable and necessary out-of-pocket costs and expenses incurred in connection therewith);
(ii) will promptly notify the Company’s General Counsel, in writing, upon receipt of any requests from anyone other than an employee or agent of one of the Related Companies for information regarding any Related Company which could reasonably be construed as being proprietary, non-public or confidential, or if the Grantee becomes aware of any potential claim or proposed litigation against any Related Company;
(iii) will refrain from providing any information related to any claim or potential litigation against any Related Company to any person who is not a representative of the Company without the Company’s prior written permission, unless required to provide information pursuant to legal process;
(iv) will not disclose or misuse any confidential information or material concerning any Related Company; and
(v) will not engage in any activity detrimental to the interests of any Related Company, including an act of dishonesty, moral turpitude or other misconduct that has or could have a detrimental impact on the business or reputation of any Related Company.
(b) In further consideration of the grant of Performance Shares hereunder, the Grantee specifically agrees that, if required by law to provide sworn testimony regarding any matter related to any Related Company: the Grantee will consult with and have Company designated legal counsel present for such testimony (with the Company being responsible for the costs of such designated counsel); the Grantee will cooperate with the Company’s attorneys to assist their efforts, especially on matters the Grantee has been privy to, holding all privileged attorney-client matters in strictest confidence.
|
7 |
|
(c) Notwithstanding anything herein to the contrary, nothing in this Agreement shall (i) prohibit the Grantee from reporting possible violations of federal law or regulation to any governmental agency or entity in accordance with any whistleblower protection provisions of state or federal law or regulations, (ii) prohibit the Grantee from communication with any governmental agency or entity or otherwise participating in any investigation or proceeding that may be conducted by such governmental agency or entity, including providing documents or information, (iii) require notification or prior approval by the Company or the Company’s General Counsel of any such reports, communications or disclosures, or (iv) limit the Grantee’s right to receive an award for information relating to a possible securities law violation to the Securities and Exchange Commission.
18. Noncompetition and Other Prohibited Activities. (a) In addition to any other obligations of the Grantee under law or any other agreement with any Related Company, in consideration of the grant of Performance Shares hereunder, the Grantee, during the continuation of his or her employment by any Related Company and during the one-year period commencing upon his or her Termination of Employment for any reason (or, if the Grantee is receiving benefits under a severance plan or agreement, the period of time set forth in the non-competition agreement entered into by the Grantee in connection with the receipt of such severance benefits), will not, directly or indirectly:
(i) be employed, or retained as an independent contractor, or otherwise provide advisory or consulting services (in each case, whether compensated or not compensated), in a sales-related capacity, marketing role, strategic planning role, financial role, or in a product research and development role for any Competitive Business;
(ii) be employed by, or retained as an independent contractor by, or otherwise provide advisory or consulting services to (in each case, whether compensated or not compensated), any Competitive Business in any sort of position or capacity involving the performance of services that are the same as, or substantially similar to, the services the Grantee performed while an employee of any Related Company;
(iii) serve (whether compensated or not compensated) as an officer or director of any Competitive Business;
(iv) organize, own (other than owning up to 5% of the outstanding stock of a publicly traded company) or operate any Competitive Business;
(v) (w) be employed, or retained as an independent contractor (in each case, whether compensated or not compensated) by, (x) provide advisory or consulting services (in each case, whether compensated or not compensated) to, (y) organize or operate or (z) serve as a director or official of (in each case, whether compensated or not-compensated) any Anti-Tobacco Organization;
(vi) (x) be employed, or retained as an independent contractor (in each case, whether compensated or not compensated) by, (y) provide advisory or consulting services (in each case, whether compensated or not compensated) to or (z) serve as a director or official of (in each case, whether compensated or non-compensated) any Regulator; or
|
8 |
|
(vii) solicit, offer employment to, or hire any employee, independent contractor or any other individual providing services to any Related Company (other than secretarial and clerical personnel), who was employed by, or provided services to, any Related Company, at the time of the Grantee’s Termination of Employment, or who was employed by, or provided services to, any Related Company during the 90-day period preceding such date, to become employed by or otherwise provide services to, any person, firm, entity or corporation, or approach any such person for any of the foregoing reasons.
As used in this Agreement, the term “including,” or variations thereof, shall not be a term of limitation, but rather shall be deemed to be followed by the words “without limitation.”
(b) For purposes of Section 17 and Section 18 of this Agreement, the terms set forth below have the following definitions:
(i) “Anti-Tobacco Organization” means any firm, organization, entity, group, or sole proprietorship, the activities or purposes of which include opposing, advocating or lobbying against, or seeking the imposition of restrictions or prohibitions with respect to, any of the Related Companies’ Businesses or the use or consumption of any of the Products.
(ii) “Competitive Business” means any corporation, limited liability company, partnership, person, firm, organization, entity, enterprise, business or activity that is engaged in any of the Related Companies’ Businesses in the Territory or seeking to engage in any of the Related Companies’ Businesses in the Territory.
(iii) “Governmental Authority” means the government of the United States of America, any other nation or political subdivision thereof, whether state or local, and any agency, authority, administration, instrumentality, regulatory body, court or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.
(iv) “Regulator” means: (x) the U.S. Food and Drug Administration (the “FDA”), the Center for Tobacco Products established within the FDA (the “CTP”), the Tobacco Products Scientific Advisory Committee established within the CTP, or any other office, division, branch, committee, department or other body (collectively, an “Organizational Body”) established by the FDA or by an Organizational Body; or (y) any other Governmental Authority having the authority to regulate, or make recommendations regarding any proposed regulations affecting, any part of any of the Related Companies’ Businesses.
(v) “Related Companies’ Businesses” means the businesses of manufacturing, distributing, advertising, promoting, marketing or selling any of the following products (collectively, “Products”): (w) any cigarette, cigar, little cigar, “roll-your-own” tobacco, smokeless or smoke-free tobacco product (including moist snuff, dry snuff, snus, loose leaf, plug and twist tobacco and any other smokeless or smoke-free tobacco, including dissolvable products, that may be invented through the date of Grantee’s Termination of Employment); (x) any nicotine replacement therapy products, including nicotine gum, mouth spray and pouches, and any products otherwise marketed or intended to be used as part of a smoking cessation program; (y) any product commonly referred to as an “e-cigarette”; and (z)
|
9 |
|
any other product, including any tobacco or cigarette substitute, that any Related Company invents, develops and/or markets through the date of the Grantee’s Termination of Employment.
(vi) “Related Company” means, at any time, individually, the Company and each of its subsidiaries; and “Related Companies” means, at any time, collectively, the Company and all of its subsidiaries, and, in any case, each and all of their respective subsidiaries, parents, affiliates (including partnerships and joint ventures in which any Related Company is a partner or joint venturer), successors and assigns.
(vii) “Territory” means (x) the United States of America, its territories, commonwealths and possessions (including duty-free stores or outlets located anywhere in any of the foregoing places); (y) U.S. military installations located anywhere in the world; and (z) any other location in which any Related Company conducts any of the Related Companies’ Businesses through the date of the Grantee’s Termination of Employment.
(c) Notwithstanding anything to the contrary contained in this Agreement, Section 18 of this Agreement will not prohibit a Grantee from engaging in the authorized practice of law, whether for a firm, corporation or otherwise, in any jurisdiction that prohibits agreements restricting the right of an individual to engage in such practice; provided, however , a Grantee will continue to be bound by any and all applicable professional and ethical rules of conduct that govern the use or disclosure of confidential information obtained during the course of any representation of the Company or any of its subsidiaries; and, provided further , this Agreement does prohibit a Grantee from engaging in any of the activities outlined in Section 18(a) of this Agreement in a non-legal, business role.
(d) The Grantee understands and agrees that:
(i) the purpose of this Section 18 is solely to protect the Related Companies’ legitimate business interests, including, but not limited to, the Related Companies’ confidential information, customer relationships and goodwill, all of which contribute to the Related Companies’ competitive advantage in operating the Related Companies’ Businesses in the Territory;
(ii) the Related Companies manufacture, distribute, advertise, promote, market and sell Products in the Territory, and the restrictive covenants contained in this Agreement are necessary to protect the Related Companies’ legitimate business assets and interests, and they are reasonable in time, territory, and scope, and in all other respects;
(iii) the restrictive covenants contained in this Agreement constitute a material inducement to the Company entering this Agreement, without which the Company would not have entered into this Agreement; and
(iv) the covenants set forth in this Section 18 are essential elements of this Agreement and shall be construed as agreements independent of any other provision in this Agreement, and the existence of any claim or cause of action of the Grantee against the Company or any other Related Company, whether predicated on this Agreement or otherwise, shall not excuse the Grantee’s breach, or constitute a defense to the enforcement by the Related Companies, of these restrictive covenants. The Company and the Grantee have had the
|
10 |
|
opportunity to independently consult with their respective counsel for advice in all respects concerning the reasonableness and propriety of such covenants, with specific regard to the nature of the businesses conducted by the Related Companies.
(e) The Grantee agrees that any breach of the covenants contained in Section 18 of this Agreement would irreparably injure the Related Companies and that their remedies at law would be inadequate. Accordingly, in the event of any breach or threatened breach of Section 18 of this Agreement, the Related Companies, in addition to any other rights and remedies available at law or in equity, shall be entitled to an injunction (and/or other equitable relief), restraining such breach or threatened breach, and be entitled to the reimbursement of court costs, attorneys’ fees and other costs and expenses incurred in connection with enforcing this Agreement. The existence of any claim or cause of action on the part of the Grantee against any Related Company shall not constitute a defense to the enforcement of these provisions. This Agreement shall be enforceable by any Related Company, either alone or together with any other Related Company or Related Companies. The rights and remedies hereunder provided to the Related Companies shall be cumulative and shall be in addition to any other rights or remedies available at law, in equity or under this Agreement.
(f) If any of the provisions of Section 18 of this Agreement are determined by a court of law to be excessively broad, whether as to geographical area, time, scope or otherwise, such provision shall be reduced to whatever extent is reasonable and shall be enforced as so modified. Any provisions of Section 18 of this Agreement not so modified shall remain in full force and effect.
19. Recoupment Provisions. (a) Subject to the clawback provisions of the Sarbanes-Oxley Act of 2002, the Committee may, in its sole discretion, direct that the Company recoup, and upon demand by the Company the Grantee agrees to return to the Company, all or a portion of any Shares paid to the Grantee hereunder computed using financial information or performance metrics later found to be materially inaccurate. The number of Shares to be recovered shall be equal to the excess of the number of Shares paid out over the number of Shares that would have been paid out had such financial information or performance metric been fairly stated at the time the payout was made.
(b) The Committee may direct recoupment of Shares pursuant to Section 19(a) of this Agreement whether or not it directs recoupment of related AIAP payouts. The Committee also may amend a yearly AIAP payout percent for purposes of recoupment of Shares under this Agreement without directing recoupment of related AIAP payouts.
(c) If the Company reasonably determines that the Grantee has materially violated any of the Grantee’s obligations under Section 17 or 18 of this Agreement, then effective the date on which such violation began, (i) any Performance Shares that have not yet vested and been paid to the Grantee under this Agreement shall be forfeited and cancelled, and (ii) the Company may, in its sole discretion, recoup any and all of the Shares previously paid to the Grantee under this Agreement.
(d) If, after a demand for recoupment of Shares under Section 19 of this Agreement, the Grantee fails to return such Shares to the Company, the Grantee acknowledges
|
11 |
|
that the Company (or the Company through the actions of any of its subsidiaries employing the Grantee, if applicable) has the right to effect the recovery of the then current value of such Shares and the amount of its court costs, attorneys’ fees and other costs and expenses incurred in connection with enforcing this Agreement by (i) deducting (subject to applicable law and the terms and conditions of the Plan) from any amounts the Company (and if applicable, any Subsidiary employing the Grantee) owes to the Grantee (including, but not limited to, wages or other compensation), except with respect to any non-qualified deferred compensation under Section 409A of the Code, (ii) withholding, except with respect to any non-qualified deferred
compensation under Section 409A of the Code, payment of future increases in compensation (including the payment of any discretionary bonus amount) or grants of compensatory awards that otherwise would have been made in accordance with the Company’s or any of its subsidiaries’ otherwise applicable compensation practices, or (iii) any combination of the foregoing. The right of recoupment set forth in the preceding sentence shall not be the exclusive remedy of the Company, and the Company may exercise each and every other remedy available to it under applicable law.
20. Qualified Performance-Based Awards . If the Grantee is a Covered Employee, the grant of Performance Shares evidenced by this Agreement shall be considered a Qualified Performance-Based Award. In furtherance thereof, and notwithstanding anything in this Agreement or the Plan to the contrary, the Earned Number of Performance Shares that the Grantee may earn for the Performance Period pursuant to the grant evidenced by this Agreement (the “Earned Shares”) shall be determined by the Committee based on, and must have a value (the “Earned Shares Value”) that in no event exceeds a value equal to, the percentage of the Company’s cumulative Cash Net Income (as defined below) for the Performance Period previously established by the Board of Directors of the Company in resolutions adopted on [February 4, 2016] to apply with respect to the Grantee for the Performance Period (the “Award Pool Value”). Notwithstanding the prior sentence, the Committee shall have the power and authority, in its sole and absolute exercise of negative discretion, to reduce the Earned Shares such that the Earned Shares Value will be less than the Award Pool Value, which reduction may be made by taking into account the factors described above under Section 3 of this Agreement or any other criteria the Committee deems appropriate. The reductions in Earned Shares Value, if any, shall not result in any increases in the value of performance shares earned by any other Participant. For purposes of this Agreement, the term “Cash Net Income” shall mean the Company’s net income from continuing operations in the consolidated statement of income adjusted for the impact of non-cash items, such as depreciation, amortization, unrealized gains and losses, intangible asset impairments and other non-cash gains/losses included in net income (as reported in the Company’s annual reports for 2016, 2017 and 2018, respectively).
21. Electronic Signature . This Agreement is delivered electronically. The Grantee consents to using an electronic signature to sign this Agreement and be legally bound to his or her acceptance or rejection of the grant. By electronically signing the Agreement, the Grantee also consents to entering into this Agreement in electronic form. The Grantee acknowledges that his or her electronic signature will have the same legal force and effect as a handwritten signature. The Grantee’s electronic signature, including date and time of signing will be stored electronically with the Performance Share grant record.
|
12 |
|
22. GOVERNING LAWS . THE LAWS OF THE STATE OF NORTH CAROLINA SHALL GOVERN THE INTERPRETATION, VALIDITY AND PERFORMANCE OF THE TERMS OF THIS AGREEMENT, REGARDLESS OF THE LAW THAT MIGHT BE APPLIED UNDER PRINCIPLES OF CONFLICTS OF LAWS. EXCEPT AS OTHERWISE PROVIDED IN THIS SECTION 22, ANY CONTROVERSY OR DISPUTE ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL BE SETTLED EXCLUSIVELY IN THE COURTS (FEDERAL AND STATE) SITUATED IN THE STATE OF NORTH CAROLINA, FORSYTH COUNTY. THE GRANTEE CONSENTS TO PERSONAL JURISDICTION IN THE STATE OF NORTH CAROLINA AND IN THE COURTS THEREOF FOR THE ENFORCEMENT OF THIS AGREEMENT, AND WAIVES ANY RIGHTS THE GRANTEE OTHERWISE MAY HAVE UNDER THE LAWS OF ANY JURISDICTION TO OBJECT ON ANY BASIS TO JURISDICTION OR VENUE WITHIN THE STATE OF NORTH CAROLINA TO ENFORCE THIS AGREEMENT. IN ADDITION, AND NOTWITHSTANDING THE FOREGOING, THE COMPANY MAY ELECT, IN ITS DISCRETION, TO SEEK A TEMPORARY RESTRAINING ORDER OR PRELIMINARY OR PERMANENT INJUNCTIVE (OR SIMILAR) RELIEF TO ENFORCE ITS RIGHTS UNDER SECTIONS 17 AND 18 OF THIS AGREEMENT IN ANY JURISDICTION OR COURT ANYWHERE IN THE WORLD THAT THE COMPANY DETERMINES TO BE APPROPRIATE, AND THE GRANTEE HEREBY CONSENTS TO VENUE IN ANY SUCH JURISDICTION OR COURT IN SUCH EVENT.
IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Grantee have executed this Agreement as of the Date of Grant first above written.
REYNOLDS AMERICAN INC. |
|
By: |
|
|
Authorized Signature |
|
|
|
|
|
|
/s/ JOSEPH P. FRAGNITO
Grantee’s Signature
Print Name: Joseph P. Fragnito
|
13 |
|
Exhibit 10.48
REYNOLDS AMERICAN INC.
LONG-TERM INCENTIVE PROGRAM
_________________________________________
RESTRICTED STOCK UNIT AGREEMENT
________________________________________
DATE OF GRANT: October 24, 2016
1. Grant . Pursuant to the provisions of the Reynolds American Inc. Amended and Restated 2009 Omnibus Incentive Compensation Plan (the “Plan”), Reynolds American Inc. (the “Company”), on the date set forth above, has granted to
Joseph P. Fragnito (the “Grantee”),
subject to the terms and conditions which follow and the terms and conditions of the Plan, an initial grant (the “Target Number”) of
21,101 Restricted Stock Units.
A copy of the Plan has been provided to the Grantee and is made part of this Restricted Stock Unit Agreement (this “Agreement”) with the same force and effect as if set forth in this Agreement itself. All capitalized terms used in this Agreement shall have the meaning set forth in the Plan, unless otherwise defined in this Agreement.
2. Value . Each Restricted Stock Unit shall be equal in value to one share of common stock, par value $0.0001 per share, of the Company or any security or other consideration into which such share may be changed by reason of any transaction or event of the type referred to in Section 11 of the Plan (each, a “Share”).
3. Performance Periods . (a) Subject to the terms and conditions of this Agreement, 50% of the Target Number (the “2017 Target Number”) shall have a twelve-month performance period, consisting of the period beginning October 1, 2016 and ending September 30, 2017 (the “2017 Performance Period”), after which the 2017 Target Number of Restricted Stock Units, if and when vested, will be paid in Shares. At the end of the 2017 Performance Period, the value of the 2017 Target Number of Restricted Stock Units that vest as provided in Section 4 of this Agreement, and are paid as provided in Section 5 of this Agreement, shall not exceed any maximum limits set by the Board of Directors pursuant to its resolutions adopted on September 15, 2016, or otherwise contained in the Plan.
(b) Subject to the terms and conditions of this Agreement, the remaining 50% of the Target Number (the “2018 Target Number”) shall have a twelve- month performance period, consisting of the period beginning October 1, 2017 and ending September 30, 2018, (the “2018 Performance Period”), after which the 2018 Target Number of Restricted St ock Units, if
NAI-1502151968v3
(c) and when vested, will be paid in Shares. At the end of the 201 8 Performance Period, the value of the 201 8 Target Number of Restricted Stock Units that ve st as provided in Section 4 of this Agreement, and are paid as provided in Section 5 of this Agreement, shall not exceed any maximum limits set by the Board of Directors pursuant to its resolutions adopted on September 15, 2016 , or otherwise contained in the Plan.
4. Vesting . (a) Subject to the terms and conditions of this Agreement, the 2017 Target Number of Restricted Stock Units shall vest, if at all, on December 15, 2017 (the “First Vesting Date”), and the 2018 Target Number of Restricted Stock Units shall vest, if at all, on December 15, 2018 (the “Second Vesting Date”) (including in the event of a Change of Control in connection with which the Restricted Stock Units are Assumed), if the Grantee remains employed by the Company or a Subsidiary on each such date.
(b) Notwithstanding anything in Section 4(a) of this Agreement to the contrary but subject to the other terms of this Agreement, in the event of the Grantee’s Termination of Employment where the Grantee is eligible for and accepts severance benefits under a Company-sponsored severance plan or agreement with the Company (with eligibility for severance benefits to be determined in the sole discretion of the Company) prior to both the First Vesting Date and the occurrence of a Change of Control: (i) the number of Restricted Stock Units that will vest on the First Vesting Date shall be equal to the product of (x) the 2017 Target Number and (y) a fraction, the numerator of which shall be the number of days b etween the Date of Grant and the date of the Grantee’s Termination of Employment, and the denominator of which shall be the number of days between the Date of Grant and the First Vesting Date ; and (ii) the number of Restricted Stock Units that will vest on the Second Vesting Date shall be equal to the product of (x) the 2018 Target Number and (y) a fraction, the numerator of which shall be the number of days between the Date of Grant and the date of the Grantee’s Termination of Employment, and the denominator of which shall be the number of days between the Date of Grant and the Second Vesting Date , and any remaining Restricted Stock Units that are at either such time not vested will be forfeited and cancelled on the First Vesting Date or the Second Vesting Date, a s applicable. Furthermore, notwithstanding anything in Section 4(a) of this Agreement to the contrary, in the event of the Grantee’s Termination of Employment where the Grantee is eligible for and accepts severance benefits under a Company-sponsored severance plan or agreement with the Company (with eligibility for severance benefits to be determined in the sole discretion of the Company) after the First Vesting Date but prior to both the Second Vesting Date and the occurrence of a Change of Control, the number of Restricted Stock Units that will vest on the Second Vesting Date shall be equal to the product of (A) the 2018 Target Number and (B) a fraction, the numerator of which shall be the number of days between the Date of Grant and the date of the Grantee’s Termination of Employment, and the denominator of which shall be the number of days between the Date of Grant and the Second Vesting Date, and any remaining Restricted Stock Units that are at that time not vested will be forfeited and cancelled on the Second Vesting Date.
(c) Notwithstanding anything in Section 4(a) of this Agreement to the contrary but subject to the other terms of this Agreement, in the event of (i) the Grantee’s death or (ii) the Grantee’s Termination of Employment due to Permanent Disability (as such term is defined below), in each case, prior to both the First Vesting Date and the occurrence of a Change of Control, and while the Grantee is an active employee of the Company or a Subsidiary, the
2
NAI-1502151968v3
number of Restricted Stock Units that will vest on the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, shall be equal to the sum of (x) the product of (A) the 2017 Target Number and (B) a fraction, the numerator of which shall be the number of da ys between the Date of Grant and the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, and the denominator of which shall be the number of days between the Date of Grant and the First Vesting Date, and (y) the product of (A) the 201 8 Target Number and (B) a fraction, the numerator of which shall be the number of days between the Date of Grant and the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, and the denominator of which shall be the number of days between the Date of Grant and the Second Vesting Date, and any remaining Restricted Stock Units that are at that time not vested will be forfeited and cancelled on the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable. Furthermore, notwithstanding anything in Section 4(a) of this Agreement to the contrary, in the event of (I) the Grantee’s death or (II) the Grantee’s Termination of Employment due to Permanent Disability (as such term is defined below), in each case, after the First Vesting Date but prior to both the Second Vesting Date and the occurrence of a Change of Control and while the Grantee is an active employee of the Company or a Subsidiary, the number of Restricted Stock Units that will vest on the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, shall be equal to the product of (X) the 201 8 Target Number and (Y) a fraction, the numerator of which shall be the number of days between the Date of Grant and the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable, and the denominator of which shall be the number of days between the Date of Grant and the Second Vesting Date, and any remaining Restricted Stock Units that are at that time not vested will be forfeited and cancelled on the date of the Grantee’s death or the date of the Grantee’s Termination of Employment due to Permanent Disability, as applicable. For purposes of this Agreement, the term “Permanent Disability” shall mean that the Grantee has become eligible for and is in receipt of benefits under the Company’s Long-Term Disability Plan.
(d) (i) Notwithstanding anything in Section 4(a) or Section 4(b) of this Agreement to the contrary but subject to the other terms of this Agreement, in the event of a Change of Control that occurs prior to the Second Vesting Date in connection with which the Restricted Stock Units are not Assumed, all of the Restricted Stock Units that remain outstanding at the time of such Change of Control will vest on the date of such Change of Control.
(ii) For purposes of this Agreement, the Restricted Stock Units shall be considered “Assumed” in connection with a Change of Control if this Agreement is continued without change in connection with such Change of Control or, if this Agreement is modified or the Restricted Stock Units are adjusted in connection with such Change of Control, the following requirements are satisfied: (w) the value of the Restricted Stock Units is not reduced by such modification or adjustment, (x) the Restricted Stock Units as so modified or adjusted relate to publicly traded equity securities of the Company or its successor in the Change of Control (or another entity that is affiliated with the Company or its successor following the Change of Control), (y) if the Grantee is subject to U.S. federal income tax under the Code, the tax consequences under the Code of the Restricted Stock Units as so modified or adjusted are not less
3
NAI-1502151968v3
favorable to the Grantee than the tax consequences of the Restricted Stock Units before such modification or adjustment, and (z) the other terms and conditions of the Restricted Stock Units as so modified or adjusted are not less favorable to the Grantee than the terms and conditions of the Restricted Stock Units before such modification or adjustment (including the provisions that would apply in the event of a subsequent Change of Control and in the event of the Grantee’s Termination of Employment) and are consistent with Sections 4(d)(iii) and (iv). The Restricted Stock Units may be Assumed only to the extent such assumption does not result in the Restricted Stock Units failing to comply with Section 409A of the Code. The determination of whether the conditions of this Section 4(d)(ii) are satisfied will be made by the Committee, as constituted immediately before the Change of Control, in its sole discretion.
(iii) Notwithstanding anything in Section 4(a) of this Agreement to the contrary but subject to the other terms of this Agreement, if the Restricted Stock Units are Assumed in connection with a Change of Control and the Grantee incurs a Qualified Termination before the Second Vesting Date, but within the two year period following the Change of Control, all of the Restricted Stock Units that remain outstanding at the time of such Change of Control shall vest upon such Qualified Termination.
(iv) For purposes of this Section 4(d), a “Qualified Termination” shall mean (x) a Termination of Employment in connection with which the Grantee is or would be eligible to receive severance benefits under a severance plan or agreement that the Company sponsors or is party to as of the Change of Control (based on the terms of such plan or agreement in effect immediately prior to the Change of Control), (y) the Grantee’s death or (z) the Grantee’s Termination of Employment due to Permanent Disability.
(e) Notwithstanding anything in this Agreement to the contrary but subject to the other terms of this Agreement, in the event of the Grantee’s (i) voluntary Termination of Employment (other than the Grantee’s Termination of Employment where the Grantee is eligible for and accepts severance benefits under a Company-sponsored severance plan or agreement with the Company), (ii) involuntary Termination of Employment where the Grantee is not eligible for severance benefits under a Company-sponsored severance plan or agreement with the Company (including, without limitation, a Termination of Employment for Cause, as such term is defined in the relevant severance plan or agreement) or (iii) involuntary Termination of Employment where the Grantee is eligible for but does not accept the severance benefits under the relevant Company-sponsored severance plan or agreement with the Company, in each case, prior to the First Vesting Date or the Second Vesting Date, as applicable, any Restricted Stock Units that are at that time not vested shall be immediately forfeited and cancelled and shall not be considered outstanding.
5. Payment . (a) Payment of vested Restricted Stock Units shall be made only in Shares. At the Company’s sole discretion, such Shares may be issued in certificated or book-entry form.
(b) Except as set forth in Section 5(c) of this Agreement, or except under such other circumstances as the Committee deems appropriate if the Grantee is not a “Covered
4
NAI-1502151968v3
Employee” within the meaning of Section 162(m) of the Code, no payment of vested Restricted Stock Units shall be made to the Grantee prior to the First Vesting Date or the Second Vesting Date, as applicable. Except as otherwise provided by this Agreement, payment of vested Restricted Stock Units with respect to the 201 7 Performance Period shall be made as soon as practicable following the First Vesting Date, and in any event no later than 90 days after the First Vesting Date, and payment of vested Restricted Stock Units with respect to the 201 8 Performance Period shall be made as soon as practicable following the Second Vesting Date, and in any event no later than 90 days after the Second Vesting Date.
(c) In the event that the Restricted Stock Units vest pursuant to Section 4(c), or pursuant to Section 4(d)(i) or Section 4(d)(iii) of this Agreement in connection with or following a Change of Control that constitutes a “change in control event” for purposes of Section 409A of the Code, the payment of the vested Restricted Stock Units shall be made as soon as practicable after the applicable vesting event, and in any event no later than 90 days after the date such event occurs.
(d) Any payment to which the Grantee is entitled under this Agreement by reason of (or otherwise after) the Grantee’s death shall be made to the Grantee’s estate.
6. Termination of Employment . For purposes of this Agreement, the term “Termination of Employment” shall mean termination from active employment with the Company or a Subsidiary, a successor to the Company or a Subsidiary in a Change of Control, or another entity that is affiliated with the Company or its successor following the Change of Control; it does not mean the termination of pay and benefits at the end of a period of salary continuation (or other form of severance pay or pay in lieu of salary).
7. Dividend Equivalent Payment . At the time of the payment of any vested Restricted Stock Units, the Grantee shall receive a cash dividend equivalent payment in an amount equal to the product of (a) the 2017 Target Number and the 2018 Target Number , as applicable, and (b) the aggregate amount of dividends per share declared and paid to the Company’s shareholders on Shares during the period from the Date of Grant through the date of the payment of the Restricted Stock Units, without interest (the “Actual Dividends Paid”); provided , however , that in the event that Section 4(b), 4(c) or 4(d) applies, the amount of the dividend equivalent payment to the Grantee shall be equal to the product of (i) the number of Restricted Stock Units in which the Grantee becomes vested pursuant to Section 4(b), 4(c) or 4(d) of this Agreement, as applicable, and (ii) the Actual Dividends Paid. Notwithstanding anything in this Section 7 to the contrary, to the extent the payment of the vested Restricted Stock Units occurs after both the date a dividend has been declared by the Company and the record date for such dividend, but prior to the dividend payment date related thereto, the amount of the Actual Dividend Paid also shall include such dividend. In the case of a dividend payment to be paid in property, the dividend payment shall be deemed to be the fair market value of the property at the time of distribution of the dividend payment to the Grantee, as determined by the Committee.
8. Rights as a Shareholder . The Grantee shall not be, nor have any of the rights or privileges of, a shareholder of the Company with respect to the Restricted Stock Units unless and
5
NAI-1502151968v3
until, and to the extent, the Restricted Stock Units vest and Shares have been paid to the Grantee in accordance with Section 5 of this Agreement.
9. Transferability . Other than as specifically provided in this Agreement with regard to the death of the Grantee, this Agreement and any benefit provided or accruing hereunder shall not be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge; and any attempt to do so shall be void. No such benefit shall, prior to receipt thereof by the Grantee, be in any manner liable for or subject to the debts, contracts, liabilities, engagements or torts of the Grantee.
10. No Right to Employment . Neither the execution and delivery of this Agreement nor the granting of the Restricted Stock Units evidenced by this Agreement shall constitute any agreement or understanding, express or implied, on the part of the Company or its subsidiaries to employ the Grantee for any specific period or in any specific capacity or shall prevent the Company or its subsidiaries from terminating the Grantee’s employment at any time with or without cause.
11. Application of Laws . The granting of Restricted Stock Units under this Agreement shall be subject to all applicable laws, rules and regulations and to such approvals of any governmental agencies as may be required.
12. Notices . Any notices required to be given hereunder to the Company shall be addressed to the Corporate Secretary, Reynolds American Inc., Post Office Box 2990, Winston-Salem, NC 27102-2990, and any notice required to be given hereunder to the Grantee shall be sent to the Grantee’s address as shown on the records of the Company.
13. Taxes . Any taxes required by federal, state or local laws to be withheld by the Company in respect of the grant of Restricted Stock Units or payment of Shares in respect of vested Restricted Stock Units hereunder shall be paid to the Company by the Grantee by the time such taxes are required to be paid or deposited by the Company. The Grantee hereby authorizes the necessary withholding of Shares by the Company to satisfy the minimum statutory tax withholding amount prior to delivery of Shares in respect of vested Restricted Stock Units.
14. Administration and Interpretation . In consideration of the grant of Restricted Stock Units hereunder, the Grantee specifically agrees that the Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan and Agreement as are consistent therewith and to interpret or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee shall be final, conclusive, and binding upon the Grantee, the Company and all other interested persons. No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement. The Committee may delegate its interpretive authority as permitted by the provisions of the Plan.
15. Compliance with Section 409A of the Code . This Agreement is intended to comply with Section 409A of the Code and shall be construed and interpreted in accordance with such intent. If any period in which a payment under this Agreement is to be made begins and
6
NAI-1502151968v3
ends in two different years, the Grantee shall not have a right to designate the taxable year of payment.
16. Amendment . This Agreement is subject to the Plan, a copy of which has been provided to the Grantee. The Board of Directors and the Committee, as applicable, may amend the Plan, and the Committee may amend this Agreement, at any time in any way, except that, other than as otherwise provided by the Plan, any amendment of the Plan or this Agreement that would impair the Grantee’s rights under this Agreement may not be made without the Grantee’s written consent.
17. Litigation Assistance . (a) In addition to any other obligations of the Grantee under law or any other agreement with any Related Company, in consideration of the grant of Restricted Stock Units hereunder, the Grantee specifically agrees that the Grantee:
(i) if requested by the Company, will personally provide reasonable assistance and cooperation to the Related Companies in activities related to the prosecution or defense of any pending or future lawsuits or claims involving any Related Company (with the Company reimbursing the Grantee for reasonable and necessary out-of-pocket costs and expenses incurred in connection therewith);
(ii) will promptly notify the Company’s General Counsel, in writing, upon receipt of any requests from anyone other than an employee or agent of one of the Related Companies for information regarding any Related Company which could reasonably be construed as being proprietary, non-public or confidential, or if the Grantee becomes aware of any potential claim or proposed litigation against any Related Company;
(iii) will refrain from providing any information related to any claim or potential litigation against any Related Company to any person who is not a representative of the Company without the Company’s prior written permission, unless required to provide information pursuant to legal process;
(iv) will not disclose or misuse any confidential information or material concerning any Related Company; and
(v) will not engage in any activity detrimental to the interests of any Related Company, including an act of dishonesty, moral turpitude or other misconduct that has or could have a detrimental impact on the business or reputation of any Related Company.
(b) In further consideration of the grant of Restricted Stock Units hereunder, the Grantee specifically agrees that, if required by law to provide sworn testimony regarding any matter related to any Related Company: the Grantee will consult with and have Company designated legal counsel present for such testimony (with the Company being responsible for the costs of such designated counsel); the Grantee will cooperate with the Company’s attorneys to assist their efforts, especially on matters the Grantee has been privy to, holding all privileged attorney-client matters in strictest confidence.
7
NAI-1502151968v3
(c) Notwithstanding anything herein to the contrary, nothing in this Agreement shall (i) prohibit the Grantee from reporting possible violations of federal law or regulation to any governmental agency or entity in accordance with any whistleblower protection provisions of state or federal law or regulations, (ii) prohibit the Grantee from communication with any governmental agency or entity or otherwise participating in any investigation or proceeding that may be conducted by such governmental agency or entity, including providing documents or information, (iii) require notification or prior approval by the Company or the Company’s General Counsel of any such reports, communications or disclosures, or (iv) limit the Grantee’s right to receive an award for information relating to a possible securities law violation to the Securities and Exchange Commission.
18. Noncompetition and Other Prohibited Activities . (a) In addition to any other obligations of the Grantee under law or any other agreement with any Related Company, in consideration of the grant of Restricted Stock Units hereunder, the Grantee, during the continuation of his or her employment by any Related Company and during the one-year period commencing upon his or her Termination of Employment for any reason (or, if the Grantee is receiving benefits under a severance plan or agreement, the period of time set forth in the non-competition agreement entered into by the Grantee in connection with the receipt of such severance benefits), will not, directly or indirectly:
(i) be employed, or retained as an independent contractor, or otherwise provide advisory or consulting services (in each case, whether compensated or not compensated), in a sales-related capacity, marketing role, strategic planning role, financial role, or in a product research and development role for any Competitive Business;
(ii) be employed by, or retained as an independent contractor by, or otherwise provide advisory or consulting services to (in each case, whether compensated or not compensated), any Competitive Business in any sort of position or capacity involving the performance of services that are the same as, or substantially similar to, the services the Grantee performed while an employee of any Related Company;
(iii) serve (whether compensated or not compensated) as an officer or director of any Competitive Business;
(iv) organize, own (other than owning up to 5% of the outstanding stock of a publicly traded company) or operate any Competitive Business;
(v) (w) be employed, or retained as an independent contractor (in each case, whether compensated or not compensated) by, (x) provide advisory or consulting services (in each case, whether compensated or not compensated) to, (y) organize or operate or (z) serve as a director or official of (in each case, whether compensated or not-compensated) any Anti-Tobacco Organization;
(vi) (x) be employed, or retained as an independent contractor (in each case, whether compensated or not compensated) by, (y) provide advisory or consulting services (in each case, whether compensated or not compensated) to or (z) serve as a
8
NAI-1502151968v3
director or official of (in each case, whether compensated or non-compensated) any Regulator; or
(vii) solicit, offer employment to, or hire any employee, independent contractor or any other individual providing services to any Related Company (other than secretarial and clerical personnel), who was employed by, or provided services to, any Related Company, at the time of the Grantee’s Termination of Employment, or who was employed by, or provided services to, any Related Company during the 90-day period preceding such date, to become employed by or otherwise provide services to, any person, firm, entity or corporation, or approach any such person for any of the foregoing reasons.
As used in this Agreement, the term “including,” or variations thereof, shall not be a term of limitation, but rather shall be deemed to be followed by the words “without limitation.”
(b) For purposes of Section 17 and Section 18 of this Agreement, the terms set forth below have the following definitions:
(i) “Anti-Tobacco Organization” means any firm, organization, entity, group, or sole proprietorship, the activities or purposes of which include opposing, advocating or lobbying against, or seeking the imposition of restrictions or prohibitions with respect to, any of the Related Companies’ Businesses or the use or consumption of any of the Products.
(ii) “Competitive Business” means any corporation, limited liability company, partnership, person, firm, organization, entity, enterprise, business or activity that is engaged in any of the Related Companies’ Businesses in the Territory or seeking to engage in any of the Related Companies’ Businesses in the Territory.
(iii) “Governmental Authority” means the government of the United States of America, any other nation or political subdivision thereof, whether state or local, and any agency, authority, administration, instrumentality, regulatory body, court or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.
(iv) “Regulator” means: (x) the U.S. Food and Drug Administration (the “FDA”), the Center for Tobacco Products established within the FDA (the “CTP”), the Tobacco Products Scientific Advisory Committee established within the CTP, or any other office, division, branch, committee, department or other body (collectively, an “Organizational Body”) established by the FDA or by an Organizational Body; or (y) any other Governmental Authority having the authority to regulate, or make recommendations regarding any proposed regulations affecting, any part of any of the Related Companies’ Businesses.
(v) “Related Companies’ Businesses” means the businesses of manufacturing, distributing, advertising, promoting, marketing or selling any of the following products (collectively, “Products”): (w) any cigarette, cigar, little cigar, “roll-
9
NAI-1502151968v3
your-own” tobacco, smokeless or smoke-free tobacco product (including moist snuff, dry snuff, snus, loose leaf, plug and twist tobacco and any other smokeless or smoke-free tobacco, including dissolvable products, that may be invented through the date of Grantee’s Termination of Employment); (x) any nicotine replacement therapy products, including nicotine gum, mouth spray and pouches, and any products otherwise marketed or intended to be used as part of a smoking cessation program; (y) any product commonly referred to as an “e-cigarette”; and (z) any other product, including any tobacco or cigarette substitute, that any Related Company invents, develops and/or markets through the date of the Grantee’s Termination of Employment.
(vi) “Related Company” means, at any time, individually, the Company and each of its subsidiaries; and “Related Companies” means, at any time, collectively, the Company and all of its subsidiaries, and, in any case, each and all of their respective subsidiaries, parents, affiliates (including partnerships and joint ventures in which any Related Company is a partner or joint venturer), successors and assigns.
(vii) “Territory” means (x) the United States of America, its territories, commonwealths and possessions (including duty-free stores or outlets located anywhere in any of the foregoing places); (y) U.S. military installations located anywhere in the world; and (z) any other location in which any Related Company conducts any of the Related Companies’ Businesses through the date of the Grantee’s Termination of Employment.
(c) Notwithstanding anything to the contrary contained in this Agreement, Section 18 of this Agreement will not prohibit the Grantee from engaging in the authorized practice of law, whether for a firm, corporation or otherwise, in any jurisdiction that prohibits agreements restricting the right of an individual to engage in such practice; provided , however , the Grantee will continue to be bound by any and all applicable professional and ethical rules of conduct that govern the use or disclosure of confidential information obtained during the course of any representation of the Company or any of its subsidiaries; and, provided further , this Agreement does prohibit the Grantee from engaging in any of the activities outlined in Section 18(a) of this Agreement in a non-legal, business role.
(d) The Grantee understands and agrees that:
(i) the purpose of this Section 18 is solely to protect the Related Companies’ legitimate business interests, including, but not limited to, the Related Companies’ confidential information, customer relationships and goodwill, all of which contribute to the Related Companies’ competitive advantage in operating the Related Companies’ Businesses in the Territory;
(ii) the Related Companies manufacture, distribute, advertise, promote, market and sell Products in the Territory, and the restrictive covenants contained in this Agreement are necessary to protect the Related Companies’ legitimate business assets and interests, and they are reasonable in time, territory, and scope, and in all other respects;
10
NAI-1502151968v3
(iii) the restrictive covenants contained in this Agreement constitute a material inducement to the Company entering this Agreement, without which the Company would not have entered into this Agreement; and
(iv) the covenants set forth in this Section 18 are essential elements of this Agreement and shall be construed as agreements independent of any other provision in this Agreement, and the existence of any claim or cause of action of the Grantee against the Company or any other Related Company, whether predicated on this Agreement or otherwise, shall not excuse the Grantee’s breach, or constitute a defense to the enforcement by the Related Companies, of these restrictive covenants. The Company and the Grantee have had the opportunity to independently consult with their respective counsel for advice in all respects concerning the reasonableness and propriety of such covenants, with specific regard to the nature of the businesses conducted by the Related Companies.
(e) The Grantee agrees that any breach of the covenants contained in Section 18 of this Agreement would irreparably injure the Related Companies and that their remedies at law would be inadequate. Accordingly, in the event of any breach or threatened breach of Section 18 of this Agreement, the Related Companies, in addition to any other rights and remedies available at law or in equity, shall be entitled to an injunction (and/or other equitable relief), restraining such breach or threatened breach, and be entitled to the reimbursement of court costs, attorneys’ fees and other costs and expenses incurred in connection with enforcing this Agreement. The existence of any claim or cause of action on the part of the Grantee against any Related Company shall not constitute a defense to the enforcement of these provisions. This Agreement shall be enforceable by any Related Company, either alone or together with any other Related Company or Related Companies. The rights and remedies hereunder provided to the Related Companies shall be cumulative and shall be in addition to any other rights or remedies available at law, in equity or under this Agreement.
(f) If any of the provisions of Section 18 of this Agreement are determined by a court of law to be excessively broad, whether as to geographical area, time, scope or otherwise, such provision shall be reduced to whatever extent is reasonable and shall be enforced as so modified. Any provisions of Section 18 of this Agreement not so modified shall remain in full force and effect.
19. Recoupment Provisions . (a) Subject to the clawback provisions of the Sarbanes-Oxley Act of 2002, the Committee may, in its sole discretion, direct that the Company recoup, and upon demand by the Company the Grantee agrees to return to the Company, all or a portion of any Shares paid to the Grantee hereunder computed using financial information or performance metrics later found to be materially inaccurate. The number of Shares to be recovered shall be equal to the excess of the number of Shares paid out over the number of Shares that would have been paid out had such financial information or performance metric been fairly stated at the time the payout was made.
(b) If the Company reasonably determines that the Grantee has materially violated any of the Grantee’s obligations under Section 17 or 18 of this Agreement, then effective the date on which such violation began, (i) any Restricted Stock Units that have not yet
11
NAI-1502151968v3
vested and been paid to the Grantee under this Agreement shall be forfeited and cancelled, and (ii) the Company may, in its sole discretion, recoup any and all of the Shares previously paid to the Grantee under this Agreement.
(c) If, after a demand for recoupment of Shares under Section 19 of this Agreement, the Grantee fails to return such Shares to the Company, the Grantee acknowledges that the Company (or the Company through the actions of any of its subsidiaries employing the Grantee, if applicable) has the right to effect the recovery of the then current value of such Shares and the amount of its court costs, attorneys’ fees and other costs and expenses incurred in connection with enforcing this Agreement by (i) deducting (subject to applicable law and the terms and conditions of the Plan) from any amounts the Company (and if applicable, any Subsidiary employing the Grantee) owes to the Grantee (including, but not limited to, wages or other compensation), except with respect to any non-qualified deferred compensation under Section 409A of the Code, (ii) withholding, except with respect to any non-qualified deferred compensation under Section 409A of the Code, payment of future increases in compensation (including the payment of any discretionary bonus amount) or grants of compensatory awards that otherwise would have been made in accordance with the Company’s or any of its subsidiaries’ otherwise applicable compensation practices, or (iii) any combination of the foregoing. The right of recoupment set forth in the preceding sentence shall not be the exclusive remedy of the Company, and the Company may exercise each and every other remedy available to it under applicable law.
20. Qualified Performance-Based Awards . If the Grantee is a Covered Employee, the grant of Restricted Stock Units evidenced by this Agreement shall be considered a Qualified Performance-Based Award. In furtherance thereof, and notwithstanding anything in this Agreement or the Plan to the contrary, the 2017 Target Number of Restricted Stock Units or the 2018 Target Number of Restricted Stock Units, as applicable, that the Grantee may earn for the 2017 Performance Period or 2018 Performance Period, as applicable, pursuant to the grant evidenced by this Agreement (the “Earned Shares”) shall be determined by the Committee based on, and must have a value (the “Earned Shares Value”) that in no event exceeds a value equal to, the percentage of the Company’s cumulative Cash Net Income (as defined below) for the 2017 Performance Period or 2018 Performance Period, as applicable, previously established by the Board of Directors of the Company in resolutions adopted on September 15, 2016 to apply with respect to the Grantee for the 2017 Performance Period or the 2018 Performance Period, as applicable (the “Award Pool Value”). Notwithstanding the prior sentence, the Committee shall have the power and authority, in its sole and absolute exercise of negative discretion, to reduce the Earned Shares such that the Earned Shares Value will be less than the Award Pool Value, which reduction may be made by taking into account any criteria the Committee deems appropriate. The reductions in Earned Shares Value, if any, shall not result in any increases in the value of Restricted Stock Units earned by any other Participant. For purposes of this Agreement, the term “Cash Net Income” shall mean the Company’s net income from continuing operations in the consolidated statement of income adjusted for the impact of non-cash items, such as depreciation, amortization, unrealized gains and losses, intangible asset impairments and other non-cash gains/losses included in net income (as reported in the Company’s quarterly and annual reports for the period from October 1, 2016 through September 30, 2018).
12
NAI-1502151968v3
21. Electronic Signature . This Agreement is delivered electronically. The Grantee consents to using an electronic signature to sign this Agreement and be legally bound to his or her acceptance or rejection of the grant. By electronically signing the Agreement, the Grantee also consents to entering into this Agreement in electronic form. The Grantee acknowledges that his or her electronic signature will have the same legal force and effect as a handwritten signature. The Grantee’s electronic signature, including date and time of signing will be stored electronically with the Restricted Stock Unit grant record.
22. GOVERNING LAWS . THE LAWS OF THE STATE OF NORTH CAROLINA SHALL GOVERN THE INTERPRETATION, VALIDITY AND PERFORMANCE OF THE TERMS OF THIS AGREEMENT, REGARDLESS OF THE LAW THAT MIGHT BE APPLIED UNDER PRINCIPLES OF CONFLICTS OF LAWS. EXCEPT AS OTHERWISE PROVIDED IN THIS SECTION 22, ANY CONTROVERSY OR DISPUTE ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL BE SETTLED EXCLUSIVELY IN THE COURTS (FEDERAL AND STATE) SITUATED IN THE STATE OF NORTH CAROLINA, FORSYTH COUNTY. THE GRANTEE CONSENTS TO PERSONAL JURISDICTION IN THE STATE OF NORTH CAROLINA AND IN THE COURTS THEREOF FOR THE ENFORCEMENT OF THIS AGREEMENT, AND WAIVES ANY RIGHTS THE GRANTEE OTHERWISE MAY HAVE UNDER THE LAWS OF ANY JURISDICTION TO OBJECT ON ANY BASIS TO JURISDICTION OR VENUE WITHIN THE STATE OF NORTH CAROLINA TO ENFORCE THIS AGREEMENT. IN ADDITION, AND NOTWITHSTANDING THE FOREGOING, THE COMPANY MAY ELECT, IN ITS DISCRETION, TO SEEK A TEMPORARY RESTRAINING ORDER OR PRELIMINARY OR PERMANENT INJUNCTIVE (OR SIMILAR) RELIEF TO ENFORCE ITS RIGHTS UNDER SECTIONS 17 AND 18 OF THIS AGREEMENT IN ANY JURISDICTION OR COURT ANYWHERE IN THE WORLD THAT THE COMPANY DETERMINES TO BE APPROPRIATE, AND THE GRANTEE HEREBY CONSENTS TO VENUE IN ANY SUCH JURISDICTION OR COURT IN SUCH EVENT.
IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Grantee have executed this Agreement as of the Date of Grant first above written.
REYNOLDS AMERICAN INC. |
|
By: |
|
|
Authorized Signature |
Grantee’s Signature: /s/ JOSEPH P. FRAGNITO
Print Name: Joseph P. Fragnito
13
NAI-1502151968v3
Exhibit 12.1
REYNOLDS AMERICAN INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Dollars in Millions)
(Unaudited)
|
|
For the Years Ended December 31, |
|
|||||||||||||||||
|
|
2016 |
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
|
2012 |
|
|||||
Earnings before fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes |
|
$ |
9,691 |
|
|
$ |
6,384 |
|
|
$ |
2,262 |
|
|
$ |
2,741 |
|
|
$ |
1,953 |
|
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and debt expense (1) |
|
|
626 |
|
|
|
570 |
|
|
|
286 |
|
|
|
259 |
|
|
|
234 |
|
Interest portion of rental expense (2) |
|
|
9 |
|
|
|
9 |
|
|
|
8 |
|
|
|
8 |
|
|
|
6 |
|
Add: Fixed Charges |
|
|
635 |
|
|
|
579 |
|
|
|
294 |
|
|
|
267 |
|
|
|
240 |
|
Earnings before fixed charges: |
|
$ |
10,326 |
|
|
$ |
6,963 |
|
|
$ |
2,556 |
|
|
$ |
3,008 |
|
|
$ |
2,193 |
|
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and debt expense (1) |
|
$ |
626 |
|
|
$ |
570 |
|
|
$ |
286 |
|
|
$ |
259 |
|
|
$ |
234 |
|
Interest portion of rental expense (2) |
|
|
9 |
|
|
|
9 |
|
|
|
8 |
|
|
|
8 |
|
|
|
6 |
|
Total fixed charges |
|
$ |
635 |
|
|
$ |
579 |
|
|
$ |
294 |
|
|
$ |
267 |
|
|
$ |
240 |
|
Ratio of earnings to fixed charges (3) |
|
|
16.3 |
|
|
|
12.0 |
|
|
|
8.7 |
|
|
|
11.3 |
|
|
|
9.1 |
|
(1) |
Interest and debt expense includes interest on indebtedness, amortization of debt discount and expenses, and excludes interest related to reserves on income taxes, as such interest is included in provision for income taxes. |
(2) |
One-third of rent expense is the portion deemed representative of the interest factor. |
(3) |
Based on rounded thousands. |
Exhibit 21.1
REYNOLDS AMERICAN INC.
SUBSIDIARIES
(As of January 18, 2017)
Name of Entity |
|
Place of Incorporation |
American Snuff Company, LLC |
|
Delaware |
Conwood Holdings, Inc. |
|
Delaware |
Kentucky BioProcessing, Inc. |
|
North Carolina |
LOEC, Inc. |
|
Delaware |
Lorillard, LLC |
|
Delaware |
Lorillard Holdings Company, Inc. |
|
Delaware |
Lorillard Licensing Company LLC |
|
North Carolina |
Lorillard Q-Tech, Inc. |
|
Delaware |
Lorillard Technologies, Inc. |
|
Delaware |
Niconovum USA, Inc. |
|
North Carolina |
Niconovum AB |
|
Sweden |
Northern Brands International, Inc. |
|
Delaware |
One Park Media Services, Inc. |
|
Delaware |
R. J. Reynolds Global Products, Inc. |
|
Delaware |
R.J. Reynolds Tobacco B.V. |
|
Netherlands |
R.J. Reynolds Tobacco (CI), Co. |
|
Cayman Islands |
R.J. Reynolds Tobacco Co. |
|
Delaware |
R. J. Reynolds Tobacco Company |
|
North Carolina |
R.J. Reynolds Tobacco C.V. (1) |
|
Netherlands |
R.J. Reynolds Tobacco Holdings, Inc. |
|
Delaware |
R. J. Reynolds Tobacco International, Inc. |
|
Delaware |
R. J. Reynolds Vapor Company |
|
North Carolina |
Reynolds Asia-Pacific Limited |
|
Hong Kong |
Reynolds Finance Company |
|
Delaware |
Reynolds Innovations (China) Limited |
|
China |
Reynolds Innovations Inc. |
|
North Carolina |
Reynolds International Holdings B.V. |
|
Netherlands |
Reynolds Technologies, Inc. |
|
Delaware |
RAI Innovations Company |
|
North Carolina |
RAI International, Inc. |
|
Delaware |
RAI Services Company |
|
North Carolina |
RAI Strategic Holdings, Inc. |
|
North Carolina |
RAI Trade Marketing Services Company |
|
North Carolina |
RJR Realty Relocation Services, Inc. |
|
North Carolina |
Rosswil LLC |
|
Delaware |
Santa Fe Natural Tobacco Company, Inc. |
|
New Mexico |
S.F. Imports, Inc. |
|
Delaware |
Spot You More, Inc. |
|
North Carolina |
Santa Fe Natural Tobacco Company Foundation (2) |
|
New Mexico |
Reynolds American Foundation (2) |
|
North Carolina |
(1) |
Limited partnership owned 10% by R. J. Reynolds Global Products, Inc. and 90% by R.J. Reynolds Tobacco Co. (Delaware entity) |
(2) |
Non-profit corporation |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Reynolds American Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-117813, 333-117814, 333-159009, and 333-186618) on Form S-8, and (No. 333-211316) on Form S-3 of Reynolds American Inc. of our reports dated February 9, 2017, with respect to the consolidated balance sheets of Reynolds American Inc. as of December 31, 2016 and 2015, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and the effectiveness of internal control over financial reporting as of December 31, 2016, which reports appear in the December 31, 2016 Annual Report on Form 10-K of Reynolds American Inc.
/s/ KPMG LLP
Greensboro, North Carolina
February 9, 2017
Exhibit 31.1
I, Debra A. Crew, certify that:
1. |
I have reviewed this annual report on Form 10-K of Reynolds American Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: February 9, 2017
/s/ Debra A. Crew |
Debra A. Crew |
President and |
Chief Executive Officer |
Exhibit 31.2
I, Andrew D. Gilchrist, certify that:
1. |
I have reviewed this annual report on Form 10-K of Reynolds American Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: February 9, 2017
/s/ Andrew D. Gilchrist |
Andrew D. Gilchrist |
Executive Vice President and |
Chief Financial Officer |
Exhibit 32.1
REYNOLDS AMERICAN INC.
Certification Pursuant to 18 U.S.C. §1350
Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Debra A. Crew, Chief Executive Officer, and Andrew D. Gilchrist, Chief Financial Officer, of Reynolds American Inc. (“RAI”), hereby certifies, to her or his knowledge, that:
|
1) |
RAI’s Annual Report on Form 10-K for the year ended December 31, 2016, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
2) |
the information contained in RAI’s Annual Report on Form 10-K for the year ended December 31, 2016, fairly presents, in all material respects, the financial condition and results of operations of RAI. |
EXECUTED this 9 th day of February, 2017.
/s/ Debra A. Crew |
Debra A. Crew, President and |
Chief Executive Officer of Reynolds American Inc. |
|
|
/s/ Andrew D. Gilchrist |
Andrew D. Gilchrist, Executive Vice President and |
Chief Financial Officer of Reynolds American Inc. |